{"docstore/data": {"81caa7d6-c7c1-437c-a367-26b8c6136804": {"__data__": {"id_": "81caa7d6-c7c1-437c-a367-26b8c6136804", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  ", "original_text": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71e330b8-83f5-4e1b-960d-540255721639", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n", "original_text": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.  "}, "hash": "c705a10fd565493eb7d321a2a0928fa0bf2c1105b1dea63c1afaff80c363950b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71e330b8-83f5-4e1b-960d-540255721639": {"__data__": {"id_": "71e330b8-83f5-4e1b-960d-540255721639", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n", "original_text": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81caa7d6-c7c1-437c-a367-26b8c6136804", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  ", "original_text": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adc7fc90c2526a818a08568f82284c2608cc9e930749ec42e94f906d02e48044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "252f0102-48ec-4c5d-8245-3f1bd3afe6e0", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.  ", "original_text": "Today's call is being recorded.  "}, "hash": "3e8d40b6fb7ad8e786e23e472bd15148c63091edb599d99d5ce710b1b521ceb7", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.  ", "start_char_idx": 48, "end_char_idx": 227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "252f0102-48ec-4c5d-8245-3f1bd3afe6e0": {"__data__": {"id_": "252f0102-48ec-4c5d-8245-3f1bd3afe6e0", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.  ", "original_text": "Today's call is being recorded.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71e330b8-83f5-4e1b-960d-540255721639", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n", "original_text": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b2691aa081104ace007326ecec5d3aa19d79fe63d676088f04b5d08b0a8dc71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9b8ed38-af9d-4702-adf3-79c6f6b3022c", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome . ", "original_text": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  "}, "hash": "4d19ba1b4f5dcf1c3c3752d327cf410ab10f022dd8ba39e461345612fda29bb3", "class_name": "RelatedNodeInfo"}}, "text": "Today's call is being recorded.  ", "start_char_idx": 227, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9b8ed38-af9d-4702-adf3-79c6f6b3022c": {"__data__": {"id_": "f9b8ed38-af9d-4702-adf3-79c6f6b3022c", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome . ", "original_text": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "252f0102-48ec-4c5d-8245-3f1bd3afe6e0", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.  ", "original_text": "Today's call is being recorded.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8bb4575afc9c4ddfbeeeba8b6bbfce692fed0f49a51220c0e410d2b7d633aba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af350fed-2b12-4681-b7d2-57f9760fbf12", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  ", "original_text": "Please go ahead, sir.  \n \n"}, "hash": "447ceb57c74fffe7b438eac85a5c92ac3260184bcdc9a61e94a9ed51c05afade", "class_name": "RelatedNodeInfo"}}, "text": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  ", "start_char_idx": 260, "end_char_idx": 347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af350fed-2b12-4681-b7d2-57f9760fbf12": {"__data__": {"id_": "af350fed-2b12-4681-b7d2-57f9760fbf12", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9b8ed38-af9d-4702-adf3-79c6f6b3022c", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome . ", "original_text": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a9fe79bd69ffa7af1ceec24ca73762720151ca26eea33dc288ddd86f14cf431", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5037caa-feb0-42ac-acee-20ce03cc98f3", "node_type": "1", "metadata": {"window": "Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "original_text": "Kevin Moran :   Good morning.  "}, "hash": "d8b271bd805555c568d32d92de7c2a70eab08e7a1313d68c3a4419b1cf19838d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead, sir.  \n \n", "start_char_idx": 347, "end_char_idx": 373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5037caa-feb0-42ac-acee-20ce03cc98f3": {"__data__": {"id_": "e5037caa-feb0-42ac-acee-20ce03cc98f3", "embedding": null, "metadata": {"window": "Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "original_text": "Kevin Moran :   Good morning.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af350fed-2b12-4681-b7d2-57f9760fbf12", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "507d5ec330cb95c72c82161233b9595e74e13aaa95f8f8c2474b0da3c39db82b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9486922-4824-4ad1-b0a0-4f1a1a6a40df", "node_type": "1", "metadata": {"window": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n", "original_text": "And welcome . "}, "hash": "1e343322b88d4257ff4fe481f242a6679bf9fa2ad00ddecd6b1d1eaec873a396", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :   Good morning.  ", "start_char_idx": 373, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9486922-4824-4ad1-b0a0-4f1a1a6a40df": {"__data__": {"id_": "d9486922-4824-4ad1-b0a0-4f1a1a6a40df", "embedding": null, "metadata": {"window": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n", "original_text": "And welcome . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5037caa-feb0-42ac-acee-20ce03cc98f3", "node_type": "1", "metadata": {"window": "Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "original_text": "Kevin Moran :   Good morning.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3f0ec241313d9f5f36bd855f22d918d3abc44f5a7569510f97337d48a32c6ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b54c581-872d-44fc-aa97-e7ca6176dcda", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements . ", "original_text": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  "}, "hash": "afdc0b6cd813c108fa66c333d8fad9c6cecabb8e9210a50fea1be12cda8bc913", "class_name": "RelatedNodeInfo"}}, "text": "And welcome . ", "start_char_idx": 404, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b54c581-872d-44fc-aa97-e7ca6176dcda": {"__data__": {"id_": "5b54c581-872d-44fc-aa97-e7ca6176dcda", "embedding": null, "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements . ", "original_text": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9486922-4824-4ad1-b0a0-4f1a1a6a40df", "node_type": "1", "metadata": {"window": "I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.   Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n", "original_text": "And welcome . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e8ded125f2eff2f1fa753b784ba4b445f9721fa2a419964b411526e305abc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ab69b48-1611-49a9-ae86-ff2ab4ddca30", "node_type": "1", "metadata": {"window": "Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . "}, "hash": "485c36e2e33d8e00774a0ad99615fc2809ba1e5aa2dac695435bb5f0841e75f0", "class_name": "RelatedNodeInfo"}}, "text": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  ", "start_char_idx": 418, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ab69b48-1611-49a9-ae86-ff2ab4ddca30": {"__data__": {"id_": "9ab69b48-1611-49a9-ae86-ff2ab4ddca30", "embedding": null, "metadata": {"window": "Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b54c581-872d-44fc-aa97-e7ca6176dcda", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements . ", "original_text": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "869ec4dfbf18864621abab5c6311c5ae8ce80cc3f6b59e78cd74e525b28a9bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2d08e0e-f486-4771-8bc3-613c82eff296", "node_type": "1", "metadata": {"window": "And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n"}, "hash": "2efda25dc0ab02f4ff089aef7fcc763ea4359892cb1e182057014e5b71a1f3ae", "class_name": "RelatedNodeInfo"}}, "text": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "start_char_idx": 539, "end_char_idx": 662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2d08e0e-f486-4771-8bc3-613c82eff296": {"__data__": {"id_": "f2d08e0e-f486-4771-8bc3-613c82eff296", "embedding": null, "metadata": {"window": "And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ab69b48-1611-49a9-ae86-ff2ab4ddca30", "node_type": "1", "metadata": {"window": "Kevin Moran :   Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3320b30daa926a0bc82244499b425312fed162f425d31e3e377acb5a5c8d8504", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87b771c0-83b0-4543-a830-f03088d2f648", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  ", "original_text": "During the call we will be making forward -looking statements . "}, "hash": "d53ea944ecd9002aea81cd51515aa995d989695321eaa1ef5e7e1863225430c7", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n", "start_char_idx": 662, "end_char_idx": 780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87b771c0-83b0-4543-a830-f03088d2f648": {"__data__": {"id_": "87b771c0-83b0-4543-a830-f03088d2f648", "embedding": null, "metadata": {"window": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  ", "original_text": "During the call we will be making forward -looking statements . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2d08e0e-f486-4771-8bc3-613c82eff296", "node_type": "1", "metadata": {"window": "And welcome .  Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60aabb34b9e5cd17243c9de0ff7d6c0c0913fcbef3398091717175860d60c9a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3317a8e1-aff5-47e7-9258-c8e2acb37712", "node_type": "1", "metadata": {"window": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . "}, "hash": "77bd91e56077a33ebf68796edee98cc55ebb94424e5fae08b36164c2794abcb4", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will be making forward -looking statements . ", "start_char_idx": 780, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3317a8e1-aff5-47e7-9258-c8e2acb37712": {"__data__": {"id_": "3317a8e1-aff5-47e7-9258-c8e2acb37712", "embedding": null, "metadata": {"window": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87b771c0-83b0-4543-a830-f03088d2f648", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s First-Quarter \nFiscal 2023 results along with updates to our full year outlook.   You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  ", "original_text": "During the call we will be making forward -looking statements . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01e03c192dc20905330fa12451c6486a464ad47eb8efc9e2f9ebc5178b6f1f4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed105fb3-1646-4d3d-9c6e-4fc581ea5afa", "node_type": "1", "metadata": {"window": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. "}, "hash": "a1028b71b3cab1c53f53698f2bd83e689264ff291db8e18b27d45f8cf07fe6e4", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "start_char_idx": 844, "end_char_idx": 1012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed105fb3-1646-4d3d-9c6e-4fc581ea5afa": {"__data__": {"id_": "ed105fb3-1646-4d3d-9c6e-4fc581ea5afa", "embedding": null, "metadata": {"window": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3317a8e1-aff5-47e7-9258-c8e2acb37712", "node_type": "1", "metadata": {"window": "You can find today\u2019s press release  and \nearnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6412b4e40301b4f8902abfab9065a7780c3c2b0adb63cb1118c16c9bed568ffa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a15969ff-44e4-4927-bee6-95dd55bb5a9f", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  "}, "hash": "9ac9545aef446384d09aeed242f867794cbada383635243d90fe47e0087de899", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "start_char_idx": 1012, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a15969ff-44e4-4927-bee6-95dd55bb5a9f": {"__data__": {"id_": "a15969ff-44e4-4927-bee6-95dd55bb5a9f", "embedding": null, "metadata": {"window": "During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed105fb3-1646-4d3d-9c6e-4fc581ea5afa", "node_type": "1", "metadata": {"window": "Joining me today are \nJason Hollar, Chief Executive Offic er, and Trish English, Interim Chief Financial Officer.  \n \n During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e2ec90e6eb2b753326b7cbec6c07c15a5e5884e220ca75742d54116468a086a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8d88eb1-cf78-44cd-8309-a7da8c7c42c4", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n"}, "hash": "94f9705753a7f9f85971bb18386dbb696172098a4581536672d2d01757bc29df", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  ", "start_char_idx": 1180, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8d88eb1-cf78-44cd-8309-a7da8c7c42c4": {"__data__": {"id_": "e8d88eb1-cf78-44cd-8309-a7da8c7c42c4", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a15969ff-44e4-4927-bee6-95dd55bb5a9f", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements .  The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dab404b399f280f5618a98488dcbb376796a1a4b5c6bb19bcbcab4c35ee4df7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d91b5b31-bf19-4516-9bc0-99a6bca5a8a7", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  "}, "hash": "a2f0f7ba14cc9643ec54f4f4c9b7d11f75b371a215e881c42e3a8595209a361f", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "start_char_idx": 1321, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d91b5b31-bf19-4516-9bc0-99a6bca5a8a7": {"__data__": {"id_": "d91b5b31-bf19-4516-9bc0-99a6bca5a8a7", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8d88eb1-cf78-44cd-8309-a7da8c7c42c4", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c02988b65c118edfa5153bbace8acaf922d0f602b72ea5c6936d3dfe308bbfd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a442c11a-48b6-4869-b4bf-a43d0df1eaff", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. ", "original_text": "With that, I will now turn the call \nover the Jason.  \n \n"}, "hash": "5f1fe2782ff24573466ead2d3805dedc9ff1366457993edb3a73fda475236b93", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "start_char_idx": 1446, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a442c11a-48b6-4869-b4bf-a43d0df1eaff": {"__data__": {"id_": "a442c11a-48b6-4869-b4bf-a43d0df1eaff", "embedding": null, "metadata": {"window": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. ", "original_text": "With that, I will now turn the call \nover the Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d91b5b31-bf19-4516-9bc0-99a6bca5a8a7", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7363c66bccaeee3ebffe46c09cb82a52d332d586a98b0823a4f04d82ea90f169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67dd57e5-bf30-422c-9010-8863eec1c543", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  ", "original_text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n"}, "hash": "47c1b19efd3be1e1d0663b4f1247c2f7b96b6ea2949394712bdb48bd3b4657fa", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call \nover the Jason.  \n \n", "start_char_idx": 1617, "end_char_idx": 1674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67dd57e5-bf30-422c-9010-8863eec1c543": {"__data__": {"id_": "67dd57e5-bf30-422c-9010-8863eec1c543", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  ", "original_text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a442c11a-48b6-4869-b4bf-a43d0df1eaff", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will b e on a non-GAAP basis unless they are \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. ", "original_text": "With that, I will now turn the call \nover the Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9311d287e600a8d5b7dcf8bbb2f3ad7903879be68ef14065f7f0d3d29a37d98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c820fbec-7290-4955-ba9b-d2ba1e062f6c", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n", "original_text": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n"}, "hash": "540bc4aeec6d3d1b8fb0eb81fa22d905829087c05cecf331235a5c42e3705496", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "start_char_idx": 1674, "end_char_idx": 1738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c820fbec-7290-4955-ba9b-d2ba1e062f6c": {"__data__": {"id_": "c820fbec-7290-4955-ba9b-d2ba1e062f6c", "embedding": null, "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n", "original_text": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67dd57e5-bf30-422c-9010-8863eec1c543", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  ", "original_text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c076dd85bebeefd9c3ceefc11770b84e6062a5041a1495a51c0248aa15a8b8d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80cbc1df-e4e5-4391-b351-b7bf0bd24789", "node_type": "1", "metadata": {"window": "With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. ", "original_text": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. "}, "hash": "58247388ebd8e812c3bfbe9214fce5a8400fa2d49e857a3079d6236ea8fa081e", "class_name": "RelatedNodeInfo"}}, "text": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n", "start_char_idx": 1738, "end_char_idx": 1891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80cbc1df-e4e5-4391-b351-b7bf0bd24789": {"__data__": {"id_": "80cbc1df-e4e5-4391-b351-b7bf0bd24789", "embedding": null, "metadata": {"window": "With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. ", "original_text": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c820fbec-7290-4955-ba9b-d2ba1e062f6c", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n", "original_text": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98e833f60b14a9a5efd1917d3a939df0545e60b07291d3a4ef7dcc797ef9a990", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1006e2dd-a7c8-49d5-99de-91be004cc0c7", "node_type": "1", "metadata": {"window": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n", "original_text": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  "}, "hash": "b518941f348ca7aa752a9e35a86ca7559e6da9ceac7f5e33d14fcba5167fae19", "class_name": "RelatedNodeInfo"}}, "text": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. ", "start_char_idx": 1891, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1006e2dd-a7c8-49d5-99de-91be004cc0c7": {"__data__": {"id_": "1006e2dd-a7c8-49d5-99de-91be004cc0c7", "embedding": null, "metadata": {"window": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n", "original_text": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80cbc1df-e4e5-4391-b351-b7bf0bd24789", "node_type": "1", "metadata": {"window": "With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. ", "original_text": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abf549c7ae329ed2aa82fcd8505b243c6df3fa8dc40e27955fa1aafdbfcebaba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "565b7e1f-b23d-41bf-b3c5-a77dc663dd54", "node_type": "1", "metadata": {"window": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n"}, "hash": "aa04972b5b378125b71c20e4d2153116cb9b3b34429a15bdcda6680d6eea8775", "class_name": "RelatedNodeInfo"}}, "text": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  ", "start_char_idx": 2130, "end_char_idx": 2247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "565b7e1f-b23d-41bf-b3c5-a77dc663dd54": {"__data__": {"id_": "565b7e1f-b23d-41bf-b3c5-a77dc663dd54", "embedding": null, "metadata": {"window": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1006e2dd-a7c8-49d5-99de-91be004cc0c7", "node_type": "1", "metadata": {"window": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n", "original_text": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.  ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75fc5abcc5478f2240622c6e7a0c10608d8bba31e42e98b9017409828f7ef2a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f9a4765-fc0a-4dcb-af9a-0b51035f9e60", "node_type": "1", "metadata": {"window": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. "}, "hash": "a532c12ff1a7910cc7579d0f5e7595098c631f455bf19cbef8685e31d165fa60", "class_name": "RelatedNodeInfo"}}, "text": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n", "start_char_idx": 2247, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f9a4765-fc0a-4dcb-af9a-0b51035f9e60": {"__data__": {"id_": "0f9a4765-fc0a-4dcb-af9a-0b51035f9e60", "embedding": null, "metadata": {"window": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "565b7e1f-b23d-41bf-b3c5-a77dc663dd54", "node_type": "1", "metadata": {"window": "Now that I\u2019ve had a couple months to settle into the CEO role, I am feeling even more energized and \nexcited about the opportunities in front of us.  \n \n My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bde75e4e91888eedb22ebd644be1441b81a8b8d26daab4839356cf34ee0d54dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3467e56-299f-4dbc-bece-d96704e87b5d", "node_type": "1", "metadata": {"window": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n"}, "hash": "95d57f3816d221f6915f0d82f4f5410c1757c51e0f224a3fc7f95e320b47fe60", "class_name": "RelatedNodeInfo"}}, "text": "Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. ", "start_char_idx": 2406, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3467e56-299f-4dbc-bece-d96704e87b5d": {"__data__": {"id_": "f3467e56-299f-4dbc-bece-d96704e87b5d", "embedding": null, "metadata": {"window": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f9a4765-fc0a-4dcb-af9a-0b51035f9e60", "node_type": "1", "metadata": {"window": "My recent conversations with customers, suppliers, employees, and shareholders have reinforced my \npercepti ons that :  Our company\u2019s role in healthcare and our mission to improve the lives of people \nevery day remain as critical as ever.  Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e85aaef3d1cfd8d4001d59bfb9769c60358bfa55bd3784053d7fcf82fd05a0cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b07dfe64-a28a-4d87-b64c-671a7441cb7b", "node_type": "1", "metadata": {"window": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n "}, "hash": "3f793a7db693743ce0c3be9ff4471bda1b7316618b33d57529947fbb298473e0", "class_name": "RelatedNodeInfo"}}, "text": "However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n", "start_char_idx": 2589, "end_char_idx": 2695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b07dfe64-a28a-4d87-b64c-671a7441cb7b": {"__data__": {"id_": "b07dfe64-a28a-4d87-b64c-671a7441cb7b", "embedding": null, "metadata": {"window": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f11d64d560b7ed652c68b2337a1912e1806899c1bd9995ff2a1606698e1db80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3467e56-299f-4dbc-bece-d96704e87b5d", "node_type": "1", "metadata": {"window": "Our customers and their patients rely on us to deliver the right \nproducts, to the right places, at the right time.   And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30bb789827e4be54f403ac956225fb977842d054f578e7d4bf15d240d8bbce31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9d77d99-a2cc-48e0-bc9c-b1fd7770a10d", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "original_text": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds. "}, "hash": "2220342414bf47b03ab93c40a2392651b30540770701826c9a3ece8a0e5b51de", "class_name": "RelatedNodeInfo"}}, "text": "Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "start_char_idx": 2695, "end_char_idx": 2849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9d77d99-a2cc-48e0-bc9c-b1fd7770a10d": {"__data__": {"id_": "a9d77d99-a2cc-48e0-bc9c-b1fd7770a10d", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "original_text": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b07dfe64-a28a-4d87-b64c-671a7441cb7b", "node_type": "1", "metadata": {"window": "And yet, there\u2019s also a collective recognition of the \nneed for simplification, focused execution, and clarification of our company\u2019s strategic direction.  \n \n Our goal today, along with reviewing our recent results, is to summarize the key near -term prioritie s \nand progress to -date on our plans, which I will discuss later in my remarks.  However, before I turn it \nover to Trish, let me share some initial perspective on the first quarter.  \n \n Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "original_text": "Overall, our performance in the first -quarter demonstrated continued stable  fundamentals in our \nlargest business, and tangible progress in Medical.  \n ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "703588d3d0427f3a8b2d07c758c364931280fd89de0dfa6833efd4481c171370", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbfb7216-2c91-42c5-9288-2166ac194744", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n", "original_text": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n"}, "hash": "4317977a8fa8ded76d056c5489cf492f9fa136dea6084adc8882e5a3a3159434", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds. ", "start_char_idx": 0, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbfb7216-2c91-42c5-9288-2166ac194744": {"__data__": {"id_": "bbfb7216-2c91-42c5-9288-2166ac194744", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n", "original_text": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9d77d99-a2cc-48e0-bc9c-b1fd7770a10d", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "original_text": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d448fd4bb6e8f1b633c0f9cfec4644c6951189ea6a37bb5775da70515112309", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59e1f5ea-2b8d-4bf6-a853-dfbdb0e929f5", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n", "original_text": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember . "}, "hash": "8a7617caf8665925ee9b575424911983ee7b360b6f8a837f729f0bd10f0d8ec1", "class_name": "RelatedNodeInfo"}}, "text": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n", "start_char_idx": 155, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59e1f5ea-2b8d-4bf6-a853-dfbdb0e929f5": {"__data__": {"id_": "59e1f5ea-2b8d-4bf6-a853-dfbdb0e929f5", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n", "original_text": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember . ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbfb7216-2c91-42c5-9288-2166ac194744", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n", "original_text": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d513fb98dac9f076cad60b800f725a21ac0988bff8d41ac5804d7dd35c97071a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e3c5f1c-5113-4ac7-a994-787f3a57a663", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n", "original_text": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. "}, "hash": "2b7dd7f2fcf1bbfbffc79074e233ae12ccbf7948ab819a2f47f4ed2ca13e61e7", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember . ", "start_char_idx": 276, "end_char_idx": 383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e3c5f1c-5113-4ac7-a994-787f3a57a663": {"__data__": {"id_": "6e3c5f1c-5113-4ac7-a994-787f3a57a663", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n", "original_text": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59e1f5ea-2b8d-4bf6-a853-dfbdb0e929f5", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n", "original_text": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember . ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66190dc8321a1c26407c46f3d25e41a648640004a3a4a5f140b590f80e9250ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "865cf553-177d-4208-b028-4c103c9e121d", "node_type": "1", "metadata": {"window": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone. ", "original_text": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n"}, "hash": "59978188cfc3dd941c0b199815cdda43efd2bd8d10cf09690914d62104cd5bb5", "class_name": "RelatedNodeInfo"}}, "text": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "start_char_idx": 383, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "865cf553-177d-4208-b028-4c103c9e121d": {"__data__": {"id_": "865cf553-177d-4208-b028-4c103c9e121d", "embedding": null, "metadata": {"window": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone. ", "original_text": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e3c5f1c-5113-4ac7-a994-787f3a57a663", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n", "original_text": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3d9325ccaae661136e0b3fcff0966bf4fe34abf320dac6a243e38224a3f9dcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9113967a-48d1-4cc7-a88d-80d7d7f22264", "node_type": "1", "metadata": {"window": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n", "original_text": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n"}, "hash": "f4bda01e6b8abe9a217ea3f98168784a055b8e5f92c802db613ddbbec205b161", "class_name": "RelatedNodeInfo"}}, "text": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n", "start_char_idx": 613, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9113967a-48d1-4cc7-a88d-80d7d7f22264": {"__data__": {"id_": "9113967a-48d1-4cc7-a88d-80d7d7f22264", "embedding": null, "metadata": {"window": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n", "original_text": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "865cf553-177d-4208-b028-4c103c9e121d", "node_type": "1", "metadata": {"window": "We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone. ", "original_text": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33ef4f41ae44446726058259f6a7fd86d5d2563c3270c7a5b6f36156f297d7b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41883b94-c385-45c2-be31-b2fe3b29863f", "node_type": "1", "metadata": {"window": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n", "original_text": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n"}, "hash": "23cc4e5b359ae3d74fac75461638e2eab2152e0c43cb8ef2a28edc4e3318857b", "class_name": "RelatedNodeInfo"}}, "text": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n", "start_char_idx": 755, "end_char_idx": 902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41883b94-c385-45c2-be31-b2fe3b29863f": {"__data__": {"id_": "41883b94-c385-45c2-be31-b2fe3b29863f", "embedding": null, "metadata": {"window": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n", "original_text": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9113967a-48d1-4cc7-a88d-80d7d7f22264", "node_type": "1", "metadata": {"window": "In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n", "original_text": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "716d5ca796cf6b66ea32a690ed5105fa5fff28d2434471f1000c17acb3a11443", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "248023f3-f413-45fc-8412-5fe45e76ed99", "node_type": "1", "metadata": {"window": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n", "original_text": "Trish Englis h:   Thanks Jason, and good morning everyone. "}, "hash": "69f4abbb7a5c52e28522092377720cde5327243e2afc91aec8479673593e73d3", "class_name": "RelatedNodeInfo"}}, "text": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n", "start_char_idx": 902, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "248023f3-f413-45fc-8412-5fe45e76ed99": {"__data__": {"id_": "248023f3-f413-45fc-8412-5fe45e76ed99", "embedding": null, "metadata": {"window": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n", "original_text": "Trish Englis h:   Thanks Jason, and good morning everyone. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41883b94-c385-45c2-be31-b2fe3b29863f", "node_type": "1", "metadata": {"window": "While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business.  We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n", "original_text": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4b1d6079966a671ff7f3484b93a23ee6c6bbfa033e18c8d396112a38f5c0fc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff9fba3a-84bc-41e1-bb0e-0c13a7336ab6", "node_type": "1", "metadata": {"window": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n", "original_text": "It\u2019s great to speak with you all.  \n \n"}, "hash": "1bee985c8c7f9cb8c084baac7959fc48f2e21c087dc995102c4001bd8ac259e0", "class_name": "RelatedNodeInfo"}}, "text": "Trish Englis h:   Thanks Jason, and good morning everyone. ", "start_char_idx": 983, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff9fba3a-84bc-41e1-bb0e-0c13a7336ab6": {"__data__": {"id_": "ff9fba3a-84bc-41e1-bb0e-0c13a7336ab6", "embedding": null, "metadata": {"window": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n", "original_text": "It\u2019s great to speak with you all.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "248023f3-f413-45fc-8412-5fe45e76ed99", "node_type": "1", "metadata": {"window": "We are highly -focused on executing our Medical Improvement \nPlan initiatives, which I will cover in greater detail  later in my remarks.  \n \n Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n", "original_text": "Trish Englis h:   Thanks Jason, and good morning everyone. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d901ace9bb518e6436424d3d59682662a428d0af3a3236c0f9b8ed01b34851e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b6234ec-4dcd-4b6b-bcab-7b97a4aca040", "node_type": "1", "metadata": {"window": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. ", "original_text": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n"}, "hash": "9a2642a31af9082254c404c9ac6f000b4f93ccfd90add828cf95f24f5c2aefe8", "class_name": "RelatedNodeInfo"}}, "text": "It\u2019s great to speak with you all.  \n \n", "start_char_idx": 1042, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b6234ec-4dcd-4b6b-bcab-7b97a4aca040": {"__data__": {"id_": "5b6234ec-4dcd-4b6b-bcab-7b97a4aca040", "embedding": null, "metadata": {"window": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. ", "original_text": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff9fba3a-84bc-41e1-bb0e-0c13a7336ab6", "node_type": "1", "metadata": {"window": "Across the company, our team is operating with urgency to drive our businesses forward and \ncommitted to creating value for our shareholders .  \n \n Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n", "original_text": "It\u2019s great to speak with you all.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4465aa32614194b38fffbc7e7aeb9dfecfc378446501e30b4b2ffe09b43480c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11d13401-65af-4c8e-b61b-4b3fd36d6bd3", "node_type": "1", "metadata": {"window": "Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n", "original_text": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n"}, "hash": "0485c315b516b1c0c904dba1720dff1048bda09c23cee142c2110e3bffcc2531", "class_name": "RelatedNodeInfo"}}, "text": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n", "start_char_idx": 1080, "end_char_idx": 1318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11d13401-65af-4c8e-b61b-4b3fd36d6bd3": {"__data__": {"id_": "11d13401-65af-4c8e-b61b-4b3fd36d6bd3", "embedding": null, "metadata": {"window": "Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n", "original_text": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b6234ec-4dcd-4b6b-bcab-7b97a4aca040", "node_type": "1", "metadata": {"window": "Now, I\u2019ll turn it over to Trish to dive deeper into our results and outlook.  \n \n Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. ", "original_text": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb3db53e970a5c42ae9717089ceb367d101c9e4495cc9688ba6d4bf6d488ae6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b7c13b5-1129-4aff-9e76-423f7c1c95b2", "node_type": "1", "metadata": {"window": "It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n", "original_text": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n"}, "hash": "e23e7577498f9ebeffdb5519b22bb2322ebf06e08ae076cfcd2da2977c949317", "class_name": "RelatedNodeInfo"}}, "text": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n", "start_char_idx": 1318, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b7c13b5-1129-4aff-9e76-423f7c1c95b2": {"__data__": {"id_": "2b7c13b5-1129-4aff-9e76-423f7c1c95b2", "embedding": null, "metadata": {"window": "It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n", "original_text": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11d13401-65af-4c8e-b61b-4b3fd36d6bd3", "node_type": "1", "metadata": {"window": "Trish Englis h:   Thanks Jason, and good morning everyone.  It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n", "original_text": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ebe459b7091e8321cb07b9063aec62491a898426c83c621cff09afe39f9137b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec65bd90-2c17-46dc-b59e-4ad1b7af22a4", "node_type": "1", "metadata": {"window": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. ", "original_text": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. "}, "hash": "db9fa430000e69a91df556f5046196ab25583292971e1370ca00535c4085d793", "class_name": "RelatedNodeInfo"}}, "text": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n", "start_char_idx": 1414, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec65bd90-2c17-46dc-b59e-4ad1b7af22a4": {"__data__": {"id_": "ec65bd90-2c17-46dc-b59e-4ad1b7af22a4", "embedding": null, "metadata": {"window": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. ", "original_text": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b7c13b5-1129-4aff-9e76-423f7c1c95b2", "node_type": "1", "metadata": {"window": "It\u2019s great to speak with you all.  \n \n Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n", "original_text": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b9042a548b80a00b8a5e3450facdce89bfcc4ece803856dcf16451922562196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7cead67-ba2c-40b8-82eb-5a75fb6a8683", "node_type": "1", "metadata": {"window": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n", "original_text": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n"}, "hash": "2e21414aa6de5bee28423e524a0fb844366939f2f163143952ae7a1c00638bbe", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. ", "start_char_idx": 1618, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7cead67-ba2c-40b8-82eb-5a75fb6a8683": {"__data__": {"id_": "b7cead67-ba2c-40b8-82eb-5a75fb6a8683", "embedding": null, "metadata": {"window": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n", "original_text": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec65bd90-2c17-46dc-b59e-4ad1b7af22a4", "node_type": "1", "metadata": {"window": "Today I\u2019ll share details on three areas of focus \u2013 our consolidated first quarter results, the key drivers \nunderlying our segments\u2019 performance, and our updated fiscal \u201823 out look before turning it back to \nJason for final remarks.  \n \n First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. ", "original_text": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a01cf443f835733c11d38a4ff6d4d5126d1131126a07e225f73e487c55d840c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "245d7555-986c-4313-a0dc-2ef24eaa1cb5", "node_type": "1", "metadata": {"window": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n", "original_text": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n"}, "hash": "ed727a5a62f59b250db593a3f7dede08b03756cdaca9c3fe4bf76dc4eee45e3f", "class_name": "RelatedNodeInfo"}}, "text": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n", "start_char_idx": 1778, "end_char_idx": 1906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "245d7555-986c-4313-a0dc-2ef24eaa1cb5": {"__data__": {"id_": "245d7555-986c-4313-a0dc-2ef24eaa1cb5", "embedding": null, "metadata": {"window": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n", "original_text": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7cead67-ba2c-40b8-82eb-5a75fb6a8683", "node_type": "1", "metadata": {"window": "First quarter total company revenue increased 13 %, driven by Pharma  segment sales growth.  \n \n Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n", "original_text": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d14e8895afe40af1e88e1777858528fc6708ef4c92de7318875493a371a4192b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99fc5be9-15ef-4c30-9e5d-6a3fd0588523", "node_type": "1", "metadata": {"window": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. ", "original_text": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. "}, "hash": "d6a76d6480d0c7d39d2f437b3d9015d254cdc8e58b03a75a8f49697cb5172218", "class_name": "RelatedNodeInfo"}}, "text": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n", "start_char_idx": 1906, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99fc5be9-15ef-4c30-9e5d-6a3fd0588523": {"__data__": {"id_": "99fc5be9-15ef-4c30-9e5d-6a3fd0588523", "embedding": null, "metadata": {"window": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. ", "original_text": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "245d7555-986c-4313-a0dc-2ef24eaa1cb5", "node_type": "1", "metadata": {"window": "Gross margin decreased 2 % to $1.6 billion due to net inflationary impacts in Medical and one month\u2019s \nimpac t of the Cordis divestiture, partially offset by our Pharma  generics program performance.  \n \n Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n", "original_text": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cf5e73316077ef0588aa580723939a7aea710acc1eab7ec23642876858d9eba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bc58ef3-9ffa-4676-9e40-c8134913385c", "node_type": "1", "metadata": {"window": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n"}, "hash": "ed9c0294b4a2c68f4259c542fc4b38c5388b3ef751c93de480294313fd1872dd", "class_name": "RelatedNodeInfo"}}, "text": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. ", "start_char_idx": 2114, "end_char_idx": 2276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bc58ef3-9ffa-4676-9e40-c8134913385c": {"__data__": {"id_": "3bc58ef3-9ffa-4676-9e40-c8134913385c", "embedding": null, "metadata": {"window": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99fc5be9-15ef-4c30-9e5d-6a3fd0588523", "node_type": "1", "metadata": {"window": "Consolidated SG&A increased 7 %, reflecting inflationary supply chain costs and other operating \nexpenses such as higher costs to support Pharma  sales growth.  This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. ", "original_text": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aa7aedcfcdd8d0f3b75e7c7875b250ccbfd292f07ff99f0a7f64a5f68aaa579", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a151dbb-8668-4d97-b66d-6eee6f3ad314", "node_type": "1", "metadata": {"window": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n"}, "hash": "33e6af2166aeee63656dd08fe684b4a98e0d266376b9e36d5b2a63f520b63cb9", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n", "start_char_idx": 2276, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a151dbb-8668-4d97-b66d-6eee6f3ad314": {"__data__": {"id_": "1a151dbb-8668-4d97-b66d-6eee6f3ad314", "embedding": null, "metadata": {"window": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bc58ef3-9ffa-4676-9e40-c8134913385c", "node_type": "1", "metadata": {"window": "This inc rease was partially offset by \nthe Cordis divestiture and benefits from enterprise -wide cost savings initiatives.  \n \n Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "473dbb28a9b9fde847354a3127c06d2ae6b3015d726f79b76eac786e596f86d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64b5de7b-e8e4-46e7-b4d6-9efbeb9bf64b", "node_type": "1", "metadata": {"window": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. "}, "hash": "991ac518a04b739c63046c9752fc0560c59cc58d35be42d372a19846be2928fe", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n", "start_char_idx": 2383, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64b5de7b-e8e4-46e7-b4d6-9efbeb9bf64b": {"__data__": {"id_": "64b5de7b-e8e4-46e7-b4d6-9efbeb9bf64b", "embedding": null, "metadata": {"window": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a151dbb-8668-4d97-b66d-6eee6f3ad314", "node_type": "1", "metadata": {"window": "Operating earnings decreased 20 % to $423 million, reflecting the decline in Medical segment profit, \nprimarily due to net inflationary impacts,  and partially offset by growth in Pharma  segment profit.  \n \n Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "576519dc96bc80db9f12526f5f34841dbc75013ecdf7bd7ce040b0c7d0c69547", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce98f3f6-51cf-4719-8d53-13cfbcda6326", "node_type": "1", "metadata": {"window": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n "}, "hash": "6c354d28121f3916467da3e789fb176be93ef8311bc8a27fbdf019cee709819d", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. ", "start_char_idx": 2543, "end_char_idx": 2647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce98f3f6-51cf-4719-8d53-13cfbcda6326": {"__data__": {"id_": "ce98f3f6-51cf-4719-8d53-13cfbcda6326", "embedding": null, "metadata": {"window": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bd10ed8717ad0650fe53027da952b8736617a5084c74a64a99e496bf422e2ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64b5de7b-e8e4-46e7-b4d6-9efbeb9bf64b", "node_type": "1", "metadata": {"window": "Now, moving below the line, Interest and Other decreased 25 % to $27 million  dollars , primarily driven \nby increased interest income from cash and equivalents.  As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b098a279d61d2bc9c8c34365e6fe76b7ce02826843083b1c3a88fd8b7a9ac14b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e34732c-9d26-4c3a-b18d-01c8178fb417", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "original_text": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n"}, "hash": "9490c1a7fceb46e2d8277021fa8b40d1fd4a2afc89382a04c7f41eb2f1eec93b", "class_name": "RelatedNodeInfo"}}, "text": "We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "start_char_idx": 2647, "end_char_idx": 2883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e34732c-9d26-4c3a-b18d-01c8178fb417": {"__data__": {"id_": "5e34732c-9d26-4c3a-b18d-01c8178fb417", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "original_text": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce98f3f6-51cf-4719-8d53-13cfbcda6326", "node_type": "1", "metadata": {"window": "As a reminder, our debt is largely fixed rate, \nresulting in a net benefit from rising interest rates.  \n \n Our first quarter Effective Tax Rate finished at 16.9 %, approximate ly 7 percentage points lower than \nprior year due to certain favorable discrete items.  \n \n Diluted weighted average shares were $273 million, 6 % lower than a year ago due to share \nrepurchases.  We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "original_text": "We are focused on balanced, disciplined, and shareholder -friendly c apital deployment \nand in mid -September, we initiated a $1 billion  dollar Accelerated Share Repurchase program that we \nexpect to complete in the second quarter.  \n ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c535321f2ee8eff567c2f9163684277a0f58e7e35c080093f085262b31eb4aad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d1f62a9-e475-4b36-8ee6-9d16da5f6776", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n", "original_text": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars. "}, "hash": "5670f0935f921213db6efab05fedbdd7febfeb7b70310cee92cae7ebfd537b92", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n", "start_char_idx": 0, "end_char_idx": 87, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d1f62a9-e475-4b36-8ee6-9d16da5f6776": {"__data__": {"id_": "2d1f62a9-e475-4b36-8ee6-9d16da5f6776", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n", "original_text": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e34732c-9d26-4c3a-b18d-01c8178fb417", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "original_text": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12eb05c7c7b0d4a8427e83ff298d289bad2f123270dddb9cf21a25db71d2bb87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72418f0c-5b24-4f8a-9911-4820ec7069df", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n", "original_text": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement. "}, "hash": "c19e0c1afa8a503649d4d5c4ab67461aee25d977b94417808bc830e92f475c6d", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars. ", "start_char_idx": 87, "end_char_idx": 212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72418f0c-5b24-4f8a-9911-4820ec7069df": {"__data__": {"id_": "72418f0c-5b24-4f8a-9911-4820ec7069df", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n", "original_text": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d1f62a9-e475-4b36-8ee6-9d16da5f6776", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n", "original_text": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "574a5f6f1a8e010eab1f7172cd02b313bcf10027db4d7d440c7974f2f3bdb720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5d8a459-c908-405c-87c4-d879593dec84", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n", "original_text": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n"}, "hash": "a4079bb8f852914a927ff23d032184b37feee931e50da83f4cca9d9408494ae8", "class_name": "RelatedNodeInfo"}}, "text": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement. ", "start_char_idx": 212, "end_char_idx": 376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5d8a459-c908-405c-87c4-d879593dec84": {"__data__": {"id_": "f5d8a459-c908-405c-87c4-d879593dec84", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n", "original_text": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72418f0c-5b24-4f8a-9911-4820ec7069df", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n", "original_text": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f82c0ad4d793bb6637adfb1433004192c8a77975983d0554408bebced6c0db7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88935146-bf2a-403b-8247-c57cef81a366", "node_type": "1", "metadata": {"window": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n", "original_text": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n"}, "hash": "fde139aa0dcb32cc5e9040d69d4a8e320f536a6047609bf926988b80e703fae7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "start_char_idx": 376, "end_char_idx": 455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88935146-bf2a-403b-8247-c57cef81a366": {"__data__": {"id_": "88935146-bf2a-403b-8247-c57cef81a366", "embedding": null, "metadata": {"window": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n", "original_text": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5d8a459-c908-405c-87c4-d879593dec84", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n", "original_text": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d19b46be9e4729ec23be8e6482d1291524bf3d07c5b6163403211e225f124a18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0335b08-bc3d-4e90-a758-d7e0ae2c474c", "node_type": "1", "metadata": {"window": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. ", "original_text": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n"}, "hash": "5904418b72386c4f5ba7e4241af31e34c8afc00b712616e722c98bb045d1e4dc", "class_name": "RelatedNodeInfo"}}, "text": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n", "start_char_idx": 455, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0335b08-bc3d-4e90-a758-d7e0ae2c474c": {"__data__": {"id_": "f0335b08-bc3d-4e90-a758-d7e0ae2c474c", "embedding": null, "metadata": {"window": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. ", "original_text": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88935146-bf2a-403b-8247-c57cef81a366", "node_type": "1", "metadata": {"window": "Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n", "original_text": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c615dd21e760a26a40bb130d16e5708c0c56046cd20038aa81c6a50adbd1ddd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db6646ed-4060-4da9-a8ec-0c08e9bdf0a0", "node_type": "1", "metadata": {"window": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. ", "original_text": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n"}, "hash": "fe5b9b3f9e47bc1a9c848fadbef9cf8f137217ee620556c35a25af8225eb879e", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n", "start_char_idx": 585, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db6646ed-4060-4da9-a8ec-0c08e9bdf0a0": {"__data__": {"id_": "db6646ed-4060-4da9-a8ec-0c08e9bdf0a0", "embedding": null, "metadata": {"window": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. ", "original_text": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0335b08-bc3d-4e90-a758-d7e0ae2c474c", "node_type": "1", "metadata": {"window": "This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. ", "original_text": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79b62d2ebe943822d824b9297019d20b5561ca64e6829c77b0bb1f48912fa572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbbb8af2-fafb-4d84-823f-e9074b4b4952", "node_type": "1", "metadata": {"window": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n", "original_text": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n"}, "hash": "4bbcb9bf4e94118993b38d35f7471ce4e8f04bbbc06b106c47f1aab03f29aebc", "class_name": "RelatedNodeInfo"}}, "text": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n", "start_char_idx": 847, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbbb8af2-fafb-4d84-823f-e9074b4b4952": {"__data__": {"id_": "bbbb8af2-fafb-4d84-823f-e9074b4b4952", "embedding": null, "metadata": {"window": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n", "original_text": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db6646ed-4060-4da9-a8ec-0c08e9bdf0a0", "node_type": "1", "metadata": {"window": "Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. ", "original_text": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2daa7afaaf36435496cac2afa5391c445087c9367fddfe69942d94f43efae26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd6c6f48-cbfb-4a58-a498-538911bcc4bb", "node_type": "1", "metadata": {"window": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n", "original_text": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. "}, "hash": "e45c8e3283efe685cc15ff00a77518a3823ae94c42c0910ec158d96b07461140", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n", "start_char_idx": 1071, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd6c6f48-cbfb-4a58-a498-538911bcc4bb": {"__data__": {"id_": "bd6c6f48-cbfb-4a58-a498-538911bcc4bb", "embedding": null, "metadata": {"window": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n", "original_text": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbbb8af2-fafb-4d84-823f-e9074b4b4952", "node_type": "1", "metadata": {"window": "We ended the period with a cash position of $3.5 billion  dollars , with no outstanding borrowings on \nour credit facilities.  \n \n Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n", "original_text": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d9f36f61527794b0151c48ef7c7373285ea0fa902f1dee35856b0fb525e4d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50c131ef-9df4-4415-a92b-dd2c95944ebf", "node_type": "1", "metadata": {"window": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n", "original_text": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. "}, "hash": "d5eb5d4a2136d1b603cb415daba66cf91b017d4a218a1864bb842e18cdf63457", "class_name": "RelatedNodeInfo"}}, "text": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. ", "start_char_idx": 1221, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50c131ef-9df4-4415-a92b-dd2c95944ebf": {"__data__": {"id_": "50c131ef-9df4-4415-a92b-dd2c95944ebf", "embedding": null, "metadata": {"window": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n", "original_text": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd6c6f48-cbfb-4a58-a498-538911bcc4bb", "node_type": "1", "metadata": {"window": "Now turning to the segments, beginning with Pharma  on slide 5\u2026  \n \nFirst-quarter revenue increased 15% to $46 billion  dollars , driven by branded Pharmaceutical  sales \ngrowth from existing and net new Pharmaceutical  Distribution and Specialty customers.  \n \n Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n", "original_text": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82c3cecf95b773fd8ac302c8652170570aa05e3bdb16b3c4692fc4b28125cdc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4addedea-9696-4e3b-9be1-81c0d522c757", "node_type": "1", "metadata": {"window": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n", "original_text": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n"}, "hash": "79dcbda12bce15ffd008ac0df384f966dbf11d7b84c81041d0c828f49215cdaa", "class_name": "RelatedNodeInfo"}}, "text": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. ", "start_char_idx": 1366, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4addedea-9696-4e3b-9be1-81c0d522c757": {"__data__": {"id_": "4addedea-9696-4e3b-9be1-81c0d522c757", "embedding": null, "metadata": {"window": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n", "original_text": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50c131ef-9df4-4415-a92b-dd2c95944ebf", "node_type": "1", "metadata": {"window": "Pharma  segment profit increased 6 % to $431 million  dollars , driven by generics program performance \nand a higher contr ibution from brand and specialty products, partially offset by inflationary supply \nchain costs.  \n \n During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n", "original_text": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0e5cb8b9bfb7cce2dcaff4e1fa14621b4f8810e0c190fe5f8b57abba4770f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec5fc4c0-9d2c-4133-8004-79f280fc02e5", "node_type": "1", "metadata": {"window": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. ", "original_text": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n"}, "hash": "6ca7ec7d31e11078d08a850f15fecc012af17ec36597e75eb0ec01d426b0032a", "class_name": "RelatedNodeInfo"}}, "text": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n", "start_char_idx": 1494, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec5fc4c0-9d2c-4133-8004-79f280fc02e5": {"__data__": {"id_": "ec5fc4c0-9d2c-4133-8004-79f280fc02e5", "embedding": null, "metadata": {"window": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. ", "original_text": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4addedea-9696-4e3b-9be1-81c0d522c757", "node_type": "1", "metadata": {"window": "During the quarter, we were pleased to see strong execution and continued consistent market \ndynamics in our generics program, including Red Oak.  \n \n As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n", "original_text": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1750928c0c5abdc3c53519bcee16c60a04818f7fb05041f538815afd2c0fae51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e9c5c1-e98f-4e7e-9263-18aee2fae710", "node_type": "1", "metadata": {"window": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n"}, "hash": "245befbddec52e075a2f536c41895a7009541a798994fc81947ce0b9b48cd6b0", "class_name": "RelatedNodeInfo"}}, "text": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n", "start_char_idx": 1653, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e9c5c1-e98f-4e7e-9263-18aee2fae710": {"__data__": {"id_": "85e9c5c1-e98f-4e7e-9263-18aee2fae710", "embedding": null, "metadata": {"window": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec5fc4c0-9d2c-4133-8004-79f280fc02e5", "node_type": "1", "metadata": {"window": "As we\u2019ve pr eviously noted, inflation continues to impact supply chain costs across the industry, \nparticularly within transportation and labor.  We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. ", "original_text": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5c4ba7260bacc149c5c99a9bf5b931aa400ee2450377f6b11ac8090cef02099", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d134be35-91be-4e4b-ae30-008878b38daf", "node_type": "1", "metadata": {"window": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n"}, "hash": "115a731b6ae0e85e8faaba431f40ed73a163eb72b243bb42a9c1f7254a354a0f", "class_name": "RelatedNodeInfo"}}, "text": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n", "start_char_idx": 1896, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d134be35-91be-4e4b-ae30-008878b38daf": {"__data__": {"id_": "d134be35-91be-4e4b-ae30-008878b38daf", "embedding": null, "metadata": {"window": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e9c5c1-e98f-4e7e-9263-18aee2fae710", "node_type": "1", "metadata": {"window": "We saw an approximate $20 million dollar year-over-year \nheadwind from these areas, which was consistent with our expectations.  This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58ebb6d3e161dcb378412c3371e6528372d5a40dafba69f8d115dfa6a501b827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad4897bd-5436-4339-be53-d32f20ea03fe", "node_type": "1", "metadata": {"window": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. "}, "hash": "6f24a43e577114875a1fd20f8854f12b7716e1f61bf8744c5dc448dbb5ae150b", "class_name": "RelatedNodeInfo"}}, "text": "Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n", "start_char_idx": 1996, "end_char_idx": 2198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad4897bd-5436-4339-be53-d32f20ea03fe": {"__data__": {"id_": "ad4897bd-5436-4339-be53-d32f20ea03fe", "embedding": null, "metadata": {"window": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d134be35-91be-4e4b-ae30-008878b38daf", "node_type": "1", "metadata": {"window": "This  headwind was \neffectively offset by year -over-year tailwinds from our completed ERP technology enhancements and \nlower opioid -related legal costs.  \n \n Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aff1f19afba36d9cec4e1812b39b8ad102a2a07b5fb4bc451aa10d84d243389e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4a4b64d-fe1a-4c07-b00c-cb743a287e74", "node_type": "1", "metadata": {"window": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n "}, "hash": "e1131531143945c48e336b6d5182121b550a373e2a277dccef91fe12b374de8d", "class_name": "RelatedNodeInfo"}}, "text": "Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. ", "start_char_idx": 2198, "end_char_idx": 2358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4a4b64d-fe1a-4c07-b00c-cb743a287e74": {"__data__": {"id_": "f4a4b64d-fe1a-4c07-b00c-cb743a287e74", "embedding": null, "metadata": {"window": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cffd3829d150fdf653e4369bee832c774f3b067f310b738e8d95aaeae66c02fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad4897bd-5436-4339-be53-d32f20ea03fe", "node_type": "1", "metadata": {"window": "Okay, turning to Medical on slide 6 \u2026 \n \nFirst-quarter revenue decreased 9 % to $3.8 billion  dollars  driven by lower Products and Distribution \nsales, primarily due to PPE pricing and volumes, and to a lesser extent the Cordis divestiture. \n Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions. ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a53229d94d2c4669fecf3a8677f4d84d2eb20199f6f5b9ec5bdc64024eb088de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "247e6f15-86da-4256-b87f-07e5293fee77", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "original_text": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears. "}, "hash": "12fa86f45d95a06f5e83fddef2f9191fba38cadabc19849db41c5d234f579fe6", "class_name": "RelatedNodeInfo"}}, "text": "This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "start_char_idx": 2358, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "247e6f15-86da-4256-b87f-07e5293fee77": {"__data__": {"id_": "247e6f15-86da-4256-b87f-07e5293fee77", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "original_text": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4a4b64d-fe1a-4c07-b00c-cb743a287e74", "node_type": "1", "metadata": {"window": "Continued strong growth in our at -Home Solutions business offset some of this revenue decline.  \n \n Medical s egment loss of $8 million dollar s was due to net inflationary impacts in Products and \nDistribution as well as a lower contribution from PPE, both of which I will discuss in more detail.  \n \n Importantly, these results reflect approximately $20 millio n dollars in total inventor y charges related to \nour previously -announced simplification actions.  This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "original_text": "This includes the sale of our gloves portfolio that is \nprimarily utilized in non -healthcare industries.   \n ", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "391f89cdcda0c5c554a403c6827707532a1eb2d14cae0e093807f0cbbaea1fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65d0ea34-5eba-4059-abf5-2949c2015f85", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n", "original_text": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n"}, "hash": "5d7cbd47ed5f848f6d1d68bb9591a078e6ce4374653f7b9a1e09ab5942e3741e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears. ", "start_char_idx": 0, "end_char_idx": 128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65d0ea34-5eba-4059-abf5-2949c2015f85": {"__data__": {"id_": "65d0ea34-5eba-4059-abf5-2949c2015f85", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n", "original_text": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "247e6f15-86da-4256-b87f-07e5293fee77", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "original_text": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13ceff7e51b2ef39c77a7dce0024bfba03141ab49512ca83349fe8feed273d0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dd48c65-b2da-41c7-b83a-71df96e4ea47", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment. ", "original_text": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %. "}, "hash": "02faabeda0546999ffefcc376fdeb7de00df2ed12917bd75774cb959f84b407d", "class_name": "RelatedNodeInfo"}}, "text": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n", "start_char_idx": 128, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dd48c65-b2da-41c7-b83a-71df96e4ea47": {"__data__": {"id_": "9dd48c65-b2da-41c7-b83a-71df96e4ea47", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment. ", "original_text": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65d0ea34-5eba-4059-abf5-2949c2015f85", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n", "original_text": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "647e3e3989022197e7bb1587e89cdbfd0bdf7ef5db4b752d552619a04833815e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a293b13-ee8a-4372-beeb-c936fc86ba60", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. ", "original_text": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. "}, "hash": "fd179f1bb7d27f25262df2073ea4554ff27e56211ebae8f6d1b00f1aaa56f9e7", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %. ", "start_char_idx": 306, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a293b13-ee8a-4372-beeb-c936fc86ba60": {"__data__": {"id_": "2a293b13-ee8a-4372-beeb-c936fc86ba60", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. ", "original_text": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dd48c65-b2da-41c7-b83a-71df96e4ea47", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment. ", "original_text": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a03de135a41c59e403c4b8fbe26a8b56b01f4a5a2b566af4ab6abd57afc416f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98c347cf-e956-4ae5-a538-45c93ffa0c8f", "node_type": "1", "metadata": {"window": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. ", "original_text": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n"}, "hash": "6dd29dcfdbb71d226425cf6be277759a11c7229f37de432d9006e3b36019c1d3", "class_name": "RelatedNodeInfo"}}, "text": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "start_char_idx": 561, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98c347cf-e956-4ae5-a538-45c93ffa0c8f": {"__data__": {"id_": "98c347cf-e956-4ae5-a538-45c93ffa0c8f", "embedding": null, "metadata": {"window": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. ", "original_text": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a293b13-ee8a-4372-beeb-c936fc86ba60", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. ", "original_text": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3f1f9fc1ba073cd89f712abbec397aa053f5cd621a11d858af1179db0951ad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1b0ca97-5776-4b7c-8106-e27e01d972ba", "node_type": "1", "metadata": {"window": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n", "original_text": "Now, a quick update on the overall utilization environment. "}, "hash": "2503421e7df93902907e7f18118620d7994c2540bbf5f28a3705e971a7bc319e", "class_name": "RelatedNodeInfo"}}, "text": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n", "start_char_idx": 708, "end_char_idx": 779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1b0ca97-5776-4b7c-8106-e27e01d972ba": {"__data__": {"id_": "d1b0ca97-5776-4b7c-8106-e27e01d972ba", "embedding": null, "metadata": {"window": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n", "original_text": "Now, a quick update on the overall utilization environment. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98c347cf-e956-4ae5-a538-45c93ffa0c8f", "node_type": "1", "metadata": {"window": "These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. ", "original_text": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "192d66f1d1e772a6ca180f51794c16ad7775e834ee1c30336ad183dd74278405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b4a2fa-7f21-47e0-b962-d16e2eb849bb", "node_type": "1", "metadata": {"window": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . ", "original_text": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. "}, "hash": "c23aa377ae03d8d42bcb064f96c425175cb89d842ef261bdc407314168c80217", "class_name": "RelatedNodeInfo"}}, "text": "Now, a quick update on the overall utilization environment. ", "start_char_idx": 779, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19b4a2fa-7f21-47e0-b962-d16e2eb849bb": {"__data__": {"id_": "19b4a2fa-7f21-47e0-b962-d16e2eb849bb", "embedding": null, "metadata": {"window": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . ", "original_text": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1b0ca97-5776-4b7c-8106-e27e01d972ba", "node_type": "1", "metadata": {"window": "During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n", "original_text": "Now, a quick update on the overall utilization environment. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef15d1e2ae926c93c19f0a4c5cdd776bd95b7a391ac5c6de6f3aa7fafa4b7991", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5dd7c53-b8bf-479f-abcb-92df7e0fd629", "node_type": "1", "metadata": {"window": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. ", "original_text": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. "}, "hash": "7feb83014392e265322eafaaed70e4beca42bb77c6ed67ced0cbe4bf7185e9c4", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. ", "start_char_idx": 839, "end_char_idx": 1043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5dd7c53-b8bf-479f-abcb-92df7e0fd629": {"__data__": {"id_": "a5dd7c53-b8bf-479f-abcb-92df7e0fd629", "embedding": null, "metadata": {"window": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. ", "original_text": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b4a2fa-7f21-47e0-b962-d16e2eb849bb", "node_type": "1", "metadata": {"window": "Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July.  Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . ", "original_text": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d8651e4c91d384d8ce56b301137604f840dd7c8f24dff5e45312d5e2748ab72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c53cdb8b-3497-463f-bb6f-0df913379631", "node_type": "1", "metadata": {"window": "Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. ", "original_text": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n"}, "hash": "d91dc4e85f2144fe9c0519fdbb213ddc600304f94893cc148c98c3c3e6227ae1", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. ", "start_char_idx": 1043, "end_char_idx": 1171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c53cdb8b-3497-463f-bb6f-0df913379631": {"__data__": {"id_": "c53cdb8b-3497-463f-bb6f-0df913379631", "embedding": null, "metadata": {"window": "Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. ", "original_text": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5dd7c53-b8bf-479f-abcb-92df7e0fd629", "node_type": "1", "metadata": {"window": "Jason will \nelaborate on our plans for further mitigation shortly.  \n \n Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. ", "original_text": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17fff979df04a4d33310c4c9b522f0a0f9be97ba3a67c9c2b511de028ebee492", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b2d5aba-588b-4430-9a58-e6ee13f18d97", "node_type": "1", "metadata": {"window": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n", "original_text": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . "}, "hash": "71425c3b523f5f639af5c872ec6d1b75435e24b6d40133652700d8545c927889", "class_name": "RelatedNodeInfo"}}, "text": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n", "start_char_idx": 1171, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b2d5aba-588b-4430-9a58-e6ee13f18d97": {"__data__": {"id_": "7b2d5aba-588b-4430-9a58-e6ee13f18d97", "embedding": null, "metadata": {"window": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n", "original_text": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c53cdb8b-3497-463f-bb6f-0df913379631", "node_type": "1", "metadata": {"window": "Now, a quick update on the overall utilization environment.  We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. ", "original_text": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47648b6ff853d9178b4404691d0b7c4688ae24ccceea1a1198c6858b567bd5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d541af51-676c-48bb-8cc3-2abc7b9c547f", "node_type": "1", "metadata": {"window": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n", "original_text": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. "}, "hash": "73fd70c2afaf2e0c2b72053c8f3864e3a3ca57537239da84bf7314b4caf66633", "class_name": "RelatedNodeInfo"}}, "text": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . ", "start_char_idx": 1327, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d541af51-676c-48bb-8cc3-2abc7b9c547f": {"__data__": {"id_": "d541af51-676c-48bb-8cc3-2abc7b9c547f", "embedding": null, "metadata": {"window": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n", "original_text": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b2d5aba-588b-4430-9a58-e6ee13f18d97", "node_type": "1", "metadata": {"window": "We\u2019ve previously noted some overall \nvolume softness in o ur Products and Distribution business, including a lower demand for PPE, which \nwe believe primarily reflects customers\u2019 higher inventory levels.  In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n", "original_text": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars . ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f90d67b5675d7f5bd0c2b022591ddccc35df53f27c73fc4767cf199fa8baa699", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a332841-fdc3-4495-868b-c6cc5df1fcd5", "node_type": "1", "metadata": {"window": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. ", "original_text": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. "}, "hash": "cf0c3ae44f7c48bcd1051728a7430d063641f9849e03e3fa74937b2173048ef5", "class_name": "RelatedNodeInfo"}}, "text": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. ", "start_char_idx": 1460, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a332841-fdc3-4495-868b-c6cc5df1fcd5": {"__data__": {"id_": "5a332841-fdc3-4495-868b-c6cc5df1fcd5", "embedding": null, "metadata": {"window": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. ", "original_text": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d541af51-676c-48bb-8cc3-2abc7b9c547f", "node_type": "1", "metadata": {"window": "In the first quarter, we saw generally \nconsistent overall Products and Distribution volumes sequentially, inclu ding with PPE.  While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n", "original_text": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc515381717dbae32f5700cdd49a92fc0000cd88b357d4671fb3ae896b881c20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb952270-1aff-42ab-875d-dcbc8b882736", "node_type": "1", "metadata": {"window": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n", "original_text": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n"}, "hash": "ff59cb4f70b36fa9ec1812117102f1fa5e6204eb40b127ce0c8c55834d713436", "class_name": "RelatedNodeInfo"}}, "text": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. ", "start_char_idx": 1640, "end_char_idx": 1843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb952270-1aff-42ab-875d-dcbc8b882736": {"__data__": {"id_": "cb952270-1aff-42ab-875d-dcbc8b882736", "embedding": null, "metadata": {"window": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n", "original_text": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a332841-fdc3-4495-868b-c6cc5df1fcd5", "node_type": "1", "metadata": {"window": "While we do \nanticipate gradual improvement in volumes relative to these recent lows, we continue to expect \nchoppiness in demand levels going forward.  \n \n Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. ", "original_text": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ccc10e94dbc42f88d966b41f16c2d2ac0fa228107e812f53311b3f6f293c1eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a97e93d3-027e-4ba2-acce-be2a79657014", "node_type": "1", "metadata": {"window": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. ", "original_text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n"}, "hash": "67ca4a9dd14f7f3e5aea5a0eb2f5c3e1e9474fb6b742f693a249375eb517daec", "class_name": "RelatedNodeInfo"}}, "text": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n", "start_char_idx": 1843, "end_char_idx": 1993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a97e93d3-027e-4ba2-acce-be2a79657014": {"__data__": {"id_": "a97e93d3-027e-4ba2-acce-be2a79657014", "embedding": null, "metadata": {"window": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. ", "original_text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb952270-1aff-42ab-875d-dcbc8b882736", "node_type": "1", "metadata": {"window": "Now, for our fiscal \u201823 outlook, beginning on slide 8 \u2026 \n \nWe are reiterating our EPS guidance of $5.05  dollars to $5.40  dollars .  This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n", "original_text": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a95642f6c3e6b47ee55ae73bd45e528e2fa0e41971fe6a13f2422fd07a4e5ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6fa57f3-69c1-442e-b636-36ccf1a08904", "node_type": "1", "metadata": {"window": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n", "original_text": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. "}, "hash": "512e8e907b524163b71f65cbc4375ea084667278104dbfccf102d39a1c58aa67", "class_name": "RelatedNodeInfo"}}, "text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n", "start_char_idx": 1993, "end_char_idx": 2074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6fa57f3-69c1-442e-b636-36ccf1a08904": {"__data__": {"id_": "c6fa57f3-69c1-442e-b636-36ccf1a08904", "embedding": null, "metadata": {"window": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n", "original_text": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a97e93d3-027e-4ba2-acce-be2a79657014", "node_type": "1", "metadata": {"window": "This includes our updated \nMedical Segment outlook, which has been adjusted for the impact of simplification actions in the first \nquarter, and a few below -the-line improvements.  Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. ", "original_text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def0fc9b63bfea2ed9b50f502fa89cb81d5bdc7e7a827513d63935f7f5b5b790", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7528849-0e07-4ba9-afd1-d2525d3fbae0", "node_type": "1", "metadata": {"window": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n", "original_text": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n"}, "hash": "d82cad5fc588350bfac68d9e6b71e32968677d1fc4b53bd0d0cf882a5a766e60", "class_name": "RelatedNodeInfo"}}, "text": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. ", "start_char_idx": 2074, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7528849-0e07-4ba9-afd1-d2525d3fbae0": {"__data__": {"id_": "c7528849-0e07-4ba9-afd1-d2525d3fbae0", "embedding": null, "metadata": {"window": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n", "original_text": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6fa57f3-69c1-442e-b636-36ccf1a08904", "node_type": "1", "metadata": {"window": "Based on the first quart er performance, we are \nconfident in lowering the top end of the ranges for Interest and Other, our Effective Tax Rate, and \ndiluted weighted average shares for the fiscal year.  We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n", "original_text": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44d1ed5d2d366827e84bca7d92c2539c15ed297f51c20b70522a897f5cf3bed9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "088258af-f9c5-4c7c-97dd-242a7c60af78", "node_type": "1", "metadata": {"window": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. ", "original_text": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. "}, "hash": "3bb76d8f170b6b81d65ce7ebf5db59237066834cdb44cdbc88cc520a7f2c5b30", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n", "start_char_idx": 2163, "end_char_idx": 2288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "088258af-f9c5-4c7c-97dd-242a7c60af78": {"__data__": {"id_": "088258af-f9c5-4c7c-97dd-242a7c60af78", "embedding": null, "metadata": {"window": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. ", "original_text": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7528849-0e07-4ba9-afd1-d2525d3fbae0", "node_type": "1", "metadata": {"window": "We now expect I&O in the range of $140 to $160 \nmillion  dollars , an ETR between 23 % and 2 4%, and diluted shares between $262 to $264 million.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n", "original_text": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9362791c1643570c797787099903a8e4826daf1ac4c853ee53ef12fd766981b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9030a6dd-34fe-455a-a4cb-5bff2554e42b", "node_type": "1", "metadata": {"window": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n"}, "hash": "fd2bba83f6aeba0b5c9d98b3dd6366dd55ed3cc7a9578740d2bed36551ef5755", "class_name": "RelatedNodeInfo"}}, "text": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. ", "start_char_idx": 2288, "end_char_idx": 2520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9030a6dd-34fe-455a-a4cb-5bff2554e42b": {"__data__": {"id_": "9030a6dd-34fe-455a-a4cb-5bff2554e42b", "embedding": null, "metadata": {"window": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "088258af-f9c5-4c7c-97dd-242a7c60af78", "node_type": "1", "metadata": {"window": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n \n We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. ", "original_text": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32349449d407ac8beb4fa493a82c1994776582ce0d3e58b89cbbfb795674e704", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f459b2b6-c821-4c58-b0ea-d7012235d780", "node_type": "1", "metadata": {"window": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n"}, "hash": "b7069c1fbdfef54f2a0029d3aad2e39e1f866e52c4b5b6a6bae0e1b29c221b85", "class_name": "RelatedNodeInfo"}}, "text": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n", "start_char_idx": 2520, "end_char_idx": 2636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f459b2b6-c821-4c58-b0ea-d7012235d780": {"__data__": {"id_": "f459b2b6-c821-4c58-b0ea-d7012235d780", "embedding": null, "metadata": {"window": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9030a6dd-34fe-455a-a4cb-5bff2554e42b", "node_type": "1", "metadata": {"window": "We are also reiterating our fiscal \u201823 outlook for the Pharma  segment, seen on slide 9.  We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "073b3220fcedaf990bb13b5382b76f9739fbf855cbc2ae5b6d4be2d9d2f8d911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b92fb9e7-16ac-4215-a400-6990be756464", "node_type": "1", "metadata": {"window": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. "}, "hash": "0a71d72664b9759123b113565c356faa85fe7fab5c7e8396c3214baa7a17ea2d", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n", "start_char_idx": 2636, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b92fb9e7-16ac-4215-a400-6990be756464": {"__data__": {"id_": "b92fb9e7-16ac-4215-a400-6990be756464", "embedding": null, "metadata": {"window": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f459b2b6-c821-4c58-b0ea-d7012235d780", "node_type": "1", "metadata": {"window": "We continue to \nexpect revenue growt h in the range of 10 % to 14 % and segment profit growth in the range of 2 % to \n5%. \n \n Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9493479dc2eb24611d1f2e1c1bad882ce6b64739873f4f2469c4ff244d07ebfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c61e903c-4521-4c84-9bb6-b8f448e39486", "node_type": "1", "metadata": {"window": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain "}, "hash": "7daefabe1ed8c1d084e02b5e493e160a5953b0c280dbcf0800953a8819a86f7a", "class_name": "RelatedNodeInfo"}}, "text": "With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. ", "start_char_idx": 2821, "end_char_idx": 3012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c61e903c-4521-4c84-9bb6-b8f448e39486": {"__data__": {"id_": "c61e903c-4521-4c84-9bb6-b8f448e39486", "embedding": null, "metadata": {"window": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf35e9f0a8dcf04b9e2c93ef72a31558b1368d3d1fd37b2f191ff3121963735", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b92fb9e7-16ac-4215-a400-6990be756464", "node_type": "1", "metadata": {"window": "Before transitioning to Medical, two key call -outs on the Pharma  cadence:  \n \nFirst, with a stronger start to the year, we now expect more balanced year -over-year profit growth \nbetween the first and second halves of fiscal \u201823.  And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0800c3dbcf098e629bb37fb87db31a4ee40b51e325236bf3e655ec37cfb17ec5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d5b0871-1381-42d9-bb3b-3798bc120c9f", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "original_text": " \nPage 5 of 14 \n \nsignificantly elevated. "}, "hash": "fee7f88d155b0cc4b1c86c963664ac4c25c5a8160c8916740b2ca7a16f3c7056", "class_name": "RelatedNodeInfo"}}, "text": "The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "start_char_idx": 3012, "end_char_idx": 3213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d5b0871-1381-42d9-bb3b-3798bc120c9f": {"__data__": {"id_": "5d5b0871-1381-42d9-bb3b-3798bc120c9f", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "original_text": " \nPage 5 of 14 \n \nsignificantly elevated. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c61e903c-4521-4c84-9bb6-b8f448e39486", "node_type": "1", "metadata": {"window": "And, specifically for the second quarter, we expect \nsegment profit dollars to be similar to the first quarter.  \n \n Turning to Medical , we expect segment profit ranging from flat to a decline of  20%, which as I \nindicated, reflects the impact of the simplification actions in the first quarter.  \n \n With respect to inflation and our mitigation actions, there is no change to our expectation of a net \nimpact of approximately $300 million in fiscal \u201823, or a minimal yea r-over-year impact.  The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "original_text": "The macro -\neconomic environment remains dynamic, and while we\u2019ve seen some decreases in spot rates of \ncertain cost drivers such as international freight, other areas, such as commodity costs, remain ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0b076ad8f1c90f00898e708860ab6c265accb24c9029a02ffb6e24a4148bdf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ef26e2c-dfa8-446e-8a63-7ce97f736875", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. ", "original_text": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay. "}, "hash": "9a4672701c546bfce789069dd3dd37be9628808dfd7a3927737a3f09055b8000", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 14 \n \nsignificantly elevated. ", "start_char_idx": 0, "end_char_idx": 42, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ef26e2c-dfa8-446e-8a63-7ce97f736875": {"__data__": {"id_": "5ef26e2c-dfa8-446e-8a63-7ce97f736875", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. ", "original_text": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d5b0871-1381-42d9-bb3b-3798bc120c9f", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "original_text": " \nPage 5 of 14 \n \nsignificantly elevated. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a51c426e16bea86a4fc94fdc2e3ca00cf888d30d45143c03588d5dc6872b53fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19039780-9c53-4969-be1f-2beaef7f63c7", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. ", "original_text": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures. "}, "hash": "2551b0d3bc4be5983b024e0a1f4a3180184cbb18c65a84ad4bc745f01d423332", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay. ", "start_char_idx": 42, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19039780-9c53-4969-be1f-2beaef7f63c7": {"__data__": {"id_": "19039780-9c53-4969-be1f-2beaef7f63c7", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. ", "original_text": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ef26e2c-dfa8-446e-8a63-7ce97f736875", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. ", "original_text": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0590a4310e08abda5710c61de099bf34e4fb21905b00158fa80e3b2644da67af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaf89700-0758-4d8f-b4ef-7efc7c86ebfe", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n", "original_text": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n"}, "hash": "7740cf5de3b2afdf353a45b2f53c8cb217ac4bd4b8968bd42f1a49244f7502cf", "class_name": "RelatedNodeInfo"}}, "text": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures. ", "start_char_idx": 238, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaf89700-0758-4d8f-b4ef-7efc7c86ebfe": {"__data__": {"id_": "aaf89700-0758-4d8f-b4ef-7efc7c86ebfe", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n", "original_text": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19039780-9c53-4969-be1f-2beaef7f63c7", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. ", "original_text": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a99aa55ed749d2ae41c67f354a6512a0367044ae8097f04eac6d5c4e16eb271a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098edc09-2a8e-4319-9b3f-5c0982accedf", "node_type": "1", "metadata": {"window": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n", "original_text": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. "}, "hash": "b3d23e67a60510cdc89978e0bad1612d85f5d223978920126ad9d5233976968b", "class_name": "RelatedNodeInfo"}}, "text": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "start_char_idx": 429, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098edc09-2a8e-4319-9b3f-5c0982accedf": {"__data__": {"id_": "098edc09-2a8e-4319-9b3f-5c0982accedf", "embedding": null, "metadata": {"window": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n", "original_text": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaf89700-0758-4d8f-b4ef-7efc7c86ebfe", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n", "original_text": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19be3f77ea176c466e81a4a997decab974debd02a551157c1a0a995f8137d7d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af03e13e-0ede-46ec-8fff-115ad15f7ab4", "node_type": "1", "metadata": {"window": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n", "original_text": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. "}, "hash": "02bfd420795940fa636bef225f17c8ac0f424f345add094a59a5ec3887564c79", "class_name": "RelatedNodeInfo"}}, "text": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. ", "start_char_idx": 612, "end_char_idx": 785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af03e13e-0ede-46ec-8fff-115ad15f7ab4": {"__data__": {"id_": "af03e13e-0ede-46ec-8fff-115ad15f7ab4", "embedding": null, "metadata": {"window": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n", "original_text": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098edc09-2a8e-4319-9b3f-5c0982accedf", "node_type": "1", "metadata": {"window": "As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n", "original_text": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26fc2e8a59b52141d97b3bfbc0fa588b97c065d086b5daffdc44b386ad61e164", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c8c826d-0f4c-4f52-80ab-63b1dc76b872", "node_type": "1", "metadata": {"window": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. ", "original_text": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n"}, "hash": "eb42a6a598ab17785d142986b95fa63b1e108a249834a4e48e769398d9e7f4cb", "class_name": "RelatedNodeInfo"}}, "text": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. ", "start_char_idx": 785, "end_char_idx": 959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c8c826d-0f4c-4f52-80ab-63b1dc76b872": {"__data__": {"id_": "8c8c826d-0f4c-4f52-80ab-63b1dc76b872", "embedding": null, "metadata": {"window": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. ", "original_text": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af03e13e-0ede-46ec-8fff-115ad15f7ab4", "node_type": "1", "metadata": {"window": "While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n", "original_text": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2573c2bcf662857f50171884de7adb8f3724db3f221df411a0327c632d97dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd52e18-a932-4fb1-8680-ab20ae00d598", "node_type": "1", "metadata": {"window": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. ", "original_text": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n"}, "hash": "5852c627b9f64bcd9fda4a9641c9fc59731734ae89139faa7a4ce2bd4caa1011", "class_name": "RelatedNodeInfo"}}, "text": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n", "start_char_idx": 959, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd52e18-a932-4fb1-8680-ab20ae00d598": {"__data__": {"id_": "6bd52e18-a932-4fb1-8680-ab20ae00d598", "embedding": null, "metadata": {"window": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. ", "original_text": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c8c826d-0f4c-4f52-80ab-63b1dc76b872", "node_type": "1", "metadata": {"window": "It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. ", "original_text": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e558e81027776f6880403f5e60d8cf05ddb54d00b08a472798c004e5c404dacc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c76627-6aa7-4662-b700-9a035ce97629", "node_type": "1", "metadata": {"window": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n", "original_text": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n"}, "hash": "1cee2bb1ec86290220b52fe4ef5c434fb399428c2896f597a5f23b878df6eace", "class_name": "RelatedNodeInfo"}}, "text": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n", "start_char_idx": 1064, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c76627-6aa7-4662-b700-9a035ce97629": {"__data__": {"id_": "a8c76627-6aa7-4662-b700-9a035ce97629", "embedding": null, "metadata": {"window": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n", "original_text": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd52e18-a932-4fb1-8680-ab20ae00d598", "node_type": "1", "metadata": {"window": "On Medical\u2019s quarterly cadence \u2026 \n \nIn Q2 we expect similar segment profit dollars as the first quarter, excluding the impact of the first -\nquarter simplification actions.  As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. ", "original_text": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d582affcb2117643b540d9954c807d5dd7381bca5608ad56571fc417281dd655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e882f0e4-298f-4598-b4c9-e19391b47e7c", "node_type": "1", "metadata": {"window": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. ", "original_text": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. "}, "hash": "7436df9f5082b682c8b759deaa0dc1d15b65c12c347761b29e2d5e3d8a7aeddd", "class_name": "RelatedNodeInfo"}}, "text": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n", "start_char_idx": 1146, "end_char_idx": 1374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e882f0e4-298f-4598-b4c9-e19391b47e7c": {"__data__": {"id_": "e882f0e4-298f-4598-b4c9-e19391b47e7c", "embedding": null, "metadata": {"window": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. ", "original_text": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c76627-6aa7-4662-b700-9a035ce97629", "node_type": "1", "metadata": {"window": "As we have noted before, we continue to expect the substa ntial majority \nof segment profit to come in the second half of fiscal \u201823, and particularly in the fourth quarter.  This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n", "original_text": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc25a83ad7f23e1d330c6bab51c0782bb9ae0a83a5fd527260cf4f136a2e0520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2036cfaa-6705-42fa-a3d1-3a9f00358e13", "node_type": "1", "metadata": {"window": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  ", "original_text": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. "}, "hash": "b4350a5aa572633209b2d15b37c52194c8eeecc7d1f4c2f081465f9c90896712", "class_name": "RelatedNodeInfo"}}, "text": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. ", "start_char_idx": 1374, "end_char_idx": 1545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2036cfaa-6705-42fa-a3d1-3a9f00358e13": {"__data__": {"id_": "2036cfaa-6705-42fa-a3d1-3a9f00358e13", "embedding": null, "metadata": {"window": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  ", "original_text": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e882f0e4-298f-4598-b4c9-e19391b47e7c", "node_type": "1", "metadata": {"window": "This \nsequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE.  \n \n With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. ", "original_text": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81707133c14263792fc33d57d325f11fe93d6f6d62253e4e6eead84cac1fb2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f1fc6e4-eb30-4bdf-af9e-45f97f6e14ff", "node_type": "1", "metadata": {"window": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  ", "original_text": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n"}, "hash": "fe63947d8ea84ca9cb62aa2142412c8d0af88ec02bfa38d63a0c83ae3edc00ac", "class_name": "RelatedNodeInfo"}}, "text": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. ", "start_char_idx": 1545, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f1fc6e4-eb30-4bdf-af9e-45f97f6e14ff": {"__data__": {"id_": "0f1fc6e4-eb30-4bdf-af9e-45f97f6e14ff", "embedding": null, "metadata": {"window": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  ", "original_text": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2036cfaa-6705-42fa-a3d1-3a9f00358e13", "node_type": "1", "metadata": {"window": "With that, I\u2019ll now turn it over to Jaso n. \n \nJason Hollar :   Thanks Trish.  \n \n I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  ", "original_text": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46371b587800c3cad2d289d3369cfd9ab91ba6a4bf6421625dbd1ffe03c56a4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48814efd-6010-4515-aab6-d81642da92af", "node_type": "1", "metadata": {"window": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n", "original_text": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. "}, "hash": "8034315f931934a777d595032d592c4ddf01249a35eb85138f1b9375d0fd4eed", "class_name": "RelatedNodeInfo"}}, "text": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n", "start_char_idx": 1735, "end_char_idx": 1919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48814efd-6010-4515-aab6-d81642da92af": {"__data__": {"id_": "48814efd-6010-4515-aab6-d81642da92af", "embedding": null, "metadata": {"window": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n", "original_text": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f1fc6e4-eb30-4bdf-af9e-45f97f6e14ff", "node_type": "1", "metadata": {"window": "I concluded our August earnings call with 3 key takeaways that I\u2019d like to provide updates o n. \n \nNumber one :  Improving the underlying performance of the Medical segment through our Medical \nImprovement Plan initiatives.  \n \n The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  ", "original_text": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4c060d6e2e8a61c15f50eb58b021f240047932d2328e95ac62926a654bb30e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4d7685d-2188-462b-aa6a-94e417648253", "node_type": "1", "metadata": {"window": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. ", "original_text": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  "}, "hash": "f47731f74fbde7da29f472766696dfd83b491941556fc9ed6e48c297d7596524", "class_name": "RelatedNodeInfo"}}, "text": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. ", "start_char_idx": 1919, "end_char_idx": 2049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4d7685d-2188-462b-aa6a-94e417648253": {"__data__": {"id_": "c4d7685d-2188-462b-aa6a-94e417648253", "embedding": null, "metadata": {"window": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. ", "original_text": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48814efd-6010-4515-aab6-d81642da92af", "node_type": "1", "metadata": {"window": "The key driver to achieving our segment profit target of at least $650 million by fiscal \u201825 is our \nmitigation actions for inflation and global supply chain constraints.  Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n", "original_text": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b243dc6ecee4788321660dc6f9fde4cc922c55a41403326dfd771515da891e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9130aa79-47ee-4f84-a7eb-d30296815f69", "node_type": "1", "metadata": {"window": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n", "original_text": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  "}, "hash": "fe46f69b9cfeab6fafd0e70e9f0e21af818c967af759e669fe38ab6220fd0db5", "class_name": "RelatedNodeInfo"}}, "text": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  ", "start_char_idx": 2049, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9130aa79-47ee-4f84-a7eb-d30296815f69": {"__data__": {"id_": "9130aa79-47ee-4f84-a7eb-d30296815f69", "embedding": null, "metadata": {"window": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n", "original_text": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4d7685d-2188-462b-aa6a-94e417648253", "node_type": "1", "metadata": {"window": "Though elevated inflation has \npersisted in the macro environment for lon ger than expected, we are on track to exit fiscal \u201823 \noffsetting at least 50% of the gross impact on our business.  As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. ", "original_text": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.  ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5db5361135f66b16e20151bcd1a503e3d1473f062c1791fcd6d21d3fd4b4a602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "143bbc86-2e8f-4f42-9af3-b1001ac395b1", "node_type": "1", "metadata": {"window": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  ", "original_text": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n"}, "hash": "75a31b1084918f7ca33e3474efdfa20d9cb82e4f124b93651403960b381dec5d", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  ", "start_char_idx": 2170, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "143bbc86-2e8f-4f42-9af3-b1001ac395b1": {"__data__": {"id_": "143bbc86-2e8f-4f42-9af3-b1001ac395b1", "embedding": null, "metadata": {"window": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  ", "original_text": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9130aa79-47ee-4f84-a7eb-d30296815f69", "node_type": "1", "metadata": {"window": "As I\u2019ve previously mentioned, we plan to \nfully address the impact of inflation and global supply chain constraints through mitigation initiat ives \nby the time we exit fiscal \u201824. \n \n Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n", "original_text": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.  ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40d1694a80b18e9399c8ae4ad4f3b97e3ae0057afb8290cad95c93f4f4a82624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d11cb7-2b78-491c-91ba-b61451f40a77", "node_type": "1", "metadata": {"window": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. "}, "hash": "042f4363fbe466b5b44dc91df8843b8bb3db98802c8bd800db53bb2af517c5c3", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n", "start_char_idx": 2345, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d11cb7-2b78-491c-91ba-b61451f40a77": {"__data__": {"id_": "81d11cb7-2b78-491c-91ba-b61451f40a77", "embedding": null, "metadata": {"window": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "143bbc86-2e8f-4f42-9af3-b1001ac395b1", "node_type": "1", "metadata": {"window": "Our third wave of price increases went into effect on October 1st, and we are planning additional \nactions for the third quarter.  To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  ", "original_text": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd721fb4c53a3addc775d0ec4df5eb335fa81f559e44470a1d768f2372c233d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f117879-6895-4f16-8878-b8b698754877", "node_type": "1", "metadata": {"window": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n"}, "hash": "9e169cc76ea9934782a0be22a94cba3c2988b198eb4a8e67d9e41d3a9dc53ae3", "class_name": "RelatedNodeInfo"}}, "text": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. ", "start_char_idx": 2531, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f117879-6895-4f16-8878-b8b698754877": {"__data__": {"id_": "4f117879-6895-4f16-8878-b8b698754877", "embedding": null, "metadata": {"window": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d11cb7-2b78-491c-91ba-b61451f40a77", "node_type": "1", "metadata": {"window": "To date, we have adjusted product categories representing nearly 90% of \nUS Cardinal Health Brand sales, excluding PPE.   Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8a02995341d7e4032a3a93b50450556093091260c417779482c047364b7f23a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9b2f28b-abf8-4fac-a679-0288295b588a", "node_type": "1", "metadata": {"window": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  "}, "hash": "9b012207460eef7275e343c24fea3162d8d9c0f3621019d3b3658625f010272f", "class_name": "RelatedNodeInfo"}}, "text": "This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n", "start_char_idx": 2705, "end_char_idx": 2835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9b2f28b-abf8-4fac-a679-0288295b588a": {"__data__": {"id_": "a9b2f28b-abf8-4fac-a679-0288295b588a", "embedding": null, "metadata": {"window": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f117879-6895-4f16-8878-b8b698754877", "node_type": "1", "metadata": {"window": "Additionally, we\u2019ve successfully adjusted language \nin product contracts as they\u2019ve renewed to allow for greater pricing flexibility to respond to macro -\neconomic dynamics.   We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "237479ff0e0fb0ab38c93177f0cf5c3e114caf08e253ed5c037770172e95bd77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15ef6ca7-914a-43a0-9c3a-9b2b0efb93a0", "node_type": "1", "metadata": {"window": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   "}, "hash": "20cb2c07c4ad291ee4a426ab11ef054347fcfe60477645b0bd6c32416aadc76e", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  ", "start_char_idx": 2835, "end_char_idx": 3030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15ef6ca7-914a-43a0-9c3a-9b2b0efb93a0": {"__data__": {"id_": "15ef6ca7-914a-43a0-9c3a-9b2b0efb93a0", "embedding": null, "metadata": {"window": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6d59db2e009fc8f6e730b9e9c393f49fa7de81a01bfd7bf542f5a85f735fad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9b2f28b-abf8-4fac-a679-0288295b588a", "node_type": "1", "metadata": {"window": "We\u2019ve also executed distribution fee incr eases to offset higher transportation, \nlabor and fuel costs, and continue to explore other opportunities for further offsets with urgency.  \n \n Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.  ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7662b7a004f312e33d3e13fd26c59cfe09891392c72db66a87c55e20ee310742", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "805fd641-3afb-40a3-9a4e-99f8a09a7120", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "original_text": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n"}, "hash": "ef1407688f59f9388c9eb70e95aae20a5fa3597b3392aa9933030c6809ed4d4d", "class_name": "RelatedNodeInfo"}}, "text": "The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "start_char_idx": 3030, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "805fd641-3afb-40a3-9a4e-99f8a09a7120": {"__data__": {"id_": "805fd641-3afb-40a3-9a4e-99f8a09a7120", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "original_text": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15ef6ca7-914a-43a0-9c3a-9b2b0efb93a0", "node_type": "1", "metadata": {"window": "Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to \noptimize and  grow our $4.6 billion Cardinal Health Brand portfolio.  This will be achieved through new \nproduct innovation and increased product availability as a result of targeted investments.  \n \n Additionally, I am confident in our ability to optimize our cost structur e and our sourcing and \nmanufacturing footprints as we focus on driving simplification across the Medical organization.   The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "original_text": "The \nteam is energized by the goals we have laid out in the Medical Improvement Plan and has already hit \nthe ground running on execution.   ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fe802a70f5f41ec1794fc3c167cf969c7422c2a2bc2a6a62fc139194d446189", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03854e7f-446b-4071-a003-76c1ec07b820", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. ", "original_text": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment. "}, "hash": "18c5a4d79b776a392d072928577d4a8f308dfd0cc8ad830786aebc96c8f6b976", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n", "start_char_idx": 0, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03854e7f-446b-4071-a003-76c1ec07b820": {"__data__": {"id_": "03854e7f-446b-4071-a003-76c1ec07b820", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. ", "original_text": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "805fd641-3afb-40a3-9a4e-99f8a09a7120", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "original_text": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "950fdc5709a2d76be39d33202cba2823118e9ec3430a7766d2b4cd1c06cf4297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6740b4cc-e709-4858-baf5-196da7742213", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n", "original_text": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n"}, "hash": "d48f38759a6242c5b3b531c6f05382402a476c1da2a3f2699c2439a164bb41dd", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment. ", "start_char_idx": 230, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6740b4cc-e709-4858-baf5-196da7742213": {"__data__": {"id_": "6740b4cc-e709-4858-baf5-196da7742213", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n", "original_text": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03854e7f-446b-4071-a003-76c1ec07b820", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. ", "original_text": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da85e44eb1b749ea4bcdd9eb70173aae8b1962c43e1b8b3d13ea43ea6e35b833", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48871490-f1ac-419f-9677-ea1d14e328cb", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. ", "original_text": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. "}, "hash": "d7032e0d9e29c2c828491318f999120365635950ad405ca201633cd249e86fb1", "class_name": "RelatedNodeInfo"}}, "text": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n", "start_char_idx": 364, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48871490-f1ac-419f-9677-ea1d14e328cb": {"__data__": {"id_": "48871490-f1ac-419f-9677-ea1d14e328cb", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. ", "original_text": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6740b4cc-e709-4858-baf5-196da7742213", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n", "original_text": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f449b461cbe0d7da0aa299f2e39e73009a88ff01e98fc7951a17ff92a4575b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed650193-7112-4e11-83dd-9ca4b5cba20f", "node_type": "1", "metadata": {"window": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. ", "original_text": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. "}, "hash": "bd5f78e5044a56dc0f12b5e9fa06a93f6ba2f7e9656c73ea2d6a76ec0a3fa588", "class_name": "RelatedNodeInfo"}}, "text": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "start_char_idx": 593, "end_char_idx": 827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed650193-7112-4e11-83dd-9ca4b5cba20f": {"__data__": {"id_": "ed650193-7112-4e11-83dd-9ca4b5cba20f", "embedding": null, "metadata": {"window": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. ", "original_text": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48871490-f1ac-419f-9677-ea1d14e328cb", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. ", "original_text": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26af5a92d66eb1cb19f197c979a974e520aada98e659b55f646c053e77f72625", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bc7cca7-dd98-4d3b-8d8e-70f7b58e98bb", "node_type": "1", "metadata": {"window": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. ", "original_text": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n"}, "hash": "b1cd14529c0cf4617f43febaaa4779fee7e75c5c20d0d3041fecb4057504fa19", "class_name": "RelatedNodeInfo"}}, "text": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. ", "start_char_idx": 827, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bc7cca7-dd98-4d3b-8d8e-70f7b58e98bb": {"__data__": {"id_": "9bc7cca7-dd98-4d3b-8d8e-70f7b58e98bb", "embedding": null, "metadata": {"window": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. ", "original_text": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed650193-7112-4e11-83dd-9ca4b5cba20f", "node_type": "1", "metadata": {"window": "Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. ", "original_text": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "260b1cfbff7145eb7aa2b99d2a0783cae99aedebb12094f8b20c92a8441b80be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dfb2a3b-6c2d-4fe4-ae13-22aacc571005", "node_type": "1", "metadata": {"window": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n", "original_text": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. "}, "hash": "42784141df96ad6bd68beb2531ae05c7b4dea800520993cea02987f4bae37304", "class_name": "RelatedNodeInfo"}}, "text": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n", "start_char_idx": 1147, "end_char_idx": 1246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dfb2a3b-6c2d-4fe4-ae13-22aacc571005": {"__data__": {"id_": "8dfb2a3b-6c2d-4fe4-ae13-22aacc571005", "embedding": null, "metadata": {"window": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n", "original_text": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bc7cca7-dd98-4d3b-8d8e-70f7b58e98bb", "node_type": "1", "metadata": {"window": "Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. ", "original_text": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b717dc3ee1f5e58b8607e5b604d9fd16fe7a7eb9bc79f116c3a78e0e36361177", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd1f58b2-fc73-45d5-89a2-4cc4650092a8", "node_type": "1", "metadata": {"window": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. ", "original_text": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. "}, "hash": "fb727f2e7b81fe230f374bdd99784c2b1da931b0c72bf94e529a9f93321d2228", "class_name": "RelatedNodeInfo"}}, "text": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. ", "start_char_idx": 1246, "end_char_idx": 1420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd1f58b2-fc73-45d5-89a2-4cc4650092a8": {"__data__": {"id_": "fd1f58b2-fc73-45d5-89a2-4cc4650092a8", "embedding": null, "metadata": {"window": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. ", "original_text": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dfb2a3b-6c2d-4fe4-ae13-22aacc571005", "node_type": "1", "metadata": {"window": "Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us.  These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n", "original_text": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e62b8e7a79977b0aeee7aac7067ae9abb7d401835947bf298f97970c9808cbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "968253e0-c3d4-465a-bc07-5995df65972d", "node_type": "1", "metadata": {"window": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n", "original_text": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. "}, "hash": "afe81c9d36197869bc53c620c63295140333d1ee30eb336084fce25d9e94507d", "class_name": "RelatedNodeInfo"}}, "text": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. ", "start_char_idx": 1420, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "968253e0-c3d4-465a-bc07-5995df65972d": {"__data__": {"id_": "968253e0-c3d4-465a-bc07-5995df65972d", "embedding": null, "metadata": {"window": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n", "original_text": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd1f58b2-fc73-45d5-89a2-4cc4650092a8", "node_type": "1", "metadata": {"window": "These changes are intended to maximize the strength of \nour Pharmaceutical  Distribution and Specialty businesses, bringing together similar services under \none team, enabling us to respond faster and more effectively to changes in the healthcare landscape \nwhile keeping the customer at the center of everything we do.  Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. ", "original_text": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11406eb05c4ddcc372598a394063315cac520c54a3b2a1ff4becc4aa7c263a0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc766f33-10b3-4466-b0fb-2c6db9d8b6cd", "node_type": "1", "metadata": {"window": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. ", "original_text": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n"}, "hash": "db9d8df7c0b7cb3c15b39aa6f52b44f96632c3547fd4098e9a6576d62254c133", "class_name": "RelatedNodeInfo"}}, "text": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. ", "start_char_idx": 1645, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc766f33-10b3-4466-b0fb-2c6db9d8b6cd": {"__data__": {"id_": "dc766f33-10b3-4466-b0fb-2c6db9d8b6cd", "embedding": null, "metadata": {"window": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. ", "original_text": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "968253e0-c3d4-465a-bc07-5995df65972d", "node_type": "1", "metadata": {"window": "Simply, it is allowing us to reposition \nwith both the right talent and organizational design.  \n \n In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n", "original_text": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53e6a79556346541934a87b39993662bb43bc2a1a19d5dc68d95769db91745af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "398cae81-4b01-46d7-ad0e-07661f85b7d9", "node_type": "1", "metadata": {"window": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n", "original_text": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. "}, "hash": "a3e4bbd2c0ee64002fcf98fa4dfd0350373592d023308ab06e1f8815727a3d6b", "class_name": "RelatedNodeInfo"}}, "text": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n", "start_char_idx": 1875, "end_char_idx": 2042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "398cae81-4b01-46d7-ad0e-07661f85b7d9": {"__data__": {"id_": "398cae81-4b01-46d7-ad0e-07661f85b7d9", "embedding": null, "metadata": {"window": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n", "original_text": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc766f33-10b3-4466-b0fb-2c6db9d8b6cd", "node_type": "1", "metadata": {"window": "In Specialty, we  have a robust service offering both downstream with provi ders and upstream with \nbioPharma  manufacturers, and we continue to build upon our capabilities.  In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. ", "original_text": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92c398e9c4a48687139f1203700f6fd924138bc60924a62450c61b41e65addda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b30a55b9-b546-4f31-989e-52f9030b8b72", "node_type": "1", "metadata": {"window": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation. ", "original_text": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n"}, "hash": "b6dde9ff7b5425fe1b468ddbf274e374bd8ebdeb12048d0d7aef72ea642988b4", "class_name": "RelatedNodeInfo"}}, "text": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. ", "start_char_idx": 2042, "end_char_idx": 2225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b30a55b9-b546-4f31-989e-52f9030b8b72": {"__data__": {"id_": "b30a55b9-b546-4f31-989e-52f9030b8b72", "embedding": null, "metadata": {"window": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation. ", "original_text": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "398cae81-4b01-46d7-ad0e-07661f85b7d9", "node_type": "1", "metadata": {"window": "In the area of Oncology, \nwe\u2019ve expanded our best -in-class offering for value -based care, NavistaTs, which will continue to \nserve as a vital resource for oncolog ists transitioning to the new CMS Enhancing Oncology Model.  In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n", "original_text": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "629eb89f9eb2b029b7083dcdfcfdc86d33f42b35babcd69dda8d4355e202eb45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af4ec454-722e-4a6b-8629-c2a2008a2e10", "node_type": "1", "metadata": {"window": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n", "original_text": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. "}, "hash": "43e1c6815c2e9547bf1908e3c9d386ce89b5c1186193050b7fa23fefb67501c1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n", "start_char_idx": 2225, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af4ec454-722e-4a6b-8629-c2a2008a2e10": {"__data__": {"id_": "af4ec454-722e-4a6b-8629-c2a2008a2e10", "embedding": null, "metadata": {"window": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n", "original_text": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b30a55b9-b546-4f31-989e-52f9030b8b72", "node_type": "1", "metadata": {"window": "In \nRheumatology, we\u2019ve closed on our recent tuck -in acquisition of the Bendcare GPO and our \ninvestment in their managed services organization has expanded our capabilities in the space and \ncontrib uted to new customer growth.  In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation. ", "original_text": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc85e118017a3d2d96c643d87b19cee61f877789dcb57f26a76896453acb58fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65425950-8017-4de1-a501-5d1ab460c38d", "node_type": "1", "metadata": {"window": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. ", "original_text": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n"}, "hash": "67656318a62e98be636f49a8cbb7d322d0683ac866d8e1b1c6a61d54b0a85660", "class_name": "RelatedNodeInfo"}}, "text": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. ", "start_char_idx": 2319, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65425950-8017-4de1-a501-5d1ab460c38d": {"__data__": {"id_": "65425950-8017-4de1-a501-5d1ab460c38d", "embedding": null, "metadata": {"window": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. ", "original_text": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af4ec454-722e-4a6b-8629-c2a2008a2e10", "node_type": "1", "metadata": {"window": "In just 30 days, this cross -functional leadership team worked \ndiligently to onboard over 250 healthcare providers onto our distribution and logistics platforms.  \n \n With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n", "original_text": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20e27c0be483d373a130b3994076cf940c9737b8df3083e6e68c98a060a2bf7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27efda1e-ec97-4c86-b5f2-65504ddcee4e", "node_type": "1", "metadata": {"window": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects. ", "original_text": "And finally, number three :  A relentless focus on shareholder value creation. "}, "hash": "5bf48f8d3c303e25e5baa8b7562422d5c0073f2b8912b126bd3ebb5997395853", "class_name": "RelatedNodeInfo"}}, "text": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n", "start_char_idx": 2534, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27efda1e-ec97-4c86-b5f2-65504ddcee4e": {"__data__": {"id_": "27efda1e-ec97-4c86-b5f2-65504ddcee4e", "embedding": null, "metadata": {"window": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects. ", "original_text": "And finally, number three :  A relentless focus on shareholder value creation. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65425950-8017-4de1-a501-5d1ab460c38d", "node_type": "1", "metadata": {"window": "With biosimilars, we remain well -positioned to distribute and pr ovide the surrounding services as they \ncome to market, particularly in the new therapeutic areas and sites of care.  We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. ", "original_text": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b7d5b54832a8ac54abb2518d651755c8f3411b5d3f9eb46d1960290d6b9fd77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ec56a46-2688-4b2b-a684-b531b59f034c", "node_type": "1", "metadata": {"window": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. ", "original_text": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n"}, "hash": "e680e2d120b92983195b75bf3610cfef64e691ea2981569ea1f3fcb38a340c6c", "class_name": "RelatedNodeInfo"}}, "text": "And finally, number three :  A relentless focus on shareholder value creation. ", "start_char_idx": 2750, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ec56a46-2688-4b2b-a684-b531b59f034c": {"__data__": {"id_": "7ec56a46-2688-4b2b-a684-b531b59f034c", "embedding": null, "metadata": {"window": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. ", "original_text": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27efda1e-ec97-4c86-b5f2-65504ddcee4e", "node_type": "1", "metadata": {"window": "We continue to expect \nincreased contributions from biosimilars in fiscal \u201823 and beyond.  \n \n Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects. ", "original_text": "And finally, number three :  A relentless focus on shareholder value creation. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb51b4ea9053bc274ce0658f8d0852937f7a0f64837883bdcc6ec468b59f7592", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c155191b-e34e-463b-9711-221e077f6136", "node_type": "1", "metadata": {"window": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. "}, "hash": "438c9f78f46ea9a58f7ad08dada531dfbdf72b085141f1dde7ff987d3361af1d", "class_name": "RelatedNodeInfo"}}, "text": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n", "start_char_idx": 2829, "end_char_idx": 2969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c155191b-e34e-463b-9711-221e077f6136": {"__data__": {"id_": "c155191b-e34e-463b-9711-221e077f6136", "embedding": null, "metadata": {"window": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ec56a46-2688-4b2b-a684-b531b59f034c", "node_type": "1", "metadata": {"window": "Upstream in Specialty, our third -party logistics b usiness continues its strong growth, with more than \ndouble the launches in the first quarter compared to a year ago, as well as double -digit new contract \nwins.  And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. ", "original_text": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bbf3ccf5c73657e0d61cec132d0ee0204624314d58aa8c9ca5f83ae84f11e12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ee7bbad-6d5e-4177-893b-be18e7df3db4", "node_type": "1", "metadata": {"window": "And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We are prioritizing organic growth, deploying capex to the highest value projects. "}, "hash": "4415a9b31c9260c79dde203cc24bcc1692bd325483788abf311a5cbb03cf5e91", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. ", "start_char_idx": 2969, "end_char_idx": 3081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ee7bbad-6d5e-4177-893b-be18e7df3db4": {"__data__": {"id_": "5ee7bbad-6d5e-4177-893b-be18e7df3db4", "embedding": null, "metadata": {"window": "And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We are prioritizing organic growth, deploying capex to the highest value projects. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c155191b-e34e-463b-9711-221e077f6136", "node_type": "1", "metadata": {"window": "And, our continued investment towards the digital transformation of our Sonexus access and \npatie nt support business has enabled us to realize benefits from new business wins and expansion of \nexisting clients.  \n \n And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1ca8c437a82e258f39972ce33ccb65de86d80560669633866b386a4a256bcb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ec9d3e0-63ad-497a-bcfe-cbcc780cb46a", "node_type": "1", "metadata": {"window": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. "}, "hash": "8e185a0443d59da79666e82ea8925aede68ea783ec8bc041c53fc58ca03225c4", "class_name": "RelatedNodeInfo"}}, "text": "We are prioritizing organic growth, deploying capex to the highest value projects. ", "start_char_idx": 3081, "end_char_idx": 3164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ec9d3e0-63ad-497a-bcfe-cbcc780cb46a": {"__data__": {"id_": "1ec9d3e0-63ad-497a-bcfe-cbcc780cb46a", "embedding": null, "metadata": {"window": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ee7bbad-6d5e-4177-893b-be18e7df3db4", "node_type": "1", "metadata": {"window": "And finally, number three :  A relentless focus on shareholder value creation.  This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We are prioritizing organic growth, deploying capex to the highest value projects. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e22bc3ab1a39cf9a91d915f3b70fd1349fdc81bfaf349a972b6008362ced9313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa45efb6-e593-4b7b-ba1e-41729bd2f3c2", "node_type": "1", "metadata": {"window": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We were pleased to initiate the $1 billion Accelerated Share Repurchase program "}, "hash": "dd3e4fc1680f11a3f5795b2da4a1f5c575faed1406dcd7867a1eab84b3f61fd1", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. ", "start_char_idx": 3164, "end_char_idx": 3296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa45efb6-e593-4b7b-ba1e-41729bd2f3c2": {"__data__": {"id_": "fa45efb6-e593-4b7b-ba1e-41729bd2f3c2", "embedding": null, "metadata": {"window": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86b1b17080c9b80ceb7de593f0b2579773d5ca5449f354501cd2ba3d874abfff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ec9d3e0-63ad-497a-bcfe-cbcc780cb46a", "node_type": "1", "metadata": {"window": "This includes maximizing \nsustainable, profitable growth and cash  flow generation, as well as our return of capital to \nshareholders .  \n \n We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return. ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68291cb71a0de189bfcf624f55b06b417bedbd23479bc231a894c6ae689e3d32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b916a725-8134-40e6-91c2-33cc06c068bd", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n"}, "hash": "7e2cec17cc784fc80cc42c0b7d1c7d195b86cf6c34fef4397d37739d92792b4b", "class_name": "RelatedNodeInfo"}}, "text": "We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "start_char_idx": 3296, "end_char_idx": 3376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b916a725-8134-40e6-91c2-33cc06c068bd": {"__data__": {"id_": "b916a725-8134-40e6-91c2-33cc06c068bd", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa45efb6-e593-4b7b-ba1e-41729bd2f3c2", "node_type": "1", "metadata": {"window": "We continue to expect strong and resilient cash flow generation, supporting our capital allocation \npriorities.  We are prioritizing organic growth, deploying capex to the highest value projects.  We\u2019ve \nmade tremendous progress on reducing our long -term debt,  which has created additional flexibility for \nshareholder return.  We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "original_text": "We were pleased to initiate the $1 billion Accelerated Share Repurchase program ", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e76b6ebf062c9686ca9592376282cdc424d4d8e49e2143a2da6cc595f16592", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7bd5305-bc0d-4097-8a3f-ff1c357b3b2c", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. ", "original_text": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations. "}, "hash": "89839055a0245cc4fac9348608d290bd3288649fa781b87c970090d8223bacdd", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n", "start_char_idx": 0, "end_char_idx": 196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7bd5305-bc0d-4097-8a3f-ff1c357b3b2c": {"__data__": {"id_": "a7bd5305-bc0d-4097-8a3f-ff1c357b3b2c", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. ", "original_text": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b916a725-8134-40e6-91c2-33cc06c068bd", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f001abafafa05723b84a8d4639bc01c8e10d10aa96006131c7ca4b714e7b0ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f2bba4a-84a1-49a9-aef5-f6d95afc4a82", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n", "original_text": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business. "}, "hash": "bc6f0e628e73b26f38377e468fc6b819c01e61882394d269e4c13a13553143d2", "class_name": "RelatedNodeInfo"}}, "text": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations. ", "start_char_idx": 196, "end_char_idx": 494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f2bba4a-84a1-49a9-aef5-f6d95afc4a82": {"__data__": {"id_": "6f2bba4a-84a1-49a9-aef5-f6d95afc4a82", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n", "original_text": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7bd5305-bc0d-4097-8a3f-ff1c357b3b2c", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. ", "original_text": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96f6cf11de6b096c39ff84f6401097633737ec36515694eb92afc962d3631ed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "946eab80-65af-43e9-bfb5-a318cb5704f9", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. ", "original_text": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n"}, "hash": "d8ae1156498ee1245563e5e2966fa40dd97eb4c478184f5184c6873ca6d8310d", "class_name": "RelatedNodeInfo"}}, "text": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business. ", "start_char_idx": 494, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "946eab80-65af-43e9-bfb5-a318cb5704f9": {"__data__": {"id_": "946eab80-65af-43e9-bfb5-a318cb5704f9", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. ", "original_text": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f2bba4a-84a1-49a9-aef5-f6d95afc4a82", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n", "original_text": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc4337f4360c6497a158572a95e327babad2c372240f2075e877f30652274c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1902d9df-3330-46e8-8916-6326d824e0d5", "node_type": "1", "metadata": {"window": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. ", "original_text": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. "}, "hash": "faf51c42852261f0756186112784a73798d53789e08580589debfc6e39df6027", "class_name": "RelatedNodeInfo"}}, "text": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "start_char_idx": 644, "end_char_idx": 745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1902d9df-3330-46e8-8916-6326d824e0d5": {"__data__": {"id_": "1902d9df-3330-46e8-8916-6326d824e0d5", "embedding": null, "metadata": {"window": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. ", "original_text": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "946eab80-65af-43e9-bfb5-a318cb5704f9", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. ", "original_text": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35121394fc33c22a642a59910c42fcda9217c1f6c55bdc26db85062bc7d82262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7e106e6-a6ca-4d77-ada1-b4f3d0b47574", "node_type": "1", "metadata": {"window": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n", "original_text": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n"}, "hash": "06a0ede888d2b8176c3fa2584c5db38b39422e854ff032022ffbe5af170f872d", "class_name": "RelatedNodeInfo"}}, "text": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. ", "start_char_idx": 745, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7e106e6-a6ca-4d77-ada1-b4f3d0b47574": {"__data__": {"id_": "f7e106e6-a6ca-4d77-ada1-b4f3d0b47574", "embedding": null, "metadata": {"window": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n", "original_text": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1902d9df-3330-46e8-8916-6326d824e0d5", "node_type": "1", "metadata": {"window": "Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. ", "original_text": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acca37c8260cb4c54f2446616c9b02f783c4bc5ff31da670ef45ee1e220a1e5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c529f367-41e3-4c6e-9d64-b2fac6db2b41", "node_type": "1", "metadata": {"window": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n", "original_text": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. "}, "hash": "f257a97f5d0c67e065a5c3f8c9f3527dee25a8295ffc0519c48719ebd54a7671", "class_name": "RelatedNodeInfo"}}, "text": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n", "start_char_idx": 871, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c529f367-41e3-4c6e-9d64-b2fac6db2b41": {"__data__": {"id_": "c529f367-41e3-4c6e-9d64-b2fac6db2b41", "embedding": null, "metadata": {"window": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n", "original_text": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7e106e6-a6ca-4d77-ada1-b4f3d0b47574", "node_type": "1", "metadata": {"window": "Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n", "original_text": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4641f83176e4daf1e69411640e2a13a2f070f11731ff21f8e68cb5f6e8ac9c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbb52249-0be1-4d80-9d10-617d1fec82ba", "node_type": "1", "metadata": {"window": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you. ", "original_text": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. "}, "hash": "d2e59d441700ebbdecf6a97020507ef4d03ac49794b7ade65e20ee17b231d4ad", "class_name": "RelatedNodeInfo"}}, "text": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. ", "start_char_idx": 1124, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbb52249-0be1-4d80-9d10-617d1fec82ba": {"__data__": {"id_": "bbb52249-0be1-4d80-9d10-617d1fec82ba", "embedding": null, "metadata": {"window": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you. ", "original_text": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c529f367-41e3-4c6e-9d64-b2fac6db2b41", "node_type": "1", "metadata": {"window": "We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n", "original_text": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "818ca9fb16d58cbdfe2e0f654ed4a7ac6a55abfd6e33965a3c5389dc032459a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02f3551a-5139-44e3-8f90-d6d46febaeee", "node_type": "1", "metadata": {"window": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. ", "original_text": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n"}, "hash": "2dca5bb88de451c5dc954e95b2ce9846dcff9c827bc4fe9bb78b721b8c3a7c34", "class_name": "RelatedNodeInfo"}}, "text": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. ", "start_char_idx": 1229, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02f3551a-5139-44e3-8f90-d6d46febaeee": {"__data__": {"id_": "02f3551a-5139-44e3-8f90-d6d46febaeee", "embedding": null, "metadata": {"window": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. ", "original_text": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbb52249-0be1-4d80-9d10-617d1fec82ba", "node_type": "1", "metadata": {"window": "In closing, I recognize there is still a lot to accomplis h, yet I remain excited about these opportunities \nto drive growth.  I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you. ", "original_text": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06589fff908ead80a335f92eb9aec268acf00a750fea2915d1c310181cff4e00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e72e1f4-ce98-47cb-ae70-7e986423e13c", "node_type": "1", "metadata": {"window": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n", "original_text": "With that, we will take your questions.  \n \n"}, "hash": "8964695b85c5346991949aa91337ad6768c79fa66f4cabe734bb0d374e2f2a37", "class_name": "RelatedNodeInfo"}}, "text": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n", "start_char_idx": 1363, "end_char_idx": 1611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e72e1f4-ce98-47cb-ae70-7e986423e13c": {"__data__": {"id_": "8e72e1f4-ce98-47cb-ae70-7e986423e13c", "embedding": null, "metadata": {"window": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n", "original_text": "With that, we will take your questions.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02f3551a-5139-44e3-8f90-d6d46febaeee", "node_type": "1", "metadata": {"window": "I believe that our resilient business mode ls, robust operating cash flow generation, \nfavorable capital structure, and capital allocation flexibility differentiate us in this time of macro -\neconomic uncertaint y, and I am confident in our future.  \n \n Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. ", "original_text": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "517b5b20f8f51af47dd0d8fad8b6d2b37b1f762acb886b5d1b1d7a5ac1eaf18c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c1808e2-7339-434a-8c29-30fd2316ae68", "node_type": "1", "metadata": {"window": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.  ", "original_text": "Operator :   Thank you. "}, "hash": "0776119009eda74b20b5328e08ee9b5720fc7f6a1ed7b3efe227031992887107", "class_name": "RelatedNodeInfo"}}, "text": "With that, we will take your questions.  \n \n", "start_char_idx": 1611, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c1808e2-7339-434a-8c29-30fd2316ae68": {"__data__": {"id_": "0c1808e2-7339-434a-8c29-30fd2316ae68", "embedding": null, "metadata": {"window": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.  ", "original_text": "Operator :   Thank you. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e72e1f4-ce98-47cb-ae70-7e986423e13c", "node_type": "1", "metadata": {"window": "Before we open it up to Q&A, I do want to spend a mom ent thanking our dedicated team around the \nglobe.  I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n", "original_text": "With that, we will take your questions.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea67c30f15de156336900d79c1a1d4675dbb9fe2ec2ae8b5cdeaef8c3f6ac61e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dea01cf-2a43-441c-bcdc-5c806cf1406e", "node_type": "1", "metadata": {"window": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question. ", "original_text": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. "}, "hash": "1602cb587e923d213e38b6016c11cc43f5d541aea47a2b9d5c87c35ce92e7ab6", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   Thank you. ", "start_char_idx": 1655, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dea01cf-2a43-441c-bcdc-5c806cf1406e": {"__data__": {"id_": "7dea01cf-2a43-441c-bcdc-5c806cf1406e", "embedding": null, "metadata": {"window": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question. ", "original_text": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c1808e2-7339-434a-8c29-30fd2316ae68", "node_type": "1", "metadata": {"window": "I\u2019ve had a number of opportunities to connect with them across the last couple months, and it\u2019s \ntruly a privilege to lead every day.  They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.  ", "original_text": "Operator :   Thank you. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98425869cc1e13e7148a1e9ad2b599f5200fb5cb58baf17eb2f455db67fd4008", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5670436-b17b-4ba7-b7ec-58a2ec12ab04", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. ", "original_text": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n"}, "hash": "45f4c131d43546ad91dcd09a831c6af52f27b6d7953507e43876105c2a453b51", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. ", "start_char_idx": 1679, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5670436-b17b-4ba7-b7ec-58a2ec12ab04": {"__data__": {"id_": "b5670436-b17b-4ba7-b7ec-58a2ec12ab04", "embedding": null, "metadata": {"window": "With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. ", "original_text": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dea01cf-2a43-441c-bcdc-5c806cf1406e", "node_type": "1", "metadata": {"window": "They are driving the execution of the initiatives that we\u2019ve \ndiscussed to day to deliver for our shareholders, for our customers and for their patients, and we are \nvery much looking forward to the opportunities that remain ahead .             \n \n With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question. ", "original_text": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e121920b4e06e337a10669fabcb9f1500a011cccf2bac84916e64bb9ab2efcd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3034a288-b5bb-4f23-9bdf-31912a744aa5", "node_type": "1", "metadata": {"window": "Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n", "original_text": "Elizabeth Anderson :  Hi, guys.  "}, "hash": "082355fc7a3a14ee9a64b293ae02e88b3e380e3bdd19b8575df001c35c262e0c", "class_name": "RelatedNodeInfo"}}, "text": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n", "start_char_idx": 1788, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3034a288-b5bb-4f23-9bdf-31912a744aa5": {"__data__": {"id_": "3034a288-b5bb-4f23-9bdf-31912a744aa5", "embedding": null, "metadata": {"window": "Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n", "original_text": "Elizabeth Anderson :  Hi, guys.  ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5670436-b17b-4ba7-b7ec-58a2ec12ab04", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. ", "original_text": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06b9a0b6068c139b87dad18fbc1179180be14482a3ff7b150d5bbe0246b22293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d8aae92-29ca-42af-8e7a-1ab06c752f9b", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. ", "original_text": "Thanks so much for the question. "}, "hash": "5ab6228cb4a0f9fb9c0a88b5c7d0cc6f72c4c8197348ff42fa9089697c25e4fb", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson :  Hi, guys.  ", "start_char_idx": 1863, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d8aae92-29ca-42af-8e7a-1ab06c752f9b": {"__data__": {"id_": "1d8aae92-29ca-42af-8e7a-1ab06c752f9b", "embedding": null, "metadata": {"window": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. ", "original_text": "Thanks so much for the question. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3034a288-b5bb-4f23-9bdf-31912a744aa5", "node_type": "1", "metadata": {"window": "Operator :   Thank you.  Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n", "original_text": "Elizabeth Anderson :  Hi, guys.  ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d66f6a937baa662123782cbbabda615c6c2e595d4716337af383ee38d9f6407", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e76f5c0-c47e-4ad1-914b-4670cfde61e2", "node_type": "1", "metadata": {"window": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n", "original_text": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. "}, "hash": "f618a8094f81b7a88256fdd1197d83d9d890c7f309bf5a7ba407be3a0bb7d3c7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 1896, "end_char_idx": 1929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e76f5c0-c47e-4ad1-914b-4670cfde61e2": {"__data__": {"id_": "3e76f5c0-c47e-4ad1-914b-4670cfde61e2", "embedding": null, "metadata": {"window": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n", "original_text": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8aae92-29ca-42af-8e7a-1ab06c752f9b", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, if you would like to ask a question, please press star \none on your telepho ne keypad.  We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. ", "original_text": "Thanks so much for the question. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "336c5725b8fe28c2d6dd266e4afff5b0df0841565c3f43915dd4ceda3f9e73f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cca75ae7-7613-42b6-b84a-a5d5b566b5ce", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.  ", "original_text": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n"}, "hash": "4f1adb5d182afdee36c6f6cc788d2a70a526f36d5157fd4c0930c7de53e02015", "class_name": "RelatedNodeInfo"}}, "text": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. ", "start_char_idx": 1929, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cca75ae7-7613-42b6-b84a-a5d5b566b5ce": {"__data__": {"id_": "cca75ae7-7613-42b6-b84a-a5d5b566b5ce", "embedding": null, "metadata": {"window": "Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.  ", "original_text": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e76f5c0-c47e-4ad1-914b-4670cfde61e2", "node_type": "1", "metadata": {"window": "We will take the first question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n", "original_text": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2b160870e39624f0c58ea1a56bc43008896e2856afd691be9421b28e63f75fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b16756-7400-4b4d-abe7-d60722c5271a", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n", "original_text": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. "}, "hash": "a2fd99fd22467e565896f13618408d7ece89e868c8732b716291928c102d7029", "class_name": "RelatedNodeInfo"}}, "text": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n", "start_char_idx": 2053, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b16756-7400-4b4d-abe7-d60722c5271a": {"__data__": {"id_": "90b16756-7400-4b4d-abe7-d60722c5271a", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n", "original_text": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cca75ae7-7613-42b6-b84a-a5d5b566b5ce", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi, guys.   Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.  ", "original_text": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1f8ce72a556088a0cf637e42f21fc3e5e627eddd340d771aa296042fc19d16b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9c1107a-e48f-4129-a9d9-65520668d625", "node_type": "1", "metadata": {"window": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n", "original_text": "Thanks.  \n \n"}, "hash": "7120a2655a1f266cecde1853e6ef96d812d645893d90813dbe1923001b54aba3", "class_name": "RelatedNodeInfo"}}, "text": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. ", "start_char_idx": 2185, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9c1107a-e48f-4129-a9d9-65520668d625": {"__data__": {"id_": "d9c1107a-e48f-4129-a9d9-65520668d625", "embedding": null, "metadata": {"window": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n", "original_text": "Thanks.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b16756-7400-4b4d-abe7-d60722c5271a", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n", "original_text": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c09c443590635e17e12d2afcafcc705eb261b71894d478d45192d7438f3fe73d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64913e24-6bfc-4647-9f0a-acc9b700b9de", "node_type": "1", "metadata": {"window": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.  ", "original_text": "Jason Hollar :   Sure.  "}, "hash": "19af01da0f70c4510b2d1276e608537c66eb3dc702385d96b8a3bda785b1a733", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 2383, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64913e24-6bfc-4647-9f0a-acc9b700b9de": {"__data__": {"id_": "64913e24-6bfc-4647-9f0a-acc9b700b9de", "embedding": null, "metadata": {"window": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.  ", "original_text": "Jason Hollar :   Sure.  ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9c1107a-e48f-4129-a9d9-65520668d625", "node_type": "1", "metadata": {"window": "I was just wondering if you could talk \na little bit about the sort of embedded expectations in the back half  of the year.  You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n", "original_text": "Thanks.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98035ab6d48f5e408e7a19dc9e1ee545238bf7c981e40881d0482089d62fc8bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c71c78f-aba0-44e8-9208-b95b9b02f196", "node_type": "1", "metadata": {"window": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. ", "original_text": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n"}, "hash": "774952189070eb17bff81fbd2a2d8b94fe09f6420b29d78a995933c4455e2094", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Sure.  ", "start_char_idx": 2395, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c71c78f-aba0-44e8-9208-b95b9b02f196": {"__data__": {"id_": "3c71c78f-aba0-44e8-9208-b95b9b02f196", "embedding": null, "metadata": {"window": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. ", "original_text": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64913e24-6bfc-4647-9f0a-acc9b700b9de", "node_type": "1", "metadata": {"window": "You obviously, it's the \nfirst quarter and you had some nice outperformance and hitting some early milestones on key initiatives . \n But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.  ", "original_text": "Jason Hollar :   Sure.  ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a1ade960808c627548efa2e358e8ec2889247430371aed4967bd8d11d81ac7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c81d35a-e279-4af8-9cd4-6ae6944fabb1", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. ", "original_text": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n"}, "hash": "01db27150698992e4220d78ad470ab937fb5bdac4d79a2610f7a714efff6c6b8", "class_name": "RelatedNodeInfo"}}, "text": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n", "start_char_idx": 2419, "end_char_idx": 2520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c81d35a-e279-4af8-9cd4-6ae6944fabb1": {"__data__": {"id_": "7c81d35a-e279-4af8-9cd4-6ae6944fabb1", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. ", "original_text": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c71c78f-aba0-44e8-9208-b95b9b02f196", "node_type": "1", "metadata": {"window": "But in terms of how we think about that outperformance versus sort of how you still see the progression \nin term s of the quarterly ramp in the back half, more colo r on that would be very helpful.  Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. ", "original_text": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2f3bccd992937d16ea9c807ec6861b7a91d6e895d3a709461d1d56a73d74b4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2ac5d99-2e9a-4a16-abee-45e787ebbb54", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . ", "original_text": "Jason Hollar :  Okay.  "}, "hash": "9700f045dcf3793d5cec6edb0789a1f3dca7c6009102e12e4a70e9181ad16d15", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n", "start_char_idx": 2520, "end_char_idx": 2639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2ac5d99-2e9a-4a16-abee-45e787ebbb54": {"__data__": {"id_": "a2ac5d99-2e9a-4a16-abee-45e787ebbb54", "embedding": null, "metadata": {"window": "Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . ", "original_text": "Jason Hollar :  Okay.  ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c81d35a-e279-4af8-9cd4-6ae6944fabb1", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. ", "original_text": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "645f7a431594b6d1bb4407ed01bcbda8cf62f1c98a5fb184df3900ad94b92b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac6112e0-42ff-4955-8c0a-f3d0603bd502", "node_type": "1", "metadata": {"window": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year . ", "original_text": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. "}, "hash": "6c4a356bf4f701436ecced5df012d1d1a9a87effe4856381de148c6da0b0acc6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Okay.  ", "start_char_idx": 2639, "end_char_idx": 2662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac6112e0-42ff-4955-8c0a-f3d0603bd502": {"__data__": {"id_": "ac6112e0-42ff-4955-8c0a-f3d0603bd502", "embedding": null, "metadata": {"window": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year . ", "original_text": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2ac5d99-2e9a-4a16-abee-45e787ebbb54", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.   Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . ", "original_text": "Jason Hollar :  Okay.  ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8b7315b576dc74529b5a488720e9333b9595991df696e8856c9692f07f9b84d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a732961e-41bd-40e4-8399-3551b76c28ee", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. "}, "hash": "85d90d0bc0fc648ff07f1a7fb2b549bd2718eb6865f34247d86aa96eea79b847", "class_name": "RelatedNodeInfo"}}, "text": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. ", "start_char_idx": 2662, "end_char_idx": 2782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a732961e-41bd-40e4-8399-3551b76c28ee": {"__data__": {"id_": "a732961e-41bd-40e4-8399-3551b76c28ee", "embedding": null, "metadata": {"window": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac6112e0-42ff-4955-8c0a-f3d0603bd502", "node_type": "1", "metadata": {"window": "Is your question, Elizabeth, specific to any particular business or you just talking \ngenerally.  \n \n Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year . ", "original_text": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b0c1a452541d8edbb905503e4cf02d276917d4ffe5a1c1a65bbdf3a85394dae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1caa5c8e-91b0-49ea-8c48-820bd326332d", "node_type": "1", "metadata": {"window": "Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . "}, "hash": "ddfa78f4719e9901b7d1f67b88795841b81d0b866280916de8b57a349e8f74a6", "class_name": "RelatedNodeInfo"}}, "text": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. ", "start_char_idx": 2782, "end_char_idx": 2869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1caa5c8e-91b0-49ea-8c48-820bd326332d": {"__data__": {"id_": "1caa5c8e-91b0-49ea-8c48-820bd326332d", "embedding": null, "metadata": {"window": "Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a732961e-41bd-40e4-8399-3551b76c28ee", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :   Specifically in terms of Medical, but I would also be curious on the Pharma  side \nas well.  \n \n Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8413460e72b45d57aa10b7d6d31fb2c92218228e8c148849a69904263ed55074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4528246c-dd70-45b0-b109-585b8140c97e", "node_type": "1", "metadata": {"window": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "We do expect further price adjustm ents in the \nthird quarter of the fiscal year . "}, "hash": "c5a9137904338fb416e14e556d85c3b371bebda3143bacee61b030382dd5570e", "class_name": "RelatedNodeInfo"}}, "text": "And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . ", "start_char_idx": 2869, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4528246c-dd70-45b0-b109-585b8140c97e": {"__data__": {"id_": "4528246c-dd70-45b0-b109-585b8140c97e", "embedding": null, "metadata": {"window": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "We do expect further price adjustm ents in the \nthird quarter of the fiscal year . ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1caa5c8e-91b0-49ea-8c48-820bd326332d", "node_type": "1", "metadata": {"window": "Jason Hollar :  Okay.   Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st . ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4fdc9d67ebf0639c5242cd9692053b35aece26b79aaf54b2393e82aaec1b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "143c878a-56de-4fde-818c-fdd44c7f34c7", "node_type": "1", "metadata": {"window": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. "}, "hash": "88ec6448d80018f47ba432b8fdc4cb1b42e7d04b2b040ed2c0afd60e44f6e085", "class_name": "RelatedNodeInfo"}}, "text": "We do expect further price adjustm ents in the \nthird quarter of the fiscal year . ", "start_char_idx": 3015, "end_char_idx": 3098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "143c878a-56de-4fde-818c-fdd44c7f34c7": {"__data__": {"id_": "143c878a-56de-4fde-818c-fdd44c7f34c7", "embedding": null, "metadata": {"window": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e33350b6-8aa3-448f-955e-6a6438e22a26", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ac26372bd6494edb6ad1f611e0692ed4432e538cfe9cb9bf48214ca06e5295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4528246c-dd70-45b0-b109-585b8140c97e", "node_type": "1", "metadata": {"window": "Yeah, for Medical  specifically, it's - the biggest driver by far will be the mitigation \nactions to address inflation.  That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "We do expect further price adjustm ents in the \nthird quarter of the fiscal year . ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "225181fa762a94f216f8884b7d71fb7d467830b534ebca150a993d2804d81de3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb836f82-73c7-4286-8e97-3ce580ce8525", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "original_text": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated . "}, "hash": "7513d0db923e5fff46563426fcd4f0fa6a1349fe6914ee391724a50f4674d2e4", "class_name": "RelatedNodeInfo"}}, "text": "And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "start_char_idx": 3098, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb836f82-73c7-4286-8e97-3ce580ce8525": {"__data__": {"id_": "cb836f82-73c7-4286-8e97-3ce580ce8525", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "original_text": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "143c878a-56de-4fde-818c-fdd44c7f34c7", "node_type": "1", "metadata": {"window": "That's  as we talked our first pricing actions went in place March 1st of \nfiscal \u201822.  And then we had another wave in July of fiscal - the very beginning of fiscal \u201923, and then \nanother price adjustment that occurred October 1st .  We do expect further price adjustm ents in the \nthird quarter of the fiscal year .  And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "original_text": "And then at the same time, we would expect, especially in the fourth \nquarter of fiscal \u201823 to start to see some of the lower costs, especially with the international freight \npiece finally starting to hit our P& L. ", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fcb0b1de94114b1479c0a8f51659d5aba7fa3228aab035391c5db6ec5335424", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29381fd4-fa02-462e-93bd-9137060829cb", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. ", "original_text": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.  "}, "hash": "201d4ad5c1390370d6bf6f4e6c4b81e9c94b909f1a6306bb2c3476bece4de3e2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated . ", "start_char_idx": 0, "end_char_idx": 98, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29381fd4-fa02-462e-93bd-9137060829cb": {"__data__": {"id_": "29381fd4-fa02-462e-93bd-9137060829cb", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. ", "original_text": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.  ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb836f82-73c7-4286-8e97-3ce580ce8525", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "original_text": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee6fae5d6cf4027e6261de927e8f13fb47834a6d482524d77de1593af544b1a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f25d762c-e5f5-4cb1-b2eb-af85fcfde042", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet . ", "original_text": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point . "}, "hash": "b6c0ff1077db01d798853bdf9b2491c7396a6653942c86637ddb6804bca2dae6", "class_name": "RelatedNodeInfo"}}, "text": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.  ", "start_char_idx": 98, "end_char_idx": 235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f25d762c-e5f5-4cb1-b2eb-af85fcfde042": {"__data__": {"id_": "f25d762c-e5f5-4cb1-b2eb-af85fcfde042", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet . ", "original_text": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29381fd4-fa02-462e-93bd-9137060829cb", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. ", "original_text": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.  ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d0997d2c3653e407701b0598dd6b716c407b7aa2db34193f5483aedf92cd46f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25c85344-453c-44ff-b8f5-7ce54e870b98", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . ", "original_text": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n"}, "hash": "7d704cef0599456c9521879029d43b113515c39586ef655789aae8407bdbe07a", "class_name": "RelatedNodeInfo"}}, "text": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point . ", "start_char_idx": 235, "end_char_idx": 394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25c85344-453c-44ff-b8f5-7ce54e870b98": {"__data__": {"id_": "25c85344-453c-44ff-b8f5-7ce54e870b98", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . ", "original_text": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f25d762c-e5f5-4cb1-b2eb-af85fcfde042", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet . ", "original_text": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82051d381dc846b24202fe6ad8a4e654f0b9d49b72bf179e03460f47a99af313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75021f30-6f2f-48da-a59d-c3e239e6d358", "node_type": "1", "metadata": {"window": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . ", "original_text": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. "}, "hash": "ba6a8adc9b548b2c146a1c8019f84ed4e44eba4b9bbe420514e1054dede0ef87", "class_name": "RelatedNodeInfo"}}, "text": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "start_char_idx": 394, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75021f30-6f2f-48da-a59d-c3e239e6d358": {"__data__": {"id_": "75021f30-6f2f-48da-a59d-c3e239e6d358", "embedding": null, "metadata": {"window": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . ", "original_text": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25c85344-453c-44ff-b8f5-7ce54e870b98", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . ", "original_text": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e15ef4893118dd157773c66870b9ed01731543024ae4c50d949f9c9b9686689e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e17446ba-e4aa-4471-9e9d-d3608b1b4d26", "node_type": "1", "metadata": {"window": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n", "original_text": "We talked about the higher cost PPE being on our balance sheet . "}, "hash": "e16de7820f1f52a2c80ac99ca766a3a2438fbd01d40c07ac605420cadd549c3c", "class_name": "RelatedNodeInfo"}}, "text": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. ", "start_char_idx": 480, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e17446ba-e4aa-4471-9e9d-d3608b1b4d26": {"__data__": {"id_": "e17446ba-e4aa-4471-9e9d-d3608b1b4d26", "embedding": null, "metadata": {"window": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n", "original_text": "We talked about the higher cost PPE being on our balance sheet . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75021f30-6f2f-48da-a59d-c3e239e6d358", "node_type": "1", "metadata": {"window": "And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . ", "original_text": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE. ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f72bb072fbf146435291f5510615d1ae8c35fc477618ce7d5b00a78bc184740f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dad71223-f4b5-463b-a376-77578cd379ab", "node_type": "1", "metadata": {"window": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . ", "original_text": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . "}, "hash": "6afd1c649736169ed2f83399873d4680619dc4b6f1dc0e5e8c2df356a05c3fcd", "class_name": "RelatedNodeInfo"}}, "text": "We talked about the higher cost PPE being on our balance sheet . ", "start_char_idx": 595, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dad71223-f4b5-463b-a376-77578cd379ab": {"__data__": {"id_": "dad71223-f4b5-463b-a376-77578cd379ab", "embedding": null, "metadata": {"window": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . ", "original_text": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e17446ba-e4aa-4471-9e9d-d3608b1b4d26", "node_type": "1", "metadata": {"window": "But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n", "original_text": "We talked about the higher cost PPE being on our balance sheet . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2791d77c5c5c5f5f4f5a4bcc4cb27ef7a092db0362e6622cbec53b3b637bce06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb75b24f-2ff6-40ee-820f-05d075823b09", "node_type": "1", "metadata": {"window": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . ", "original_text": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . "}, "hash": "e1e983adc7327f1dd0d3d1a68397307db8fde4a402ac3bc5e664e05a130b4cff", "class_name": "RelatedNodeInfo"}}, "text": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . ", "start_char_idx": 660, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb75b24f-2ff6-40ee-820f-05d075823b09": {"__data__": {"id_": "fb75b24f-2ff6-40ee-820f-05d075823b09", "embedding": null, "metadata": {"window": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . ", "original_text": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dad71223-f4b5-463b-a376-77578cd379ab", "node_type": "1", "metadata": {"window": "We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . ", "original_text": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51ee915e48789929e2e5153814234845a26e17110bf9622d482811314bc0d427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63916d07-4f71-4c21-af2b-611aef96bb74", "node_type": "1", "metadata": {"window": "We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n", "original_text": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n"}, "hash": "c0e6f6610d0bc8f65fc70ee1a1e9579187dc68cc58cd4782f18e7c531f26b044", "class_name": "RelatedNodeInfo"}}, "text": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . ", "start_char_idx": 792, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63916d07-4f71-4c21-af2b-611aef96bb74": {"__data__": {"id_": "63916d07-4f71-4c21-af2b-611aef96bb74", "embedding": null, "metadata": {"window": "We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n", "original_text": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb75b24f-2ff6-40ee-820f-05d075823b09", "node_type": "1", "metadata": {"window": "The other key components from a first half, second half perspective for Medical is just the \nnormalisation of PPE.  We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . ", "original_text": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52e72856cb795d8ab7cd9badef19c835eb61bf49bdc0f026d0eca37b581753e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb073199-b3e0-4c0b-942e-dd3a6523f76e", "node_type": "1", "metadata": {"window": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n", "original_text": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . "}, "hash": "dc02e7790b98c13372a0012a0901d4a5dc84f42307d91225df64f497ef21c33b", "class_name": "RelatedNodeInfo"}}, "text": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n", "start_char_idx": 991, "end_char_idx": 1158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb073199-b3e0-4c0b-942e-dd3a6523f76e": {"__data__": {"id_": "cb073199-b3e0-4c0b-942e-dd3a6523f76e", "embedding": null, "metadata": {"window": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n", "original_text": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63916d07-4f71-4c21-af2b-611aef96bb74", "node_type": "1", "metadata": {"window": "We talked about the higher cost PPE being on our balance sheet .  When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n", "original_text": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f30ac6496083e34ceb34ae5641e9834733e799fd1b05cf92ba802f1eb0f1c086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c75773c-0504-47d2-b3f9-08b9b95eae83", "node_type": "1", "metadata": {"window": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason . ", "original_text": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . "}, "hash": "18a621cdb2a208accd813aab26f8481ca90601f7765df3255a22670b04158ff0", "class_name": "RelatedNodeInfo"}}, "text": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . ", "start_char_idx": 1158, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c75773c-0504-47d2-b3f9-08b9b95eae83": {"__data__": {"id_": "4c75773c-0504-47d2-b3f9-08b9b95eae83", "embedding": null, "metadata": {"window": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason . ", "original_text": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb073199-b3e0-4c0b-942e-dd3a6523f76e", "node_type": "1", "metadata": {"window": "When \nvolumes fell quite a bit at the latter part of fiscal \u201822, that meant that higher costs stayed in our \nbalance sheet longer .  And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n", "original_text": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd78bfaa1e1c358feca52c6ea6402d3895c6ec45de2ffa8fe34601c5bf6bcaae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d9c87b5-c40a-4078-b10d-9b93a5a63d8b", "node_type": "1", "metadata": {"window": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . ", "original_text": "The next question, please.  \n \n"}, "hash": "6a169c1a27e57aaf2613f1a8b6ad0e4b98514e9a3b0f937e288e3544c86fd994", "class_name": "RelatedNodeInfo"}}, "text": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . ", "start_char_idx": 1325, "end_char_idx": 1530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d9c87b5-c40a-4078-b10d-9b93a5a63d8b": {"__data__": {"id_": "4d9c87b5-c40a-4078-b10d-9b93a5a63d8b", "embedding": null, "metadata": {"window": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . ", "original_text": "The next question, please.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c75773c-0504-47d2-b3f9-08b9b95eae83", "node_type": "1", "metadata": {"window": "And while we're pleased to see that - feels like we've come off the lows here \nfrom the fourth quarter in terms of demand, it remains still something that will take a few quarters to \nwork through .  And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason . ", "original_text": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44c64cd16f735c8aba90cd64428f6d1045d7dc12bdb7feef2f4ce5e62ade9ea5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f876901-8e79-4eab-b86e-f3abc3084841", "node_type": "1", "metadata": {"window": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things . ", "original_text": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n"}, "hash": "284535038c8fe9d0abd11ee1df8d5a014f7c991f45adf6dc5bbc2e72b64354dc", "class_name": "RelatedNodeInfo"}}, "text": "The next question, please.  \n \n", "start_char_idx": 1530, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f876901-8e79-4eab-b86e-f3abc3084841": {"__data__": {"id_": "0f876901-8e79-4eab-b86e-f3abc3084841", "embedding": null, "metadata": {"window": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things . ", "original_text": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d9c87b5-c40a-4078-b10d-9b93a5a63d8b", "node_type": "1", "metadata": {"window": "And then beyond that, really for all of our businesses, it's j ust normal cost reduction and \nother growth initiatives over the course of the year just build up.   \n \n Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . ", "original_text": "The next question, please.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82be0784ca097d58290f4a0c64c142321978f6d5651127478bbb935cb8e4ab16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35181e82-92f8-453a-b6e1-93e271e7a272", "node_type": "1", "metadata": {"window": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . ", "original_text": "Lisa Gill :   Thanks very much, Jason . "}, "hash": "c605f386de6e368c7968eda4682446796b1815cf2ce4dc272816a6c37ad897fc", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n", "start_char_idx": 1561, "end_char_idx": 1644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35181e82-92f8-453a-b6e1-93e271e7a272": {"__data__": {"id_": "35181e82-92f8-453a-b6e1-93e271e7a272", "embedding": null, "metadata": {"window": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . ", "original_text": "Lisa Gill :   Thanks very much, Jason . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f876901-8e79-4eab-b86e-f3abc3084841", "node_type": "1", "metadata": {"window": "Within Pharma , the specific item to remember from a first half, second half, specifically the third \nquarter is always just the recognition of the brand infl ation .  While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things . ", "original_text": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd3fbac48efc6c4916ba22d5539f951a71b827fb0e7f9b057499d61787211edc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb038b25-429f-493f-8cb9-bbebbf5a7400", "node_type": "1", "metadata": {"window": "The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics . ", "original_text": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . "}, "hash": "ae641376e345cea41e841806085988c9bfe79abfd8986f40b9ffe3e3598cbd9c", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill :   Thanks very much, Jason . ", "start_char_idx": 1644, "end_char_idx": 1684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb038b25-429f-493f-8cb9-bbebbf5a7400": {"__data__": {"id_": "bb038b25-429f-493f-8cb9-bbebbf5a7400", "embedding": null, "metadata": {"window": "The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics . ", "original_text": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35181e82-92f8-453a-b6e1-93e271e7a272", "node_type": "1", "metadata": {"window": "While that continues to be a small portion \nof our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter and \nthat's the biggest driver for that particular business .  The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . ", "original_text": "Lisa Gill :   Thanks very much, Jason . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65c37bf13aaea8d242ef9c8db582cea685d3b4bc71bac6f133a1823c9225be2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "788c3ec8-ead7-4979-86d0-d34c4d020514", "node_type": "1", "metadata": {"window": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  ", "original_text": "So a few things . "}, "hash": "51fc9f06152467e952e984e8cae73e7019e070852cba640b54c0a13e6b413ab6", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . ", "start_char_idx": 1684, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "788c3ec8-ead7-4979-86d0-d34c4d020514": {"__data__": {"id_": "788c3ec8-ead7-4979-86d0-d34c4d020514", "embedding": null, "metadata": {"window": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  ", "original_text": "So a few things . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb038b25-429f-493f-8cb9-bbebbf5a7400", "node_type": "1", "metadata": {"window": "The next question, please.  \n \n Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics . ", "original_text": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec32056c8c198f07df6ec2467a3cd48bc83da437e8243642a786e86c5b97f606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c75d95b-50f3-498d-a31a-518b212e29d5", "node_type": "1", "metadata": {"window": "Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . ", "original_text": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . "}, "hash": "7ae5103998062bf4cdd282c7b0f218a50bf9bf8a45ed3e1c69473de0ffe0e0f8", "class_name": "RelatedNodeInfo"}}, "text": "So a few things . ", "start_char_idx": 1783, "end_char_idx": 1801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c75d95b-50f3-498d-a31a-518b212e29d5": {"__data__": {"id_": "5c75d95b-50f3-498d-a31a-518b212e29d5", "embedding": null, "metadata": {"window": "Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . ", "original_text": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "788c3ec8-ead7-4979-86d0-d34c4d020514", "node_type": "1", "metadata": {"window": "Operator :   We will now take the next question from Lisa Gill with JP Morgan.  \n \n Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  ", "original_text": "So a few things . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a0ef3beba38979fa8cbfafb5c607850d9c53d0a24078d06029a5899563e908", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2087861a-3354-48f6-9fa1-e387d417880f", "node_type": "1", "metadata": {"window": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ? ", "original_text": "I kind of think of where we need to be in generics . "}, "hash": "048426ca44a434911d07bd89f73b3607f55345c6dd6f564fcb47c44f502f2b25", "class_name": "RelatedNodeInfo"}}, "text": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . ", "start_char_idx": 1801, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2087861a-3354-48f6-9fa1-e387d417880f": {"__data__": {"id_": "2087861a-3354-48f6-9fa1-e387d417880f", "embedding": null, "metadata": {"window": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ? ", "original_text": "I kind of think of where we need to be in generics . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c75d95b-50f3-498d-a31a-518b212e29d5", "node_type": "1", "metadata": {"window": "Lisa Gill :   Thanks very much, Jason .  I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . ", "original_text": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ee4330c0df34fdcabef1128d9142c4190cbd80f1b0f59f41a62c33c7efce897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70f3b0b0-3789-4054-b702-9ac7e6e3698c", "node_type": "1", "metadata": {"window": "So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are. ", "original_text": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  "}, "hash": "26f3b0062beb33d0d1c8bc7ee38019cafece873736a476142a4b405668e6dc0d", "class_name": "RelatedNodeInfo"}}, "text": "I kind of think of where we need to be in generics . ", "start_char_idx": 1966, "end_char_idx": 2019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70f3b0b0-3789-4054-b702-9ac7e6e3698c": {"__data__": {"id_": "70f3b0b0-3789-4054-b702-9ac7e6e3698c", "embedding": null, "metadata": {"window": "So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are. ", "original_text": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2087861a-3354-48f6-9fa1-e387d417880f", "node_type": "1", "metadata": {"window": "I wanted to spend a couple of minutes on the Pharmaceu tical \ndistribution side of your business .  So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ? ", "original_text": "I kind of think of where we need to be in generics . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66f98b447de48f10085f9e1e18c7ce6624d273f8165e5fc104795e692ae0a980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66a87917-5548-406d-bd90-701c7b01cecf", "node_type": "1", "metadata": {"window": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n", "original_text": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . "}, "hash": "a859f99ef0b0341a21734097cdf89cbd4421f4eef444f6b4586053a4264768a0", "class_name": "RelatedNodeInfo"}}, "text": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  ", "start_char_idx": 2019, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66a87917-5548-406d-bd90-701c7b01cecf": {"__data__": {"id_": "66a87917-5548-406d-bd90-701c7b01cecf", "embedding": null, "metadata": {"window": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n", "original_text": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70f3b0b0-3789-4054-b702-9ac7e6e3698c", "node_type": "1", "metadata": {"window": "So a few things .  One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are. ", "original_text": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?  ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5c5801440be9096534653ee3074a2dfabb81b94fe940eedfd42a3932bc472a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "770b16e3-0c20-4901-84b2-6f81594c54aa", "node_type": "1", "metadata": {"window": "I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point . ", "original_text": "Can you maybe \njust talk about where you see that over time ? "}, "hash": "c7b6dcb520bb12128083a89bb5af28a2504edc2df2f8527c27d5145d6ace3a32", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . ", "start_char_idx": 2114, "end_char_idx": 2246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "770b16e3-0c20-4901-84b2-6f81594c54aa": {"__data__": {"id_": "770b16e3-0c20-4901-84b2-6f81594c54aa", "embedding": null, "metadata": {"window": "I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point . ", "original_text": "Can you maybe \njust talk about where you see that over time ? ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66a87917-5548-406d-bd90-701c7b01cecf", "node_type": "1", "metadata": {"window": "One, one of the things that really stuck out t o me is \nyou talked about strong performance in your generic program  and having enhancing program s going \nforward .  I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n", "original_text": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c23524b3be3e4bf7c63765b123c0550640eac924cabd58ece4b73c89316cc62a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee7db4a2-d7d0-42f2-bc69-4197b1dc42f1", "node_type": "1", "metadata": {"window": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . ", "original_text": "And again, even your guidance is above where industry \nrates are. "}, "hash": "e2ab5af1a0f898f22943942b11e57f3ae79fc36452e3698f3b956bb0b4bbc3e2", "class_name": "RelatedNodeInfo"}}, "text": "Can you maybe \njust talk about where you see that over time ? ", "start_char_idx": 2246, "end_char_idx": 2308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee7db4a2-d7d0-42f2-bc69-4197b1dc42f1": {"__data__": {"id_": "ee7db4a2-d7d0-42f2-bc69-4197b1dc42f1", "embedding": null, "metadata": {"window": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . ", "original_text": "And again, even your guidance is above where industry \nrates are. ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "770b16e3-0c20-4901-84b2-6f81594c54aa", "node_type": "1", "metadata": {"window": "I kind of think of where we need to be in generics .  So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point . ", "original_text": "Can you maybe \njust talk about where you see that over time ? ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "754befae91ed01d65cca05933494a3add0e69fa23324ed917717020f9fb9dce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bb6c6e0-5622-4f39-ab27-4437d1b1c73d", "node_type": "1", "metadata": {"window": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . ", "original_text": "What's the key drivers there?  \n \n"}, "hash": "f42198cefdbddb22f91efde29355991ed25c97424c9be9342949195c9b70b0f6", "class_name": "RelatedNodeInfo"}}, "text": "And again, even your guidance is above where industry \nrates are. ", "start_char_idx": 2308, "end_char_idx": 2374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bb6c6e0-5622-4f39-ab27-4437d1b1c73d": {"__data__": {"id_": "8bb6c6e0-5622-4f39-ab27-4437d1b1c73d", "embedding": null, "metadata": {"window": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . ", "original_text": "What's the key drivers there?  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee7db4a2-d7d0-42f2-bc69-4197b1dc42f1", "node_type": "1", "metadata": {"window": "So maybe can you talk about what you're \nseeing in the market and incremental opportun ities?   And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . ", "original_text": "And again, even your guidance is above where industry \nrates are. ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd0e610f03bcff025f7292631b3d88f9fdab37dfcdff6c26115cdf0a92e1567f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29f50929-33cd-474f-b86f-04106c7d9474", "node_type": "1", "metadata": {"window": "Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that . ", "original_text": "Jason Hollar :  Let me start with the revenue point . "}, "hash": "444e226369459e694d6852b721a99410fa01a5b224762cf0427044cfde6a4b73", "class_name": "RelatedNodeInfo"}}, "text": "What's the key drivers there?  \n \n", "start_char_idx": 2374, "end_char_idx": 2408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29f50929-33cd-474f-b86f-04106c7d9474": {"__data__": {"id_": "29f50929-33cd-474f-b86f-04106c7d9474", "embedding": null, "metadata": {"window": "Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that . ", "original_text": "Jason Hollar :  Let me start with the revenue point . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bb6c6e0-5622-4f39-ab27-4437d1b1c73d", "node_type": "1", "metadata": {"window": "And then secondly, when I look at the revenue \non Pharmaceutical  distribution, you're coming in well above where the industry is .  Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . ", "original_text": "What's the key drivers there?  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0a117394b4dabcc0f4a322c7256cd0729724eed7f214160b152504f87ac29ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c37d9601-c818-4b7b-b600-2033ec09c8e1", "node_type": "1", "metadata": {"window": "And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners . ", "original_text": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . "}, "hash": "70316dee59bbd68b4c742647cc4c12d4a5d5374a86d1356fa996c0ef666c8f70", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Let me start with the revenue point . ", "start_char_idx": 2408, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c37d9601-c818-4b7b-b600-2033ec09c8e1": {"__data__": {"id_": "c37d9601-c818-4b7b-b600-2033ec09c8e1", "embedding": null, "metadata": {"window": "And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners . ", "original_text": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29f50929-33cd-474f-b86f-04106c7d9474", "node_type": "1", "metadata": {"window": "Can you maybe \njust talk about where you see that over time ?  And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that . ", "original_text": "Jason Hollar :  Let me start with the revenue point . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "097c461a898e6e67919471f1ee5291d94e2bb8e1266773cc172995adf0354183", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91b27834-1006-4c92-a4c0-01005ce4ece9", "node_type": "1", "metadata": {"window": "What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . ", "original_text": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . "}, "hash": "92ef3d64ed091e3e8558ed88935537324c70be2d8dc145472550f49ae4cf4384", "class_name": "RelatedNodeInfo"}}, "text": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . ", "start_char_idx": 2462, "end_char_idx": 2583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91b27834-1006-4c92-a4c0-01005ce4ece9": {"__data__": {"id_": "91b27834-1006-4c92-a4c0-01005ce4ece9", "embedding": null, "metadata": {"window": "What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . ", "original_text": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c37d9601-c818-4b7b-b600-2033ec09c8e1", "node_type": "1", "metadata": {"window": "And again, even your guidance is above where industry \nrates are.  What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners . ", "original_text": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6700d6c3e3096388999c739fa4ba021f9b05c6a0cd1df4775aa58d1a2b2bd757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c96feea-06e9-426f-a279-b4446eef1838", "node_type": "1", "metadata": {"window": "Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars . ", "original_text": "But brand has been very \nstrong and our larger customers have been an overweight of that . "}, "hash": "e713e049966707bd1ce05a7be3db492210d1594fff34e163f004a290ca7bd7c0", "class_name": "RelatedNodeInfo"}}, "text": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . ", "start_char_idx": 2583, "end_char_idx": 2689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c96feea-06e9-426f-a279-b4446eef1838": {"__data__": {"id_": "0c96feea-06e9-426f-a279-b4446eef1838", "embedding": null, "metadata": {"window": "Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars . ", "original_text": "But brand has been very \nstrong and our larger customers have been an overweight of that . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91b27834-1006-4c92-a4c0-01005ce4ece9", "node_type": "1", "metadata": {"window": "What's the key drivers there?  \n \n Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . ", "original_text": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3db1dceea7e9a8a5dded247b0cdeb93ab635039eb9985b4221417fed63dc52a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae41ae8-9cae-4eaf-acd6-b4a1badb2314", "node_type": "1", "metadata": {"window": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n", "original_text": "So we're kind of winning with the \nwinners . "}, "hash": "3d0f630350408222783550bf2b9f478da1abbe5c63c43dd4faeae037325659f6", "class_name": "RelatedNodeInfo"}}, "text": "But brand has been very \nstrong and our larger customers have been an overweight of that . ", "start_char_idx": 2689, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae41ae8-9cae-4eaf-acd6-b4a1badb2314": {"__data__": {"id_": "0ae41ae8-9cae-4eaf-acd6-b4a1badb2314", "embedding": null, "metadata": {"window": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n", "original_text": "So we're kind of winning with the \nwinners . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c96feea-06e9-426f-a279-b4446eef1838", "node_type": "1", "metadata": {"window": "Jason Hollar :  Let me start with the revenue point .  So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars . ", "original_text": "But brand has been very \nstrong and our larger customers have been an overweight of that . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66e53acda0b49073afdf1ba55a5b175cc006989ddfa65b49e287b10e7e4a4e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81fe9f6d-d2f5-47e9-a2bb-edb03385e2fe", "node_type": "1", "metadata": {"window": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . ", "original_text": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . "}, "hash": "eb18058631c3178bd054672af397152d1971ba83a17a05ec9a91f4972d95b51f", "class_name": "RelatedNodeInfo"}}, "text": "So we're kind of winning with the \nwinners . ", "start_char_idx": 2780, "end_char_idx": 2825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81fe9f6d-d2f5-47e9-a2bb-edb03385e2fe": {"__data__": {"id_": "81fe9f6d-d2f5-47e9-a2bb-edb03385e2fe", "embedding": null, "metadata": {"window": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . ", "original_text": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae41ae8-9cae-4eaf-acd6-b4a1badb2314", "node_type": "1", "metadata": {"window": "So revenue for this particular quarter we \nhighlighted was driven by brand products as our - with our larger customers .  So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n", "original_text": "So we're kind of winning with the \nwinners . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3084dc67d8913bec75e08abafae701d70fae04af265b67ba2d966ba955cca17a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3520cc9-17c7-4567-b2c1-90b3ea667e8e", "node_type": "1", "metadata": {"window": "But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars . "}, "hash": "54dd105886b85fa5dfea13267baaf2cf188faaeafe4dceb0403718e87f77fb12", "class_name": "RelatedNodeInfo"}}, "text": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . ", "start_char_idx": 2825, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3520cc9-17c7-4567-b2c1-90b3ea667e8e": {"__data__": {"id_": "c3520cc9-17c7-4567-b2c1-90b3ea667e8e", "embedding": null, "metadata": {"window": "But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81fe9f6d-d2f5-47e9-a2bb-edb03385e2fe", "node_type": "1", "metadata": {"window": "So when you think about \nthe flow through of that, that typically brings with it a lower margin profile .  But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . ", "original_text": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b8f63f0d4627838d74368c8586f06b5550dc0e8e8153e33de40f0ea1abaf1e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "031c19dc-af7d-4226-a0df-154c420e82d1", "node_type": "1", "metadata": {"window": "So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "That's fairly consistent to what we've seen \nfor quite some time.  \n \n"}, "hash": "ec20d4e7907d805e6d148564ba097041390745c911749ff211496686e68cd18e", "class_name": "RelatedNodeInfo"}}, "text": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars . ", "start_char_idx": 2988, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "031c19dc-af7d-4226-a0df-154c420e82d1": {"__data__": {"id_": "031c19dc-af7d-4226-a0df-154c420e82d1", "embedding": null, "metadata": {"window": "So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "That's fairly consistent to what we've seen \nfor quite some time.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3520cc9-17c7-4567-b2c1-90b3ea667e8e", "node_type": "1", "metadata": {"window": "But brand has been very \nstrong and our larger customers have been an overweight of that .  So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98e1e8517fccc32e830dfd317de4c6fcb17edb53158198abe27e5dc84d313e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbe85cc5-2630-42b9-b264-bed37920317f", "node_type": "1", "metadata": {"window": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . "}, "hash": "6c3705b7099d7ecde0b416a205cf96c5069fb4219fb3d6b02f1b2fdb973bdc0d", "class_name": "RelatedNodeInfo"}}, "text": "That's fairly consistent to what we've seen \nfor quite some time.  \n \n", "start_char_idx": 3078, "end_char_idx": 3148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbe85cc5-2630-42b9-b264-bed37920317f": {"__data__": {"id_": "cbe85cc5-2630-42b9-b264-bed37920317f", "embedding": null, "metadata": {"window": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "031c19dc-af7d-4226-a0df-154c420e82d1", "node_type": "1", "metadata": {"window": "So we're kind of winning with the \nwinners .  We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "That's fairly consistent to what we've seen \nfor quite some time.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fe0e522e75d93d53a76ad9ebd5adaf75126e92c025e082aeffb42e54b8d8a39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c54d3117-4d14-4e1f-9277-f41ec67eb09c", "node_type": "1", "metadata": {"window": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n "}, "hash": "3d96690fce45fdfd90506228f35265194f4e5e3ffcd4ebf99daa7c4cdaa378e8", "class_name": "RelatedNodeInfo"}}, "text": "We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . ", "start_char_idx": 3148, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c54d3117-4d14-4e1f-9277-f41ec67eb09c": {"__data__": {"id_": "c54d3117-4d14-4e1f-9277-f41ec67eb09c", "embedding": null, "metadata": {"window": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01583edb-346a-409d-a686-087dac013a41", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce7750b9205ad94d1a5419bddf5ec994a2b0a7e5a35d4e5081da5ae90759530d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbe85cc5-2630-42b9-b264-bed37920317f", "node_type": "1", "metadata": {"window": "We are - our bigger customers have been growing nicely and th at has been driving our \nrevenue quite a bit higher, but that tends to be the lower margin product .  And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a096d2aa50358035375aa7cfc22a44417d0479d600b1f249d617c997303022", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95725823-483d-4bdb-8ce9-b135facb2c44", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace . ", "original_text": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry . "}, "hash": "2ebd140db6b7e6512dc5e0dcc87334448a0291a4975dcfd03d7f235671bcfc68", "class_name": "RelatedNodeInfo"}}, "text": "And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "start_char_idx": 3266, "end_char_idx": 3518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95725823-483d-4bdb-8ce9-b135facb2c44": {"__data__": {"id_": "95725823-483d-4bdb-8ce9-b135facb2c44", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace . ", "original_text": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c54d3117-4d14-4e1f-9277-f41ec67eb09c", "node_type": "1", "metadata": {"window": "And so that's why you don't \nsee quite the same flow through in terms of margin dollars .  That's fairly consistent to what we've seen \nfor quite some time.  \n \n We also highlighted in the third quarter of fiscal \u201822 some new business wins that did benefit our \nrevenue as well .  And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "original_text": "And with that it means that the first half of fiscal \u201823, we would anticipate our revenue \nhaving a little bit of a tailwind relative to the ful l year because we will then anniversary lap that new \nbusiness win come the third quarter of fiscal \u201823. \n ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ead0181ae4a046e06efd446b4f533fba5961088f3f150f80b897a09e7cd06137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab4f640d-2960-4275-8170-148700dcb587", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well . ", "original_text": "The first question on generic . "}, "hash": "1e62468e9cd565d05d85c297cd0d713a268726a87f8c24d0c72cbbcff021faa7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry . ", "start_char_idx": 0, "end_char_idx": 63, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab4f640d-2960-4275-8170-148700dcb587": {"__data__": {"id_": "ab4f640d-2960-4275-8170-148700dcb587", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well . ", "original_text": "The first question on generic . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95725823-483d-4bdb-8ce9-b135facb2c44", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace . ", "original_text": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39a4286105e2d164a50cc3b45dd3c979b31e5374f73d3f98ffb4ccea59b8fcdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cfc0f7f-7f4f-4816-b60b-a8afd3c02237", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . ", "original_text": "Yeah . "}, "hash": "07e1c3aa3a8e1962074829b6f49aa968c231790712d1d1f57598a868f6b51cd7", "class_name": "RelatedNodeInfo"}}, "text": "The first question on generic . ", "start_char_idx": 63, "end_char_idx": 95, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cfc0f7f-7f4f-4816-b60b-a8afd3c02237": {"__data__": {"id_": "0cfc0f7f-7f4f-4816-b60b-a8afd3c02237", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . ", "original_text": "Yeah . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab4f640d-2960-4275-8170-148700dcb587", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well . ", "original_text": "The first question on generic . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20cb025c751b4355283ae0fc08d5f9d2acd521f527583c30dd69fb9234fa38c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29c89711-2bdd-45a7-8cc6-99371d256f5d", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations . ", "original_text": "So it continues to be a \nvery consistent dynamics in the marketplace . "}, "hash": "96c81d1d5bc15c51e431b357f839463a68b2c4d408b0f96e76ed96061b56dbdb", "class_name": "RelatedNodeInfo"}}, "text": "Yeah . ", "start_char_idx": 95, "end_char_idx": 102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29c89711-2bdd-45a7-8cc6-99371d256f5d": {"__data__": {"id_": "29c89711-2bdd-45a7-8cc6-99371d256f5d", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations . ", "original_text": "So it continues to be a \nvery consistent dynamics in the marketplace . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cfc0f7f-7f4f-4816-b60b-a8afd3c02237", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . ", "original_text": "Yeah . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7ee6e3ed0d15f4ab88d3e8e326dc793c46ea13818f3c9d90a5d06f8bbd2bb66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d90aa712-614a-42f7-b68e-fdc44ebb3cda", "node_type": "1", "metadata": {"window": "The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system . ", "original_text": "You know, some of the new business wins have \nbenefited that as well . "}, "hash": "48eea868a671949ad6fdb0580d035e737ffe3b3c848782d958fe888a51c9d8fd", "class_name": "RelatedNodeInfo"}}, "text": "So it continues to be a \nvery consistent dynamics in the marketplace . ", "start_char_idx": 102, "end_char_idx": 173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d90aa712-614a-42f7-b68e-fdc44ebb3cda": {"__data__": {"id_": "d90aa712-614a-42f7-b68e-fdc44ebb3cda", "embedding": null, "metadata": {"window": "The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system . ", "original_text": "You know, some of the new business wins have \nbenefited that as well . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29c89711-2bdd-45a7-8cc6-99371d256f5d", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations . ", "original_text": "So it continues to be a \nvery consistent dynamics in the marketplace . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d48141dbbc7f6b75309c8d3fdfe928169834dba080ee8c48fc10ea9fe79cd96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a32abfc-d5dc-4d35-a269-434ec3052075", "node_type": "1", "metadata": {"window": "Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers . ", "original_text": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . "}, "hash": "4293d140cff5aa4debf8a45fecdf455b7c60fa06327f4710be52850ae86fbd03", "class_name": "RelatedNodeInfo"}}, "text": "You know, some of the new business wins have \nbenefited that as well . ", "start_char_idx": 173, "end_char_idx": 244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a32abfc-d5dc-4d35-a269-434ec3052075": {"__data__": {"id_": "5a32abfc-d5dc-4d35-a269-434ec3052075", "embedding": null, "metadata": {"window": "Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers . ", "original_text": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d90aa712-614a-42f7-b68e-fdc44ebb3cda", "node_type": "1", "metadata": {"window": "The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system . ", "original_text": "You know, some of the new business wins have \nbenefited that as well . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4addfa067e9932d68ff63e721703cd2dea5f4da87378414dbc574b6d05a1ffef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d31b2b25-c58e-4026-b4b5-83834a74734c", "node_type": "1", "metadata": {"window": "So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n", "original_text": "So it feels a little bit more \nas business as usual and less fluctuations . "}, "hash": "b2979eb90b92710af96af6907429bfacf416a0a59c46e544919638aa4203208e", "class_name": "RelatedNodeInfo"}}, "text": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . ", "start_char_idx": 244, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d31b2b25-c58e-4026-b4b5-83834a74734c": {"__data__": {"id_": "d31b2b25-c58e-4026-b4b5-83834a74734c", "embedding": null, "metadata": {"window": "So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n", "original_text": "So it feels a little bit more \nas business as usual and less fluctuations . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a32abfc-d5dc-4d35-a269-434ec3052075", "node_type": "1", "metadata": {"window": "Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers . ", "original_text": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1f3b1da96276bf17f365b53fffea02f9592db425518a32bbafdb6013ed5b08c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d51b350-a222-4d5b-ba6c-efd0b1d357df", "node_type": "1", "metadata": {"window": "You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n", "original_text": "And then underlying that, driving margin through sourcing \nand driving the new business through our system . "}, "hash": "3ab7de086e55779eb9d49ac62a5d83bd968f6b86559a84ecc9a53e7c104c1743", "class_name": "RelatedNodeInfo"}}, "text": "So it feels a little bit more \nas business as usual and less fluctuations . ", "start_char_idx": 484, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d51b350-a222-4d5b-ba6c-efd0b1d357df": {"__data__": {"id_": "1d51b350-a222-4d5b-ba6c-efd0b1d357df", "embedding": null, "metadata": {"window": "You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n", "original_text": "And then underlying that, driving margin through sourcing \nand driving the new business through our system . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d31b2b25-c58e-4026-b4b5-83834a74734c", "node_type": "1", "metadata": {"window": "So it continues to be a \nvery consistent dynamics in the marketplace .  You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n", "original_text": "So it feels a little bit more \nas business as usual and less fluctuations . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15161c81d981bb10338d55305a8c103908294dfbf15b51b1ac122af079b9c911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92eb9d0c-1318-4bfd-97a5-a17bfa6825ee", "node_type": "1", "metadata": {"window": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.  ", "original_text": "So those are the prim ary drivers . "}, "hash": "07d9bffb5e269e56687a24137b8370a5c5308a4f363f6c9c59ff5f1b433ee061", "class_name": "RelatedNodeInfo"}}, "text": "And then underlying that, driving margin through sourcing \nand driving the new business through our system . ", "start_char_idx": 560, "end_char_idx": 669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92eb9d0c-1318-4bfd-97a5-a17bfa6825ee": {"__data__": {"id_": "92eb9d0c-1318-4bfd-97a5-a17bfa6825ee", "embedding": null, "metadata": {"window": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.  ", "original_text": "So those are the prim ary drivers . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d51b350-a222-4d5b-ba6c-efd0b1d357df", "node_type": "1", "metadata": {"window": "You know, some of the new business wins have \nbenefited that as well .  You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n", "original_text": "And then underlying that, driving margin through sourcing \nand driving the new business through our system . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98628b3f17a56b7447f627d60a6df56655fa348c02e555338328ac57594cfeb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f624bdeb-13a9-4183-9f0d-d95f045621f1", "node_type": "1", "metadata": {"window": "So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question . ", "original_text": "Next question, \nplease.  \n \n"}, "hash": "df5e88f45491eb905ea4789db378295b1377cd225ddf941d5e2a79948689df34", "class_name": "RelatedNodeInfo"}}, "text": "So those are the prim ary drivers . ", "start_char_idx": 669, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f624bdeb-13a9-4183-9f0d-d95f045621f1": {"__data__": {"id_": "f624bdeb-13a9-4183-9f0d-d95f045621f1", "embedding": null, "metadata": {"window": "So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question . ", "original_text": "Next question, \nplease.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92eb9d0c-1318-4bfd-97a5-a17bfa6825ee", "node_type": "1", "metadata": {"window": "You know, we continue to have very strong performance within Red Oak \nsourcing and the underlying utilisation continues to be much more consistent and stable and \npredictable than what we 've seen ever since the beginning of the pandemic .  So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.  ", "original_text": "So those are the prim ary drivers . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "897f148a1c781daff1b447cdaf59a77a816eb23a89f9b776eefeb9f315aae2a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92de5baa-297c-4f1e-ba84-26a199c37ab9", "node_type": "1", "metadata": {"window": "And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting . ", "original_text": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n"}, "hash": "8407611680a016f91b712871a30554df31f4c0ff1ded94e0766a9a3fb2ae452e", "class_name": "RelatedNodeInfo"}}, "text": "Next question, \nplease.  \n \n", "start_char_idx": 705, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92de5baa-297c-4f1e-ba84-26a199c37ab9": {"__data__": {"id_": "92de5baa-297c-4f1e-ba84-26a199c37ab9", "embedding": null, "metadata": {"window": "And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting . ", "original_text": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f624bdeb-13a9-4183-9f0d-d95f045621f1", "node_type": "1", "metadata": {"window": "So it feels a little bit more \nas business as usual and less fluctuations .  And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question . ", "original_text": "Next question, \nplease.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3d5bf04cbeb896154e75f82a9613530aae4a3de5da8127f053532d506f2638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d57673fc-cd17-472f-964a-3731f201b098", "node_type": "1", "metadata": {"window": "So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . ", "original_text": "Kevin Caliendo :   Great.  "}, "hash": "1405ce170209d53ebc4dd040bd8a7cad8e4737d67ae7d9623f69923b422fe91a", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n", "start_char_idx": 733, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d57673fc-cd17-472f-964a-3731f201b098": {"__data__": {"id_": "d57673fc-cd17-472f-964a-3731f201b098", "embedding": null, "metadata": {"window": "So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . ", "original_text": "Kevin Caliendo :   Great.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92de5baa-297c-4f1e-ba84-26a199c37ab9", "node_type": "1", "metadata": {"window": "And then underlying that, driving margin through sourcing \nand driving the new business through our system .  So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting . ", "original_text": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97e739c40a06f69b949fa1bdf868721961e9d011de28ee1f75d7d3f3e47bc73e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7383b0c-bded-4a4b-8844-76f07015d858", "node_type": "1", "metadata": {"window": "Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts . ", "original_text": "Thanks for taking my question . "}, "hash": "de405d13dafdfa30fd4d28c74446e044d1b7ce0b99884df53fdee828b4f90cdb", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :   Great.  ", "start_char_idx": 805, "end_char_idx": 832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7383b0c-bded-4a4b-8844-76f07015d858": {"__data__": {"id_": "e7383b0c-bded-4a4b-8844-76f07015d858", "embedding": null, "metadata": {"window": "Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts . ", "original_text": "Thanks for taking my question . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d57673fc-cd17-472f-964a-3731f201b098", "node_type": "1", "metadata": {"window": "So those are the prim ary drivers .  Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . ", "original_text": "Kevin Caliendo :   Great.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4970b95c0c5588bb890c20e7aa0461f78f813fab92aa88b65fa08c00c441154f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a360186-4bfd-4445-8e1b-7cfeeab56a36", "node_type": "1", "metadata": {"window": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?  ", "original_text": "I wanted to talk a little bit about the \ncontracting . "}, "hash": "f3a11d01f3febbbe8ffa86e54384897b05479d82200ec1f9855124f14d437aac", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question . ", "start_char_idx": 832, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a360186-4bfd-4445-8e1b-7cfeeab56a36": {"__data__": {"id_": "2a360186-4bfd-4445-8e1b-7cfeeab56a36", "embedding": null, "metadata": {"window": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?  ", "original_text": "I wanted to talk a little bit about the \ncontracting . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7383b0c-bded-4a4b-8844-76f07015d858", "node_type": "1", "metadata": {"window": "Next question, \nplease.  \n \n Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts . ", "original_text": "Thanks for taking my question . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82df26061bba6aa16c8a373b02b5daa53c484e50f4bcad72db5a136d9b42a35a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "836d243b-23c5-4ee1-a013-f492a06dc7e1", "node_type": "1", "metadata": {"window": "Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?  ", "original_text": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . "}, "hash": "bec406aa7433137fbd6de53a167578145fb6982487d884494250359b5960dc33", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to talk a little bit about the \ncontracting . ", "start_char_idx": 864, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "836d243b-23c5-4ee1-a013-f492a06dc7e1": {"__data__": {"id_": "836d243b-23c5-4ee1-a013-f492a06dc7e1", "embedding": null, "metadata": {"window": "Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?  ", "original_text": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a360186-4bfd-4445-8e1b-7cfeeab56a36", "node_type": "1", "metadata": {"window": "Operator :   The next question comes from Kevin Caliendo with UBS.   \n \n Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?  ", "original_text": "I wanted to talk a little bit about the \ncontracting . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23e770229e6e265816c30601774d0ac2f90e8cfe90b8934539810d9eb541ec3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99f46372-fcfa-4d83-981f-5e2a12144460", "node_type": "1", "metadata": {"window": "Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? ", "original_text": "So I just want to understand more about how you're \namending these contracts . "}, "hash": "adfb3b0c1e3c18035deecbccfbf1a986c50f0823c132f683f31ffc835a771bc8", "class_name": "RelatedNodeInfo"}}, "text": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . ", "start_char_idx": 919, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99f46372-fcfa-4d83-981f-5e2a12144460": {"__data__": {"id_": "99f46372-fcfa-4d83-981f-5e2a12144460", "embedding": null, "metadata": {"window": "Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? ", "original_text": "So I just want to understand more about how you're \namending these contracts . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "836d243b-23c5-4ee1-a013-f492a06dc7e1", "node_type": "1", "metadata": {"window": "Kevin Caliendo :   Great.   Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?  ", "original_text": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a42fd83fd9618e80144592b8945d60d37d50f14013c5f53e46ed4cfab34f3eeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "560c9c98-2967-47ea-8d2f-3f9c98a1f2e4", "node_type": "1", "metadata": {"window": "I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works. ", "original_text": "Are customers comfortable with this?  "}, "hash": "2f8e12a17a8dde4f26de8ef27613c15b12bf7380e07074818468ee62cf368f3b", "class_name": "RelatedNodeInfo"}}, "text": "So I just want to understand more about how you're \namending these contracts . ", "start_char_idx": 1061, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "560c9c98-2967-47ea-8d2f-3f9c98a1f2e4": {"__data__": {"id_": "560c9c98-2967-47ea-8d2f-3f9c98a1f2e4", "embedding": null, "metadata": {"window": "I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works. ", "original_text": "Are customers comfortable with this?  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99f46372-fcfa-4d83-981f-5e2a12144460", "node_type": "1", "metadata": {"window": "Thanks for taking my question .  I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? ", "original_text": "So I just want to understand more about how you're \namending these contracts . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38e306f663b7a84b87067aa57d003d7f925592d94f3bb415295057b6bf6d36a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f615bc8f-e36a-4b1b-9cb3-9aaf48b229d3", "node_type": "1", "metadata": {"window": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  ", "original_text": "Is there any pushback?  "}, "hash": "a0b063e26087f9bb0b8133550230342bad80b34bed0cc648edd0f3401608eaad", "class_name": "RelatedNodeInfo"}}, "text": "Are customers comfortable with this?  ", "start_char_idx": 1140, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f615bc8f-e36a-4b1b-9cb3-9aaf48b229d3": {"__data__": {"id_": "f615bc8f-e36a-4b1b-9cb3-9aaf48b229d3", "embedding": null, "metadata": {"window": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  ", "original_text": "Is there any pushback?  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "560c9c98-2967-47ea-8d2f-3f9c98a1f2e4", "node_type": "1", "metadata": {"window": "I wanted to talk a little bit about the \ncontracting .  I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works. ", "original_text": "Are customers comfortable with this?  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66f803470e78efe859d04e636e7d484907655b9e9adb76b074294bbff9d79563", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb96e5e5-0f20-4481-bfea-0d78021d3bb7", "node_type": "1", "metadata": {"window": "So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.  ", "original_text": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? "}, "hash": "6a5f23489ab3653c97aaf26ba0661d422e7f291ceb1fc3190aac74691cc4dba4", "class_name": "RelatedNodeInfo"}}, "text": "Is there any pushback?  ", "start_char_idx": 1178, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb96e5e5-0f20-4481-bfea-0d78021d3bb7": {"__data__": {"id_": "eb96e5e5-0f20-4481-bfea-0d78021d3bb7", "embedding": null, "metadata": {"window": "So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.  ", "original_text": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f615bc8f-e36a-4b1b-9cb3-9aaf48b229d3", "node_type": "1", "metadata": {"window": "I think the last time Cardinal went through a  lot of contracting through COVID, it ended up \nkind of working against you as things reverse .  So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  ", "original_text": "Is there any pushback?  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3528425b6dc0aa6fffc79e8b11514c3731662aa8f07d7af910352ec1bbbda49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8d496c9-512d-4c86-917e-b1cefe8fcd17", "node_type": "1", "metadata": {"window": "Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . ", "original_text": "So just wondering how it works. "}, "hash": "037b0c271d63a45342a8866563d83a6eb892937c440b0ca637b7c93a077d640b", "class_name": "RelatedNodeInfo"}}, "text": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? ", "start_char_idx": 1202, "end_char_idx": 1337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8d496c9-512d-4c86-917e-b1cefe8fcd17": {"__data__": {"id_": "f8d496c9-512d-4c86-917e-b1cefe8fcd17", "embedding": null, "metadata": {"window": "Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . ", "original_text": "So just wondering how it works. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb96e5e5-0f20-4481-bfea-0d78021d3bb7", "node_type": "1", "metadata": {"window": "So I just want to understand more about how you're \namending these contracts .  Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.  ", "original_text": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general? ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab2a4f13b91de0d8a51501d3da7bedec1d3a8349491584d980c7456050f46b8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8edd8373-aff7-4f35-abae-2fb2c0ca526b", "node_type": "1", "metadata": {"window": "Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n", "original_text": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  "}, "hash": "a6743f8b885918fbeb2aa82ce1f4785e24520d5fa882ba0b029207aa85b129c0", "class_name": "RelatedNodeInfo"}}, "text": "So just wondering how it works. ", "start_char_idx": 1337, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8edd8373-aff7-4f35-abae-2fb2c0ca526b": {"__data__": {"id_": "8edd8373-aff7-4f35-abae-2fb2c0ca526b", "embedding": null, "metadata": {"window": "Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n", "original_text": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8d496c9-512d-4c86-917e-b1cefe8fcd17", "node_type": "1", "metadata": {"window": "Are customers comfortable with this?   Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . ", "original_text": "So just wondering how it works. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "287af90826085592d371aa4b0d783f5bd1949eb83f9b04de64041c2fd8642584", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bf40960-8a68-4120-ba36-082610aff97e", "node_type": "1", "metadata": {"window": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure. ", "original_text": "Anything there would b e helpful.  "}, "hash": "475e8340b056e8d7536d17d349c66d80449c5494a22fd0581c673bf61366b24d", "class_name": "RelatedNodeInfo"}}, "text": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  ", "start_char_idx": 1369, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf40960-8a68-4120-ba36-082610aff97e": {"__data__": {"id_": "5bf40960-8a68-4120-ba36-082610aff97e", "embedding": null, "metadata": {"window": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure. ", "original_text": "Anything there would b e helpful.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8edd8373-aff7-4f35-abae-2fb2c0ca526b", "node_type": "1", "metadata": {"window": "Is there any pushback?   There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n", "original_text": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a482d3b2709a4e8e57169f62d0429e0eb51b0281bad9b4d7c3c2362caec32a38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d504e6fc-afec-4b95-a389-2607c5a637b7", "node_type": "1", "metadata": {"window": "So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n", "original_text": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . "}, "hash": "b443b9119f210229476c57da2e99f4c04bc67cc4250d309a41e9a4485f901782", "class_name": "RelatedNodeInfo"}}, "text": "Anything there would b e helpful.  ", "start_char_idx": 1460, "end_char_idx": 1495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d504e6fc-afec-4b95-a389-2607c5a637b7": {"__data__": {"id_": "d504e6fc-afec-4b95-a389-2607c5a637b7", "embedding": null, "metadata": {"window": "So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n", "original_text": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf40960-8a68-4120-ba36-082610aff97e", "node_type": "1", "metadata": {"window": "There \nseemingly is ef forts amongst almost all hospital companies to reduce their supply costs right now or \nreduce costs in general?  So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure. ", "original_text": "Anything there would b e helpful.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdac918d8d8746577c63d3ffbaacc5ad0cdda5d1289166ddc64c60b326de56d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bb7aea5-73f2-4671-a153-f286b604f717", "node_type": "1", "metadata": {"window": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n", "original_text": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n"}, "hash": "6e5f6142e4c8d7b0e41d07c417858c904e72c3646be1975ae58944ee8dd0e54b", "class_name": "RelatedNodeInfo"}}, "text": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . ", "start_char_idx": 1495, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bb7aea5-73f2-4671-a153-f286b604f717": {"__data__": {"id_": "5bb7aea5-73f2-4671-a153-f286b604f717", "embedding": null, "metadata": {"window": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n", "original_text": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d504e6fc-afec-4b95-a389-2607c5a637b7", "node_type": "1", "metadata": {"window": "So just wondering how it works.  Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n", "original_text": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e422e7b049aeb8db899422ccd9055315b4e4edd42e222db5f18f5e8e5b7f7523", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41c204bf-351a-4738-88b9-3f6d5316245a", "node_type": "1", "metadata": {"window": "Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay. ", "original_text": "Jason Hollar :   Sure. "}, "hash": "a4578b7b2248f9dc20737075073b085084cc900e53c91e0dcb86599385cb2615", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n", "start_char_idx": 1687, "end_char_idx": 1804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41c204bf-351a-4738-88b9-3f6d5316245a": {"__data__": {"id_": "41c204bf-351a-4738-88b9-3f6d5316245a", "embedding": null, "metadata": {"window": "Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay. ", "original_text": "Jason Hollar :   Sure. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bb7aea5-73f2-4671-a153-f286b604f717", "node_type": "1", "metadata": {"window": "Does it - is it impacting you immediately or \nis this more of a cushion for longer -term?   Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n", "original_text": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69a22d1d75e02b21991caee27c67616f094729421a7f5456ee9213062e3a83c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a0dd58-3d03-4af0-9b8d-6de23dbd7221", "node_type": "1", "metadata": {"window": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . ", "original_text": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n"}, "hash": "c16a691fb9ca910836bc479e7829ae3f6c4e0a7d5372198531c0553389e3fd28", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Sure. ", "start_char_idx": 1804, "end_char_idx": 1827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a0dd58-3d03-4af0-9b8d-6de23dbd7221": {"__data__": {"id_": "35a0dd58-3d03-4af0-9b8d-6de23dbd7221", "embedding": null, "metadata": {"window": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . ", "original_text": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41c204bf-351a-4738-88b9-3f6d5316245a", "node_type": "1", "metadata": {"window": "Anything there would b e helpful.   And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay. ", "original_text": "Jason Hollar :   Sure. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "852e462a4d5d3c991c1f3f9fb386af2bbe63709fde2fc3aad5e59098d525ff67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79326658-365b-4fa6-aa77-c7eaba75b05f", "node_type": "1", "metadata": {"window": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  ", "original_text": "Kevin Caliendo :   Yeah.  \n \n"}, "hash": "15cc3135a465956f0c034e0947ab7f22076d3f4fe28a2dd3a4645b0dd0837cf8", "class_name": "RelatedNodeInfo"}}, "text": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n", "start_char_idx": 1827, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79326658-365b-4fa6-aa77-c7eaba75b05f": {"__data__": {"id_": "79326658-365b-4fa6-aa77-c7eaba75b05f", "embedding": null, "metadata": {"window": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  ", "original_text": "Kevin Caliendo :   Yeah.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a0dd58-3d03-4af0-9b8d-6de23dbd7221", "node_type": "1", "metadata": {"window": "And then one other follow -\nup is I read that there was a real estate transaction done and if that was part of the business review \npotential outcomes was to maybe monetise some real estate .  Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . ", "original_text": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "834648cb435b063af219bfc8cfec875e158e54151e8c67888967cf2aec01c878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc26469e-f2dc-4fe5-af0a-09d4ed8134fc", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years. ", "original_text": "Jason Hollar :   Yeah , okay. "}, "hash": "73b33ef6df09879486495d6cf178db12b2b5203abcd923a4814e697c2c0e76ed", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :   Yeah.  \n \n", "start_char_idx": 1951, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc26469e-f2dc-4fe5-af0a-09d4ed8134fc": {"__data__": {"id_": "fc26469e-f2dc-4fe5-af0a-09d4ed8134fc", "embedding": null, "metadata": {"window": "Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years. ", "original_text": "Jason Hollar :   Yeah , okay. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79326658-365b-4fa6-aa77-c7eaba75b05f", "node_type": "1", "metadata": {"window": "Can you talk about the opportunity size \nto be able to do  that in terms of generating capital for the business?  \n \n Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  ", "original_text": "Kevin Caliendo :   Yeah.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecdb065eeb0fba9732237ee9bce1683c8985bd48ed210da1ff7d4aa4a8dc4175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1920b398-a5fc-4af5-9dcb-afdc838d51c6", "node_type": "1", "metadata": {"window": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  ", "original_text": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . "}, "hash": "a0d19f8ff384759a8763252b1b17c8bb15f6ef515173260495b41f6a0a3faaf0", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Yeah , okay. ", "start_char_idx": 1980, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1920b398-a5fc-4af5-9dcb-afdc838d51c6": {"__data__": {"id_": "1920b398-a5fc-4af5-9dcb-afdc838d51c6", "embedding": null, "metadata": {"window": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  ", "original_text": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc26469e-f2dc-4fe5-af0a-09d4ed8134fc", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.  So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years. ", "original_text": "Jason Hollar :   Yeah , okay. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49265152da3295767354930d5d21cef5ccbd131931815f0f2c20251c78b3b5bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4ae37a3-774f-4d5f-8b10-33988e478514", "node_type": "1", "metadata": {"window": "Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations. ", "original_text": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  "}, "hash": "975310b05b2abe0b45dc6127fffa9e696d7023aaa8a05d3ffda280452ff7767c", "class_name": "RelatedNodeInfo"}}, "text": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . ", "start_char_idx": 2010, "end_char_idx": 2142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4ae37a3-774f-4d5f-8b10-33988e478514": {"__data__": {"id_": "c4ae37a3-774f-4d5f-8b10-33988e478514", "embedding": null, "metadata": {"window": "Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations. ", "original_text": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1920b398-a5fc-4af5-9dcb-afdc838d51c6", "node_type": "1", "metadata": {"window": "So on the contracting, first of all, Kevin, I'm presuming you're talking about the \nMedical inflationary price impacts ? \n \n Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  ", "original_text": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "397b5fcbc2a8dc10cf3d2e75aa9473148f5b59c153351f0d5ea548660d0a8537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1923768-9a59-457c-9603-ed6ff58f70ab", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.  ", "original_text": "So \nas you can imagine, those contracts roll over, over the course of multiple years. "}, "hash": "03802cf50cba60ff1090b5c5b307be59a94d59bdeb7bab76a0ae800b8559ec13", "class_name": "RelatedNodeInfo"}}, "text": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  ", "start_char_idx": 2142, "end_char_idx": 2392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1923768-9a59-457c-9603-ed6ff58f70ab": {"__data__": {"id_": "b1923768-9a59-457c-9603-ed6ff58f70ab", "embedding": null, "metadata": {"window": "Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.  ", "original_text": "So \nas you can imagine, those contracts roll over, over the course of multiple years. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4ae37a3-774f-4d5f-8b10-33988e478514", "node_type": "1", "metadata": {"window": "Kevin Caliendo :   Yeah.  \n \n Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations. ", "original_text": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "576186d8835d2cd5a75a99dbdf7671db5b6fbeb05d587eb4ba1bb1f7461520cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4877284b-e3f8-46fc-bdf3-fc36ea888e20", "node_type": "1", "metadata": {"window": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere. ", "original_text": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  "}, "hash": "87f22a746af17cf4fded56c320517da80c6f90ed589629c45a84ad71698f4de5", "class_name": "RelatedNodeInfo"}}, "text": "So \nas you can imagine, those contracts roll over, over the course of multiple years. ", "start_char_idx": 2392, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4877284b-e3f8-46fc-bdf3-fc36ea888e20": {"__data__": {"id_": "4877284b-e3f8-46fc-bdf3-fc36ea888e20", "embedding": null, "metadata": {"window": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere. ", "original_text": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1923768-9a59-457c-9603-ed6ff58f70ab", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah , okay.  So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.  ", "original_text": "So \nas you can imagine, those contracts roll over, over the course of multiple years. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb477a74a3f07b92900c90102aa6d15ae98736e6a5599b0aaac8bbf57b9c5e89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdcecb0e-7f8d-4c1c-8d09-4f41dd4c51e8", "node_type": "1", "metadata": {"window": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  ", "original_text": "However, I'll tell you, it's \ngoing consistent with my expectations. "}, "hash": "baab063dab2835db4de6bac4fdfe58043aa9681caea7737bed4b60345ca4eecb", "class_name": "RelatedNodeInfo"}}, "text": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  ", "start_char_idx": 2478, "end_char_idx": 2579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdcecb0e-7f8d-4c1c-8d09-4f41dd4c51e8": {"__data__": {"id_": "cdcecb0e-7f8d-4c1c-8d09-4f41dd4c51e8", "embedding": null, "metadata": {"window": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  ", "original_text": "However, I'll tell you, it's \ngoing consistent with my expectations. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4877284b-e3f8-46fc-bdf3-fc36ea888e20", "node_type": "1", "metadata": {"window": "So the way  the pricing that we've defined, those are temporary in nature \nto get us to the contracting that you're talking about .  So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere. ", "original_text": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c29e3628a9a98e86ab5ad2d3e7ef31c0e2343c2cbae488a24182ed07a923b538", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c224a566-a66e-4796-ba55-4119114dfc7f", "node_type": "1", "metadata": {"window": "So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  ", "original_text": "These are never easy conversations.  "}, "hash": "6d37212ac1d9e43226d38d756af5749aad51d54a025a5054493d47174d07e694", "class_name": "RelatedNodeInfo"}}, "text": "However, I'll tell you, it's \ngoing consistent with my expectations. ", "start_char_idx": 2579, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c224a566-a66e-4796-ba55-4119114dfc7f": {"__data__": {"id_": "c224a566-a66e-4796-ba55-4119114dfc7f", "embedding": null, "metadata": {"window": "So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  ", "original_text": "These are never easy conversations.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdcecb0e-7f8d-4c1c-8d09-4f41dd4c51e8", "node_type": "1", "metadata": {"window": "So as the contracts renew, those temporary price \nincreases are then flowed through to the permanent structure with - then having adjustm ents within \nthere so that we don't have the same issue again in the future that we've had to experience here.   So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  ", "original_text": "However, I'll tell you, it's \ngoing consistent with my expectations. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fffef5e27c3647529298bc71245e5e458d28c41b1aab00be23cfa183db66fbf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38fc554d-c3ab-4bcb-9aef-07fe134c8090", "node_type": "1", "metadata": {"window": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  ", "original_text": "But to your point and \nhow you even frame the question, inflation is everywhere. "}, "hash": "9ace3e6d889687ea1350f42d74f3ee6bf4872f4a4a2e7a61ee4fabf33a2f6b3d", "class_name": "RelatedNodeInfo"}}, "text": "These are never easy conversations.  ", "start_char_idx": 2648, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38fc554d-c3ab-4bcb-9aef-07fe134c8090": {"__data__": {"id_": "38fc554d-c3ab-4bcb-9aef-07fe134c8090", "embedding": null, "metadata": {"window": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  ", "original_text": "But to your point and \nhow you even frame the question, inflation is everywhere. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c224a566-a66e-4796-ba55-4119114dfc7f", "node_type": "1", "metadata": {"window": "So \nas you can imagine, those contracts roll over, over the course of multiple years.  We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  ", "original_text": "These are never easy conversations.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da50c87d743ff0d1ae20541775c6806038402450e625764eeca7263db593d7c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d23fe7e-f5f1-4b7e-b08e-ae1a7b905468", "node_type": "1", "metadata": {"window": "However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable . ", "original_text": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  "}, "hash": "dfc9db4839a6d8f456498af8f4ff41ef5affac22fade53d80799af2725b127e9", "class_name": "RelatedNodeInfo"}}, "text": "But to your point and \nhow you even frame the question, inflation is everywhere. ", "start_char_idx": 2685, "end_char_idx": 2766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d23fe7e-f5f1-4b7e-b08e-ae1a7b905468": {"__data__": {"id_": "7d23fe7e-f5f1-4b7e-b08e-ae1a7b905468", "embedding": null, "metadata": {"window": "However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable . ", "original_text": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38fc554d-c3ab-4bcb-9aef-07fe134c8090", "node_type": "1", "metadata": {"window": "We've highlighted \nthree to four years and we're still in th e earlier phases of innings with that.   However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  ", "original_text": "But to your point and \nhow you even frame the question, inflation is everywhere. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4091e17fe48064e575a582781cbc18e0beac891afd2aab9897858daca4daaa7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d9f3de0-45fc-4963-a04a-ba7103dab56f", "node_type": "1", "metadata": {"window": "These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  ", "original_text": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  "}, "hash": "6b1f04718e91ac3edf8a2fddf842ff8ebc6e2238b2cae2f5d2dca89f84f00e0f", "class_name": "RelatedNodeInfo"}}, "text": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  ", "start_char_idx": 2766, "end_char_idx": 2875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d9f3de0-45fc-4963-a04a-ba7103dab56f": {"__data__": {"id_": "9d9f3de0-45fc-4963-a04a-ba7103dab56f", "embedding": null, "metadata": {"window": "These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  ", "original_text": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d23fe7e-f5f1-4b7e-b08e-ae1a7b905468", "node_type": "1", "metadata": {"window": "However, I'll tell you, it's \ngoing consistent with my expectations.  These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable . ", "original_text": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98b427d1c1f532643939bc700f2024d714a0ee5061dfd2e6555f7b855b0ad258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a67a2851-2e10-498f-ae37-c27d453328cb", "node_type": "1", "metadata": {"window": "But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. ", "original_text": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  "}, "hash": "60845c77dba2a22478f11ff0432885b14a13912c1dce9f256935a6959777a5b6", "class_name": "RelatedNodeInfo"}}, "text": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  ", "start_char_idx": 2875, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a67a2851-2e10-498f-ae37-c27d453328cb": {"__data__": {"id_": "a67a2851-2e10-498f-ae37-c27d453328cb", "embedding": null, "metadata": {"window": "But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. ", "original_text": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d9f3de0-45fc-4963-a04a-ba7103dab56f", "node_type": "1", "metadata": {"window": "These are never easy conversations.   But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  ", "original_text": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "004e1e01e4244ef384eb936bbd33d9db668612bfb7b81dfedb80d349deae1cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "218bd519-7b29-4b99-9e97-32054231024a", "node_type": "1", "metadata": {"window": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. ", "original_text": "So there's some \ncomponents that will be more variable . "}, "hash": "a45772f865bf832d4da40dfcb3967d89fe4c9b27154918b4812c7eca464b9b1c", "class_name": "RelatedNodeInfo"}}, "text": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  ", "start_char_idx": 2977, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "218bd519-7b29-4b99-9e97-32054231024a": {"__data__": {"id_": "218bd519-7b29-4b99-9e97-32054231024a", "embedding": null, "metadata": {"window": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. ", "original_text": "So there's some \ncomponents that will be more variable . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a67a2851-2e10-498f-ae37-c27d453328cb", "node_type": "1", "metadata": {"window": "But to your point and \nhow you even frame the question, inflation is everywhere.  And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. ", "original_text": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ccacfdf3eb933ea08db15406519c9b14b1daebfd0f0db763d5b60ed7167ad6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04fdfc4e-1e99-4fb0-929d-00aa359fefff", "node_type": "1", "metadata": {"window": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  "}, "hash": "02beaf7172db00c86f230b149b7c885bde93f0346eedb1b71f2460d8a79bd926", "class_name": "RelatedNodeInfo"}}, "text": "So there's some \ncomponents that will be more variable . ", "start_char_idx": 3089, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04fdfc4e-1e99-4fb0-929d-00aa359fefff": {"__data__": {"id_": "04fdfc4e-1e99-4fb0-929d-00aa359fefff", "embedding": null, "metadata": {"window": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "218bd519-7b29-4b99-9e97-32054231024a", "node_type": "1", "metadata": {"window": "And while some of this is more temporary \nin nature, a lot of it is going to be long lasting and permanent.   You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. ", "original_text": "So there's some \ncomponents that will be more variable . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ba6692da297c3ccf1e4cba0a5efccf5838bdcd38a6bc582ee4b417538c815dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f519fa9-130d-4cbf-80bc-6b6a086e8cca", "node_type": "1", "metadata": {"window": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. "}, "hash": "ee9a84446a2b1ea13a9a380e4b43ff5d3290f35f8e2d8d94bfa35b25a9b47f80", "class_name": "RelatedNodeInfo"}}, "text": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  ", "start_char_idx": 3146, "end_char_idx": 3273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f519fa9-130d-4cbf-80bc-6b6a086e8cca": {"__data__": {"id_": "1f519fa9-130d-4cbf-80bc-6b6a086e8cca", "embedding": null, "metadata": {"window": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04fdfc4e-1e99-4fb0-929d-00aa359fefff", "node_type": "1", "metadata": {"window": "You know, when you think about \nespecially labo r, right, those costs a re never going to come down.   And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.  ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8a2277e46760ef4523b3de0d4ecc6340a5606c39fa437f7a43833edd7847ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7cd5573-c078-4d18-be27-45c557cdc035", "node_type": "1", "metadata": {"window": "So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. "}, "hash": "5d9c7fe612ec5fd60ab6ec97eb7607ea0559dea5f98328eb2132e3b8dead7af1", "class_name": "RelatedNodeInfo"}}, "text": "And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. ", "start_char_idx": 3273, "end_char_idx": 3490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7cd5573-c078-4d18-be27-45c557cdc035": {"__data__": {"id_": "f7cd5573-c078-4d18-be27-45c557cdc035", "embedding": null, "metadata": {"window": "So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f519fa9-130d-4cbf-80bc-6b6a086e8cca", "node_type": "1", "metadata": {"window": "And a lot of the transportation \ncosts feel like it's going to be at very elevated levels for quite some time.   So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52450f4bd9a657fe4e468cd0cf043d88b5c3ed17c78e2be251eb036d2e96196b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32f9cf4-7188-4a9f-83a7-f7f7e7cae33d", "node_type": "1", "metadata": {"window": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "And you can just look at our public financial "}, "hash": "648b955069fb871264ea67bbbaaf573beb8caa4013d7713367d770a5c17e2743", "class_name": "RelatedNodeInfo"}}, "text": "So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. ", "start_char_idx": 3490, "end_char_idx": 3675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32f9cf4-7188-4a9f-83a7-f7f7e7cae33d": {"__data__": {"id_": "e32f9cf4-7188-4a9f-83a7-f7f7e7cae33d", "embedding": null, "metadata": {"window": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "And you can just look at our public financial ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d792693cd184d211fdb6a69c73ff1b9790acb16b437da94273d5b7cbcf99b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7cd5573-c078-4d18-be27-45c557cdc035", "node_type": "1", "metadata": {"window": "So there's some \ncomponents that will be more variable .  But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs. ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd36187697ba85a5d8992558053ba7b93c007325fbbd9150e626f3d15eb34ed5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13bbffca-f782-4613-b272-15f165a262c2", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.  ", "original_text": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.  "}, "hash": "47c8e36d34120af060f6fc44ffe4dd3382017c0ced14c82c876c1dadc9ae595b", "class_name": "RelatedNodeInfo"}}, "text": "And you can just look at our public financial ", "start_char_idx": 3675, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13bbffca-f782-4613-b272-15f165a262c2": {"__data__": {"id_": "13bbffca-f782-4613-b272-15f165a262c2", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.  ", "original_text": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32f9cf4-7188-4a9f-83a7-f7f7e7cae33d", "node_type": "1", "metadata": {"window": "But ultimately, the one thing that's clear to us is that the re will \nbe a permanent step -up increase in that level of cost.   And depending upon exactly how the Fed \nmoves here and how macroeconomic factors roll into this, we need to be positioned so that we have \na structure that allows us to claw this back by the tim e we exit fiscal \u201824.  So again, not easy, but it's a \nprocess that our customers understand that we're in the middle of this supply chain and that we have \nto have the assistance bill to offset these costs.  And you can just look at our public financial ", "original_text": "And you can just look at our public financial ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ee7ff5b4991713b67fc7c2ebb8c483232e94fbfcdc75f9636c5a66233ffcc73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d0cbfbd-8086-4b6c-8735-81e3533563bf", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation. ", "original_text": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n"}, "hash": "d7c5cdc6a8824580ba402091013322bde49f7f6ce2a563f147cae97c764e1369", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.  ", "start_char_idx": 0, "end_char_idx": 97, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d0cbfbd-8086-4b6c-8735-81e3533563bf": {"__data__": {"id_": "2d0cbfbd-8086-4b6c-8735-81e3533563bf", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation. ", "original_text": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13bbffca-f782-4613-b272-15f165a262c2", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.  ", "original_text": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f19fb6344c39c124493587713d71b1d1656817b487479116534bdec1adf0b91a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8660d11-1316-46b5-b063-92bc449ec6de", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.  ", "original_text": "As it relates to the real estate transaction, we've  had some small transactions. "}, "hash": "325323b1b0c05a055ee9a462bdbb855911e05f5bd0270e369e4e6baed010a233", "class_name": "RelatedNodeInfo"}}, "text": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n", "start_char_idx": 97, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8660d11-1316-46b5-b063-92bc449ec6de": {"__data__": {"id_": "e8660d11-1316-46b5-b063-92bc449ec6de", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.  ", "original_text": "As it relates to the real estate transaction, we've  had some small transactions. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d0cbfbd-8086-4b6c-8735-81e3533563bf", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation. ", "original_text": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddf2742fb921602535a7a52b3324edfdf5cbfd42ff0c2b65a07d94f6309b3c95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "573bf3e0-dde3-4ea2-84ec-229d12f45cb8", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.  ", "original_text": "There's nothing \nmaterial at all to call out.  "}, "hash": "bc45ccb4335da6fc0a0c5a83785df10ac9a2c7024a8c2378eec8f5e851a87a1e", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the real estate transaction, we've  had some small transactions. ", "start_char_idx": 232, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "573bf3e0-dde3-4ea2-84ec-229d12f45cb8": {"__data__": {"id_": "573bf3e0-dde3-4ea2-84ec-229d12f45cb8", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.  ", "original_text": "There's nothing \nmaterial at all to call out.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8660d11-1316-46b5-b063-92bc449ec6de", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.  ", "original_text": "As it relates to the real estate transaction, we've  had some small transactions. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdf6cb348642f1aeadd6926b89489cea89c4fdcf7375cf25a32b739f51993333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "626be553-4f98-4868-bf70-0d4de2b2d9b4", "node_type": "1", "metadata": {"window": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that. ", "original_text": "You know, there's always evaluation. "}, "hash": "b99971eb6a5902d6258590c96b6eae7c3d73ffc7bfe0bb408cb67c4b2d148dd8", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing \nmaterial at all to call out.  ", "start_char_idx": 314, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "626be553-4f98-4868-bf70-0d4de2b2d9b4": {"__data__": {"id_": "626be553-4f98-4868-bf70-0d4de2b2d9b4", "embedding": null, "metadata": {"window": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that. ", "original_text": "You know, there's always evaluation. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "573bf3e0-dde3-4ea2-84ec-229d12f45cb8", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.  ", "original_text": "There's nothing \nmaterial at all to call out.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21ce0f2a7430e33c89dc5c4ebfdfd6618d9348097fb0d41b73c36c4d057615e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52ac8821-89e8-480e-b012-ba2d29e61cd0", "node_type": "1", "metadata": {"window": "As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n", "original_text": "We do own some real estate.  "}, "hash": "86e9d1a115757239c4153995500d6312b2069d2b2caf24c53acbb76b58f15854", "class_name": "RelatedNodeInfo"}}, "text": "You know, there's always evaluation. ", "start_char_idx": 361, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52ac8821-89e8-480e-b012-ba2d29e61cd0": {"__data__": {"id_": "52ac8821-89e8-480e-b012-ba2d29e61cd0", "embedding": null, "metadata": {"window": "As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n", "original_text": "We do own some real estate.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "626be553-4f98-4868-bf70-0d4de2b2d9b4", "node_type": "1", "metadata": {"window": "We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that. ", "original_text": "You know, there's always evaluation. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed37ce9b4a1fc0f29b5c05ed10a5b2f9304969875e715da9293d757df5665a25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cf607b0-5afc-4c12-8b5c-e030d8b3650e", "node_type": "1", "metadata": {"window": "There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n", "original_text": "It is a \ncomponent of one of those factors that we look at.  "}, "hash": "d1f7adfd5b0f6260959de8ccc7359ab9c986364faf5b5b48e6ce9e54e8d46877", "class_name": "RelatedNodeInfo"}}, "text": "We do own some real estate.  ", "start_char_idx": 398, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cf607b0-5afc-4c12-8b5c-e030d8b3650e": {"__data__": {"id_": "5cf607b0-5afc-4c12-8b5c-e030d8b3650e", "embedding": null, "metadata": {"window": "There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n", "original_text": "It is a \ncomponent of one of those factors that we look at.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52ac8821-89e8-480e-b012-ba2d29e61cd0", "node_type": "1", "metadata": {"window": "As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n", "original_text": "We do own some real estate.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84ee075606ea79889e66b9122b3a929a8fcddc700464d12f3b6c99c2b00e20af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4acdf9ef-beaf-4933-95f0-6a9479fb91eb", "node_type": "1", "metadata": {"window": "You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks. ", "original_text": "At this point, it's too early to talk about any type  of \nopportunity with that. "}, "hash": "b13863ccada8dac24bcebefadbef33ceff7722ae2a7f365aa9ae3395f63fae67", "class_name": "RelatedNodeInfo"}}, "text": "It is a \ncomponent of one of those factors that we look at.  ", "start_char_idx": 427, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4acdf9ef-beaf-4933-95f0-6a9479fb91eb": {"__data__": {"id_": "4acdf9ef-beaf-4933-95f0-6a9479fb91eb", "embedding": null, "metadata": {"window": "You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks. ", "original_text": "At this point, it's too early to talk about any type  of \nopportunity with that. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cf607b0-5afc-4c12-8b5c-e030d8b3650e", "node_type": "1", "metadata": {"window": "There's nothing \nmaterial at all to call out.   You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n", "original_text": "It is a \ncomponent of one of those factors that we look at.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ebf3defaeb41602b5176ffda255eb8d42bc248e36936009632954ed01d92767", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42428262-0b13-4887-acfb-f81e4afa83a0", "node_type": "1", "metadata": {"window": "We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  ", "original_text": "Next question, please.  \n \n"}, "hash": "a8223ba179f18bef8cae7c0adf88d05154527776f860569e147f5b2ce5fe0e7b", "class_name": "RelatedNodeInfo"}}, "text": "At this point, it's too early to talk about any type  of \nopportunity with that. ", "start_char_idx": 488, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42428262-0b13-4887-acfb-f81e4afa83a0": {"__data__": {"id_": "42428262-0b13-4887-acfb-f81e4afa83a0", "embedding": null, "metadata": {"window": "We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  ", "original_text": "Next question, please.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4acdf9ef-beaf-4933-95f0-6a9479fb91eb", "node_type": "1", "metadata": {"window": "You know, there's always evaluation.  We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks. ", "original_text": "At this point, it's too early to talk about any type  of \nopportunity with that. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0155d9b5f8de170cf74385376aa1ab56401317d25ce2b01021cb273692b3a79e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e3b1cbb-bdcf-4c09-953e-0952ed966cbb", "node_type": "1", "metadata": {"window": "It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? ", "original_text": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n"}, "hash": "90ae73b0fb5a97df6513bec142ee16ee601ff96bcd180c8ade923c9f2f92d754", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 569, "end_char_idx": 596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e3b1cbb-bdcf-4c09-953e-0952ed966cbb": {"__data__": {"id_": "8e3b1cbb-bdcf-4c09-953e-0952ed966cbb", "embedding": null, "metadata": {"window": "It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? ", "original_text": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42428262-0b13-4887-acfb-f81e4afa83a0", "node_type": "1", "metadata": {"window": "We do own some real estate.   It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  ", "original_text": "Next question, please.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19d3ecf75fe409f82c17bcfa200cb8b25ed9dd961045e3dd63f242ccaef09995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc2ec5e2-ffca-415c-b952-7fddeee1978e", "node_type": "1", "metadata": {"window": "At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n", "original_text": "Erin Wright :   Great , thanks. "}, "hash": "714573a2ac12c29d9792860fc19f1b39deb95444ca9baba13ef7a6baefe811c7", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n", "start_char_idx": 596, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc2ec5e2-ffca-415c-b952-7fddeee1978e": {"__data__": {"id_": "bc2ec5e2-ffca-415c-b952-7fddeee1978e", "embedding": null, "metadata": {"window": "At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n", "original_text": "Erin Wright :   Great , thanks. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e3b1cbb-bdcf-4c09-953e-0952ed966cbb", "node_type": "1", "metadata": {"window": "It is a \ncomponent of one of those factors that we look at.   At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? ", "original_text": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c8d2c9975a6168598e642267b9d2117c49ef7e316ba75137e67da63ea27142f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89e2e0a1-eefa-4595-aa7e-12967894231d", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.  ", "original_text": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  "}, "hash": "5352ccaff41827a8884b586c4336aa8ef706ff2a117bdabf31fa94b9ab6c5d5a", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wright :   Great , thanks. ", "start_char_idx": 674, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89e2e0a1-eefa-4595-aa7e-12967894231d": {"__data__": {"id_": "89e2e0a1-eefa-4595-aa7e-12967894231d", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.  ", "original_text": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc2ec5e2-ffca-415c-b952-7fddeee1978e", "node_type": "1", "metadata": {"window": "At this point, it's too early to talk about any type  of \nopportunity with that.  Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n", "original_text": "Erin Wright :   Great , thanks. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de23a21b6901f87f43ab0ddd5f5ebbfd3174db32cfcd5324bc9f56bb28edf5e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d864c245-3523-4a9b-a0c4-928b75ed6df0", "node_type": "1", "metadata": {"window": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n", "original_text": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? "}, "hash": "52a718666cfe920635fcbc3a6459da358abfae57db39a5e1940d583eb2dcfb19", "class_name": "RelatedNodeInfo"}}, "text": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  ", "start_char_idx": 706, "end_char_idx": 883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d864c245-3523-4a9b-a0c4-928b75ed6df0": {"__data__": {"id_": "d864c245-3523-4a9b-a0c4-928b75ed6df0", "embedding": null, "metadata": {"window": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n", "original_text": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e2e0a1-eefa-4595-aa7e-12967894231d", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.  ", "original_text": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0513c6de138c0bf2064160b6568a952489d4bc7d22a6cd1204d4fbca8dcb8b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ea0f370-dbfd-4a88-959a-aac5692e17ab", "node_type": "1", "metadata": {"window": "Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment. ", "original_text": "Thanks.  \n \n"}, "hash": "4dfddf33fb659a2c7b274d680fe85855558daf7bae47a14c8d9ff59e71aa13a7", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? ", "start_char_idx": 883, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ea0f370-dbfd-4a88-959a-aac5692e17ab": {"__data__": {"id_": "2ea0f370-dbfd-4a88-959a-aac5692e17ab", "embedding": null, "metadata": {"window": "Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment. ", "original_text": "Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d864c245-3523-4a9b-a0c4-928b75ed6df0", "node_type": "1", "metadata": {"window": "Operator :  The next question comes from Erin Wright with Morgan Stanley.  \n \n Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n", "original_text": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others? ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8825e4b79fb56925fe1e47f9641316590d7e422bac8c2463aa63ae1bf27c78c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce920e7-5091-4850-acc4-bb80ac85bd49", "node_type": "1", "metadata": {"window": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . ", "original_text": "Jason Hollar :   Yeah.  "}, "hash": "1e9979e2e9cb6f7b2aeae5cedac5a34e9a851a217b8483570a649024593214d5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1069, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bce920e7-5091-4850-acc4-bb80ac85bd49": {"__data__": {"id_": "bce920e7-5091-4850-acc4-bb80ac85bd49", "embedding": null, "metadata": {"window": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . ", "original_text": "Jason Hollar :   Yeah.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ea0f370-dbfd-4a88-959a-aac5692e17ab", "node_type": "1", "metadata": {"window": "Erin Wright :   Great , thanks.  And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment. ", "original_text": "Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70c5ec95a78a1f8d40062c123903a2d54d70af384f311f378825cde4f3af5108", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5f8f4ad-1bbc-4357-b9ce-5bd98a789c38", "node_type": "1", "metadata": {"window": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix . ", "original_text": "Well, first and foremost, absolutely appreciate and understand the question . \n"}, "hash": "526a966df4e49aee796035ead8f3282f779079b015051870ceb45185e3bcd486", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Yeah.  ", "start_char_idx": 1081, "end_char_idx": 1105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5f8f4ad-1bbc-4357-b9ce-5bd98a789c38": {"__data__": {"id_": "e5f8f4ad-1bbc-4357-b9ce-5bd98a789c38", "embedding": null, "metadata": {"window": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix . ", "original_text": "Well, first and foremost, absolutely appreciate and understand the question . \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce920e7-5091-4850-acc4-bb80ac85bd49", "node_type": "1", "metadata": {"window": "And can you speak a little bit to the long -term strategy and what's \nfeasible in terms of your opportuni ty to improve mix and increase your exposure to specialty over \ntime?   And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . ", "original_text": "Jason Hollar :   Yeah.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3ba0568595ae36bc9ebdd9b85dc8004cb1e7d00fcdcd5a20aefb4ad0d05ab2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e28686ac-90e7-4092-a296-6f1d63e2c8b0", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  ", "original_text": "This is a key reason for our recent reorganisation within the Pharma  segment. "}, "hash": "69d4396fc6be83f4fa37d65424b60276ca11cc7735ea51e968493bf0f7389e7f", "class_name": "RelatedNodeInfo"}}, "text": "Well, first and foremost, absolutely appreciate and understand the question . \n", "start_char_idx": 1105, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e28686ac-90e7-4092-a296-6f1d63e2c8b0": {"__data__": {"id_": "e28686ac-90e7-4092-a296-6f1d63e2c8b0", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  ", "original_text": "This is a key reason for our recent reorganisation within the Pharma  segment. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5f8f4ad-1bbc-4357-b9ce-5bd98a789c38", "node_type": "1", "metadata": {"window": "And as we think about kind of specialty, can you also speak to the biosimilar opportunity and \nyour near -term positioning to participate with like Humira biosimilars as well as others?  Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix . ", "original_text": "Well, first and foremost, absolutely appreciate and understand the question . \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "782cea00c0e736445f900ffb908245e036f27412d0c202177820f1579252b300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "697b2d87-1d8c-43be-905d-469d3e14ed0e", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare. ", "original_text": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . "}, "hash": "d9f10a8b292a8ab3d597bda13aadc33c6f8576558fa0b0ebcf95ba9e907ac6f1", "class_name": "RelatedNodeInfo"}}, "text": "This is a key reason for our recent reorganisation within the Pharma  segment. ", "start_char_idx": 1184, "end_char_idx": 1263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "697b2d87-1d8c-43be-905d-469d3e14ed0e": {"__data__": {"id_": "697b2d87-1d8c-43be-905d-469d3e14ed0e", "embedding": null, "metadata": {"window": "Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare. ", "original_text": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e28686ac-90e7-4092-a296-6f1d63e2c8b0", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  ", "original_text": "This is a key reason for our recent reorganisation within the Pharma  segment. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae87225e7997ec96b54c4677735c3393e7e759266852f3d15075c8105d859251", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cd24739-0d00-47dc-96d3-ffb77d8fb0d7", "node_type": "1", "metadata": {"window": "Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here. ", "original_text": "So this is all to recognise the importance of driving that favorable mix . "}, "hash": "480694165939fcf707ab99592fcbcd9befa643e80658adacd2433eaffb8f6eb3", "class_name": "RelatedNodeInfo"}}, "text": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . ", "start_char_idx": 1263, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cd24739-0d00-47dc-96d3-ffb77d8fb0d7": {"__data__": {"id_": "4cd24739-0d00-47dc-96d3-ffb77d8fb0d7", "embedding": null, "metadata": {"window": "Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here. ", "original_text": "So this is all to recognise the importance of driving that favorable mix . ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "697b2d87-1d8c-43be-905d-469d3e14ed0e", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah.   Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare. ", "original_text": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners . ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a44e0e981772e06733093f861a3f80c5396dda654415e58defb24e6c4b22d1d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f5dd86f-09a7-4b8c-ab94-757d73214e36", "node_type": "1", "metadata": {"window": "This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  ", "original_text": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  "}, "hash": "43936b151cfa5ac56b07d50cab788a24244122285c88fdcaabf5af30558a547b", "class_name": "RelatedNodeInfo"}}, "text": "So this is all to recognise the importance of driving that favorable mix . ", "start_char_idx": 1507, "end_char_idx": 1582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f5dd86f-09a7-4b8c-ab94-757d73214e36": {"__data__": {"id_": "1f5dd86f-09a7-4b8c-ab94-757d73214e36", "embedding": null, "metadata": {"window": "This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  ", "original_text": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cd24739-0d00-47dc-96d3-ffb77d8fb0d7", "node_type": "1", "metadata": {"window": "Well, first and foremost, absolutely appreciate and understand the question . \n This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here. ", "original_text": "So this is all to recognise the importance of driving that favorable mix . ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "926cc064e4eefe485edf885d00718f34b93fdd47901a3a5a01f9b233c7b60243", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "109494d9-df05-432f-a6b4-80c60a5dc6c7", "node_type": "1", "metadata": {"window": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. ", "original_text": "We did just recently acquire Bendcare. "}, "hash": "ddf8a53326715cd64f54aff7f0adc319509e917fe4e31ce7de4c9dbc5367a366", "class_name": "RelatedNodeInfo"}}, "text": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  ", "start_char_idx": 1582, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "109494d9-df05-432f-a6b4-80c60a5dc6c7": {"__data__": {"id_": "109494d9-df05-432f-a6b4-80c60a5dc6c7", "embedding": null, "metadata": {"window": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. ", "original_text": "We did just recently acquire Bendcare. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f5dd86f-09a7-4b8c-ab94-757d73214e36", "node_type": "1", "metadata": {"window": "This is a key reason for our recent reorganisation within the Pharma  segment.  We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  ", "original_text": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9939e716baf1df663ec2f2933c5aef4c07059b436e4c7c17176499ef3642dba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92508790-8fd2-42da-a6f2-9461774cc0c9", "node_type": "1", "metadata": {"window": "So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n", "original_text": "That gives us \nan additional exposure here. "}, "hash": "c373c44536b440c45e4ea4720a6436dd1eef715923e8e2aca6d03963b18db296", "class_name": "RelatedNodeInfo"}}, "text": "We did just recently acquire Bendcare. ", "start_char_idx": 1739, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92508790-8fd2-42da-a6f2-9461774cc0c9": {"__data__": {"id_": "92508790-8fd2-42da-a6f2-9461774cc0c9", "embedding": null, "metadata": {"window": "So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n", "original_text": "That gives us \nan additional exposure here. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "109494d9-df05-432f-a6b4-80c60a5dc6c7", "node_type": "1", "metadata": {"window": "We have structured \nthe team to have specialty in PD all together, reduc ing the complexity, driving not just productivity, but \nmore importantly, simplifying how we go to market with both our customers as well as the \nmanufacturing partners .  So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. ", "original_text": "We did just recently acquire Bendcare. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ced328c6211f3672a439e9f664d35ed48f56f5f1da95d63b3443fa3d8a3abc3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc802df5-cd78-498a-918d-3b3c66a672eb", "node_type": "1", "metadata": {"window": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well. ", "original_text": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  "}, "hash": "cb9d54560222ef0b72292614258f17e8fba131dc4663745756c0fe9aac822c76", "class_name": "RelatedNodeInfo"}}, "text": "That gives us \nan additional exposure here. ", "start_char_idx": 1778, "end_char_idx": 1822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc802df5-cd78-498a-918d-3b3c66a672eb": {"__data__": {"id_": "fc802df5-cd78-498a-918d-3b3c66a672eb", "embedding": null, "metadata": {"window": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well. ", "original_text": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92508790-8fd2-42da-a6f2-9461774cc0c9", "node_type": "1", "metadata": {"window": "So this is all to recognise the importance of driving that favorable mix .  The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n", "original_text": "That gives us \nan additional exposure here. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bc2d0adbc59fa27257b503f0ccf3201621dac879a761454bb2c37f209ae6cf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "683bf2e4-6d1c-458a-a160-8625a85e9c97", "node_type": "1", "metadata": {"window": "We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.  ", "original_text": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. "}, "hash": "14f21e921375a4cfb1c7f669fcd9dfa44600c92d17716583a7b83bffbf086fe1", "class_name": "RelatedNodeInfo"}}, "text": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  ", "start_char_idx": 1822, "end_char_idx": 1928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "683bf2e4-6d1c-458a-a160-8625a85e9c97": {"__data__": {"id_": "683bf2e4-6d1c-458a-a160-8625a85e9c97", "embedding": null, "metadata": {"window": "We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.  ", "original_text": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc802df5-cd78-498a-918d-3b3c66a672eb", "node_type": "1", "metadata": {"window": "The \nmarket i s going to in part be a rising tide , but we definitely want to do as much as possible to \nparticipate in as much of that growth as there is.   We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well. ", "original_text": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2446d010d55689f1b84f77e05199f238c64e6636d8bba7c2ad2c1997c1b821ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39b79ea0-8599-45a2-a4bd-e62f73b1085e", "node_type": "1", "metadata": {"window": "That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today. ", "original_text": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n"}, "hash": "fa5f3b6d757a093ef0c68a24a1bb9d23f33c10d74c03b0abf6499261efcfd309", "class_name": "RelatedNodeInfo"}}, "text": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. ", "start_char_idx": 1928, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39b79ea0-8599-45a2-a4bd-e62f73b1085e": {"__data__": {"id_": "39b79ea0-8599-45a2-a4bd-e62f73b1085e", "embedding": null, "metadata": {"window": "That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today. ", "original_text": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "683bf2e4-6d1c-458a-a160-8625a85e9c97", "node_type": "1", "metadata": {"window": "We did just recently acquire Bendcare.  That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.  ", "original_text": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54893ef8952bccfbfac5434665ca4b4fcf8fd7136eb8218f7b05e36a593600c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27e8d5f7-68d7-4e8e-b24a-2fc2a19781bb", "node_type": "1", "metadata": {"window": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n", "original_text": "On biosimilars, that is absolutely a component of this as well. "}, "hash": "1b635fe28e52036913413798d4cd04355c5658558dd59bf69d58f6e6d84191ba", "class_name": "RelatedNodeInfo"}}, "text": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n", "start_char_idx": 2071, "end_char_idx": 2176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27e8d5f7-68d7-4e8e-b24a-2fc2a19781bb": {"__data__": {"id_": "27e8d5f7-68d7-4e8e-b24a-2fc2a19781bb", "embedding": null, "metadata": {"window": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n", "original_text": "On biosimilars, that is absolutely a component of this as well. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39b79ea0-8599-45a2-a4bd-e62f73b1085e", "node_type": "1", "metadata": {"window": "That gives us \nan additional exposure here.  We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today. ", "original_text": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "276fb29e77ed71b1fe991e59b61e12d2495ff2ad72018bf152b4f5c650d3baef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0875887-4216-4d1b-be22-81a0a682fbba", "node_type": "1", "metadata": {"window": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us. ", "original_text": "You know, the same point, we've \ninvested into our capabilities and our team.  "}, "hash": "4f9b0b7a51f6b8272dbe33a26ecebb89a15240034eb0fa373199d1bdb8eb70b8", "class_name": "RelatedNodeInfo"}}, "text": "On biosimilars, that is absolutely a component of this as well. ", "start_char_idx": 2176, "end_char_idx": 2240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0875887-4216-4d1b-be22-81a0a682fbba": {"__data__": {"id_": "d0875887-4216-4d1b-be22-81a0a682fbba", "embedding": null, "metadata": {"window": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us. ", "original_text": "You know, the same point, we've \ninvested into our capabilities and our team.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27e8d5f7-68d7-4e8e-b24a-2fc2a19781bb", "node_type": "1", "metadata": {"window": "We have invested organically i n all the different businesses and tools \nthat I referenced in my script.   So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n", "original_text": "On biosimilars, that is absolutely a component of this as well. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87b9a8c55810115c72824421d2870d0eca438c216f056e16367b2cf543e549b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a197c5e-0527-44a2-a5e4-2a89aaa8a77e", "node_type": "1", "metadata": {"window": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . ", "original_text": "We participate in that today. "}, "hash": "09786e51b025be6414dfcb2fce7bb490bf5b861da80a0f8a8c32fc032e0a855b", "class_name": "RelatedNodeInfo"}}, "text": "You know, the same point, we've \ninvested into our capabilities and our team.  ", "start_char_idx": 2240, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a197c5e-0527-44a2-a5e4-2a89aaa8a77e": {"__data__": {"id_": "6a197c5e-0527-44a2-a5e4-2a89aaa8a77e", "embedding": null, "metadata": {"window": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . ", "original_text": "We participate in that today. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0875887-4216-4d1b-be22-81a0a682fbba", "node_type": "1", "metadata": {"window": "So we're investing both inorganically as well as organically and have \nnow a structure and a leadership team that's intensely focused on this.  So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us. ", "original_text": "You know, the same point, we've \ninvested into our capabilities and our team.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26c7113e3f8ff3d7a2939ff2640fd538bf296f48b5658d21615a6391fbe8970b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bef89e9-c379-440d-b1a6-901a1d4d5b7a", "node_type": "1", "metadata": {"window": "On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there. ", "original_text": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n"}, "hash": "9c7f25cc82dbdf5be6b3e901244653008d6033e600ab77af766bec413c26e710", "class_name": "RelatedNodeInfo"}}, "text": "We participate in that today. ", "start_char_idx": 2319, "end_char_idx": 2349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bef89e9-c379-440d-b1a6-901a1d4d5b7a": {"__data__": {"id_": "5bef89e9-c379-440d-b1a6-901a1d4d5b7a", "embedding": null, "metadata": {"window": "On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there. ", "original_text": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a197c5e-0527-44a2-a5e4-2a89aaa8a77e", "node_type": "1", "metadata": {"window": "So we feel like we're really \nwell posit ioned to be able to take advantage of that into the future.  \n \n On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . ", "original_text": "We participate in that today. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43544d3b8c1692ee5aa982611fcfb5fc18cab04f56a190178e6733b321526499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91a92ae1-c263-4000-a764-0926371d3acf", "node_type": "1", "metadata": {"window": "You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that. ", "original_text": "I know we get a lot of questions specifically about Humira and how that is going to benefit us. "}, "hash": "867ffdfb2d18171ad14385a6c54bf7462d9377655aeb9cc437d975fd990c7557", "class_name": "RelatedNodeInfo"}}, "text": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n", "start_char_idx": 2349, "end_char_idx": 2676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91a92ae1-c263-4000-a764-0926371d3acf": {"__data__": {"id_": "91a92ae1-c263-4000-a764-0926371d3acf", "embedding": null, "metadata": {"window": "You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that. ", "original_text": "I know we get a lot of questions specifically about Humira and how that is going to benefit us. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bef89e9-c379-440d-b1a6-901a1d4d5b7a", "node_type": "1", "metadata": {"window": "On biosimilars, that is absolutely a component of this as well.  You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there. ", "original_text": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11ece3788a93b29931fbbe5057377b66cdb85216938cb4bdbb8c0663e5b9635f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "464e7a1f-f878-47cd-b687-b00e389df704", "node_type": "1", "metadata": {"window": "We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. ", "original_text": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . "}, "hash": "6b48bb89b103cd0410bcf0b9e5736620eef1cabadf68e944ce71939a44ea9903", "class_name": "RelatedNodeInfo"}}, "text": "I know we get a lot of questions specifically about Humira and how that is going to benefit us. ", "start_char_idx": 2676, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "464e7a1f-f878-47cd-b687-b00e389df704": {"__data__": {"id_": "464e7a1f-f878-47cd-b687-b00e389df704", "embedding": null, "metadata": {"window": "We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. ", "original_text": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91a92ae1-c263-4000-a764-0926371d3acf", "node_type": "1", "metadata": {"window": "You know, the same point, we've \ninvested into our capabilities and our team.   We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that. ", "original_text": "I know we get a lot of questions specifically about Humira and how that is going to benefit us. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e306e6a23b9f60f70d25d8123c41d3751fa5700f54c4733fd45bb09a22f14d39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bbb1591-33e3-4174-af32-c6b95ed94060", "node_type": "1", "metadata": {"window": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n", "original_text": "So a lot to be learned there. "}, "hash": "bb12b57585ce64ca084c63e63614221b6fb08505308c2a2d00cc317bd0d62eeb", "class_name": "RelatedNodeInfo"}}, "text": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . ", "start_char_idx": 2772, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bbb1591-33e3-4174-af32-c6b95ed94060": {"__data__": {"id_": "9bbb1591-33e3-4174-af32-c6b95ed94060", "embedding": null, "metadata": {"window": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n", "original_text": "So a lot to be learned there. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "464e7a1f-f878-47cd-b687-b00e389df704", "node_type": "1", "metadata": {"window": "We participate in that today.  It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. ", "original_text": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions . ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d83e1147b3d1b6fb082423ca1968b684977f194c6f5d3560bdbe4340b38cb0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d28b38e7-634d-41b0-a7e1-fb02f042cc86", "node_type": "1", "metadata": {"window": "I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n", "original_text": "But the point is we are positioned \nvery well to be able to take advantage of that. "}, "hash": "2fefee2d4a5ac98f16c885ad738892d2e9c7ebbbd8ca1faa482cfe5e2af51d9f", "class_name": "RelatedNodeInfo"}}, "text": "So a lot to be learned there. ", "start_char_idx": 3015, "end_char_idx": 3045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d28b38e7-634d-41b0-a7e1-fb02f042cc86": {"__data__": {"id_": "d28b38e7-634d-41b0-a7e1-fb02f042cc86", "embedding": null, "metadata": {"window": "I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n", "original_text": "But the point is we are positioned \nvery well to be able to take advantage of that. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bbb1591-33e3-4174-af32-c6b95ed94060", "node_type": "1", "metadata": {"window": "It is a nice driver fo r our \nbusiness, not large enough that we have called it out specifically  but nonetheless, it is an area that as \nwe continue to see evolution of the sites of care and the therapeutic areas, then we would anticipate \nthat to be further opportunities for us and it fits nicely into our capabilities.  \n \n I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n", "original_text": "So a lot to be learned there. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ac218222348da4b3708ac8152e123422567f895f2b63011594e5d4e8a814c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866bc74b-9ea1-4b9a-879f-dae7a09e3a7d", "node_type": "1", "metadata": {"window": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning. ", "original_text": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. "}, "hash": "b7627dc963241380881250da1a33933c5cd698750b9f26a5e259c64ff18a86a5", "class_name": "RelatedNodeInfo"}}, "text": "But the point is we are positioned \nvery well to be able to take advantage of that. ", "start_char_idx": 3045, "end_char_idx": 3129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866bc74b-9ea1-4b9a-879f-dae7a09e3a7d": {"__data__": {"id_": "866bc74b-9ea1-4b9a-879f-dae7a09e3a7d", "embedding": null, "metadata": {"window": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning. ", "original_text": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d28b38e7-634d-41b0-a7e1-fb02f042cc86", "node_type": "1", "metadata": {"window": "I know we get a lot of questions specifically about Humira and how that is going to benefit us.  You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n", "original_text": "But the point is we are positioned \nvery well to be able to take advantage of that. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "747899151714f71ea6abd6fc38d0bacaa9a93f6dad77f21c992f8ebd18da6e26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed998c70-c941-42fe-9a4c-315b40566bab", "node_type": "1", "metadata": {"window": "So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers. ", "original_text": "Next \nquestion, please.  \n \n"}, "hash": "533168a36260ca7220eb45b331607cd35bc92455d2b1f360827377332d5c1774", "class_name": "RelatedNodeInfo"}}, "text": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. ", "start_char_idx": 3129, "end_char_idx": 3285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed998c70-c941-42fe-9a4c-315b40566bab": {"__data__": {"id_": "ed998c70-c941-42fe-9a4c-315b40566bab", "embedding": null, "metadata": {"window": "So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers. ", "original_text": "Next \nquestion, please.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866bc74b-9ea1-4b9a-879f-dae7a09e3a7d", "node_type": "1", "metadata": {"window": "You \nknow, there's a lot to be still played out here in terms of how all participants drive the different \nprocesses fo r this, specifically, the payers and PBMs, how they go to market and work with the \nmarket to implement these evolutions .  So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning. ", "original_text": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28215d6abef02dd1c477adcfb16e5c38f0f291ce14b1a5bba9c224aac80566d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "893cdb52-1c1e-4d71-a7aa-2a5351b19d8b", "node_type": "1", "metadata": {"window": "But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.  ", "original_text": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n"}, "hash": "1d451172d0fb82dc2f813dd6feb80721c268e9d1a534b713c8a9ed429be2e5ef", "class_name": "RelatedNodeInfo"}}, "text": "Next \nquestion, please.  \n \n", "start_char_idx": 3285, "end_char_idx": 3313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "893cdb52-1c1e-4d71-a7aa-2a5351b19d8b": {"__data__": {"id_": "893cdb52-1c1e-4d71-a7aa-2a5351b19d8b", "embedding": null, "metadata": {"window": "But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.  ", "original_text": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed998c70-c941-42fe-9a4c-315b40566bab", "node_type": "1", "metadata": {"window": "So a lot to be learned there.  But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers. ", "original_text": "Next \nquestion, please.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57bf3b36adadc99cdd6e6e0bfd9020c861e8290b608e3fd34a87d81e3098c629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0eebf09-e039-4573-8f02-7dba1cfd2506", "node_type": "1", "metadata": {"window": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "Michael Cherny :   Good morning. "}, "hash": "3ceb69fcfb5f2b0102b5c27f872fa49c3ac8f693ea3fb232deb2b5a8d3f0b030", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n", "start_char_idx": 3313, "end_char_idx": 3396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0eebf09-e039-4573-8f02-7dba1cfd2506": {"__data__": {"id_": "a0eebf09-e039-4573-8f02-7dba1cfd2506", "embedding": null, "metadata": {"window": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "Michael Cherny :   Good morning. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "893cdb52-1c1e-4d71-a7aa-2a5351b19d8b", "node_type": "1", "metadata": {"window": "But the point is we are positioned \nvery well to be able to take advantage of that.  But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.  ", "original_text": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e41b23645d0637c69e487c891397214b412a85f4151e84a2f0039bdcb128424", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "420f1933-30ae-4fda-a9c3-b07269df076d", "node_type": "1", "metadata": {"window": "Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "I have one kind of just technical question and then a bit more on the \nnumbers. "}, "hash": "5a265f64e0dfb0e7123494556967d2b9faec036f924ae72221d59f02a8be8657", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny :   Good morning. ", "start_char_idx": 3396, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "420f1933-30ae-4fda-a9c3-b07269df076d": {"__data__": {"id_": "420f1933-30ae-4fda-a9c3-b07269df076d", "embedding": null, "metadata": {"window": "Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "I have one kind of just technical question and then a bit more on the \nnumbers. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0eebf09-e039-4573-8f02-7dba1cfd2506", "node_type": "1", "metadata": {"window": "But there's some le vel of uncertainty, but we do have \nconfidence it will be a tailwind for us going forward as it has been in the last few years as well.  Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "Michael Cherny :   Good morning. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4332ce2716384d863ac5e61c87c285c8e25d8d5b0440d06c9b96ffb49e275df7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe6b9d4c-42c5-4b3d-b78b-56e45d006721", "node_type": "1", "metadata": {"window": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "So just first on the ASR, you said you launched it in mid -September.  "}, "hash": "ee9d0e1d25ca78e0de453daaf58fb3b80feaee0b3aed82ba0728e88485038492", "class_name": "RelatedNodeInfo"}}, "text": "I have one kind of just technical question and then a bit more on the \nnumbers. ", "start_char_idx": 3429, "end_char_idx": 3509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe6b9d4c-42c5-4b3d-b78b-56e45d006721": {"__data__": {"id_": "fe6b9d4c-42c5-4b3d-b78b-56e45d006721", "embedding": null, "metadata": {"window": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "So just first on the ASR, you said you launched it in mid -September.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "420f1933-30ae-4fda-a9c3-b07269df076d", "node_type": "1", "metadata": {"window": "Next \nquestion, please.  \n \n Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "I have one kind of just technical question and then a bit more on the \nnumbers. ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d24e8c0a4e1770eab98675e3786ed1b0c5c37d12211f5ed9f93e96e134892bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42a29fa6-8494-4b25-bbac-142e536340d0", "node_type": "1", "metadata": {"window": "Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "Is there any way to "}, "hash": "6d0d52ee0ba42dddb516ee2d7ec9caafa06f2370b06bbfb1346ccbd869ed66bf", "class_name": "RelatedNodeInfo"}}, "text": "So just first on the ASR, you said you launched it in mid -September.  ", "start_char_idx": 3509, "end_char_idx": 3580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42a29fa6-8494-4b25-bbac-142e536340d0": {"__data__": {"id_": "42a29fa6-8494-4b25-bbac-142e536340d0", "embedding": null, "metadata": {"window": "Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "Is there any way to ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "02eef37d-46f9-4e4a-9e63-5e153c088023", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c479fe2bfedeed5cccfef017cb955068c33562bbe6fb298cb8fa36b8dc7898e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe6b9d4c-42c5-4b3d-b78b-56e45d006721", "node_type": "1", "metadata": {"window": "Operator :   Our next question comes from Michael Cherny from Bank of America.  \n \n Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "So just first on the ASR, you said you launched it in mid -September.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22027d9c3897e7c30dadfdec61221303bd3ac3f3bf03514b34b591787d1611e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ef75655-e58f-46c2-a921-1d4c7e7d62fc", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.  ", "original_text": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish? "}, "hash": "8a7991adc73e40671d9c54aa0fedf4191964e377625bd3314d8a786391fd312d", "class_name": "RelatedNodeInfo"}}, "text": "Is there any way to ", "start_char_idx": 3580, "end_char_idx": 3600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ef75655-e58f-46c2-a921-1d4c7e7d62fc": {"__data__": {"id_": "1ef75655-e58f-46c2-a921-1d4c7e7d62fc", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.  ", "original_text": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish? ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42a29fa6-8494-4b25-bbac-142e536340d0", "node_type": "1", "metadata": {"window": "Michael Cherny :   Good morning.  I have one kind of just technical question and then a bit more on the \nnumbers.  So just first on the ASR, you said you launched it in mid -September.   Is there any way to ", "original_text": "Is there any way to ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2321f8f7bcef1da362235e28b6fd851aa22a8afaaaa97959619292cbb632b378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4912abf-43d2-4468-bf8f-7528a9fb73aa", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. ", "original_text": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down . "}, "hash": "d917bef4fc65556c453e06485c898a1f0db8f442bb0f57b153d21da743188545", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish? ", "start_char_idx": 0, "end_char_idx": 110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4912abf-43d2-4468-bf8f-7528a9fb73aa": {"__data__": {"id_": "a4912abf-43d2-4468-bf8f-7528a9fb73aa", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. ", "original_text": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ef75655-e58f-46c2-a921-1d4c7e7d62fc", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.  ", "original_text": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish? ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b191fb72fe34db273cf55e2b9fbc5adee5297f13fdcf6f5b08da78c6e35d4063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adaa0c8d-059a-4172-9b84-4e42f2bd9213", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.  ", "original_text": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n"}, "hash": "f1e1e56dec9a8f8a1154b0cda9adf0418e25e97b8d3009c9abe09d8f120046ee", "class_name": "RelatedNodeInfo"}}, "text": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down . ", "start_char_idx": 110, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adaa0c8d-059a-4172-9b84-4e42f2bd9213": {"__data__": {"id_": "adaa0c8d-059a-4172-9b84-4e42f2bd9213", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.  ", "original_text": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4912abf-43d2-4468-bf8f-7528a9fb73aa", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. ", "original_text": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b9e5f0fb0973e194457fccb9bd1855a5538ac895a52fc70e26fd0616d4bb8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab5e5078-d6cc-4700-85b0-af13c0ee4099", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.  ", "original_text": "Jason Hollar :   Sure.  "}, "hash": "cfd2fd4697e05c5eaf1d29d2eb55755e260a3d2c310fdd83045aee8dc28fb5bb", "class_name": "RelatedNodeInfo"}}, "text": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n", "start_char_idx": 443, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab5e5078-d6cc-4700-85b0-af13c0ee4099": {"__data__": {"id_": "ab5e5078-d6cc-4700-85b0-af13c0ee4099", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.  ", "original_text": "Jason Hollar :   Sure.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adaa0c8d-059a-4172-9b84-4e42f2bd9213", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.  ", "original_text": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed4445db737825702256396768656cc348d8f7847a0df211988ed3e7e47c882a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "819a55da-168f-48cb-a532-6385a394e584", "node_type": "1", "metadata": {"window": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  ", "original_text": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. "}, "hash": "9f5fba051a5a90c9ab3bad2bf1416356fd604e70fbecd2cfda2d2759ced902f6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Sure.  ", "start_char_idx": 547, "end_char_idx": 571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "819a55da-168f-48cb-a532-6385a394e584": {"__data__": {"id_": "819a55da-168f-48cb-a532-6385a394e584", "embedding": null, "metadata": {"window": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  ", "original_text": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab5e5078-d6cc-4700-85b0-af13c0ee4099", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.  ", "original_text": "Jason Hollar :   Sure.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc1dcd64f3f96c4e2911c25f81cff6b4063a346e75f05d358c9bd65e9d17361e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "121bb126-471a-4977-a468-d092b684921a", "node_type": "1", "metadata": {"window": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment . ", "original_text": "And like you appropriately referenced, it was \nimplemented in mid -September.  "}, "hash": "6bf575b5cfac19e0af1d3a302154974d752dc5f09f6af0e2904d4309ce49a4c9", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. ", "start_char_idx": 571, "end_char_idx": 698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "121bb126-471a-4977-a468-d092b684921a": {"__data__": {"id_": "121bb126-471a-4977-a468-d092b684921a", "embedding": null, "metadata": {"window": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment . ", "original_text": "And like you appropriately referenced, it was \nimplemented in mid -September.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "819a55da-168f-48cb-a532-6385a394e584", "node_type": "1", "metadata": {"window": "And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  ", "original_text": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f746175f7214081197dad8bd7d611fab611106969924669f54f88f8fb139b20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eb2342a-b24e-4fee-b975-ae8f88edac23", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . ", "original_text": "So a relatively small impact to the current quarter.  "}, "hash": "b3bf1647194193f76782bbb6bfd54b19b5613182b20f3433b54d29559f835f1c", "class_name": "RelatedNodeInfo"}}, "text": "And like you appropriately referenced, it was \nimplemented in mid -September.  ", "start_char_idx": 698, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eb2342a-b24e-4fee-b975-ae8f88edac23": {"__data__": {"id_": "8eb2342a-b24e-4fee-b975-ae8f88edac23", "embedding": null, "metadata": {"window": "Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . ", "original_text": "So a relatively small impact to the current quarter.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "121bb126-471a-4977-a468-d092b684921a", "node_type": "1", "metadata": {"window": "Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment . ", "original_text": "And like you appropriately referenced, it was \nimplemented in mid -September.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3c0f89614b2110b94220284bcff361a1825688a702f795a2f28d24d82fd58bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26e1da9f-8530-46e1-a452-501b338827dc", "node_type": "1", "metadata": {"window": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. ", "original_text": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  "}, "hash": "2882c421a6877736e8ed5be8cc70976de8eaea16e23a488c52afe2629d54a844", "class_name": "RelatedNodeInfo"}}, "text": "So a relatively small impact to the current quarter.  ", "start_char_idx": 777, "end_char_idx": 831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26e1da9f-8530-46e1-a452-501b338827dc": {"__data__": {"id_": "26e1da9f-8530-46e1-a452-501b338827dc", "embedding": null, "metadata": {"window": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. ", "original_text": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eb2342a-b24e-4fee-b975-ae8f88edac23", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.   As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . ", "original_text": "So a relatively small impact to the current quarter.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff32972f90914e2cd307b9464e970feae07ccd75b69fbef33cdab6a0c56c9096", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6102cce4-fbc5-493c-b817-d6fe372caf79", "node_type": "1", "metadata": {"window": "And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.  ", "original_text": "It's we're also talking about still a \nfairly uncertain macroeconomic environment . "}, "hash": "35cea049bb1b5593874aab2503ff08831389630869d2970a0e47541176c19400", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  ", "start_char_idx": 831, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6102cce4-fbc5-493c-b817-d6fe372caf79": {"__data__": {"id_": "6102cce4-fbc5-493c-b817-d6fe372caf79", "embedding": null, "metadata": {"window": "And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.  ", "original_text": "It's we're also talking about still a \nfairly uncertain macroeconomic environment . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26e1da9f-8530-46e1-a452-501b338827dc", "node_type": "1", "metadata": {"window": "As it relates to the ASR, the - your technical q uestion, yeah, about 80% is what \nyou would expect for the immediate benefit.  And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. ", "original_text": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5ea011c5a01a346b22dd2eb47dbd15e2e56185dc2cae8b255bf34a06d2efe57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd0a8936-dd8e-4002-80a0-8ac12ed192b2", "node_type": "1", "metadata": {"window": "So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  ", "original_text": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . "}, "hash": "aade8e6509744b4f7008d1fe914987dda41ba595a838c235ffe570823f6f28f9", "class_name": "RelatedNodeInfo"}}, "text": "It's we're also talking about still a \nfairly uncertain macroeconomic environment . ", "start_char_idx": 931, "end_char_idx": 1015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd0a8936-dd8e-4002-80a0-8ac12ed192b2": {"__data__": {"id_": "bd0a8936-dd8e-4002-80a0-8ac12ed192b2", "embedding": null, "metadata": {"window": "So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  ", "original_text": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6102cce4-fbc5-493c-b817-d6fe372caf79", "node_type": "1", "metadata": {"window": "And like you appropriately referenced, it was \nimplemented in mid -September.   So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.  ", "original_text": "It's we're also talking about still a \nfairly uncertain macroeconomic environment . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f66883fb68fdbc0a0dbfb12473ecf7fa6e1cf1d6fb8cb429d4526525d73114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca9b8e99-c2bc-4d8b-a220-47454303a5a5", "node_type": "1", "metadata": {"window": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.  ", "original_text": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. "}, "hash": "e0be737a3dfd856c8431c076cc39fd15427f5ef2c80c61ed0587f44874d1d84b", "class_name": "RelatedNodeInfo"}}, "text": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . ", "start_char_idx": 1015, "end_char_idx": 1149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca9b8e99-c2bc-4d8b-a220-47454303a5a5": {"__data__": {"id_": "ca9b8e99-c2bc-4d8b-a220-47454303a5a5", "embedding": null, "metadata": {"window": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.  ", "original_text": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd0a8936-dd8e-4002-80a0-8ac12ed192b2", "node_type": "1", "metadata": {"window": "So a relatively small impact to the current quarter.   As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  ", "original_text": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56472f51fe426d96c36975124e566fcdb22590e5d996cca5c3ef93652c14f168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "228820e3-504e-4309-adab-5b65b4daeda1", "node_type": "1", "metadata": {"window": "It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  ", "original_text": "And that was certainly welcomed given what the last \ncouple of years have look ed like.  "}, "hash": "9f08c43f1a8fc67b4a30763950210f2036dfd5f8c1416d677c3e52354c98f096", "class_name": "RelatedNodeInfo"}}, "text": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. ", "start_char_idx": 1149, "end_char_idx": 1320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "228820e3-504e-4309-adab-5b65b4daeda1": {"__data__": {"id_": "228820e3-504e-4309-adab-5b65b4daeda1", "embedding": null, "metadata": {"window": "It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  ", "original_text": "And that was certainly welcomed given what the last \ncouple of years have look ed like.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca9b8e99-c2bc-4d8b-a220-47454303a5a5", "node_type": "1", "metadata": {"window": "As it relates to the \nguidance changes, well, he y, it's the first quarter , it's certainly early.   It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.  ", "original_text": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec620949d25620956c21fc1828d598e1ef065e40b95da4ee2f6d99835681fe51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dfe9482-6bdf-4a75-b741-07b44eb3a273", "node_type": "1", "metadata": {"window": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . ", "original_text": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  "}, "hash": "fed30705abf130a7471693a634e0ace3b0b26835f58f9c54dae9d0b8a1bd2f2b", "class_name": "RelatedNodeInfo"}}, "text": "And that was certainly welcomed given what the last \ncouple of years have look ed like.  ", "start_char_idx": 1320, "end_char_idx": 1409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dfe9482-6bdf-4a75-b741-07b44eb3a273": {"__data__": {"id_": "4dfe9482-6bdf-4a75-b741-07b44eb3a273", "embedding": null, "metadata": {"window": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . ", "original_text": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "228820e3-504e-4309-adab-5b65b4daeda1", "node_type": "1", "metadata": {"window": "It's we're also talking about still a \nfairly uncertain macroeconomic environment .  We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  ", "original_text": "And that was certainly welcomed given what the last \ncouple of years have look ed like.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1c34cd0781ee9da5839da12a0d1f77499487f81b9b56fdc27af8f0a0c8888c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a4d36a5-5942-4813-a025-0bb1a1c0e1c3", "node_type": "1", "metadata": {"window": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n", "original_text": "And that's something that we continue to look at.  "}, "hash": "ec8553108c0b9c68335ed56faad44bd3ff2e1459aa8d09feacc3e53bdbc363ff", "class_name": "RelatedNodeInfo"}}, "text": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  ", "start_char_idx": 1409, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a4d36a5-5942-4813-a025-0bb1a1c0e1c3": {"__data__": {"id_": "9a4d36a5-5942-4813-a025-0bb1a1c0e1c3", "embedding": null, "metadata": {"window": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n", "original_text": "And that's something that we continue to look at.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dfe9482-6bdf-4a75-b741-07b44eb3a273", "node_type": "1", "metadata": {"window": "We're also talking about a lot of news out there that \nwe're always looking at in addition to our own data in terms of util ization .  So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . ", "original_text": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4596933e674dd51f7a0ebc32a07536090daa20f7cfadd755d23b66cfa87163d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b850561e-f5c1-4344-999f-c58069f298c8", "node_type": "1", "metadata": {"window": "And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n", "original_text": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  "}, "hash": "fd4bcc1b1145d89f30f337e02261a7095fe2dff2459b29b174b5a166d17d4f58", "class_name": "RelatedNodeInfo"}}, "text": "And that's something that we continue to look at.  ", "start_char_idx": 1510, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b850561e-f5c1-4344-999f-c58069f298c8": {"__data__": {"id_": "b850561e-f5c1-4344-999f-c58069f298c8", "embedding": null, "metadata": {"window": "And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n", "original_text": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a4d36a5-5942-4813-a025-0bb1a1c0e1c3", "node_type": "1", "metadata": {"window": "So as our comment \nhighlighted, we did not see a lot of surprises as it relates to utili zation in either of our businesses, \neither our segments this particular quarter.  And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n", "original_text": "And that's something that we continue to look at.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50bb9c4c842b18149c4f09b45cbd03380ed6827193cf9f4d8bff61978ca760c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72384c7b-b67f-41f8-baab-c645dc1f6fe1", "node_type": "1", "metadata": {"window": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical. ", "original_text": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . "}, "hash": "54832d1b3f29591f1c35c4948034e5fa596180d4e2de66db06ff348e2a6a8682", "class_name": "RelatedNodeInfo"}}, "text": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  ", "start_char_idx": 1561, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72384c7b-b67f-41f8-baab-c645dc1f6fe1": {"__data__": {"id_": "72384c7b-b67f-41f8-baab-c645dc1f6fe1", "embedding": null, "metadata": {"window": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical. ", "original_text": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b850561e-f5c1-4344-999f-c58069f298c8", "node_type": "1", "metadata": {"window": "And that was certainly welcomed given what the last \ncouple of years have look ed like.   But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n", "original_text": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91f3dbea40b355a99c20e91c74851708e8648b3dadba199f35446cdedc3f4c6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a8bd40-8b8d-42cb-b394-1626ac5719db", "node_type": "1", "metadata": {"window": "And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. ", "original_text": "Next question, please.  \n \n"}, "hash": "d92a378f6ee946cc7aafa9af344c99d931d991d9bc2784c7326daf9caa6cc419", "class_name": "RelatedNodeInfo"}}, "text": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . ", "start_char_idx": 1746, "end_char_idx": 1931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a8bd40-8b8d-42cb-b394-1626ac5719db": {"__data__": {"id_": "87a8bd40-8b8d-42cb-b394-1626ac5719db", "embedding": null, "metadata": {"window": "And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. ", "original_text": "Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72384c7b-b67f-41f8-baab-c645dc1f6fe1", "node_type": "1", "metadata": {"window": "But nonetheless, we continue to see more data points on that \nthrough a lot of external references.   And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical. ", "original_text": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c65ce777ac102852364c9bddd288f6212ca010720122cbab85ccb918c51a8a73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91e11346-4844-46c1-bcd1-5e2d53fa4342", "node_type": "1", "metadata": {"window": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  ", "original_text": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n"}, "hash": "6cc984cc97b8d78b7bb5f2e35946460f03c422f42ec7bfed1ef23468b87bcc00", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 1931, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91e11346-4844-46c1-bcd1-5e2d53fa4342": {"__data__": {"id_": "91e11346-4844-46c1-bcd1-5e2d53fa4342", "embedding": null, "metadata": {"window": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  ", "original_text": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a8bd40-8b8d-42cb-b394-1626ac5719db", "node_type": "1", "metadata": {"window": "And that's something that we continue to look at.   But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. ", "original_text": "Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0584ddcc7440a82feddba75107c68476143126336c836b057218c6d2af474fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f704365-2a0e-42ab-864c-70536fb2b441", "node_type": "1", "metadata": {"window": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n", "original_text": "Eric Percher :   Thank you , I'd like to return to Medical. "}, "hash": "7a258f2eb305a198957fcef23881c66bc7c914c20589bce4361ba8667fd3e6d0", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n", "start_char_idx": 1958, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f704365-2a0e-42ab-864c-70536fb2b441": {"__data__": {"id_": "1f704365-2a0e-42ab-864c-70536fb2b441", "embedding": null, "metadata": {"window": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n", "original_text": "Eric Percher :   Thank you , I'd like to return to Medical. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91e11346-4844-46c1-bcd1-5e2d53fa4342", "node_type": "1", "metadata": {"window": "But \nmathematically, I don't think there's that muc h difference in terms of the  offsets that we t ook both the \ntake down with Medical driven in part by that simplification efforts.   But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  ", "original_text": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e694416f157b0ae9f15decf0195a4ed203679828b8c4ab321a0c63ab47bf66c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "facfe395-f03e-4962-be64-f578fe99cea9", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  ", "original_text": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. "}, "hash": "fcd1122a4d111a4dd0f5c0833876978a73ebcdba0ea12af2d8e510f2054ebcaa", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :   Thank you , I'd like to return to Medical. ", "start_char_idx": 2040, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "facfe395-f03e-4962-be64-f578fe99cea9": {"__data__": {"id_": "facfe395-f03e-4962-be64-f578fe99cea9", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  ", "original_text": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f704365-2a0e-42ab-864c-70536fb2b441", "node_type": "1", "metadata": {"window": "But then also those other items \nwhere we took the top end down, it's still a reasonable range considering how early it is in the year as \nwell as the drivers that are all ar ound us .  Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n", "original_text": "Eric Percher :   Thank you , I'd like to return to Medical. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ae3c6e28611e1e87d95c80bd79bd4ab15357682fc9940cbb37224b253850b4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e20c546-9fb6-4b86-979c-7bc0e3ff6ef6", "node_type": "1", "metadata": {"window": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n", "original_text": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  "}, "hash": "18640a2e2e4af04777a64715127dc0c0f3ee2f80f9ceeecb3454278ab7d50b39", "class_name": "RelatedNodeInfo"}}, "text": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. ", "start_char_idx": 2100, "end_char_idx": 2330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e20c546-9fb6-4b86-979c-7bc0e3ff6ef6": {"__data__": {"id_": "0e20c546-9fb6-4b86-979c-7bc0e3ff6ef6", "embedding": null, "metadata": {"window": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n", "original_text": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "facfe395-f03e-4962-be64-f578fe99cea9", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  ", "original_text": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a25b11c796efbf5c145dcb1293bc929d59d3a8a95b8c73cd8940c79badcb339c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ead3158e-9623-4000-9ac4-2b38e4395485", "node_type": "1", "metadata": {"window": "Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly. ", "original_text": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n"}, "hash": "c636fa458b76db5f21ffff71dfc0f6866984247e6c5958d9a3a754a56203813c", "class_name": "RelatedNodeInfo"}}, "text": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  ", "start_char_idx": 2330, "end_char_idx": 2474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ead3158e-9623-4000-9ac4-2b38e4395485": {"__data__": {"id_": "ead3158e-9623-4000-9ac4-2b38e4395485", "embedding": null, "metadata": {"window": "Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly. ", "original_text": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e20c546-9fb6-4b86-979c-7bc0e3ff6ef6", "node_type": "1", "metadata": {"window": "Operator :   Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n", "original_text": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bca67dae598de1fedcfb4aac25b264b0b0586bef29ba51d30b9bede54475565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d82277-144e-4aeb-8eaa-4d76f64fa31f", "node_type": "1", "metadata": {"window": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n", "original_text": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  "}, "hash": "5dc24d6da734843be869027492dbd45cd868c3755393b5860d084c99df13e8db", "class_name": "RelatedNodeInfo"}}, "text": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n", "start_char_idx": 2474, "end_char_idx": 2586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d82277-144e-4aeb-8eaa-4d76f64fa31f": {"__data__": {"id_": "38d82277-144e-4aeb-8eaa-4d76f64fa31f", "embedding": null, "metadata": {"window": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n", "original_text": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ead3158e-9623-4000-9ac4-2b38e4395485", "node_type": "1", "metadata": {"window": "Eric Percher :   Thank you , I'd like to return to Medical.  And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly. ", "original_text": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5796366b697969ed878f0537c080704c45046b0953deffb09651425f17f73aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4964759b-47d6-4d85-8f15-58a420b40b85", "node_type": "1", "metadata": {"window": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing. ", "original_text": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n"}, "hash": "0ce171133094ce3a07a1904b41a803246ab9aa3926d3b7208dc0de592173fa10", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  ", "start_char_idx": 2586, "end_char_idx": 2754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4964759b-47d6-4d85-8f15-58a420b40b85": {"__data__": {"id_": "4964759b-47d6-4d85-8f15-58a420b40b85", "embedding": null, "metadata": {"window": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing. ", "original_text": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d82277-144e-4aeb-8eaa-4d76f64fa31f", "node_type": "1", "metadata": {"window": "And relative to the offsets that you're \nattempting to achieve in '23, it sounds like we ha ve three factors, the pricing efforts letting some of the \nsupply chain and cost flow through normalise and then access to private label.  Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n", "original_text": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e947ad3a29fdf90f0b128503739fa67364b244bafdff3efea8e4c7b0897595d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6937cd3f-9e96-455c-b274-880c6ddddb76", "node_type": "1", "metadata": {"window": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity. ", "original_text": "Eric Percher :   Exactly. "}, "hash": "8509b8f14eb51a5c286bc483433ff49f472f8d60f1c32a01512b4e8ee798b064", "class_name": "RelatedNodeInfo"}}, "text": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n", "start_char_idx": 2754, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6937cd3f-9e96-455c-b274-880c6ddddb76": {"__data__": {"id_": "6937cd3f-9e96-455c-b274-880c6ddddb76", "embedding": null, "metadata": {"window": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity. ", "original_text": "Eric Percher :   Exactly. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4964759b-47d6-4d85-8f15-58a420b40b85", "node_type": "1", "metadata": {"window": "Could you speak to \nwhat portion of the offset for fiscal year \u201823 falls into those buckets , and  if you think those are the r ight \nbuckets?   And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing. ", "original_text": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "488a2bd4ac260086bd2cc92edd822ac8c2147713109e9dc06cbb41e13013aa5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55b01a16-3fde-44d6-ad4f-caf51ecf526b", "node_type": "1", "metadata": {"window": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  ", "original_text": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n"}, "hash": "2b8bcd296e9037a7bd0e074dd51923f60fffe7acb3565ac6c57f3f7ed7fef88a", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :   Exactly. ", "start_char_idx": 2881, "end_char_idx": 2907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55b01a16-3fde-44d6-ad4f-caf51ecf526b": {"__data__": {"id_": "55b01a16-3fde-44d6-ad4f-caf51ecf526b", "embedding": null, "metadata": {"window": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  ", "original_text": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6937cd3f-9e96-455c-b274-880c6ddddb76", "node_type": "1", "metadata": {"window": "And then as you move to '24, how does that change in terms of how much is driven by \neach of those factors?  \n \n Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity. ", "original_text": "Eric Percher :   Exactly. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ee3adbc4ac75acfc7880787b5a0d41aa63922d511695641ed0c731b155dc48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78725f1f-cfc8-41e1-b1dc-0177979f3a8c", "node_type": "1", "metadata": {"window": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.  ", "original_text": "Jason Hollar :   Yeah, by far it's pricing. "}, "hash": "f65863b2a1404a5651bd41636f727a407cfe2a52fdfe870dbefdc28a48de143c", "class_name": "RelatedNodeInfo"}}, "text": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n", "start_char_idx": 2907, "end_char_idx": 3012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78725f1f-cfc8-41e1-b1dc-0177979f3a8c": {"__data__": {"id_": "78725f1f-cfc8-41e1-b1dc-0177979f3a8c", "embedding": null, "metadata": {"window": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.  ", "original_text": "Jason Hollar :   Yeah, by far it's pricing. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55b01a16-3fde-44d6-ad4f-caf51ecf526b", "node_type": "1", "metadata": {"window": "Jason Hollar :  So to make sure I understand the question, so we have our gross inflationary impacts \nand then we have the mitigation ac tions that get us to the net.   You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  ", "original_text": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe38a787a328ffff3292285402b6cfbbbdd59e31211f2019077589ced5c3fac6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05af221e-ba6a-42eb-8600-339275a7de8e", "node_type": "1", "metadata": {"window": "Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there. ", "original_text": "That is there's opportunity. "}, "hash": "05ba3ae0da2440f75658da92ac7866e9022ce367e4a571f0cc891c4ab0094b6a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Yeah, by far it's pricing. ", "start_char_idx": 3012, "end_char_idx": 3056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05af221e-ba6a-42eb-8600-339275a7de8e": {"__data__": {"id_": "05af221e-ba6a-42eb-8600-339275a7de8e", "embedding": null, "metadata": {"window": "Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there. ", "original_text": "That is there's opportunity. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78725f1f-cfc8-41e1-b1dc-0177979f3a8c", "node_type": "1", "metadata": {"window": "You're specifically asking about the \nmitigation actions and how to think about what's driving those both for '23 and '24?  \n \n Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.  ", "original_text": "Jason Hollar :   Yeah, by far it's pricing. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51f2025d8c9f25151ebc342c4208e7a08019414a30e44a3a0c37ab811fbe8d88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "140b202e-c88d-4424-9ef3-d75c03a024f6", "node_type": "1", "metadata": {"window": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.  ", "original_text": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  "}, "hash": "3dce9d907b53c2a637715f1fc8241c985f4dc655df261ccc66c2c4b14ab7d39b", "class_name": "RelatedNodeInfo"}}, "text": "That is there's opportunity. ", "start_char_idx": 3056, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "140b202e-c88d-4424-9ef3-d75c03a024f6": {"__data__": {"id_": "140b202e-c88d-4424-9ef3-d75c03a024f6", "embedding": null, "metadata": {"window": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.  ", "original_text": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05af221e-ba6a-42eb-8600-339275a7de8e", "node_type": "1", "metadata": {"window": "Eric Percher :   Exactly.  What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there. ", "original_text": "That is there's opportunity. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a63fd894b2774f1154bcc18771aafbd0954c5a369372eb311a27182f74407f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "292b6a48-a2a9-4296-a3a1-4a34aa7bf7ce", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n", "original_text": "But the amount that can be mo ved on those items as well as others is relatively small.  "}, "hash": "183799e56f64423f5bc554c7c14b3589bddbb6e72daf9edfc5dfa1dfdd091bde", "class_name": "RelatedNodeInfo"}}, "text": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  ", "start_char_idx": 3085, "end_char_idx": 3233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "292b6a48-a2a9-4296-a3a1-4a34aa7bf7ce": {"__data__": {"id_": "292b6a48-a2a9-4296-a3a1-4a34aa7bf7ce", "embedding": null, "metadata": {"window": "Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n", "original_text": "But the amount that can be mo ved on those items as well as others is relatively small.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "140b202e-c88d-4424-9ef3-d75c03a024f6", "node_type": "1", "metadata": {"window": "What are the most material factors of the mitigating actions and how do they \nchange '24 versus '23?  \n \n Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.  ", "original_text": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72ab30ddc9d7c805cce63bd77171017ebbd5d8128c48bd538e465f13a1f383cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9df4904-afbd-4a73-bdc9-6e57eb30e4ca", "node_type": "1", "metadata": {"window": "That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . ", "original_text": "So \npricing will be the predominant element there. "}, "hash": "fbbe270315b217eff11137fdff1303e4a5a54e4cbd21494f4e3e5ec8e8f8bafd", "class_name": "RelatedNodeInfo"}}, "text": "But the amount that can be mo ved on those items as well as others is relatively small.  ", "start_char_idx": 3233, "end_char_idx": 3322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9df4904-afbd-4a73-bdc9-6e57eb30e4ca": {"__data__": {"id_": "b9df4904-afbd-4a73-bdc9-6e57eb30e4ca", "embedding": null, "metadata": {"window": "That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . ", "original_text": "So \npricing will be the predominant element there. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "292b6a48-a2a9-4296-a3a1-4a34aa7bf7ce", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah, by far it's pricing.  That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n", "original_text": "But the amount that can be mo ved on those items as well as others is relatively small.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f71dcc8d01eaa6f1d4dbd2aa782a6b3d111203b2a156f1db89c480b4fca2a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68ae2dc9-ec5e-4407-9134-32fe44367431", "node_type": "1", "metadata": {"window": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "The other component is just the costs coming down \nnaturally as well.  "}, "hash": "2e8c6cc9c47975c5ddee006f13b041d9a5d227b0af0b774b42df901df699a139", "class_name": "RelatedNodeInfo"}}, "text": "So \npricing will be the predominant element there. ", "start_char_idx": 3322, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68ae2dc9-ec5e-4407-9134-32fe44367431": {"__data__": {"id_": "68ae2dc9-ec5e-4407-9134-32fe44367431", "embedding": null, "metadata": {"window": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "The other component is just the costs coming down \nnaturally as well.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9df4904-afbd-4a73-bdc9-6e57eb30e4ca", "node_type": "1", "metadata": {"window": "That is there's opportunity.  And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . ", "original_text": "So \npricing will be the predominant element there. ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc61ff6415795953c91fa32ccb4e35feaa860cec341628c920df5a553c915bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0927c8bf-8690-4ec5-ac6a-9f7c82885496", "node_type": "1", "metadata": {"window": "But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "So we have two things happening between now and the end of the fiscal year . \n"}, "hash": "bc5ede22972e1c9194e5c8f86ee826a4c2db1c1fa71e2a5cc6314a17ce909d45", "class_name": "RelatedNodeInfo"}}, "text": "The other component is just the costs coming down \nnaturally as well.  ", "start_char_idx": 3373, "end_char_idx": 3444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0927c8bf-8690-4ec5-ac6a-9f7c82885496": {"__data__": {"id_": "0927c8bf-8690-4ec5-ac6a-9f7c82885496", "embedding": null, "metadata": {"window": "But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "So we have two things happening between now and the end of the fiscal year . \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68ae2dc9-ec5e-4407-9134-32fe44367431", "node_type": "1", "metadata": {"window": "And of course what we want to do \nis work with our customers as much as possible to reduce what is necessary to flow through in terms \nof pricing.   But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "The other component is just the costs coming down \nnaturally as well.  ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ced9e3ad2870b7e87f728a5f184f267f5a4dc388589d5fe794eb127895d1e17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "659da11a-ed42-4dd6-a6b6-27de2f325073", "node_type": "1", "metadata": {"window": "So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . "}, "hash": "01459f62050f369646e5f14a2667f1600ef83df0da32d6315e73c78928b37e59", "class_name": "RelatedNodeInfo"}}, "text": "So we have two things happening between now and the end of the fiscal year . \n", "start_char_idx": 3444, "end_char_idx": 3522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "659da11a-ed42-4dd6-a6b6-27de2f325073": {"__data__": {"id_": "659da11a-ed42-4dd6-a6b6-27de2f325073", "embedding": null, "metadata": {"window": "So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0927c8bf-8690-4ec5-ac6a-9f7c82885496", "node_type": "1", "metadata": {"window": "But the amount that can be mo ved on those items as well as others is relatively small.   So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "So we have two things happening between now and the end of the fiscal year . \n", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e39bf26316e28ca65c067061476b30a067098ec8b27023335f2ad8c2ef1e109", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cab3a7a-f3cf-4826-922c-72d5aad7c399", "node_type": "1", "metadata": {"window": "The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "We believe we indicated similar gross costs in Q1 is what we "}, "hash": "bf7f0c61dd619b0a4969c8ba9c085b59010c2683fe1b2d35024f948178f95e5d", "class_name": "RelatedNodeInfo"}}, "text": "Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . ", "start_char_idx": 3522, "end_char_idx": 3672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cab3a7a-f3cf-4826-922c-72d5aad7c399": {"__data__": {"id_": "9cab3a7a-f3cf-4826-922c-72d5aad7c399", "embedding": null, "metadata": {"window": "The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "We believe we indicated similar gross costs in Q1 is what we ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b57d256e008b36466b67c5c7a32c12adcc71c4f912187915d3a1ba83f9a74b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "659da11a-ed42-4dd6-a6b6-27de2f325073", "node_type": "1", "metadata": {"window": "So \npricing will be the predominant element there.  The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that . ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e5ed0eab205a410f205cfdf2b8401af41ad525f0e0b02a4edba0cb535bcc485", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80fd47aa-7ac8-4012-86a9-e68a9f063625", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "original_text": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece. "}, "hash": "7d308631b4f3fffd7dd3c8860ea9e94e13c0bafa20b177c8a1660d64f3301837", "class_name": "RelatedNodeInfo"}}, "text": "We believe we indicated similar gross costs in Q1 is what we ", "start_char_idx": 3672, "end_char_idx": 3733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80fd47aa-7ac8-4012-86a9-e68a9f063625": {"__data__": {"id_": "80fd47aa-7ac8-4012-86a9-e68a9f063625", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "original_text": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cab3a7a-f3cf-4826-922c-72d5aad7c399", "node_type": "1", "metadata": {"window": "The other component is just the costs coming down \nnaturally as well.   So we have two things happening between now and the end of the fiscal year . \n Pricing will continue to go up period to period, quarter to quarter , and our costs will at some point here \npeak, which we're pretty close to that .  We believe we indicated similar gross costs in Q1 is what we ", "original_text": "We believe we indicated similar gross costs in Q1 is what we ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9404fda62362d33e0853ff122e96f5132ab2764eccc60ea346a1401bd122b56e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e2b3339-2ef8-4ada-80b7-8420ade71761", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n", "original_text": "That's the one area that we \nhave some confidence is going to come down. "}, "hash": "b5908fd43fb0d1a955237a5f7b04bd87a1893b2f83c9f98a97764c84c13299d0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece. ", "start_char_idx": 0, "end_char_idx": 96, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e2b3339-2ef8-4ada-80b7-8420ade71761": {"__data__": {"id_": "2e2b3339-2ef8-4ada-80b7-8420ade71761", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n", "original_text": "That's the one area that we \nhave some confidence is going to come down. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80fd47aa-7ac8-4012-86a9-e68a9f063625", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "original_text": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63c88d1bcc82dfca32ac435b0949239d3d6f1286d86eea59df2776364df1d18e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84394342-156c-4fa4-a783-d6ef5ee2c918", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  ", "original_text": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.  "}, "hash": "e184f1b26a3e1891247297f658a0b009afcfb98252518343f21dfa531f788dcd", "class_name": "RelatedNodeInfo"}}, "text": "That's the one area that we \nhave some confidence is going to come down. ", "start_char_idx": 96, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84394342-156c-4fa4-a783-d6ef5ee2c918": {"__data__": {"id_": "84394342-156c-4fa4-a783-d6ef5ee2c918", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  ", "original_text": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e2b3339-2ef8-4ada-80b7-8420ade71761", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n", "original_text": "That's the one area that we \nhave some confidence is going to come down. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b70fd6727701607b4f4c0255db617e478d6967da2054d89204ea1d95d3276b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae7e472c-f622-4e54-af91-aa72328563d8", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n", "original_text": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  "}, "hash": "eb172e24629ae1b6536f116d525a320c753e698ce2d346ba291fb3e7be46dc28", "class_name": "RelatedNodeInfo"}}, "text": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.  ", "start_char_idx": 169, "end_char_idx": 358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae7e472c-f622-4e54-af91-aa72328563d8": {"__data__": {"id_": "ae7e472c-f622-4e54-af91-aa72328563d8", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n", "original_text": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84394342-156c-4fa4-a783-d6ef5ee2c918", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  ", "original_text": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba992da4d4c39ee2db96941391958add50d57fedb914d6ae543a66917f4f0a91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51cb00ee-8d5d-4061-a395-4d84a9354f9b", "node_type": "1", "metadata": {"window": "That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n", "original_text": "And then a handfu l of them are actually going up . \n"}, "hash": "914ddb78b90f60facdd4f276a4eb752144e37378db6e04d561fb9a1298bd40ee", "class_name": "RelatedNodeInfo"}}, "text": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "start_char_idx": 358, "end_char_idx": 571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51cb00ee-8d5d-4061-a395-4d84a9354f9b": {"__data__": {"id_": "51cb00ee-8d5d-4061-a395-4d84a9354f9b", "embedding": null, "metadata": {"window": "That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n", "original_text": "And then a handfu l of them are actually going up . \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae7e472c-f622-4e54-af91-aa72328563d8", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n", "original_text": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "376629a670c31b5e6cf57d3d0565caadc5c92fc69eb1ac10a571638da3f89661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c29f224-fb22-45f5-9e2a-595b356c6805", "node_type": "1", "metadata": {"window": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.  ", "original_text": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  "}, "hash": "d498effcff56660b30787c3561fd6d79fefcb40d73777f4bb1c828b1e104af32", "class_name": "RelatedNodeInfo"}}, "text": "And then a handfu l of them are actually going up . \n", "start_char_idx": 571, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c29f224-fb22-45f5-9e2a-595b356c6805": {"__data__": {"id_": "5c29f224-fb22-45f5-9e2a-595b356c6805", "embedding": null, "metadata": {"window": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.  ", "original_text": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51cb00ee-8d5d-4061-a395-4d84a9354f9b", "node_type": "1", "metadata": {"window": "That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n", "original_text": "And then a handfu l of them are actually going up . \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d68870ce7d3c6d15d96147b6c723feac42e4a11a2e0ddac5c1c5da28030bee3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a17b9e4-c6c1-4b83-a025-8c1f5dd8d1ee", "node_type": "1", "metadata": {"window": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question. ", "original_text": "Next question.  \n \n"}, "hash": "3db63229ef28269acfe4081dd9bf76fd27a1122cfa0dadf9e2221abfe40d53ae", "class_name": "RelatedNodeInfo"}}, "text": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  ", "start_char_idx": 624, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a17b9e4-c6c1-4b83-a025-8c1f5dd8d1ee": {"__data__": {"id_": "0a17b9e4-c6c1-4b83-a025-8c1f5dd8d1ee", "embedding": null, "metadata": {"window": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question. ", "original_text": "Next question.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c29f224-fb22-45f5-9e2a-595b356c6805", "node_type": "1", "metadata": {"window": "And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.  ", "original_text": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19f399c250b92b5eea6f3c2ce29208cbbf6a5695ad88cb0444ffbc55533d50bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86a85b95-9236-49bb-8cec-f9266b3be8d3", "node_type": "1", "metadata": {"window": "And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again. ", "original_text": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n"}, "hash": "c2c448780541a0edac850780da64c868f031849bb4ad9b30894597c186df4b40", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 749, "end_char_idx": 768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86a85b95-9236-49bb-8cec-f9266b3be8d3": {"__data__": {"id_": "86a85b95-9236-49bb-8cec-f9266b3be8d3", "embedding": null, "metadata": {"window": "And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again. ", "original_text": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a17b9e4-c6c1-4b83-a025-8c1f5dd8d1ee", "node_type": "1", "metadata": {"window": "The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.   And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question. ", "original_text": "Next question.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d940d3ab5329edd47b6368fc5fc053aa4451f8b184007214f5f44c48321b8f51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad78af9c-3a1c-4068-ad65-f3ee294fb85a", "node_type": "1", "metadata": {"window": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  ", "original_text": "George Hill :   Yeah.  "}, "hash": "e9b8ce45e5dd00742a6e1dca60d227bfa83661ea6d62390066a0e696ad9cbf73", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n", "start_char_idx": 768, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad78af9c-3a1c-4068-ad65-f3ee294fb85a": {"__data__": {"id_": "ad78af9c-3a1c-4068-ad65-f3ee294fb85a", "embedding": null, "metadata": {"window": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  ", "original_text": "George Hill :   Yeah.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86a85b95-9236-49bb-8cec-f9266b3be8d3", "node_type": "1", "metadata": {"window": "And then a handfu l of them are actually going up . \n But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again. ", "original_text": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d7b9a2ebad85bf7888bf442a364eb1b60d5c2ec1c4e16b1e1db63a03086fe15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22591419-6fcd-47b5-8378-983ceb0d11d0", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . ", "original_text": "Good morning, guys, and thanks for taking the question. "}, "hash": "567875860c4e60e4ac8ef09c0edc847618773a0fd16213263daa82e367f04379", "class_name": "RelatedNodeInfo"}}, "text": "George Hill :   Yeah.  ", "start_char_idx": 845, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22591419-6fcd-47b5-8378-983ceb0d11d0": {"__data__": {"id_": "22591419-6fcd-47b5-8378-983ceb0d11d0", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . ", "original_text": "Good morning, guys, and thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad78af9c-3a1c-4068-ad65-f3ee294fb85a", "node_type": "1", "metadata": {"window": "But overall, I would expect to exit the year with a little bit lower cost run rate than what we have \ncoming into the year.   Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  ", "original_text": "George Hill :   Yeah.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f979e9c6f025d6831c1531e7cb40d27a5d68a7d37d7de333afc1086f305d636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d175cae6-5708-4572-9cab-830de5a97824", "node_type": "1", "metadata": {"window": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. ", "original_text": "Jason, I'm going to \ncome back to the Med segment again. "}, "hash": "a77567fbca1fc37fdd3d3d86e2fc7b9c1b06675c036f6b75e9e4fc3f0bb07b54", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys, and thanks for taking the question. ", "start_char_idx": 868, "end_char_idx": 924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d175cae6-5708-4572-9cab-830de5a97824": {"__data__": {"id_": "d175cae6-5708-4572-9cab-830de5a97824", "embedding": null, "metadata": {"window": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. ", "original_text": "Jason, I'm going to \ncome back to the Med segment again. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22591419-6fcd-47b5-8378-983ceb0d11d0", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . ", "original_text": "Good morning, guys, and thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "515604d1b2535851b62b25ebe758b89d3d03a58a57ddfecc2b49ad817886aaec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c4d869e-3f29-48b0-9c09-682c27a8376f", "node_type": "1", "metadata": {"window": "George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n", "original_text": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  "}, "hash": "7fa8ce926ac604f1e8dd7d3a39e7e4c1aa69458bc36378c5a895b92b49c55b25", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I'm going to \ncome back to the Med segment again. ", "start_char_idx": 924, "end_char_idx": 981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c4d869e-3f29-48b0-9c09-682c27a8376f": {"__data__": {"id_": "2c4d869e-3f29-48b0-9c09-682c27a8376f", "embedding": null, "metadata": {"window": "George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n", "original_text": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d175cae6-5708-4572-9cab-830de5a97824", "node_type": "1", "metadata": {"window": "Operator :  Our next question comes from George Hill with Deutsche Bank.  \n \n George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. ", "original_text": "Jason, I'm going to \ncome back to the Med segment again. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04cf8636e58a36d8f00021120962c677f4ad66e9ae9b40e8e4a37b6a8b0d5e7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fedbec4b-8b92-4cc5-8ac7-c9d518e1eaf8", "node_type": "1", "metadata": {"window": "Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. ", "original_text": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . "}, "hash": "3605486c9e9fe7b492225e374ca89a5c2225bcac51cf066f36d5c22a490bbb2d", "class_name": "RelatedNodeInfo"}}, "text": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  ", "start_char_idx": 981, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fedbec4b-8b92-4cc5-8ac7-c9d518e1eaf8": {"__data__": {"id_": "fedbec4b-8b92-4cc5-8ac7-c9d518e1eaf8", "embedding": null, "metadata": {"window": "Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. ", "original_text": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c4d869e-3f29-48b0-9c09-682c27a8376f", "node_type": "1", "metadata": {"window": "George Hill :   Yeah.   Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n", "original_text": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "feb881d6debb359bb9c9221324de75aa9268d919f731b33ba2503d72c823a22a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05e08d03-8634-4e61-ba2f-e3e4f98e034b", "node_type": "1", "metadata": {"window": "Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then . ", "original_text": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. "}, "hash": "a0830cd18e0253c63c02d68c15ae45df9820f8f8eb1248d07e47491452698c45", "class_name": "RelatedNodeInfo"}}, "text": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . ", "start_char_idx": 1108, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05e08d03-8634-4e61-ba2f-e3e4f98e034b": {"__data__": {"id_": "05e08d03-8634-4e61-ba2f-e3e4f98e034b", "embedding": null, "metadata": {"window": "Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then . ", "original_text": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fedbec4b-8b92-4cc5-8ac7-c9d518e1eaf8", "node_type": "1", "metadata": {"window": "Good morning, guys, and thanks for taking the question.  Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. ", "original_text": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f537d417bab754e2d786ffa8b9bfb3d8e496cebba60d0fcb5bd82756f465ab9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "463ffaee-6f01-4568-a447-208f58e1550b", "node_type": "1", "metadata": {"window": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products . ", "original_text": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n"}, "hash": "7798bae6983aac3e7b9a3ac925ade6491a699c739f37db1fc0029e0c94611477", "class_name": "RelatedNodeInfo"}}, "text": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. ", "start_char_idx": 1262, "end_char_idx": 1423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "463ffaee-6f01-4568-a447-208f58e1550b": {"__data__": {"id_": "463ffaee-6f01-4568-a447-208f58e1550b", "embedding": null, "metadata": {"window": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products . ", "original_text": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05e08d03-8634-4e61-ba2f-e3e4f98e034b", "node_type": "1", "metadata": {"window": "Jason, I'm going to \ncome back to the Med segment again.  I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then . ", "original_text": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56d74d19aded23c83af30b1bf831172e29d75764b79a67c117c2aefeb9ed8a53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f66956-df5f-423c-9d53-6870108f9209", "node_type": "1", "metadata": {"window": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . ", "original_text": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. "}, "hash": "32281edcc7e602b0df1f3a353c18292d6e4d66dc3b9b9da748497982afabea89", "class_name": "RelatedNodeInfo"}}, "text": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n", "start_char_idx": 1423, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f66956-df5f-423c-9d53-6870108f9209": {"__data__": {"id_": "65f66956-df5f-423c-9d53-6870108f9209", "embedding": null, "metadata": {"window": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . ", "original_text": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "463ffaee-6f01-4568-a447-208f58e1550b", "node_type": "1", "metadata": {"window": "I was just wondering if there's kind of a way to quantify like \nwhat part of the book has the new contracting terms in place.   And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products . ", "original_text": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57b04a2939606bea91790fbb4853faa4487c7aa4ef58b43f565318b7cccaf942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9a105fc-d385-4975-9b4f-8307f0b038a3", "node_type": "1", "metadata": {"window": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.  ", "original_text": "But it will be relatively consistent between now and then . "}, "hash": "4b58e2916bf4c92d3f855229e1f920cf1f716526abd7116e806723646d14a30a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. ", "start_char_idx": 1661, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9a105fc-d385-4975-9b4f-8307f0b038a3": {"__data__": {"id_": "f9a105fc-d385-4975-9b4f-8307f0b038a3", "embedding": null, "metadata": {"window": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.  ", "original_text": "But it will be relatively consistent between now and then . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f66956-df5f-423c-9d53-6870108f9209", "node_type": "1", "metadata": {"window": "And I do n't know if you can talk about \nkind of actions taken by peers and then kind of - I'd kind of roll that into kind of timing of \nimplementation .  Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . ", "original_text": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a05d4b48cc5b839d10b4793c94881cbdc65a673ee0cabb3a020f9ca9aa02ed34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95800ef0-d8b7-46d1-963f-306c4bd1ecae", "node_type": "1", "metadata": {"window": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event. ", "original_text": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products . "}, "hash": "0aed0196424d2b531fd74aa6e82af38cb17f3f81913983a49ce6a8ed6c49eb07", "class_name": "RelatedNodeInfo"}}, "text": "But it will be relatively consistent between now and then . ", "start_char_idx": 1813, "end_char_idx": 1873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95800ef0-d8b7-46d1-963f-306c4bd1ecae": {"__data__": {"id_": "95800ef0-d8b7-46d1-963f-306c4bd1ecae", "embedding": null, "metadata": {"window": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event. ", "original_text": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9a105fc-d385-4975-9b4f-8307f0b038a3", "node_type": "1", "metadata": {"window": "Like, you kind of talked about the two quarter lag between - not really the lag, but like \nkind of the timing of th e supply chain in that segment of the books.  I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.  ", "original_text": "But it will be relatively consistent between now and then . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28b4a6a4494cb3c4e141fffa8b301cc8018d211ff1039415f24977fccd707dde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aef20ec3-824c-4afe-8712-c08b1dc8e00b", "node_type": "1", "metadata": {"window": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n", "original_text": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . "}, "hash": "d717aa293a435a38dc18235de29ad3d8790fe5c9fe27bdeedb060df851e2719d", "class_name": "RelatedNodeInfo"}}, "text": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products . ", "start_char_idx": 1873, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aef20ec3-824c-4afe-8712-c08b1dc8e00b": {"__data__": {"id_": "aef20ec3-824c-4afe-8712-c08b1dc8e00b", "embedding": null, "metadata": {"window": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n", "original_text": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95800ef0-d8b7-46d1-963f-306c4bd1ecae", "node_type": "1", "metadata": {"window": "I'm just trying to think about how \nlong it takes the entire book to get re -contracted to the new terms and kind of what is the end date by \nwhich we should expect the full Med surge book to kind of be operating under the new model.  \n \n Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event. ", "original_text": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2500214e35c1a68a1a37556d12cd89521b8bb9616a73946ec6eee43614e1d239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "009b2f3f-3f85-4221-9491-9cc80abfd0e1", "node_type": "1", "metadata": {"window": "But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that. ", "original_text": "So, it's a fairly consistent stair stepping towards that.  "}, "hash": "bf3aa139bafd81e8a44609027db086597aaf7a3c7d48bd2a30b955e6e1086f87", "class_name": "RelatedNodeInfo"}}, "text": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . ", "start_char_idx": 1966, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "009b2f3f-3f85-4221-9491-9cc80abfd0e1": {"__data__": {"id_": "009b2f3f-3f85-4221-9491-9cc80abfd0e1", "embedding": null, "metadata": {"window": "But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that. ", "original_text": "So, it's a fairly consistent stair stepping towards that.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aef20ec3-824c-4afe-8712-c08b1dc8e00b", "node_type": "1", "metadata": {"window": "Jason Hollar :   Well, it's going to take at least a few more years to get to the essence of where you're \ngoing with that, to get the full book there.  But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n", "original_text": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebe97744773541bfea43d57c80cae42035be9e8d3f0cd45394ca91ef9892a9cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c30cbd3-ae2f-496a-9810-bfe161534b21", "node_type": "1", "metadata": {"window": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . ", "original_text": "It's not like one big cliff event. "}, "hash": "cdbad173b5f2c11f912d0c52a635db6998cd75a139389d88f1fc1a3401083e7b", "class_name": "RelatedNodeInfo"}}, "text": "So, it's a fairly consistent stair stepping towards that.  ", "start_char_idx": 2093, "end_char_idx": 2152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c30cbd3-ae2f-496a-9810-bfe161534b21": {"__data__": {"id_": "0c30cbd3-ae2f-496a-9810-bfe161534b21", "embedding": null, "metadata": {"window": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . ", "original_text": "It's not like one big cliff event. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "009b2f3f-3f85-4221-9491-9cc80abfd0e1", "node_type": "1", "metadata": {"window": "But it will be relatively consistent between now and then .  So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that. ", "original_text": "So, it's a fairly consistent stair stepping towards that.  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f87675da28034aa02d47101e93ce4a9d83e0e9721dbeca769467aae18267f0e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecb3850a-9bb0-4f97-97bf-b404317a52cd", "node_type": "1", "metadata": {"window": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n", "original_text": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n"}, "hash": "383f79aadb4f30113e8c8c687264a959661e56f6e7708d4fde6fd88e4003d7a8", "class_name": "RelatedNodeInfo"}}, "text": "It's not like one big cliff event. ", "start_char_idx": 2152, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecb3850a-9bb0-4f97-97bf-b404317a52cd": {"__data__": {"id_": "ecb3850a-9bb0-4f97-97bf-b404317a52cd", "embedding": null, "metadata": {"window": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n", "original_text": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c30cbd3-ae2f-496a-9810-bfe161534b21", "node_type": "1", "metadata": {"window": "So \nevery - remember, these  are not necessarily massive cliff event contracts or products .  We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . ", "original_text": "It's not like one big cliff event. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0111ada341a15f439c8bda15cf542339aed308ac91d2cdf8ae636de5893b5ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c1e38b6-2901-4102-812d-fb513e8c774e", "node_type": "1", "metadata": {"window": "So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do. ", "original_text": "So we ar e considering different ways to give you a little bit more insight to that. "}, "hash": "dc10951e1da4164101db105b9d7b3ff2a09814460839efbcc7be57113228d593", "class_name": "RelatedNodeInfo"}}, "text": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n", "start_char_idx": 2187, "end_char_idx": 2412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c1e38b6-2901-4102-812d-fb513e8c774e": {"__data__": {"id_": "3c1e38b6-2901-4102-812d-fb513e8c774e", "embedding": null, "metadata": {"window": "So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do. ", "original_text": "So we ar e considering different ways to give you a little bit more insight to that. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecb3850a-9bb0-4f97-97bf-b404317a52cd", "node_type": "1", "metadata": {"window": "We've got a \ncouple dozen different product lines and they have different dates with different GPOs and different \ncustomers .  So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n", "original_text": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "826a5257906cc5417fd8ce4f0a97630b9fe6082cbba38149bbe54a578786f1e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fd0fd0a-680f-4561-a75c-94fd97387600", "node_type": "1", "metadata": {"window": "It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan. ", "original_text": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . "}, "hash": "358a58d563c3788ebdf1228678a801859ac3368687f197683bd94959749c913b", "class_name": "RelatedNodeInfo"}}, "text": "So we ar e considering different ways to give you a little bit more insight to that. ", "start_char_idx": 2412, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fd0fd0a-680f-4561-a75c-94fd97387600": {"__data__": {"id_": "6fd0fd0a-680f-4561-a75c-94fd97387600", "embedding": null, "metadata": {"window": "It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan. ", "original_text": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c1e38b6-2901-4102-812d-fb513e8c774e", "node_type": "1", "metadata": {"window": "So, it's a fairly consistent stair stepping towards that.   It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do. ", "original_text": "So we ar e considering different ways to give you a little bit more insight to that. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b563804be2d72a98d65bd9f4bc676a5c723f72b3ae268b7cfe6e8c765036717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78df9892-ccd5-4f40-a6d8-33962ae73480", "node_type": "1", "metadata": {"window": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n", "original_text": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n"}, "hash": "93e75103ccd91b9e580782a9bab778cba43e2d6eac2853ecf434e4f3d79f115b", "class_name": "RelatedNodeInfo"}}, "text": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . ", "start_char_idx": 2497, "end_char_idx": 2609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78df9892-ccd5-4f40-a6d8-33962ae73480": {"__data__": {"id_": "78df9892-ccd5-4f40-a6d8-33962ae73480", "embedding": null, "metadata": {"window": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n", "original_text": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fd0fd0a-680f-4561-a75c-94fd97387600", "node_type": "1", "metadata": {"window": "It's not like one big cliff event.  So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan. ", "original_text": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e805f8289192e010308a537a7177ae18aed9060fb7397110a5ee86a4ce9c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd3eda59-451f-431d-bdc3-2dc65997ae7d", "node_type": "1", "metadata": {"window": "So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J. ", "original_text": "But it's the right plan , it's the right thing to do. "}, "hash": "06702c7b6f0a64956bb495dcc7aefafba2bb785f285447403d7c297c22cbc237", "class_name": "RelatedNodeInfo"}}, "text": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n", "start_char_idx": 2609, "end_char_idx": 2733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd3eda59-451f-431d-bdc3-2dc65997ae7d": {"__data__": {"id_": "dd3eda59-451f-431d-bdc3-2dc65997ae7d", "embedding": null, "metadata": {"window": "So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J. ", "original_text": "But it's the right plan , it's the right thing to do. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78df9892-ccd5-4f40-a6d8-33962ae73480", "node_type": "1", "metadata": {"window": "So, \nyou can think about it as every day we have to work on this and every day it's incredibly important \nthat we roll over the temporary prices into permanent prices, given the permanent nature of so much \nof this cost.  \n \n So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n", "original_text": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0579819ada257e23513c062b858533665c0342c17e245e97e46c51a6cf0fa689", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eec68a8-3307-4aa2-b2a8-57ecdcdcb1da", "node_type": "1", "metadata": {"window": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n", "original_text": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan. "}, "hash": "b8ed11b232f27f84e6b56d6e408c84c9acc27c0c1756ebe88f6225f7f6fbdc40", "class_name": "RelatedNodeInfo"}}, "text": "But it's the right plan , it's the right thing to do. ", "start_char_idx": 2733, "end_char_idx": 2787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eec68a8-3307-4aa2-b2a8-57ecdcdcb1da": {"__data__": {"id_": "8eec68a8-3307-4aa2-b2a8-57ecdcdcb1da", "embedding": null, "metadata": {"window": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n", "original_text": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd3eda59-451f-431d-bdc3-2dc65997ae7d", "node_type": "1", "metadata": {"window": "So we ar e considering different ways to give you a little bit more insight to that.  I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J. ", "original_text": "But it's the right plan , it's the right thing to do. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e87af89b4d60a91eea1ae0e7acc29eea1187409d6a370653fb9f4f2931add4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25af6b8d-fc86-4b87-9e46-66d0959789b2", "node_type": "1", "metadata": {"window": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J. ", "original_text": "Next question, please.  \n \n"}, "hash": "7a54eb78e3630e3f242ee65f9c712f5cdc276806761efcbcaf983c8391cdfe98", "class_name": "RelatedNodeInfo"}}, "text": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan. ", "start_char_idx": 2787, "end_char_idx": 2886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25af6b8d-fc86-4b87-9e46-66d0959789b2": {"__data__": {"id_": "25af6b8d-fc86-4b87-9e46-66d0959789b2", "embedding": null, "metadata": {"window": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J. ", "original_text": "Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eec68a8-3307-4aa2-b2a8-57ecdcdcb1da", "node_type": "1", "metadata": {"window": "I'm not going to go \ninto that further yet, other than to say we are having the success as expected with this .  We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n", "original_text": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47818cc7e527b60f4ea601980806234e5279333df55543ab726bfe890404b2c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32569c4f-69cd-45ad-93c3-5a0080b42beb", "node_type": "1", "metadata": {"window": "But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody . ", "original_text": "Operator :  Our next questio n comes from A.J. "}, "hash": "faaf098175378d9a0782b397f4589821e2620a7c248c05421798a10b1305736a", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 2886, "end_char_idx": 2913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32569c4f-69cd-45ad-93c3-5a0080b42beb": {"__data__": {"id_": "32569c4f-69cd-45ad-93c3-5a0080b42beb", "embedding": null, "metadata": {"window": "But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody . ", "original_text": "Operator :  Our next questio n comes from A.J. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25af6b8d-fc86-4b87-9e46-66d0959789b2", "node_type": "1", "metadata": {"window": "We feel it's \nthe right thing and we feel very good about this plan a nd there's still a lot of work we need to focus on . \n But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J. ", "original_text": "Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a04baeeda5f843976fc31e183ef14d99c87b183155f282f507b38376153c3a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab1abf1-8bc3-46d0-beb5-acebd66abf4e", "node_type": "1", "metadata": {"window": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask . ", "original_text": "Rice with Credit Suisse.  \n \n"}, "hash": "6b8cb1fca8c3f97c6e3c60e76d4051a799225b86e8ad470d7d45bae26ec5548d", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Our next questio n comes from A.J. ", "start_char_idx": 2913, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ab1abf1-8bc3-46d0-beb5-acebd66abf4e": {"__data__": {"id_": "5ab1abf1-8bc3-46d0-beb5-acebd66abf4e", "embedding": null, "metadata": {"window": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask . ", "original_text": "Rice with Credit Suisse.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32569c4f-69cd-45ad-93c3-5a0080b42beb", "node_type": "1", "metadata": {"window": "But it's the right plan , it's the right thing to do.  And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody . ", "original_text": "Operator :  Our next questio n comes from A.J. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec45e1f4e73067c91b24817f86a8a9144cc7d8555e6213ed99815b4328c5787f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c827dc0d-d5a8-40f1-974e-b8058f909484", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. ", "original_text": "A.J. "}, "hash": "2d2f42bd82eb2515cd54ccdd1d6b4f074e9d58e02d8185096d657509edf0bf3c", "class_name": "RelatedNodeInfo"}}, "text": "Rice with Credit Suisse.  \n \n", "start_char_idx": 2960, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c827dc0d-d5a8-40f1-974e-b8058f909484": {"__data__": {"id_": "c827dc0d-d5a8-40f1-974e-b8058f909484", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. ", "original_text": "A.J. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ab1abf1-8bc3-46d0-beb5-acebd66abf4e", "node_type": "1", "metadata": {"window": "And we have not been surprised with this at this stage \nof the year and at this stage of the plan.  Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask . ", "original_text": "Rice with Credit Suisse.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "521326731e5b385a259b71d6367fdde25c5713fd7f1d1f2f1eeb0cb6a3c1149c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3576421-06df-4c4c-9901-5b818daf5865", "node_type": "1", "metadata": {"window": "Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. ", "original_text": "Rice :  Hi, everybody . "}, "hash": "0f49046f63c0af39f9d6f30e12c771b8695d3f5741cbd0e5bd2e179cfc91a17f", "class_name": "RelatedNodeInfo"}}, "text": "A.J. ", "start_char_idx": 2955, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3576421-06df-4c4c-9901-5b818daf5865": {"__data__": {"id_": "f3576421-06df-4c4c-9901-5b818daf5865", "embedding": null, "metadata": {"window": "Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. ", "original_text": "Rice :  Hi, everybody . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c827dc0d-d5a8-40f1-974e-b8058f909484", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. ", "original_text": "A.J. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9caaa5f7f49de0715b236e84a03b0d433efc13baa57b316570f4a238ea3192e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79da06eb-0237-48c2-a6d4-bf9462347d9e", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? ", "original_text": "I might just ask . "}, "hash": "069e394b012f48cb1d5440c7f526a7b37e3c7b47a28a591eb7e44e1914211001", "class_name": "RelatedNodeInfo"}}, "text": "Rice :  Hi, everybody . ", "start_char_idx": 2994, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79da06eb-0237-48c2-a6d4-bf9462347d9e": {"__data__": {"id_": "79da06eb-0237-48c2-a6d4-bf9462347d9e", "embedding": null, "metadata": {"window": "Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? ", "original_text": "I might just ask . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3576421-06df-4c4c-9901-5b818daf5865", "node_type": "1", "metadata": {"window": "Operator :  Our next questio n comes from A.J.  Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. ", "original_text": "Rice :  Hi, everybody . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48dcfcfb2a0acfa9ab41318166c5979373323f91a30c86eb71fa3a05e54d7770", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1019c2f8-3773-45d9-b0c7-f955ad5b9bc6", "node_type": "1", "metadata": {"window": "A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  ", "original_text": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. "}, "hash": "f3e15646115b6738c79e5198d8333c12e450a9b2cf5152a0e51cdfc03a781fe2", "class_name": "RelatedNodeInfo"}}, "text": "I might just ask . ", "start_char_idx": 3018, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1019c2f8-3773-45d9-b0c7-f955ad5b9bc6": {"__data__": {"id_": "1019c2f8-3773-45d9-b0c7-f955ad5b9bc6", "embedding": null, "metadata": {"window": "A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  ", "original_text": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79da06eb-0237-48c2-a6d4-bf9462347d9e", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  \n \n A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? ", "original_text": "I might just ask . ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "999ee495aa03ee91e7a377938d39b2f6a06b78da215f4df6fb35aa23417c4721", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0840af70-2ad2-4f1a-b6b5-d9b66db64db8", "node_type": "1", "metadata": {"window": "Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. "}, "hash": "a52966d8f16ed29f10ca27df04086319d69f7542f234f3b878041ea13205e0d6", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. ", "start_char_idx": 3037, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0840af70-2ad2-4f1a-b6b5-d9b66db64db8": {"__data__": {"id_": "0840af70-2ad2-4f1a-b6b5-d9b66db64db8", "embedding": null, "metadata": {"window": "Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1019c2f8-3773-45d9-b0c7-f955ad5b9bc6", "node_type": "1", "metadata": {"window": "A.J.  Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  ", "original_text": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c19853507fc117eaf240c19f06931c6a83da5d70b7caf1a5a2bbad625151856d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4640552-d221-4850-8931-1407a4e734a2", "node_type": "1", "metadata": {"window": "I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? "}, "hash": "c36cfdb5587bf2ea49dd1c99097fa6f46d7d73a6fc97ae1452b40734d13255d6", "class_name": "RelatedNodeInfo"}}, "text": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. ", "start_char_idx": 3171, "end_char_idx": 3302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4640552-d221-4850-8931-1407a4e734a2": {"__data__": {"id_": "a4640552-d221-4850-8931-1407a4e734a2", "embedding": null, "metadata": {"window": "I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0840af70-2ad2-4f1a-b6b5-d9b66db64db8", "node_type": "1", "metadata": {"window": "Rice :  Hi, everybody .  I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "726ca330682f5cdf42b2b325d946be25a919060ccbda5b0297499fd4b468fee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7af0c3ce-69d3-4b4d-a6d4-962c9d678a31", "node_type": "1", "metadata": {"window": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  "}, "hash": "93109555fe8969240669bf0b0a691261881195624a1d3ea3ddce3a99e39ba2e3", "class_name": "RelatedNodeInfo"}}, "text": "Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? ", "start_char_idx": 3302, "end_char_idx": 3449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7af0c3ce-69d3-4b4d-a6d4-962c9d678a31": {"__data__": {"id_": "7af0c3ce-69d3-4b4d-a6d4-962c9d678a31", "embedding": null, "metadata": {"window": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4640552-d221-4850-8931-1407a4e734a2", "node_type": "1", "metadata": {"window": "I might just ask .  Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ? ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5165763664f1daedf8d82ccccc58aac8fcff4c754db9d5c34afe8812675b3fdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d0aafe-bcc4-4ea5-9a35-adf1c8989cb4", "node_type": "1", "metadata": {"window": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "I \nassume that would be preliminary if there's anything you shared then.  \n "}, "hash": "f8aea754116c81077a9d9e12fb3754fe27573790ced23e5ee3d9bac3ea20408f", "class_name": "RelatedNodeInfo"}}, "text": "And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  ", "start_char_idx": 3449, "end_char_idx": 3589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d0aafe-bcc4-4ea5-9a35-adf1c8989cb4": {"__data__": {"id_": "c0d0aafe-bcc4-4ea5-9a35-adf1c8989cb4", "embedding": null, "metadata": {"window": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "I \nassume that would be preliminary if there's anything you shared then.  \n ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db333d4fbf5a3c976f71980214d2024b09f00d7e5c246bc2fe1ab89b1dae1126", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7af0c3ce-69d3-4b4d-a6d4-962c9d678a31", "node_type": "1", "metadata": {"window": "Obviously, you've got a lot of things going on and \nseemingly having some success with your simplification and mitigation strategies.  Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?  ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b07600a8254092fd459bfe9d7f0ca7fec6f90e7455c0432e57766c93d6615b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb82ab4f-66ae-4aa4-a4a0-6a8b70414548", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "original_text": " \nPage 13 of 14 \n \nJason Hollar :   Sure. "}, "hash": "290afb9e064cd66b1192d5629bb881becb29f15d92ad77fb375ac182c1ba7f79", "class_name": "RelatedNodeInfo"}}, "text": "I \nassume that would be preliminary if there's anything you shared then.  \n ", "start_char_idx": 3589, "end_char_idx": 3665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb82ab4f-66ae-4aa4-a4a0-6a8b70414548": {"__data__": {"id_": "cb82ab4f-66ae-4aa4-a4a0-6a8b70414548", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "original_text": " \nPage 13 of 14 \n \nJason Hollar :   Sure. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d0aafe-bcc4-4ea5-9a35-adf1c8989cb4", "node_type": "1", "metadata": {"window": "Now you have this \nbusiness review  committee or the guard - and that's, I know, still early in getting up and running and \ngoing.  Are the guardrails as to the things you're already doing to improve performance versus what \nthe Business Review Committee is doing pretty clear ?  And did I hear  you right in the prepared \nremarks that you think a review committee will have an update at the calendar \u201823 Investor Day?   I \nassume that would be preliminary if there's anything you shared then.  \n ", "original_text": "I \nassume that would be preliminary if there's anything you shared then.  \n ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "defd593891c8095f3891ecec38df7bf4cfbc92e925293f443ccab352ee2b3550", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da63a681-5ddb-4ba5-a939-9c6cbc8fe525", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework. ", "original_text": "So, yeah, there's a charter for the Busi ness Review committee. "}, "hash": "1533ad47729f096aa840d7c449ca36e3177d05ffe3385f3b107f7eeb55802870", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 14 \n \nJason Hollar :   Sure. ", "start_char_idx": 0, "end_char_idx": 42, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da63a681-5ddb-4ba5-a939-9c6cbc8fe525": {"__data__": {"id_": "da63a681-5ddb-4ba5-a939-9c6cbc8fe525", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework. ", "original_text": "So, yeah, there's a charter for the Busi ness Review committee. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb82ab4f-66ae-4aa4-a4a0-6a8b70414548", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "original_text": " \nPage 13 of 14 \n \nJason Hollar :   Sure. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da7d421dfec08c2cf4777f9f4fd12864053707babaa806bf718bc77f66652c1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46e9ed08-7e5e-4c15-a69d-ccf2a230f797", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n", "original_text": "It's very \nconsistent to what I provided my comments. "}, "hash": "a2f8c075c3b56576585663e0dacda6ae302a278d78dba342be0ff366c4b4c583", "class_name": "RelatedNodeInfo"}}, "text": "So, yeah, there's a charter for the Busi ness Review committee. ", "start_char_idx": 42, "end_char_idx": 106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46e9ed08-7e5e-4c15-a69d-ccf2a230f797": {"__data__": {"id_": "46e9ed08-7e5e-4c15-a69d-ccf2a230f797", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n", "original_text": "It's very \nconsistent to what I provided my comments. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da63a681-5ddb-4ba5-a939-9c6cbc8fe525", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework. ", "original_text": "So, yeah, there's a charter for the Busi ness Review committee. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe70d3473808d6ee1fdc267b5c5f9400ae79c1dceb0823ec22d2c436a10ffa53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c80509-7867-4050-82b8-5c967abcccee", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members. ", "original_text": "Of course, there's a portfolio element, there's a strategy \nand operations element.  "}, "hash": "bc17e0df8d7cdb3775a0b4438d7922896f04ecb6841d7bf142a6760eac6810b1", "class_name": "RelatedNodeInfo"}}, "text": "It's very \nconsistent to what I provided my comments. ", "start_char_idx": 106, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c80509-7867-4050-82b8-5c967abcccee": {"__data__": {"id_": "c5c80509-7867-4050-82b8-5c967abcccee", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members. ", "original_text": "Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46e9ed08-7e5e-4c15-a69d-ccf2a230f797", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n", "original_text": "It's very \nconsistent to what I provided my comments. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0a66e2356ee57378bd23970e374e59f1e850fc243c6439ceab27a206efe7814", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dd82191-3ae3-432a-9c7e-024732462dd3", "node_type": "1", "metadata": {"window": "So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well. ", "original_text": "And you know, importantly, there's a capital allocation framework. "}, "hash": "600b22ff678e8d169ca63090f0a0b1f09dce34d0124c0f6badd20f653f022a30", "class_name": "RelatedNodeInfo"}}, "text": "Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "start_char_idx": 160, "end_char_idx": 245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dd82191-3ae3-432a-9c7e-024732462dd3": {"__data__": {"id_": "8dd82191-3ae3-432a-9c7e-024732462dd3", "embedding": null, "metadata": {"window": "So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well. ", "original_text": "And you know, importantly, there's a capital allocation framework. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c80509-7867-4050-82b8-5c967abcccee", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members. ", "original_text": "Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "181519614970af4de1c26f71e0985189a97f012c8dcab404a95ce47b80583ee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d9ea95f-42f7-4865-9044-d6c01832c784", "node_type": "1", "metadata": {"window": "It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process. ", "original_text": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n"}, "hash": "7734027588c2c3b77d55c664a28d6835c92c13092b257256eb9845e186339901", "class_name": "RelatedNodeInfo"}}, "text": "And you know, importantly, there's a capital allocation framework. ", "start_char_idx": 245, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d9ea95f-42f7-4865-9044-d6c01832c784": {"__data__": {"id_": "9d9ea95f-42f7-4865-9044-d6c01832c784", "embedding": null, "metadata": {"window": "It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process. ", "original_text": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dd82191-3ae3-432a-9c7e-024732462dd3", "node_type": "1", "metadata": {"window": "So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well. ", "original_text": "And you know, importantly, there's a capital allocation framework. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cab773a201de4b09641a4c825640df0f7833b9ab286f3d8316cc4f99acbfaa93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6653b48d-f91d-46ad-864f-5279420f254f", "node_type": "1", "metadata": {"window": "Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  ", "original_text": "We now have new board members. "}, "hash": "a92edeca5c2319597555af0c669341bddc8f93faa08f19aaa023ec31580eb2bf", "class_name": "RelatedNodeInfo"}}, "text": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n", "start_char_idx": 312, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6653b48d-f91d-46ad-864f-5279420f254f": {"__data__": {"id_": "6653b48d-f91d-46ad-864f-5279420f254f", "embedding": null, "metadata": {"window": "Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  ", "original_text": "We now have new board members. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d9ea95f-42f7-4865-9044-d6c01832c784", "node_type": "1", "metadata": {"window": "It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process. ", "original_text": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "166c2f6d4f59bb3b2898e9152ba25da79420640adb11db2e270fb476898ab086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f42b91a8-b516-494e-b0c1-e9bd5fe7c25e", "node_type": "1", "metadata": {"window": "And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  ", "original_text": "Of course, we have the Business Review Committee as well. "}, "hash": "2e26315aecd69751fc48b26f097ebf4c2006a6adf4b6060aec1fb5235eb39828", "class_name": "RelatedNodeInfo"}}, "text": "We now have new board members. ", "start_char_idx": 417, "end_char_idx": 448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f42b91a8-b516-494e-b0c1-e9bd5fe7c25e": {"__data__": {"id_": "f42b91a8-b516-494e-b0c1-e9bd5fe7c25e", "embedding": null, "metadata": {"window": "And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  ", "original_text": "Of course, we have the Business Review Committee as well. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6653b48d-f91d-46ad-864f-5279420f254f", "node_type": "1", "metadata": {"window": "Of course, there's a portfolio element, there's a strategy \nand operations element.   And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  ", "original_text": "We now have new board members. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f08edc9e701faf3141cb72f1a7e7d8dd2d8771d554cf5a7462daed52be626c79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c4d19cc-3ef1-4bf7-abf2-b0742a1ef602", "node_type": "1", "metadata": {"window": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.  ", "original_text": "So \nit's a bit more of a formalised process. "}, "hash": "744916dba97f064d4b3e358809518f0eae11e7fd6d2f96587f041ec3ff509f08", "class_name": "RelatedNodeInfo"}}, "text": "Of course, we have the Business Review Committee as well. ", "start_char_idx": 448, "end_char_idx": 506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c4d19cc-3ef1-4bf7-abf2-b0742a1ef602": {"__data__": {"id_": "3c4d19cc-3ef1-4bf7-abf2-b0742a1ef602", "embedding": null, "metadata": {"window": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.  ", "original_text": "So \nit's a bit more of a formalised process. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f42b91a8-b516-494e-b0c1-e9bd5fe7c25e", "node_type": "1", "metadata": {"window": "And you know, importantly, there's a capital allocation framework.  As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  ", "original_text": "Of course, we have the Business Review Committee as well. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9c3b8e524e84473aa57cc974860274eb2456e5ed13d909e496bd2a9c6baab5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a268fd0-15da-4614-b7b6-9c155f74505a", "node_type": "1", "metadata": {"window": "We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  ", "original_text": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  "}, "hash": "a90c98ee1d58216f7b2bae891d1c1285f0d4196ee7ca4e7f4e2b2be362f95324", "class_name": "RelatedNodeInfo"}}, "text": "So \nit's a bit more of a formalised process. ", "start_char_idx": 506, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a268fd0-15da-4614-b7b6-9c155f74505a": {"__data__": {"id_": "4a268fd0-15da-4614-b7b6-9c155f74505a", "embedding": null, "metadata": {"window": "We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  ", "original_text": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c4d19cc-3ef1-4bf7-abf2-b0742a1ef602", "node_type": "1", "metadata": {"window": "As we \ncommunicated before,  we had these types of evaluations and communication with our board prior . \n We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.  ", "original_text": "So \nit's a bit more of a formalised process. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a49ef9805a9d20d7b3789347cd5822fed99310c521d3b80c935d6b3045a4741a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca6b4f04-f05c-4c9f-8c58-cd54604841ee", "node_type": "1", "metadata": {"window": "Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.  ", "original_text": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  "}, "hash": "11fdb9be03f0e30217227054ecc00d8acc8c617edfb89c00c32bce864eea7933", "class_name": "RelatedNodeInfo"}}, "text": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  ", "start_char_idx": 551, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca6b4f04-f05c-4c9f-8c58-cd54604841ee": {"__data__": {"id_": "ca6b4f04-f05c-4c9f-8c58-cd54604841ee", "embedding": null, "metadata": {"window": "Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.  ", "original_text": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a268fd0-15da-4614-b7b6-9c155f74505a", "node_type": "1", "metadata": {"window": "We now have new board members.  Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  ", "original_text": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2a274185969fc691aa9ff686f399926e7d004a72797f25c3dd11f6942d14467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca6837a-182f-43d8-8d32-5d66a681c38b", "node_type": "1", "metadata": {"window": "So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . ", "original_text": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.  "}, "hash": "9f296770f0dd13ea8fedeab6fb1dba4649d7a3915be669c720547cdc2cf27693", "class_name": "RelatedNodeInfo"}}, "text": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  ", "start_char_idx": 676, "end_char_idx": 856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca6837a-182f-43d8-8d32-5d66a681c38b": {"__data__": {"id_": "8ca6837a-182f-43d8-8d32-5d66a681c38b", "embedding": null, "metadata": {"window": "So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . ", "original_text": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca6b4f04-f05c-4c9f-8c58-cd54604841ee", "node_type": "1", "metadata": {"window": "Of course, we have the Business Review Committee as well.  So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.  ", "original_text": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5b169421306ef41336e2b9d73a59d2afd93c5de478c4de6981aaebcee0a41f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fe542aa-e8a2-49da-a858-3440c44267e1", "node_type": "1", "metadata": {"window": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. ", "original_text": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  "}, "hash": "58777609db8961be246beeb710dad7e7967f557b880cd7b7a1939fa53405aeb8", "class_name": "RelatedNodeInfo"}}, "text": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.  ", "start_char_idx": 856, "end_char_idx": 949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fe542aa-e8a2-49da-a858-3440c44267e1": {"__data__": {"id_": "4fe542aa-e8a2-49da-a858-3440c44267e1", "embedding": null, "metadata": {"window": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. ", "original_text": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca6837a-182f-43d8-8d32-5d66a681c38b", "node_type": "1", "metadata": {"window": "So \nit's a bit more of a formalised process.  We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . ", "original_text": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8f51dc96f35dbb556a1af4d072ddfce3fce9e3f24850b9ad39995fb06ea3278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67e9e836-3445-484a-bd93-b64b438e5e1b", "node_type": "1", "metadata": {"window": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate. ", "original_text": "So from my perspective, we're getting good insights.  "}, "hash": "863fbaeab312a7e096527b4a8ae544f925719c6d603acbb9bbcec459aaf99dc7", "class_name": "RelatedNodeInfo"}}, "text": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  ", "start_char_idx": 949, "end_char_idx": 1142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67e9e836-3445-484a-bd93-b64b438e5e1b": {"__data__": {"id_": "67e9e836-3445-484a-bd93-b64b438e5e1b", "embedding": null, "metadata": {"window": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate. ", "original_text": "So from my perspective, we're getting good insights.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fe542aa-e8a2-49da-a858-3440c44267e1", "node_type": "1", "metadata": {"window": "We are taking full advantage of the insight and experience that \nall of those board members are bringing to the discussion.   And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. ", "original_text": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b2a69134ea13d348e03e6bd9eef3a0e91e0f60bd5b58c887d19c34553ea9e42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c1067b5-2d6b-4c6e-b398-417689b34527", "node_type": "1", "metadata": {"window": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n", "original_text": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . "}, "hash": "b083852f5d017f10b26a85a53cbd1b080abb625b5e7676a674e2c1e547fed801", "class_name": "RelatedNodeInfo"}}, "text": "So from my perspective, we're getting good insights.  ", "start_char_idx": 1142, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c1067b5-2d6b-4c6e-b398-417689b34527": {"__data__": {"id_": "5c1067b5-2d6b-4c6e-b398-417689b34527", "embedding": null, "metadata": {"window": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n", "original_text": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67e9e836-3445-484a-bd93-b64b438e5e1b", "node_type": "1", "metadata": {"window": "And the Business Review Committee acts \nas any other board committee where we work and provide insights and advice to the broad board and \nmake it a bit more of a formal process.   But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate. ", "original_text": "So from my perspective, we're getting good insights.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cc1b0fa23673284abffa0e2597bf955059ed63350f08f9fb7894cd2c628c5f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "298c6922-84f1-4dd8-916e-fec2e28430c7", "node_type": "1", "metadata": {"window": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout. ", "original_text": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. "}, "hash": "b0fe64933d02d43c78bc2b8e567fc9b6e89f2ebfd3178cb4cb52904735da712a", "class_name": "RelatedNodeInfo"}}, "text": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . ", "start_char_idx": 1196, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "298c6922-84f1-4dd8-916e-fec2e28430c7": {"__data__": {"id_": "298c6922-84f1-4dd8-916e-fec2e28430c7", "embedding": null, "metadata": {"window": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout. ", "original_text": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c1067b5-2d6b-4c6e-b398-417689b34527", "node_type": "1", "metadata": {"window": "But the guardrails are, as I just described there, and there's \nvery clear what we work on.   As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n", "original_text": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio . ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a10985ff26040a93b065c783ae75bb03f0cf5e98e183a2f521df9aafa8e171ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92c2b25e-5512-427c-b30f-fad229bf0cf6", "node_type": "1", "metadata": {"window": "So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right. ", "original_text": "So we \nhave that that filter as well that comes through our work that we evaluate. "}, "hash": "425cf67455f39ee6e1262eb2d2d85d423a711363ebf4f4a3736650dfd8ca2320", "class_name": "RelatedNodeInfo"}}, "text": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. ", "start_char_idx": 1418, "end_char_idx": 1527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92c2b25e-5512-427c-b30f-fad229bf0cf6": {"__data__": {"id_": "92c2b25e-5512-427c-b30f-fad229bf0cf6", "embedding": null, "metadata": {"window": "So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right. ", "original_text": "So we \nhave that that filter as well that comes through our work that we evaluate. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "298c6922-84f1-4dd8-916e-fec2e28430c7", "node_type": "1", "metadata": {"window": "As I chair it and I lead the agenda, I've  of course, also listened to the \ncommittee as to what they believe are the key areas of opportunity, and it's very collab orative and \nconstructive.   So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout. ", "original_text": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dca57fd78b1cb12ebd2377f3ffc191ddc6e8390d33207133f2ab5735b93399e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e000f196-d8a2-41da-8e99-7c4beac70a25", "node_type": "1", "metadata": {"window": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. ", "original_text": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n"}, "hash": "c0a049d6e9907cdb160a182c81e00b4a8f5f5a1d97eabedc7730b0e922bdd6fc", "class_name": "RelatedNodeInfo"}}, "text": "So we \nhave that that filter as well that comes through our work that we evaluate. ", "start_char_idx": 1527, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e000f196-d8a2-41da-8e99-7c4beac70a25": {"__data__": {"id_": "e000f196-d8a2-41da-8e99-7c4beac70a25", "embedding": null, "metadata": {"window": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. ", "original_text": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92c2b25e-5512-427c-b30f-fad229bf0cf6", "node_type": "1", "metadata": {"window": "So from my perspective, we're getting good insights.   I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right. ", "original_text": "So we \nhave that that filter as well that comes through our work that we evaluate. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4afb24aec31836d1e9ad87f159d1b5d484cef1b3c3b34eb7a820afdd20280d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62dd9cfa-ae96-427c-8743-3c28102d6445", "node_type": "1", "metadata": {"window": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.  ", "original_text": "As it relates to the readout. "}, "hash": "9909955c6fa84cfe38c25bd4c73307c41b905942e4466d9d755de0afb8db6641", "class_name": "RelatedNodeInfo"}}, "text": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n", "start_char_idx": 1610, "end_char_idx": 1749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62dd9cfa-ae96-427c-8743-3c28102d6445": {"__data__": {"id_": "62dd9cfa-ae96-427c-8743-3c28102d6445", "embedding": null, "metadata": {"window": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.  ", "original_text": "As it relates to the readout. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e000f196-d8a2-41da-8e99-7c4beac70a25", "node_type": "1", "metadata": {"window": "I think that all of our board \nmembers, but the committee specifically is doing the best we can to think through the lens of the \ninvestor , and make sure that we're driving the b usiness, we're evaluating the portfolio .  And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. ", "original_text": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d684d1e5f0ff8ed7faf2b526af17641c13e2c5846c37fdd5fa9cb6952db7897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faf7ede7-200d-4b82-9664-24e146991c85", "node_type": "1", "metadata": {"window": "So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. ", "original_text": "Yes, you heard that right. "}, "hash": "847f2336e71acdefb025c772c6a2df2fcf53c503180931ab315147a06613b151", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the readout. ", "start_char_idx": 1749, "end_char_idx": 1779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faf7ede7-200d-4b82-9664-24e146991c85": {"__data__": {"id_": "faf7ede7-200d-4b82-9664-24e146991c85", "embedding": null, "metadata": {"window": "So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. ", "original_text": "Yes, you heard that right. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62dd9cfa-ae96-427c-8743-3c28102d6445", "node_type": "1", "metadata": {"window": "And of course, \nwe're in a fairly uncertain time, both operationally and from a macro -economic perspective.  So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.  ", "original_text": "As it relates to the readout. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f14caff813dd371f9ad55917dc92158f281785a2ff383e531ae9b37567b67b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2683d71d-1cab-44ce-8046-e7e7365c4271", "node_type": "1", "metadata": {"window": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n", "original_text": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. "}, "hash": "1be5620a3688dab3b3472d8be3b14c37fc6825f9555478a9ef8ac76a4044d218", "class_name": "RelatedNodeInfo"}}, "text": "Yes, you heard that right. ", "start_char_idx": 1779, "end_char_idx": 1806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2683d71d-1cab-44ce-8046-e7e7365c4271": {"__data__": {"id_": "2683d71d-1cab-44ce-8046-e7e7365c4271", "embedding": null, "metadata": {"window": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n", "original_text": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faf7ede7-200d-4b82-9664-24e146991c85", "node_type": "1", "metadata": {"window": "So we \nhave that that filter as well that comes through our work that we evaluate.  But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. ", "original_text": "Yes, you heard that right. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25dc1d88083cdf918f4468cc48167d5325def7a135b615b180900230e8063bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c00344f-a5cb-4620-988d-003dfd4180ae", "node_type": "1", "metadata": {"window": "As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n", "original_text": "And we'll have an update as to what is potential to update at that \npoint in time.  "}, "hash": "1d83ee5f0c0ab94ebd9a01f627d12611a38482b3bc12b571cbb71e8edc404f3e", "class_name": "RelatedNodeInfo"}}, "text": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. ", "start_char_idx": 1806, "end_char_idx": 1893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c00344f-a5cb-4620-988d-003dfd4180ae": {"__data__": {"id_": "2c00344f-a5cb-4620-988d-003dfd4180ae", "embedding": null, "metadata": {"window": "As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n", "original_text": "And we'll have an update as to what is potential to update at that \npoint in time.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2683d71d-1cab-44ce-8046-e7e7365c4271", "node_type": "1", "metadata": {"window": "But nonetheless, we - as I \ncommented already, we are meeting frequently, we are meeting with urgency and we're very focused \non this.  \n \n As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n", "original_text": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28956cf6d82b4a6adf94516ebcb1e1aebdd441323065005555e5917592aa1a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f43722c-0304-496d-9e8c-2993331f874e", "node_type": "1", "metadata": {"window": "Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions. ", "original_text": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. "}, "hash": "87a1cbb814c7b0340b320f867e8c5448164c16bbf4f366201e5d44b0319090c3", "class_name": "RelatedNodeInfo"}}, "text": "And we'll have an update as to what is potential to update at that \npoint in time.  ", "start_char_idx": 1893, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f43722c-0304-496d-9e8c-2993331f874e": {"__data__": {"id_": "5f43722c-0304-496d-9e8c-2993331f874e", "embedding": null, "metadata": {"window": "Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions. ", "original_text": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c00344f-a5cb-4620-988d-003dfd4180ae", "node_type": "1", "metadata": {"window": "As it relates to the readout.  Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n", "original_text": "And we'll have an update as to what is potential to update at that \npoint in time.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "157f29e57a956577d5938966fdca76f50379e6f13a75db3acdc3b40b606e7085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f819c91-bef9-4c6a-9873-1bc9cb389338", "node_type": "1", "metadata": {"window": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere. ", "original_text": "Next question, please.  \n \n"}, "hash": "09725708bcc12386ef3f30163c45d92a9d99d5139a8aae519402f7c678e511ee", "class_name": "RelatedNodeInfo"}}, "text": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. ", "start_char_idx": 1977, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f819c91-bef9-4c6a-9873-1bc9cb389338": {"__data__": {"id_": "0f819c91-bef9-4c6a-9873-1bc9cb389338", "embedding": null, "metadata": {"window": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere. ", "original_text": "Next question, please.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f43722c-0304-496d-9e8c-2993331f874e", "node_type": "1", "metadata": {"window": "Yes, you heard that right.  The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions. ", "original_text": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0abfab9b188396e786b0ef1765695521dedf880124f9c10f23020ca8a7341455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "050005c2-5808-48bf-a47e-b4f16a39a596", "node_type": "1", "metadata": {"window": "And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . ", "original_text": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n"}, "hash": "f305364cbd977caad9b75f05cef74af8a00e2b00ec0508bd7e3f823762d1e313", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 2120, "end_char_idx": 2147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "050005c2-5808-48bf-a47e-b4f16a39a596": {"__data__": {"id_": "050005c2-5808-48bf-a47e-b4f16a39a596", "embedding": null, "metadata": {"window": "And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . ", "original_text": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f819c91-bef9-4c6a-9873-1bc9cb389338", "node_type": "1", "metadata": {"window": "The calendar \u201823 - by the first half of calendar \n\u201823, we will have that Investor Day.  And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere. ", "original_text": "Next question, please.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a79776569b9cd57df2cf843c254c4274abbfdd9540b9a66da47b9e924aa62cf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b414b7d2-2dfc-4cea-9118-2c47199d8628", "node_type": "1", "metadata": {"window": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  ", "original_text": "Charles  Rhyee :  Yeah , thanks for taking the questions. "}, "hash": "7e47904f61f6b00ce374b520e636ec04c41b23005875fa6622333efd8b4b0be4", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n", "start_char_idx": 2147, "end_char_idx": 2221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b414b7d2-2dfc-4cea-9118-2c47199d8628": {"__data__": {"id_": "b414b7d2-2dfc-4cea-9118-2c47199d8628", "embedding": null, "metadata": {"window": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  ", "original_text": "Charles  Rhyee :  Yeah , thanks for taking the questions. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "050005c2-5808-48bf-a47e-b4f16a39a596", "node_type": "1", "metadata": {"window": "And we'll have an update as to what is potential to update at that \npoint in time.   And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . ", "original_text": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d445be4cf40e96c60372f05e66c7057986098d32555f72d5044a8058eaa071d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02c35308-de08-4474-803e-771591258712", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. ", "original_text": "Just two really h ere. "}, "hash": "d00bff29d1e75c4d1ab6793000da4850ff70a3c75a135a368dd27724031b69d1", "class_name": "RelatedNodeInfo"}}, "text": "Charles  Rhyee :  Yeah , thanks for taking the questions. ", "start_char_idx": 2221, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02c35308-de08-4474-803e-771591258712": {"__data__": {"id_": "02c35308-de08-4474-803e-771591258712", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. ", "original_text": "Just two really h ere. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b414b7d2-2dfc-4cea-9118-2c47199d8628", "node_type": "1", "metadata": {"window": "And I see this as a journey and not necessarily just a sprint, but we are working with \nurgency to have as much completed by then as possible.  Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  ", "original_text": "Charles  Rhyee :  Yeah , thanks for taking the questions. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afcce987acb0fb59573091b781edfebd127e51d7282f6285f14c362131e083bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed77e1ea-3e24-4b8c-bd34-b7f9604dcff9", "node_type": "1", "metadata": {"window": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? ", "original_text": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . "}, "hash": "543040fd1ae48157740f759d107fb06205f20cba68abf6cea2064336f5bae1d4", "class_name": "RelatedNodeInfo"}}, "text": "Just two really h ere. ", "start_char_idx": 2279, "end_char_idx": 2302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed77e1ea-3e24-4b8c-bd34-b7f9604dcff9": {"__data__": {"id_": "ed77e1ea-3e24-4b8c-bd34-b7f9604dcff9", "embedding": null, "metadata": {"window": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? ", "original_text": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02c35308-de08-4474-803e-771591258712", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. ", "original_text": "Just two really h ere. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "528abc978b1c4e977ddfb71a3631374168ec750e67f0d7c287b7812459fddd9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cca25c6-d309-4a3d-9537-fd7cd61f3d6f", "node_type": "1", "metadata": {"window": "Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.  ", "original_text": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  "}, "hash": "bed28c59e4fbb9b28fc280020871628c18c4f18aafeb697ffd73f383d53e164d", "class_name": "RelatedNodeInfo"}}, "text": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . ", "start_char_idx": 2302, "end_char_idx": 2410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cca25c6-d309-4a3d-9537-fd7cd61f3d6f": {"__data__": {"id_": "1cca25c6-d309-4a3d-9537-fd7cd61f3d6f", "embedding": null, "metadata": {"window": "Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.  ", "original_text": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed77e1ea-3e24-4b8c-bd34-b7f9604dcff9", "node_type": "1", "metadata": {"window": "Operator :   Our next question comes from Charles R hyee  with Cowen.  \n \n Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? ", "original_text": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that . ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f84f8971d2cbec2851d413fc3759c80c68f2c3bd8eda1ac52158497d00989162", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "628eab36-d8cf-478e-8b99-b0a97e397570", "node_type": "1", "metadata": {"window": "Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  ", "original_text": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. "}, "hash": "f3832ceb3b818a8615c53697ec2536603a9f4d162708f863941c35979eaea3df", "class_name": "RelatedNodeInfo"}}, "text": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  ", "start_char_idx": 2410, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "628eab36-d8cf-478e-8b99-b0a97e397570": {"__data__": {"id_": "628eab36-d8cf-478e-8b99-b0a97e397570", "embedding": null, "metadata": {"window": "Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  ", "original_text": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cca25c6-d309-4a3d-9537-fd7cd61f3d6f", "node_type": "1", "metadata": {"window": "Charles  Rhyee :  Yeah , thanks for taking the questions.  Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.  ", "original_text": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4461630bea8de2eaf86fbddf391014dd9491fe695de6493c1c240727924bb1f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0264ab3-1299-4a85-86f1-87525434884e", "node_type": "1", "metadata": {"window": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there? ", "original_text": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? "}, "hash": "91c27b4fa63a5eccea3a70346cf6730c3db8f8a2b0997670e2c40f4a5fa25932", "class_name": "RelatedNodeInfo"}}, "text": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. ", "start_char_idx": 2519, "end_char_idx": 2646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0264ab3-1299-4a85-86f1-87525434884e": {"__data__": {"id_": "b0264ab3-1299-4a85-86f1-87525434884e", "embedding": null, "metadata": {"window": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there? ", "original_text": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "628eab36-d8cf-478e-8b99-b0a97e397570", "node_type": "1", "metadata": {"window": "Just two really h ere.  Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  ", "original_text": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f97ff000573dd1d3d1a647cc25c1a208a1272a80d5725a7cbe7f4579b0387a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20f07b18-586c-4e35-928a-fec4301bd764", "node_type": "1", "metadata": {"window": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n", "original_text": "And then secondly, there's been news a lot about \na shortages in amoxicillin.  "}, "hash": "34c2137e584ce4873b0a02586ac0cbacc92f8aefe367c73518ffdc14adefce2f", "class_name": "RelatedNodeInfo"}}, "text": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? ", "start_char_idx": 2646, "end_char_idx": 2797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20f07b18-586c-4e35-928a-fec4301bd764": {"__data__": {"id_": "20f07b18-586c-4e35-928a-fec4301bd764", "embedding": null, "metadata": {"window": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n", "original_text": "And then secondly, there's been news a lot about \na shortages in amoxicillin.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0264ab3-1299-4a85-86f1-87525434884e", "node_type": "1", "metadata": {"window": "Just to follow up, on the \nMedical guide - and I might have missed it, but obviously, you've changed that .  Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there? ", "original_text": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ? ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "020cf7c096d50942cb2a7c9bc8fe9c1efcac9a4dba785b471604ffb329c0261e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d97f0a38-5983-469c-842f-1560042752f2", "node_type": "1", "metadata": {"window": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure. ", "original_text": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  "}, "hash": "5b7a22afa6c1517fd368744fa20699e4847e3a85a34cdc901a86d2fc80326e2d", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, there's been news a lot about \na shortages in amoxicillin.  ", "start_char_idx": 2797, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d97f0a38-5983-469c-842f-1560042752f2": {"__data__": {"id_": "d97f0a38-5983-469c-842f-1560042752f2", "embedding": null, "metadata": {"window": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure. ", "original_text": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20f07b18-586c-4e35-928a-fec4301bd764", "node_type": "1", "metadata": {"window": "Was there - has there \nbeen any change in your assumptions in the macro -environment b etween July and now?   That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n", "original_text": "And then secondly, there's been news a lot about \na shortages in amoxicillin.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69c97f89b979d38bc517b02b7904b8241e68581fb1bd5f3d51167b641d19d17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16a3706e-79c2-4069-8127-78fb2189f173", "node_type": "1", "metadata": {"window": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah. ", "original_text": "Any thoughts on the outlook there? "}, "hash": "1c4ad391edb56a558a02d74c4fe11d0014a6195b102c18f44e69632e4f8f4e13", "class_name": "RelatedNodeInfo"}}, "text": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  ", "start_char_idx": 2876, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16a3706e-79c2-4069-8127-78fb2189f173": {"__data__": {"id_": "16a3706e-79c2-4069-8127-78fb2189f173", "embedding": null, "metadata": {"window": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah. ", "original_text": "Any thoughts on the outlook there? ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d97f0a38-5983-469c-842f-1560042752f2", "node_type": "1", "metadata": {"window": "That's - is it \nreally macro -driven is how, in fact, because it seems like you have control over the pricing part of \nthings.  Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure. ", "original_text": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28cdaea82ce84ba02e5d8fa9e6478521848aba8e078e21a406ab6458475f552d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f7068b6-7680-40ca-bdf0-795ec8f4557c", "node_type": "1", "metadata": {"window": "And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. ", "original_text": "Thanks.  \n \n"}, "hash": "262669ed2e5fc18e539e7f669d0c01de2b60a3940841a75ca258db6bfa4074b8", "class_name": "RelatedNodeInfo"}}, "text": "Any thoughts on the outlook there? ", "start_char_idx": 2967, "end_char_idx": 3002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f7068b6-7680-40ca-bdf0-795ec8f4557c": {"__data__": {"id_": "5f7068b6-7680-40ca-bdf0-795ec8f4557c", "embedding": null, "metadata": {"window": "And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. ", "original_text": "Thanks.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a3706e-79c2-4069-8127-78fb2189f173", "node_type": "1", "metadata": {"window": "Is it just waiting for the environment itself and some of the natural inflations that's floating \naround here to come in line to get to your targets ?  And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah. ", "original_text": "Any thoughts on the outlook there? ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9cff515eb44679ea17870bad291672aee90e1fb9d2a045097f07d518b5e2bb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d2178d8-25ec-4154-b314-ca4fdb9560df", "node_type": "1", "metadata": {"window": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.  ", "original_text": "Jason Hollar :   Sure. "}, "hash": "525ae04a2aa1eb492ef180d04c461a868f019ecb0d90887874fc8ec7a8496108", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 3002, "end_char_idx": 3014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d2178d8-25ec-4154-b314-ca4fdb9560df": {"__data__": {"id_": "9d2178d8-25ec-4154-b314-ca4fdb9560df", "embedding": null, "metadata": {"window": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.  ", "original_text": "Jason Hollar :   Sure. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f7068b6-7680-40ca-bdf0-795ec8f4557c", "node_type": "1", "metadata": {"window": "And then secondly, there's been news a lot about \na shortages in amoxicillin.   Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. ", "original_text": "Thanks.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b463c3d78ccdc54ad69334fb08a2ae25123c957002bf63ff6cba55be2824db1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb5b7019-eaf8-42f5-adcf-a6d8e6981008", "node_type": "1", "metadata": {"window": "Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . ", "original_text": "Yeah. "}, "hash": "1bc94e343fd0bcb2649fa0dc8d3f52c756029d95e9752450185921a8fb4aa34a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Sure. ", "start_char_idx": 19, "end_char_idx": 42, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb5b7019-eaf8-42f5-adcf-a6d8e6981008": {"__data__": {"id_": "cb5b7019-eaf8-42f5-adcf-a6d8e6981008", "embedding": null, "metadata": {"window": "Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . ", "original_text": "Yeah. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d2178d8-25ec-4154-b314-ca4fdb9560df", "node_type": "1", "metadata": {"window": "Just any of your thoughts here on drug shortages elsewhere possibly in the \nsupply chain?   Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.  ", "original_text": "Jason Hollar :   Sure. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c8570eb0493363e5d63b7135059acbc41d8e8035fbfe88bd4f8a4a9ee34cac2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b404be-313e-4ca1-bfba-fc2e29706a27", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business. ", "original_text": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. "}, "hash": "0e11f75ed1c6982eca200af5486d0b6109480fa1cf3fe86c290e445c94d5f449", "class_name": "RelatedNodeInfo"}}, "text": "Yeah. ", "start_char_idx": 3037, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b404be-313e-4ca1-bfba-fc2e29706a27": {"__data__": {"id_": "90b404be-313e-4ca1-bfba-fc2e29706a27", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business. ", "original_text": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb5b7019-eaf8-42f5-adcf-a6d8e6981008", "node_type": "1", "metadata": {"window": "Any thoughts on the outlook there?  Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . ", "original_text": "Yeah. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3502e465379d9e89f274bc6248b1efb68bbb40fa3c2539e5f1341bd996418dac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aac21ced-1868-4afa-a88d-0a97d0e970a3", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  ", "original_text": "The key item we highlighted is the simplification \ncost that has been wrapped into this.  "}, "hash": "5543d89e0872bc76e45100d98d968efdd14addd4195af5f65d86e1184454f4d7", "class_name": "RelatedNodeInfo"}}, "text": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. ", "start_char_idx": 3043, "end_char_idx": 3162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aac21ced-1868-4afa-a88d-0a97d0e970a3": {"__data__": {"id_": "aac21ced-1868-4afa-a88d-0a97d0e970a3", "embedding": null, "metadata": {"window": "Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  ", "original_text": "The key item we highlighted is the simplification \ncost that has been wrapped into this.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b404be-313e-4ca1-bfba-fc2e29706a27", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business. ", "original_text": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0350bd201483d75804adfeba65f8592ee539a4765f7e5262919865bb4b97fff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33d860dc-7623-45e9-b21f-2327dcdd1233", "node_type": "1", "metadata": {"window": "Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business. ", "original_text": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . "}, "hash": "17f5d69e391733a26a9aa93514829d005eb848088007678b147b896782992e46", "class_name": "RelatedNodeInfo"}}, "text": "The key item we highlighted is the simplification \ncost that has been wrapped into this.  ", "start_char_idx": 3162, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33d860dc-7623-45e9-b21f-2327dcdd1233": {"__data__": {"id_": "33d860dc-7623-45e9-b21f-2327dcdd1233", "embedding": null, "metadata": {"window": "Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business. ", "original_text": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aac21ced-1868-4afa-a88d-0a97d0e970a3", "node_type": "1", "metadata": {"window": "Jason Hollar :   Sure.  Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  ", "original_text": "The key item we highlighted is the simplification \ncost that has been wrapped into this.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6acf9047b104a5c4618dd23e718336b182a407dd49ddc4d29b14d23409380a93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06c6bc58-9cb0-47a4-bfec-3cdb2308cb24", "node_type": "1", "metadata": {"window": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment. ", "original_text": "Not a lot of new \nnews there for really either business. "}, "hash": "8545dfe64fbd2e6cff154bf11911bee4d0e93ff365c8881ee80c975e6564c8d5", "class_name": "RelatedNodeInfo"}}, "text": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . ", "start_char_idx": 3252, "end_char_idx": 3389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06c6bc58-9cb0-47a4-bfec-3cdb2308cb24": {"__data__": {"id_": "06c6bc58-9cb0-47a4-bfec-3cdb2308cb24", "embedding": null, "metadata": {"window": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment. ", "original_text": "Not a lot of new \nnews there for really either business. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33d860dc-7623-45e9-b21f-2327dcdd1233", "node_type": "1", "metadata": {"window": "Yeah.  In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business. ", "original_text": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes . ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3697812266ed9ad3e1b67ed0c6c59341074bca26331ef3f556fcae0e979ffff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1a76ac6-a6cc-4504-8e19-e05956b82bab", "node_type": "1", "metadata": {"window": "The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. ", "original_text": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  "}, "hash": "4f0afa7a6926293f4a1a17d58c16a22c121c693e2b51a1e6cbfa369592faa962", "class_name": "RelatedNodeInfo"}}, "text": "Not a lot of new \nnews there for really either business. ", "start_char_idx": 3389, "end_char_idx": 3446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1a76ac6-a6cc-4504-8e19-e05956b82bab": {"__data__": {"id_": "a1a76ac6-a6cc-4504-8e19-e05956b82bab", "embedding": null, "metadata": {"window": "The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. ", "original_text": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06c6bc58-9cb0-47a4-bfec-3cdb2308cb24", "node_type": "1", "metadata": {"window": "In terms of Medical, it's - the underlying performance that we are \nanticipating for the business is really unchanged.  The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment. ", "original_text": "Not a lot of new \nnews there for really either business. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f1523455e1c6ddb30f645dd43e963026e093c8d5ee02bc8f724a9e822b2958f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd681407-dc7c-46e3-b250-b86d5a411a6f", "node_type": "1", "metadata": {"window": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "As it relates to any type of product \nshortages, there's always some of that in any of our business. "}, "hash": "4a89ca78c3e39a933e21ec804969b9f838ee835ba9bbc935f401f09a1fa4702d", "class_name": "RelatedNodeInfo"}}, "text": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  ", "start_char_idx": 3446, "end_char_idx": 3582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd681407-dc7c-46e3-b250-b86d5a411a6f": {"__data__": {"id_": "dd681407-dc7c-46e3-b250-b86d5a411a6f", "embedding": null, "metadata": {"window": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "As it relates to any type of product \nshortages, there's always some of that in any of our business. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1a76ac6-a6cc-4504-8e19-e05956b82bab", "node_type": "1", "metadata": {"window": "The key item we highlighted is the simplification \ncost that has been wrapped into this.   But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. ", "original_text": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.  ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55a595eafcb184f79b15a566b55117c054244590a878c5675984fed03d2fc41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ac06e49-7d13-4ecc-9a6d-ef078d0ddd25", "node_type": "1", "metadata": {"window": "Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "There's a few items that are being \nchased within the Pharma  segment. "}, "hash": "9b61d41bec94751236c4e1412f147cecf37a95ebb4c7f0c61e99fd4547c26f6e", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to any type of product \nshortages, there's always some of that in any of our business. ", "start_char_idx": 3582, "end_char_idx": 3683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ac06e49-7d13-4ecc-9a6d-ef078d0ddd25": {"__data__": {"id_": "2ac06e49-7d13-4ecc-9a6d-ef078d0ddd25", "embedding": null, "metadata": {"window": "Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "There's a few items that are being \nchased within the Pharma  segment. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd681407-dc7c-46e3-b250-b86d5a411a6f", "node_type": "1", "metadata": {"window": "But the underlying busi ness volume utili zation, other \nperformance elements are relatively unchanged, there is always puts and takes .  Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "As it relates to any type of product \nshortages, there's always some of that in any of our business. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ded19559126b0d3b08cd46c8595bbfd4500218f384309bed280051ec5152950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f980e829-b382-4f51-a631-c52447bfcc9c", "node_type": "1", "metadata": {"window": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. "}, "hash": "c7eea1172187fe65e8ca63b2d0591e0c8a578dfdf44c8e971c7d52e3dbbd222b", "class_name": "RelatedNodeInfo"}}, "text": "There's a few items that are being \nchased within the Pharma  segment. ", "start_char_idx": 3683, "end_char_idx": 3754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f980e829-b382-4f51-a631-c52447bfcc9c": {"__data__": {"id_": "f980e829-b382-4f51-a631-c52447bfcc9c", "embedding": null, "metadata": {"window": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ac06e49-7d13-4ecc-9a6d-ef078d0ddd25", "node_type": "1", "metadata": {"window": "Not a lot of new \nnews there for really either business.  In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "There's a few items that are being \nchased within the Pharma  segment. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aad976996ca61fc0a873475ab11dc9db54d7929e974a9baf3c5e2e692ad3afbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "068e0f18-40b7-49e6-b1d2-0b2e9308cd30", "node_type": "1", "metadata": {"window": "As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "But that's why we believe that, obviously just "}, "hash": "99121c1c862671fea7f2b4fc14971f2d2ebb8fb8f54835493d8a4ffdf8eb1340", "class_name": "RelatedNodeInfo"}}, "text": "Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. ", "start_char_idx": 3754, "end_char_idx": 3974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "068e0f18-40b7-49e6-b1d2-0b2e9308cd30": {"__data__": {"id_": "068e0f18-40b7-49e6-b1d2-0b2e9308cd30", "embedding": null, "metadata": {"window": "As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "But that's why we believe that, obviously just ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8199a891a84a37f65d5afec50e828b33f076db0425efd1db0b4cbeb7c2f8dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f980e829-b382-4f51-a631-c52447bfcc9c", "node_type": "1", "metadata": {"window": "In both businesses, we had a few non -recurring items, a little bit \nof timing in Medical,  but overall, not too many surprises there.   As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a7b372b041708a519e2b39fd9c4e8bfa49c2eada3c3f3712f783107dc887f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6f248d4-343a-474c-ac22-70243d973a4b", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "original_text": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics . "}, "hash": "2cdf41c09d45d5e586a14298ce6263466c453d1b94ef8700c59a4b6894e311ed", "class_name": "RelatedNodeInfo"}}, "text": "But that's why we believe that, obviously just ", "start_char_idx": 3974, "end_char_idx": 4021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6f248d4-343a-474c-ac22-70243d973a4b": {"__data__": {"id_": "f6f248d4-343a-474c-ac22-70243d973a4b", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "original_text": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "068e0f18-40b7-49e6-b1d2-0b2e9308cd30", "node_type": "1", "metadata": {"window": "As it relates to any type of product \nshortages, there's always some of that in any of our business.  There's a few items that are being \nchased within the Pharma  segment.  Nothing that I would call very unusual and certainly nothing at \nthis stage that I would anticipate being a significant impact or really any noticeable impact for the \nsegment for the current quarter or the fiscal year.  But that's why we believe that, obviously just ", "original_text": "But that's why we believe that, obviously just ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cebb8c51932a5b144630105bfc97c810b31f865ae18c19bdd9da355a7827e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a96aa96e-7f47-4dd8-a8a0-a030602c6ecd", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n", "original_text": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery . "}, "hash": "bcd34f126bf0975e4fae9bab529024f53a7d33fc56de6597891c216653838153", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics . ", "start_char_idx": 0, "end_char_idx": 103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a96aa96e-7f47-4dd8-a8a0-a030602c6ecd": {"__data__": {"id_": "a96aa96e-7f47-4dd8-a8a0-a030602c6ecd", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n", "original_text": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6f248d4-343a-474c-ac22-70243d973a4b", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "original_text": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd44e2217ca384e84a9d01c1a125b30166832d154b05446e2a9fc753d98b0a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d35d07a-a221-4a14-81e0-21bbe20d0a2a", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n", "original_text": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace . "}, "hash": "5a74725f41cda39a5a843a917b65a8ba540266b54808f8600252996c50eb4843", "class_name": "RelatedNodeInfo"}}, "text": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery . ", "start_char_idx": 103, "end_char_idx": 196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d35d07a-a221-4a14-81e0-21bbe20d0a2a": {"__data__": {"id_": "4d35d07a-a221-4a14-81e0-21bbe20d0a2a", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n", "original_text": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a96aa96e-7f47-4dd8-a8a0-a030602c6ecd", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n", "original_text": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ff62a42a9d9e12292443a8066659175df2cd73211699d38c4795b5d9b764969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61cde1c0-0e8a-47e6-808e-52b4c17dea1a", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks. ", "original_text": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us . "}, "hash": "e91ea52e0bd1309cbc56254b0b3f378ab76e6f5d5f3f0783fb986acba857880d", "class_name": "RelatedNodeInfo"}}, "text": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace . ", "start_char_idx": 196, "end_char_idx": 395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61cde1c0-0e8a-47e6-808e-52b4c17dea1a": {"__data__": {"id_": "61cde1c0-0e8a-47e6-808e-52b4c17dea1a", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks. ", "original_text": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d35d07a-a221-4a14-81e0-21bbe20d0a2a", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n", "original_text": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04479310f46540bdc13f7c1e41ca65c53582855fa8ac15a0059a16560f40e437", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f9451a6-1c88-403c-8e6f-b6fd98eda1cd", "node_type": "1", "metadata": {"window": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning. ", "original_text": "Next question, please.  \n \n"}, "hash": "f3479baf4872f826ea7c581a4e81c48ae728357f2d5a0b868fda0f0b57ed9f32", "class_name": "RelatedNodeInfo"}}, "text": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "start_char_idx": 395, "end_char_idx": 496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f9451a6-1c88-403c-8e6f-b6fd98eda1cd": {"__data__": {"id_": "8f9451a6-1c88-403c-8e6f-b6fd98eda1cd", "embedding": null, "metadata": {"window": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning. ", "original_text": "Next question, please.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61cde1c0-0e8a-47e6-808e-52b4c17dea1a", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks. ", "original_text": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "400a6532ce73824228b0893366e3f51c8117ac92d4a98eb940c00c641c170f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adcc74ff-8d5f-4a65-aaaf-df89f8e63982", "node_type": "1", "metadata": {"window": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  ", "original_text": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n"}, "hash": "a15d953fa9d9490d18eda644c0633f83d62a96d8016985272173e7b7d585af04", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 496, "end_char_idx": 523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adcc74ff-8d5f-4a65-aaaf-df89f8e63982": {"__data__": {"id_": "adcc74ff-8d5f-4a65-aaaf-df89f8e63982", "embedding": null, "metadata": {"window": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  ", "original_text": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f9451a6-1c88-403c-8e6f-b6fd98eda1cd", "node_type": "1", "metadata": {"window": "It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning. ", "original_text": "Next question, please.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810dcbcc170cc21b5c353ba404f91ab770be06e12edbc9c4d9fcd504c572c1a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "230df1f9-7a8e-4f23-97ad-0bc810d2f92a", "node_type": "1", "metadata": {"window": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  ", "original_text": "Steven Valiquette :   Great , thanks. "}, "hash": "45da8dcc89dd03cdc27c77c3ff31196d321f0c8fd80ef143c431be9cd0ef2e0f", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n", "start_char_idx": 523, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "230df1f9-7a8e-4f23-97ad-0bc810d2f92a": {"__data__": {"id_": "230df1f9-7a8e-4f23-97ad-0bc810d2f92a", "embedding": null, "metadata": {"window": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  ", "original_text": "Steven Valiquette :   Great , thanks. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adcc74ff-8d5f-4a65-aaaf-df89f8e63982", "node_type": "1", "metadata": {"window": "And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  ", "original_text": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "405cde526e6b2f7a84ab4b7397e12df30d7ed02f4d45b4653946a04fd3afdf49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15b5dd4f-f3e5-4596-8642-0cd1f52ce719", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n", "original_text": "Good morning. "}, "hash": "6304ca8926308308dc88cdd1ba55d143a5fd67fcd6027c6e8577ca879130fccd", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette :   Great , thanks. ", "start_char_idx": 606, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15b5dd4f-f3e5-4596-8642-0cd1f52ce719": {"__data__": {"id_": "15b5dd4f-f3e5-4596-8642-0cd1f52ce719", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n", "original_text": "Good morning. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "230df1f9-7a8e-4f23-97ad-0bc810d2f92a", "node_type": "1", "metadata": {"window": "But again, it's something that we don't \nthink will be either lasting or any type of impact for us .  Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  ", "original_text": "Steven Valiquette :   Great , thanks. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0b9cbf9266cba1d0687e61f42411e3c2ccaedf23f724cd5709edd8dccc0a5a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0013317f-86c5-4e0a-9e97-78f66c81a3b2", "node_type": "1", "metadata": {"window": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n", "original_text": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  "}, "hash": "611ea1c7ce290a0db70a0c9f4aed0f923109918bdee0c669ca0e7060a625b0cc", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 644, "end_char_idx": 658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0013317f-86c5-4e0a-9e97-78f66c81a3b2": {"__data__": {"id_": "0013317f-86c5-4e0a-9e97-78f66c81a3b2", "embedding": null, "metadata": {"window": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n", "original_text": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15b5dd4f-f3e5-4596-8642-0cd1f52ce719", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n", "original_text": "Good morning. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c84b0ef372c1f164f921fb7731debee2a7e232462fbf31a6d8f86f017dc25238", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9abec3fa-15d8-4df8-afff-8e864b607319", "node_type": "1", "metadata": {"window": "Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . ", "original_text": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  "}, "hash": "a18ab32284cf977e0e4ae4500356010134cb6f38c6ffb0ffb589eac48bbf5c70", "class_name": "RelatedNodeInfo"}}, "text": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  ", "start_char_idx": 658, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9abec3fa-15d8-4df8-afff-8e864b607319": {"__data__": {"id_": "9abec3fa-15d8-4df8-afff-8e864b607319", "embedding": null, "metadata": {"window": "Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . ", "original_text": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0013317f-86c5-4e0a-9e97-78f66c81a3b2", "node_type": "1", "metadata": {"window": "Operator :  And our last question comes from Steven  Valiquette with Barclays.  \n \n Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n", "original_text": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff93ab2fc79a0cecdbd9cf012d5dbe64c0bd1c481309022739ef323b4c879cdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcfc5fee-2733-467d-8e68-235f4ecda9e1", "node_type": "1", "metadata": {"window": "Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry. ", "original_text": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n"}, "hash": "ec339edf4d0949b6666ac1a18e36bf42a3d17ceefadb09022045cd01a1c69494", "class_name": "RelatedNodeInfo"}}, "text": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  ", "start_char_idx": 961, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcfc5fee-2733-467d-8e68-235f4ecda9e1": {"__data__": {"id_": "dcfc5fee-2733-467d-8e68-235f4ecda9e1", "embedding": null, "metadata": {"window": "Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry. ", "original_text": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9abec3fa-15d8-4df8-afff-8e864b607319", "node_type": "1", "metadata": {"window": "Steven Valiquette :   Great , thanks.  Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . ", "original_text": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5874835fe12a8f9a2b134533b16ff6de815e21af5c6dc91005e0db1b7e689b50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eef9a186-c76b-467f-8a3f-6542307b1761", "node_type": "1", "metadata": {"window": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.  ", "original_text": "Thanks.  \n \n"}, "hash": "192523552b7e0544430f55749f51490f54ef883f1cc0141f9e81dbe7470a9e71", "class_name": "RelatedNodeInfo"}}, "text": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n", "start_char_idx": 1232, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eef9a186-c76b-467f-8a3f-6542307b1761": {"__data__": {"id_": "eef9a186-c76b-467f-8a3f-6542307b1761", "embedding": null, "metadata": {"window": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.  ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcfc5fee-2733-467d-8e68-235f4ecda9e1", "node_type": "1", "metadata": {"window": "Good morning.  So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry. ", "original_text": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "880775c226fae2f0a212f13f05fef457f0eecf714c577b8fd0999987694c0efc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c19e929-e0af-49e1-8634-1449e4e389b5", "node_type": "1", "metadata": {"window": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing . ", "original_text": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . "}, "hash": "88398f8ea257fafd79dcd27c5c780563102d25ba80e163251dfc14e9257bbbc0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1429, "end_char_idx": 1441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c19e929-e0af-49e1-8634-1449e4e389b5": {"__data__": {"id_": "2c19e929-e0af-49e1-8634-1449e4e389b5", "embedding": null, "metadata": {"window": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing . ", "original_text": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eef9a186-c76b-467f-8a3f-6542307b1761", "node_type": "1", "metadata": {"window": "So you guys touched on this topic a little bit, but \nthis quarter, we saw your largest publicly -traded hospital distribution and self -manufacturing Med \nsurge competitor really str uggle with delayed product reorders by their acute care hospital customers \nwho chose to deplete the stockpiled items.   I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.  ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a55b9e36994c0330d839baa762a52ee414b694bdced7ece02fb858c86215ef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd305e06-8588-42df-8718-1b98cea78b4d", "node_type": "1", "metadata": {"window": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . ", "original_text": "So we have seen destocking of our customers' invento ry. "}, "hash": "603643721d18c9252478f4bf815132b1cae30937fae3bc574346a624724b3afa", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . ", "start_char_idx": 1441, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd305e06-8588-42df-8718-1b98cea78b4d": {"__data__": {"id_": "fd305e06-8588-42df-8718-1b98cea78b4d", "embedding": null, "metadata": {"window": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . ", "original_text": "So we have seen destocking of our customers' invento ry. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c19e929-e0af-49e1-8634-1449e4e389b5", "node_type": "1", "metadata": {"window": "I know you have a different set of SKUs versus that \ncompetitor for the self -manufacture component, but can you just confirm that you gene rally are able \nto successfully track the level of inventory sitting within your health system customers in the Medical \nsegment?   And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing . ", "original_text": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dab3d62ecb425668f0f152c286317a51ff981e85ea9ca38cf073f4be5d292f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69933b9-0f26-4f20-bdbe-dc8e7be5b9ab", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull . ", "original_text": "We are very \nclose with them and have that dialogue all the time.  "}, "hash": "732b18dd0dd053f41b28cbe22105ddf333c3d3be9409ce9b00d01aa988ae46a0", "class_name": "RelatedNodeInfo"}}, "text": "So we have seen destocking of our customers' invento ry. ", "start_char_idx": 1574, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69933b9-0f26-4f20-bdbe-dc8e7be5b9ab": {"__data__": {"id_": "b69933b9-0f26-4f20-bdbe-dc8e7be5b9ab", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull . ", "original_text": "We are very \nclose with them and have that dialogue all the time.  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd305e06-8588-42df-8718-1b98cea78b4d", "node_type": "1", "metadata": {"window": "And that Cardinal will hopefully not see a similar inventory destocking trend within the \nhealth system customer base that could  be a risk factor for the recovery as the fiscal year progresses . \n Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . ", "original_text": "So we have seen destocking of our customers' invento ry. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cdf7dcc6ce6d88335e6dc855c910c04d0ae5b46198bba6437531526c0ddefd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c13a7b86-d4e5-4d81-aaa8-2bd5ea326016", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. ", "original_text": "And that is what we have been seeing . "}, "hash": "b07a61aaec5d22f40139324353cd2e2e1348b75406e1873e6f5d3a969e60530b", "class_name": "RelatedNodeInfo"}}, "text": "We are very \nclose with them and have that dialogue all the time.  ", "start_char_idx": 1631, "end_char_idx": 1698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c13a7b86-d4e5-4d81-aaa8-2bd5ea326016": {"__data__": {"id_": "c13a7b86-d4e5-4d81-aaa8-2bd5ea326016", "embedding": null, "metadata": {"window": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. ", "original_text": "And that is what we have been seeing . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69933b9-0f26-4f20-bdbe-dc8e7be5b9ab", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull . ", "original_text": "We are very \nclose with them and have that dialogue all the time.  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d748fdc1c39f4c7dd39363ddd3db5c6f2049946ed850f48a6bf885d9d0d5ac2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00418c9d-8af5-4055-9591-871776718eac", "node_type": "1", "metadata": {"window": "So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . ", "original_text": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . "}, "hash": "b377eaf3cdc498e8b18fd7cf7adb179e3c173b93238a78b31274cf4a53e60173", "class_name": "RelatedNodeInfo"}}, "text": "And that is what we have been seeing . ", "start_char_idx": 1698, "end_char_idx": 1737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00418c9d-8af5-4055-9591-871776718eac": {"__data__": {"id_": "00418c9d-8af5-4055-9591-871776718eac", "embedding": null, "metadata": {"window": "So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . ", "original_text": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c13a7b86-d4e5-4d81-aaa8-2bd5ea326016", "node_type": "1", "metadata": {"window": "Jason Hollar :   Yeah , so those types of comments are very consistent with what we've been saying in \nthe last couple of quarters .  So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. ", "original_text": "And that is what we have been seeing . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30c70b2c23633127ff54519f423b71d876822e09a694314afde424a6231b1b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be042906-1f2b-4ba3-ba33-13576880b6b5", "node_type": "1", "metadata": {"window": "We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n", "original_text": "So we're not seeing significant \nchanges in the pull . "}, "hash": "85bb5e0c2fea0ab8f7f9abcdc1019295ab717d217392ed86b53d0887dac357d5", "class_name": "RelatedNodeInfo"}}, "text": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . ", "start_char_idx": 1737, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be042906-1f2b-4ba3-ba33-13576880b6b5": {"__data__": {"id_": "be042906-1f2b-4ba3-ba33-13576880b6b5", "embedding": null, "metadata": {"window": "We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n", "original_text": "So we're not seeing significant \nchanges in the pull . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00418c9d-8af5-4055-9591-871776718eac", "node_type": "1", "metadata": {"window": "So we have seen destocking of our customers' invento ry.  We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . ", "original_text": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e66d4ed17bdbe5b3a5a20f73a1b89a825833a15763eaae0bfaef084dd59619b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf9b488e-e8ed-4f91-9dbc-dc3c6f03d99b", "node_type": "1", "metadata": {"window": "And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question. ", "original_text": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. "}, "hash": "4a60a8d026c06242cfad2c70c5b2cd17901b62fbc50fd7dbc1026c67baa352c3", "class_name": "RelatedNodeInfo"}}, "text": "So we're not seeing significant \nchanges in the pull . ", "start_char_idx": 1905, "end_char_idx": 1960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf9b488e-e8ed-4f91-9dbc-dc3c6f03d99b": {"__data__": {"id_": "cf9b488e-e8ed-4f91-9dbc-dc3c6f03d99b", "embedding": null, "metadata": {"window": "And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question. ", "original_text": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be042906-1f2b-4ba3-ba33-13576880b6b5", "node_type": "1", "metadata": {"window": "We are very \nclose with them and have that dialogue all the time.   And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n", "original_text": "So we're not seeing significant \nchanges in the pull . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1b7bda8e3aff6a0cc607169ab71217219cca33a23927bdc7eb5bc56bd45aa96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b6dbb72-934a-4365-8b4b-c673fa080465", "node_type": "1", "metadata": {"window": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.  ", "original_text": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . "}, "hash": "21f402aa954790a0425f8176d51d6eaaba1c746273cb046f2b599a9f959b2d1d", "class_name": "RelatedNodeInfo"}}, "text": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. ", "start_char_idx": 1960, "end_char_idx": 2103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b6dbb72-934a-4365-8b4b-c673fa080465": {"__data__": {"id_": "7b6dbb72-934a-4365-8b4b-c673fa080465", "embedding": null, "metadata": {"window": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.  ", "original_text": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf9b488e-e8ed-4f91-9dbc-dc3c6f03d99b", "node_type": "1", "metadata": {"window": "And that is what we have been seeing .  We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question. ", "original_text": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1f1d40342b824d84bdc98adda4b1e2b5a446fff8b058751b6a8819e5cd73532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c770d3-ad53-4ecc-abd4-0f8cd2afca88", "node_type": "1", "metadata": {"window": "So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . ", "original_text": "But there's really nothing else to add at this \npoint.   \n \n"}, "hash": "234e40b4620832ab08eb403d2c37439811b16596c650845a874b4c8e298b5191", "class_name": "RelatedNodeInfo"}}, "text": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . ", "start_char_idx": 2103, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c770d3-ad53-4ecc-abd4-0f8cd2afca88": {"__data__": {"id_": "a8c770d3-ad53-4ecc-abd4-0f8cd2afca88", "embedding": null, "metadata": {"window": "So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . ", "original_text": "But there's really nothing else to add at this \npoint.   \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b6dbb72-934a-4365-8b4b-c673fa080465", "node_type": "1", "metadata": {"window": "We \nreferenced in our comments that our volume specifically to PPE, but even more broadly is fairly \nconsistent sequentially from Q4 of last year to  Q1 of this year .  So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.  ", "original_text": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a27cdec55ddf800745810bb5410007397468f516d7b22616bdfeec3062c75bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1af883f-0a4c-4eeb-a107-a19a557a0b0d", "node_type": "1", "metadata": {"window": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. ", "original_text": "So I think that's the final question. "}, "hash": "ad0025d74f2d1cfd1a902988a599cf93a9965d7bfec094cb28d5b533cc5c9911", "class_name": "RelatedNodeInfo"}}, "text": "But there's really nothing else to add at this \npoint.   \n \n", "start_char_idx": 2405, "end_char_idx": 2465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1af883f-0a4c-4eeb-a107-a19a557a0b0d": {"__data__": {"id_": "a1af883f-0a4c-4eeb-a107-a19a557a0b0d", "embedding": null, "metadata": {"window": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. ", "original_text": "So I think that's the final question. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c770d3-ad53-4ecc-abd4-0f8cd2afca88", "node_type": "1", "metadata": {"window": "So we're not seeing significant \nchanges in the pull .  But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . ", "original_text": "But there's really nothing else to add at this \npoint.   \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02793830b495d5a42ec99a780263a8d74515ea16b16176fd3f38611bba583ff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a8bc288-e565-4298-aa12-c3f0612d754b", "node_type": "1", "metadata": {"window": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n", "original_text": "So I'll just end it with just a couple of closing comments here.  "}, "hash": "af560164f792b0e4380ac9af5c9afbbb7aff844ed3bf36222dba6b3bcd45835e", "class_name": "RelatedNodeInfo"}}, "text": "So I think that's the final question. ", "start_char_idx": 2465, "end_char_idx": 2503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a8bc288-e565-4298-aa12-c3f0612d754b": {"__data__": {"id_": "8a8bc288-e565-4298-aa12-c3f0612d754b", "embedding": null, "metadata": {"window": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n", "original_text": "So I'll just end it with just a couple of closing comments here.  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1af883f-0a4c-4eeb-a107-a19a557a0b0d", "node_type": "1", "metadata": {"window": "But we did call this out last quarter , because there was a fairly significant \nreduction we saw sequentially at the latter end of fiscal \u201822.  So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. ", "original_text": "So I think that's the final question. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f449daa508f4867d7cf4dcfe74bca13ef17394ece85219079ae0edb31fe4061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b16bc99-83f5-4c98-8de2-21a1af68307c", "node_type": "1", "metadata": {"window": "But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call. ", "original_text": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . "}, "hash": "c228c299ba61de11261c75b0587d0dd5dbb73637b3c35599b6f5fd996c31a8c8", "class_name": "RelatedNodeInfo"}}, "text": "So I'll just end it with just a couple of closing comments here.  ", "start_char_idx": 2503, "end_char_idx": 2569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b16bc99-83f5-4c98-8de2-21a1af68307c": {"__data__": {"id_": "9b16bc99-83f5-4c98-8de2-21a1af68307c", "embedding": null, "metadata": {"window": "But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call. ", "original_text": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a8bc288-e565-4298-aa12-c3f0612d754b", "node_type": "1", "metadata": {"window": "So the concept we absolutely have \nreference d ourselves and have seen, but we have seen pretty consistent demand patterns here this \nlast quarter, and while it's still very early in Q2, I can say that we haven't seen anything significantly \ndifferent so far at the beginning of this quarter as well .  But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n", "original_text": "So I'll just end it with just a couple of closing comments here.  ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a77d439b9131130f50b981887f7e33c0d3b40fbb9256bbd7ebc60469f92460f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4286c17d-a4ae-4a56-8ca1-8ae2aa6e043c", "node_type": "1", "metadata": {"window": "So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. "}, "hash": "65fd2d3a4ac30318789fb076bab6eafd510e13d5548c3f4c3c5324628cecf8cb", "class_name": "RelatedNodeInfo"}}, "text": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . ", "start_char_idx": 2569, "end_char_idx": 2710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4286c17d-a4ae-4a56-8ca1-8ae2aa6e043c": {"__data__": {"id_": "4286c17d-a4ae-4a56-8ca1-8ae2aa6e043c", "embedding": null, "metadata": {"window": "So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b16bc99-83f5-4c98-8de2-21a1af68307c", "node_type": "1", "metadata": {"window": "But there's really nothing else to add at this \npoint.   \n \n So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call. ", "original_text": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9624297351c765e312094ea822571ead682a6342cd4e3089805eeaa7f3bbda5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8dddb62-5f33-47be-a3f4-6bd2a2809b18", "node_type": "1", "metadata": {"window": "So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "So with that, thank you and have a \ngreat day.  \n \n"}, "hash": "bda9538d6bd6db6ae1dd778430e350fb11b88aa44b0688c9dcd3280ff9936e32", "class_name": "RelatedNodeInfo"}}, "text": "We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. ", "start_char_idx": 2710, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8dddb62-5f33-47be-a3f4-6bd2a2809b18": {"__data__": {"id_": "d8dddb62-5f33-47be-a3f4-6bd2a2809b18", "embedding": null, "metadata": {"window": "So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "So with that, thank you and have a \ngreat day.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4286c17d-a4ae-4a56-8ca1-8ae2aa6e043c", "node_type": "1", "metadata": {"window": "So I think that's the final question.  So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "243d29ea8b57d3462a76bc8b8dbdbf27ae8d3270132d9ebaa6d56df5b6668eaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dda059d-5027-4379-8710-c921750f266c", "node_type": "1", "metadata": {"window": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "Operator :   Thank you for joining today's call. "}, "hash": "dd10eabd9687ed33b0fa6f83ace92fccb9eb2203703e676d325969d7747ea8be", "class_name": "RelatedNodeInfo"}}, "text": "So with that, thank you and have a \ngreat day.  \n \n", "start_char_idx": 2832, "end_char_idx": 2883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dda059d-5027-4379-8710-c921750f266c": {"__data__": {"id_": "6dda059d-5027-4379-8710-c921750f266c", "embedding": null, "metadata": {"window": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "Operator :   Thank you for joining today's call. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8dddb62-5f33-47be-a3f4-6bd2a2809b18", "node_type": "1", "metadata": {"window": "So I'll just end it with just a couple of closing comments here.   I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "So with that, thank you and have a \ngreat day.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43cc7ba768a02d3f81d02f20e09b7aee0f755f72feb97ac1b1d669ad85aeccfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7511bb0b-889a-4e74-bba1-7f6cee4bff76", "node_type": "1", "metadata": {"window": "We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "You may now disconnect . "}, "hash": "9b52c415ba31eb5db4e50fbebc243d030116fb35b124ad03f0fa20904d28d081", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   Thank you for joining today's call. ", "start_char_idx": 2883, "end_char_idx": 2932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7511bb0b-889a-4e74-bba1-7f6cee4bff76": {"__data__": {"id_": "7511bb0b-889a-4e74-bba1-7f6cee4bff76", "embedding": null, "metadata": {"window": "We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "You may now disconnect . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6371d7f6-efc1-468a-a298-e99cc42a8479", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e12723bfdbcaba998fbc1932a98153100327e71dc374a7c180c799bd0f0dbeda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dda059d-5027-4379-8710-c921750f266c", "node_type": "1", "metadata": {"window": "I'll \nend where I began my comments this morning that I am pleased with the progress that we're mak ing \nin our core business fundamentals .  We are driving lasting improvements in both segments while \nmaintaining a relentless focus on shareholder value creation.  So with that, thank you and have a \ngreat day.  \n \n Operator :   Thank you for joining today's call.  You may now disconnect . ", "original_text": "Operator :   Thank you for joining today's call. ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b27881bd3fd9bf562b8e1dabaf38f46c30b05f4f3f3d106bd8659bbaa87bf53", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect . ", "start_char_idx": 2932, "end_char_idx": 2957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"81caa7d6-c7c1-437c-a367-26b8c6136804": {"doc_hash": "adc7fc90c2526a818a08568f82284c2608cc9e930749ec42e94f906d02e48044", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "71e330b8-83f5-4e1b-960d-540255721639": {"doc_hash": "4b2691aa081104ace007326ecec5d3aa19d79fe63d676088f04b5d08b0a8dc71", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "252f0102-48ec-4c5d-8245-3f1bd3afe6e0": {"doc_hash": "f8bb4575afc9c4ddfbeeeba8b6bbfce692fed0f49a51220c0e410d2b7d633aba", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "f9b8ed38-af9d-4702-adf3-79c6f6b3022c": {"doc_hash": "1a9fe79bd69ffa7af1ceec24ca73762720151ca26eea33dc288ddd86f14cf431", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "af350fed-2b12-4681-b7d2-57f9760fbf12": {"doc_hash": "507d5ec330cb95c72c82161233b9595e74e13aaa95f8f8c2474b0da3c39db82b", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "e5037caa-feb0-42ac-acee-20ce03cc98f3": {"doc_hash": "b3f0ec241313d9f5f36bd855f22d918d3abc44f5a7569510f97337d48a32c6ec", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "d9486922-4824-4ad1-b0a0-4f1a1a6a40df": {"doc_hash": "c2e8ded125f2eff2f1fa753b784ba4b445f9721fa2a419964b411526e305abc0", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "5b54c581-872d-44fc-aa97-e7ca6176dcda": {"doc_hash": "869ec4dfbf18864621abab5c6311c5ae8ce80cc3f6b59e78cd74e525b28a9bc6", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "9ab69b48-1611-49a9-ae86-ff2ab4ddca30": {"doc_hash": "3320b30daa926a0bc82244499b425312fed162f425d31e3e377acb5a5c8d8504", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "f2d08e0e-f486-4771-8bc3-613c82eff296": {"doc_hash": "60aabb34b9e5cd17243c9de0ff7d6c0c0913fcbef3398091717175860d60c9a0", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "87b771c0-83b0-4543-a830-f03088d2f648": {"doc_hash": "01e03c192dc20905330fa12451c6486a464ad47eb8efc9e2f9ebc5178b6f1f4a", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "3317a8e1-aff5-47e7-9258-c8e2acb37712": {"doc_hash": "6412b4e40301b4f8902abfab9065a7780c3c2b0adb63cb1118c16c9bed568ffa", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "ed105fb3-1646-4d3d-9c6e-4fc581ea5afa": {"doc_hash": "6e2ec90e6eb2b753326b7cbec6c07c15a5e5884e220ca75742d54116468a086a", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "a15969ff-44e4-4927-bee6-95dd55bb5a9f": {"doc_hash": "dab404b399f280f5618a98488dcbb376796a1a4b5c6bb19bcbcab4c35ee4df7e", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "e8d88eb1-cf78-44cd-8309-a7da8c7c42c4": {"doc_hash": "c02988b65c118edfa5153bbace8acaf922d0f602b72ea5c6936d3dfe308bbfd5", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "d91b5b31-bf19-4516-9bc0-99a6bca5a8a7": {"doc_hash": "7363c66bccaeee3ebffe46c09cb82a52d332d586a98b0823a4f04d82ea90f169", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "a442c11a-48b6-4869-b4bf-a43d0df1eaff": {"doc_hash": "a9311d287e600a8d5b7dcf8bbb2f3ad7903879be68ef14065f7f0d3d29a37d98", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "67dd57e5-bf30-422c-9010-8863eec1c543": {"doc_hash": "c076dd85bebeefd9c3ceefc11770b84e6062a5041a1495a51c0248aa15a8b8d3", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "c820fbec-7290-4955-ba9b-d2ba1e062f6c": {"doc_hash": "98e833f60b14a9a5efd1917d3a939df0545e60b07291d3a4ef7dcc797ef9a990", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "80cbc1df-e4e5-4391-b351-b7bf0bd24789": {"doc_hash": "abf549c7ae329ed2aa82fcd8505b243c6df3fa8dc40e27955fa1aafdbfcebaba", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "1006e2dd-a7c8-49d5-99de-91be004cc0c7": {"doc_hash": "75fc5abcc5478f2240622c6e7a0c10608d8bba31e42e98b9017409828f7ef2a9", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "565b7e1f-b23d-41bf-b3c5-a77dc663dd54": {"doc_hash": "bde75e4e91888eedb22ebd644be1441b81a8b8d26daab4839356cf34ee0d54dd", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "0f9a4765-fc0a-4dcb-af9a-0b51035f9e60": {"doc_hash": "e85aaef3d1cfd8d4001d59bfb9769c60358bfa55bd3784053d7fcf82fd05a0cb", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "f3467e56-299f-4dbc-bece-d96704e87b5d": {"doc_hash": "30bb789827e4be54f403ac956225fb977842d054f578e7d4bf15d240d8bbce31", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "b07dfe64-a28a-4d87-b64c-671a7441cb7b": {"doc_hash": "703588d3d0427f3a8b2d07c758c364931280fd89de0dfa6833efd4481c171370", "ref_doc_id": "71d91a0a-9d0a-4377-bf98-9c409b54712d"}, "a9d77d99-a2cc-48e0-bc9c-b1fd7770a10d": {"doc_hash": "2d448fd4bb6e8f1b633c0f9cfec4644c6951189ea6a37bb5775da70515112309", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "bbfb7216-2c91-42c5-9288-2166ac194744": {"doc_hash": "d513fb98dac9f076cad60b800f725a21ac0988bff8d41ac5804d7dd35c97071a", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "59e1f5ea-2b8d-4bf6-a853-dfbdb0e929f5": {"doc_hash": "66190dc8321a1c26407c46f3d25e41a648640004a3a4a5f140b590f80e9250ef", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "6e3c5f1c-5113-4ac7-a994-787f3a57a663": {"doc_hash": "e3d9325ccaae661136e0b3fcff0966bf4fe34abf320dac6a243e38224a3f9dcd", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "865cf553-177d-4208-b028-4c103c9e121d": {"doc_hash": "33ef4f41ae44446726058259f6a7fd86d5d2563c3270c7a5b6f36156f297d7b5", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "9113967a-48d1-4cc7-a88d-80d7d7f22264": {"doc_hash": "716d5ca796cf6b66ea32a690ed5105fa5fff28d2434471f1000c17acb3a11443", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "41883b94-c385-45c2-be31-b2fe3b29863f": {"doc_hash": "d4b1d6079966a671ff7f3484b93a23ee6c6bbfa033e18c8d396112a38f5c0fc1", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "248023f3-f413-45fc-8412-5fe45e76ed99": {"doc_hash": "6d901ace9bb518e6436424d3d59682662a428d0af3a3236c0f9b8ed01b34851e", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "ff9fba3a-84bc-41e1-bb0e-0c13a7336ab6": {"doc_hash": "c4465aa32614194b38fffbc7e7aeb9dfecfc378446501e30b4b2ffe09b43480c", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "5b6234ec-4dcd-4b6b-bcab-7b97a4aca040": {"doc_hash": "eb3db53e970a5c42ae9717089ceb367d101c9e4495cc9688ba6d4bf6d488ae6f", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "11d13401-65af-4c8e-b61b-4b3fd36d6bd3": {"doc_hash": "7ebe459b7091e8321cb07b9063aec62491a898426c83c621cff09afe39f9137b", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "2b7c13b5-1129-4aff-9e76-423f7c1c95b2": {"doc_hash": "8b9042a548b80a00b8a5e3450facdce89bfcc4ece803856dcf16451922562196", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "ec65bd90-2c17-46dc-b59e-4ad1b7af22a4": {"doc_hash": "a01cf443f835733c11d38a4ff6d4d5126d1131126a07e225f73e487c55d840c4", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "b7cead67-ba2c-40b8-82eb-5a75fb6a8683": {"doc_hash": "d14e8895afe40af1e88e1777858528fc6708ef4c92de7318875493a371a4192b", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "245d7555-986c-4313-a0dc-2ef24eaa1cb5": {"doc_hash": "0cf5e73316077ef0588aa580723939a7aea710acc1eab7ec23642876858d9eba", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "99fc5be9-15ef-4c30-9e5d-6a3fd0588523": {"doc_hash": "3aa7aedcfcdd8d0f3b75e7c7875b250ccbfd292f07ff99f0a7f64a5f68aaa579", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "3bc58ef3-9ffa-4676-9e40-c8134913385c": {"doc_hash": "473dbb28a9b9fde847354a3127c06d2ae6b3015d726f79b76eac786e596f86d5", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "1a151dbb-8668-4d97-b66d-6eee6f3ad314": {"doc_hash": "576519dc96bc80db9f12526f5f34841dbc75013ecdf7bd7ce040b0c7d0c69547", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "64b5de7b-e8e4-46e7-b4d6-9efbeb9bf64b": {"doc_hash": "b098a279d61d2bc9c8c34365e6fe76b7ce02826843083b1c3a88fd8b7a9ac14b", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "ce98f3f6-51cf-4719-8d53-13cfbcda6326": {"doc_hash": "c535321f2ee8eff567c2f9163684277a0f58e7e35c080093f085262b31eb4aad", "ref_doc_id": "0798e667-a5de-4f9c-a0f7-c7240bbb205f"}, "5e34732c-9d26-4c3a-b18d-01c8178fb417": {"doc_hash": "12eb05c7c7b0d4a8427e83ff298d289bad2f123270dddb9cf21a25db71d2bb87", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "2d1f62a9-e475-4b36-8ee6-9d16da5f6776": {"doc_hash": "574a5f6f1a8e010eab1f7172cd02b313bcf10027db4d7d440c7974f2f3bdb720", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "72418f0c-5b24-4f8a-9911-4820ec7069df": {"doc_hash": "f82c0ad4d793bb6637adfb1433004192c8a77975983d0554408bebced6c0db7a", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "f5d8a459-c908-405c-87c4-d879593dec84": {"doc_hash": "d19b46be9e4729ec23be8e6482d1291524bf3d07c5b6163403211e225f124a18", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "88935146-bf2a-403b-8247-c57cef81a366": {"doc_hash": "c615dd21e760a26a40bb130d16e5708c0c56046cd20038aa81c6a50adbd1ddd1", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "f0335b08-bc3d-4e90-a758-d7e0ae2c474c": {"doc_hash": "79b62d2ebe943822d824b9297019d20b5561ca64e6829c77b0bb1f48912fa572", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "db6646ed-4060-4da9-a8ec-0c08e9bdf0a0": {"doc_hash": "c2daa7afaaf36435496cac2afa5391c445087c9367fddfe69942d94f43efae26", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "bbbb8af2-fafb-4d84-823f-e9074b4b4952": {"doc_hash": "2d9f36f61527794b0151c48ef7c7373285ea0fa902f1dee35856b0fb525e4d01", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "bd6c6f48-cbfb-4a58-a498-538911bcc4bb": {"doc_hash": "82c3cecf95b773fd8ac302c8652170570aa05e3bdb16b3c4692fc4b28125cdc9", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "50c131ef-9df4-4415-a92b-dd2c95944ebf": {"doc_hash": "e0e5cb8b9bfb7cce2dcaff4e1fa14621b4f8810e0c190fe5f8b57abba4770f42", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "4addedea-9696-4e3b-9be1-81c0d522c757": {"doc_hash": "1750928c0c5abdc3c53519bcee16c60a04818f7fb05041f538815afd2c0fae51", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "ec5fc4c0-9d2c-4133-8004-79f280fc02e5": {"doc_hash": "f5c4ba7260bacc149c5c99a9bf5b931aa400ee2450377f6b11ac8090cef02099", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "85e9c5c1-e98f-4e7e-9263-18aee2fae710": {"doc_hash": "58ebb6d3e161dcb378412c3371e6528372d5a40dafba69f8d115dfa6a501b827", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "d134be35-91be-4e4b-ae30-008878b38daf": {"doc_hash": "aff1f19afba36d9cec4e1812b39b8ad102a2a07b5fb4bc451aa10d84d243389e", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "ad4897bd-5436-4339-be53-d32f20ea03fe": {"doc_hash": "a53229d94d2c4669fecf3a8677f4d84d2eb20199f6f5b9ec5bdc64024eb088de", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "f4a4b64d-fe1a-4c07-b00c-cb743a287e74": {"doc_hash": "391f89cdcda0c5c554a403c6827707532a1eb2d14cae0e093807f0cbbaea1fd9", "ref_doc_id": "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486"}, "247e6f15-86da-4256-b87f-07e5293fee77": {"doc_hash": "13ceff7e51b2ef39c77a7dce0024bfba03141ab49512ca83349fe8feed273d0f", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "65d0ea34-5eba-4059-abf5-2949c2015f85": {"doc_hash": "647e3e3989022197e7bb1587e89cdbfd0bdf7ef5db4b752d552619a04833815e", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "9dd48c65-b2da-41c7-b83a-71df96e4ea47": {"doc_hash": "a03de135a41c59e403c4b8fbe26a8b56b01f4a5a2b566af4ab6abd57afc416f3", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "2a293b13-ee8a-4372-beeb-c936fc86ba60": {"doc_hash": "d3f1f9fc1ba073cd89f712abbec397aa053f5cd621a11d858af1179db0951ad2", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "98c347cf-e956-4ae5-a538-45c93ffa0c8f": {"doc_hash": "192d66f1d1e772a6ca180f51794c16ad7775e834ee1c30336ad183dd74278405", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "d1b0ca97-5776-4b7c-8106-e27e01d972ba": {"doc_hash": "ef15d1e2ae926c93c19f0a4c5cdd776bd95b7a391ac5c6de6f3aa7fafa4b7991", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "19b4a2fa-7f21-47e0-b962-d16e2eb849bb": {"doc_hash": "7d8651e4c91d384d8ce56b301137604f840dd7c8f24dff5e45312d5e2748ab72", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "a5dd7c53-b8bf-479f-abcb-92df7e0fd629": {"doc_hash": "17fff979df04a4d33310c4c9b522f0a0f9be97ba3a67c9c2b511de028ebee492", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "c53cdb8b-3497-463f-bb6f-0df913379631": {"doc_hash": "f47648b6ff853d9178b4404691d0b7c4688ae24ccceea1a1198c6858b567bd5f", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "7b2d5aba-588b-4430-9a58-e6ee13f18d97": {"doc_hash": "f90d67b5675d7f5bd0c2b022591ddccc35df53f27c73fc4767cf199fa8baa699", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "d541af51-676c-48bb-8cc3-2abc7b9c547f": {"doc_hash": "bc515381717dbae32f5700cdd49a92fc0000cd88b357d4671fb3ae896b881c20", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "5a332841-fdc3-4495-868b-c6cc5df1fcd5": {"doc_hash": "3ccc10e94dbc42f88d966b41f16c2d2ac0fa228107e812f53311b3f6f293c1eb", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "cb952270-1aff-42ab-875d-dcbc8b882736": {"doc_hash": "0a95642f6c3e6b47ee55ae73bd45e528e2fa0e41971fe6a13f2422fd07a4e5ea", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "a97e93d3-027e-4ba2-acce-be2a79657014": {"doc_hash": "def0fc9b63bfea2ed9b50f502fa89cb81d5bdc7e7a827513d63935f7f5b5b790", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "c6fa57f3-69c1-442e-b636-36ccf1a08904": {"doc_hash": "44d1ed5d2d366827e84bca7d92c2539c15ed297f51c20b70522a897f5cf3bed9", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "c7528849-0e07-4ba9-afd1-d2525d3fbae0": {"doc_hash": "9362791c1643570c797787099903a8e4826daf1ac4c853ee53ef12fd766981b3", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "088258af-f9c5-4c7c-97dd-242a7c60af78": {"doc_hash": "32349449d407ac8beb4fa493a82c1994776582ce0d3e58b89cbbfb795674e704", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "9030a6dd-34fe-455a-a4cb-5bff2554e42b": {"doc_hash": "073b3220fcedaf990bb13b5382b76f9739fbf855cbc2ae5b6d4be2d9d2f8d911", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "f459b2b6-c821-4c58-b0ea-d7012235d780": {"doc_hash": "9493479dc2eb24611d1f2e1c1bad882ce6b64739873f4f2469c4ff244d07ebfd", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "b92fb9e7-16ac-4215-a400-6990be756464": {"doc_hash": "0800c3dbcf098e629bb37fb87db31a4ee40b51e325236bf3e655ec37cfb17ec5", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "c61e903c-4521-4c84-9bb6-b8f448e39486": {"doc_hash": "f0b076ad8f1c90f00898e708860ab6c265accb24c9029a02ffb6e24a4148bdf3", "ref_doc_id": "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6"}, "5d5b0871-1381-42d9-bb3b-3798bc120c9f": {"doc_hash": "a51c426e16bea86a4fc94fdc2e3ca00cf888d30d45143c03588d5dc6872b53fc", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "5ef26e2c-dfa8-446e-8a63-7ce97f736875": {"doc_hash": "0590a4310e08abda5710c61de099bf34e4fb21905b00158fa80e3b2644da67af", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "19039780-9c53-4969-be1f-2beaef7f63c7": {"doc_hash": "a99aa55ed749d2ae41c67f354a6512a0367044ae8097f04eac6d5c4e16eb271a", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "aaf89700-0758-4d8f-b4ef-7efc7c86ebfe": {"doc_hash": "19be3f77ea176c466e81a4a997decab974debd02a551157c1a0a995f8137d7d6", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "098edc09-2a8e-4319-9b3f-5c0982accedf": {"doc_hash": "26fc2e8a59b52141d97b3bfbc0fa588b97c065d086b5daffdc44b386ad61e164", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "af03e13e-0ede-46ec-8fff-115ad15f7ab4": {"doc_hash": "a2573c2bcf662857f50171884de7adb8f3724db3f221df411a0327c632d97dc7", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "8c8c826d-0f4c-4f52-80ab-63b1dc76b872": {"doc_hash": "e558e81027776f6880403f5e60d8cf05ddb54d00b08a472798c004e5c404dacc", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "6bd52e18-a932-4fb1-8680-ab20ae00d598": {"doc_hash": "d582affcb2117643b540d9954c807d5dd7381bca5608ad56571fc417281dd655", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "a8c76627-6aa7-4662-b700-9a035ce97629": {"doc_hash": "fc25a83ad7f23e1d330c6bab51c0782bb9ae0a83a5fd527260cf4f136a2e0520", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "e882f0e4-298f-4598-b4c9-e19391b47e7c": {"doc_hash": "81707133c14263792fc33d57d325f11fe93d6f6d62253e4e6eead84cac1fb2d6", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "2036cfaa-6705-42fa-a3d1-3a9f00358e13": {"doc_hash": "46371b587800c3cad2d289d3369cfd9ab91ba6a4bf6421625dbd1ffe03c56a4b", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "0f1fc6e4-eb30-4bdf-af9e-45f97f6e14ff": {"doc_hash": "a4c060d6e2e8a61c15f50eb58b021f240047932d2328e95ac62926a654bb30e1", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "48814efd-6010-4515-aab6-d81642da92af": {"doc_hash": "76b243dc6ecee4788321660dc6f9fde4cc922c55a41403326dfd771515da891e", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "c4d7685d-2188-462b-aa6a-94e417648253": {"doc_hash": "5db5361135f66b16e20151bcd1a503e3d1473f062c1791fcd6d21d3fd4b4a602", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "9130aa79-47ee-4f84-a7eb-d30296815f69": {"doc_hash": "40d1694a80b18e9399c8ae4ad4f3b97e3ae0057afb8290cad95c93f4f4a82624", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "143bbc86-2e8f-4f42-9af3-b1001ac395b1": {"doc_hash": "bd721fb4c53a3addc775d0ec4df5eb335fa81f559e44470a1d768f2372c233d1", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "81d11cb7-2b78-491c-91ba-b61451f40a77": {"doc_hash": "a8a02995341d7e4032a3a93b50450556093091260c417779482c047364b7f23a", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "4f117879-6895-4f16-8878-b8b698754877": {"doc_hash": "237479ff0e0fb0ab38c93177f0cf5c3e114caf08e253ed5c037770172e95bd77", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "a9b2f28b-abf8-4fac-a679-0288295b588a": {"doc_hash": "7662b7a004f312e33d3e13fd26c59cfe09891392c72db66a87c55e20ee310742", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "15ef6ca7-914a-43a0-9c3a-9b2b0efb93a0": {"doc_hash": "7fe802a70f5f41ec1794fc3c167cf969c7422c2a2bc2a6a62fc139194d446189", "ref_doc_id": "00b77079-8f9c-4cfd-aff9-bf1e6907a273"}, "805fd641-3afb-40a3-9a4e-99f8a09a7120": {"doc_hash": "950fdc5709a2d76be39d33202cba2823118e9ec3430a7766d2b4cd1c06cf4297", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "03854e7f-446b-4071-a003-76c1ec07b820": {"doc_hash": "da85e44eb1b749ea4bcdd9eb70173aae8b1962c43e1b8b3d13ea43ea6e35b833", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "6740b4cc-e709-4858-baf5-196da7742213": {"doc_hash": "3f449b461cbe0d7da0aa299f2e39e73009a88ff01e98fc7951a17ff92a4575b0", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "48871490-f1ac-419f-9677-ea1d14e328cb": {"doc_hash": "26af5a92d66eb1cb19f197c979a974e520aada98e659b55f646c053e77f72625", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "ed650193-7112-4e11-83dd-9ca4b5cba20f": {"doc_hash": "260b1cfbff7145eb7aa2b99d2a0783cae99aedebb12094f8b20c92a8441b80be", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "9bc7cca7-dd98-4d3b-8d8e-70f7b58e98bb": {"doc_hash": "b717dc3ee1f5e58b8607e5b604d9fd16fe7a7eb9bc79f116c3a78e0e36361177", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "8dfb2a3b-6c2d-4fe4-ae13-22aacc571005": {"doc_hash": "4e62b8e7a79977b0aeee7aac7067ae9abb7d401835947bf298f97970c9808cbf", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "fd1f58b2-fc73-45d5-89a2-4cc4650092a8": {"doc_hash": "11406eb05c4ddcc372598a394063315cac520c54a3b2a1ff4becc4aa7c263a0a", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "968253e0-c3d4-465a-bc07-5995df65972d": {"doc_hash": "53e6a79556346541934a87b39993662bb43bc2a1a19d5dc68d95769db91745af", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "dc766f33-10b3-4466-b0fb-2c6db9d8b6cd": {"doc_hash": "92c398e9c4a48687139f1203700f6fd924138bc60924a62450c61b41e65addda", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "398cae81-4b01-46d7-ad0e-07661f85b7d9": {"doc_hash": "629eb89f9eb2b029b7083dcdfcfdc86d33f42b35babcd69dda8d4355e202eb45", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "b30a55b9-b546-4f31-989e-52f9030b8b72": {"doc_hash": "cc85e118017a3d2d96c643d87b19cee61f877789dcb57f26a76896453acb58fd", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "af4ec454-722e-4a6b-8629-c2a2008a2e10": {"doc_hash": "20e27c0be483d373a130b3994076cf940c9737b8df3083e6e68c98a060a2bf7a", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "65425950-8017-4de1-a501-5d1ab460c38d": {"doc_hash": "2b7d5b54832a8ac54abb2518d651755c8f3411b5d3f9eb46d1960290d6b9fd77", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "27efda1e-ec97-4c86-b5f2-65504ddcee4e": {"doc_hash": "bb51b4ea9053bc274ce0658f8d0852937f7a0f64837883bdcc6ec468b59f7592", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "7ec56a46-2688-4b2b-a684-b531b59f034c": {"doc_hash": "0bbf3ccf5c73657e0d61cec132d0ee0204624314d58aa8c9ca5f83ae84f11e12", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "c155191b-e34e-463b-9711-221e077f6136": {"doc_hash": "d1ca8c437a82e258f39972ce33ccb65de86d80560669633866b386a4a256bcb9", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "5ee7bbad-6d5e-4177-893b-be18e7df3db4": {"doc_hash": "e22bc3ab1a39cf9a91d915f3b70fd1349fdc81bfaf349a972b6008362ced9313", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "1ec9d3e0-63ad-497a-bcfe-cbcc780cb46a": {"doc_hash": "68291cb71a0de189bfcf624f55b06b417bedbd23479bc231a894c6ae689e3d32", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "fa45efb6-e593-4b7b-ba1e-41729bd2f3c2": {"doc_hash": "d9e76b6ebf062c9686ca9592376282cdc424d4d8e49e2143a2da6cc595f16592", "ref_doc_id": "953a8b99-2e10-49a2-a5a2-e16e44e9d92c"}, "b916a725-8134-40e6-91c2-33cc06c068bd": {"doc_hash": "3f001abafafa05723b84a8d4639bc01c8e10d10aa96006131c7ca4b714e7b0ad", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "a7bd5305-bc0d-4097-8a3f-ff1c357b3b2c": {"doc_hash": "96f6cf11de6b096c39ff84f6401097633737ec36515694eb92afc962d3631ed6", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "6f2bba4a-84a1-49a9-aef5-f6d95afc4a82": {"doc_hash": "bc4337f4360c6497a158572a95e327babad2c372240f2075e877f30652274c22", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "946eab80-65af-43e9-bfb5-a318cb5704f9": {"doc_hash": "35121394fc33c22a642a59910c42fcda9217c1f6c55bdc26db85062bc7d82262", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "1902d9df-3330-46e8-8916-6326d824e0d5": {"doc_hash": "acca37c8260cb4c54f2446616c9b02f783c4bc5ff31da670ef45ee1e220a1e5c", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "f7e106e6-a6ca-4d77-ada1-b4f3d0b47574": {"doc_hash": "a4641f83176e4daf1e69411640e2a13a2f070f11731ff21f8e68cb5f6e8ac9c2", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "c529f367-41e3-4c6e-9d64-b2fac6db2b41": {"doc_hash": "818ca9fb16d58cbdfe2e0f654ed4a7ac6a55abfd6e33965a3c5389dc032459a8", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "bbb52249-0be1-4d80-9d10-617d1fec82ba": {"doc_hash": "06589fff908ead80a335f92eb9aec268acf00a750fea2915d1c310181cff4e00", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "02f3551a-5139-44e3-8f90-d6d46febaeee": {"doc_hash": "517b5b20f8f51af47dd0d8fad8b6d2b37b1f762acb886b5d1b1d7a5ac1eaf18c", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "8e72e1f4-ce98-47cb-ae70-7e986423e13c": {"doc_hash": "ea67c30f15de156336900d79c1a1d4675dbb9fe2ec2ae8b5cdeaef8c3f6ac61e", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "0c1808e2-7339-434a-8c29-30fd2316ae68": {"doc_hash": "98425869cc1e13e7148a1e9ad2b599f5200fb5cb58baf17eb2f455db67fd4008", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "7dea01cf-2a43-441c-bcdc-5c806cf1406e": {"doc_hash": "e121920b4e06e337a10669fabcb9f1500a011cccf2bac84916e64bb9ab2efcd4", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "b5670436-b17b-4ba7-b7ec-58a2ec12ab04": {"doc_hash": "06b9a0b6068c139b87dad18fbc1179180be14482a3ff7b150d5bbe0246b22293", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "3034a288-b5bb-4f23-9bdf-31912a744aa5": {"doc_hash": "3d66f6a937baa662123782cbbabda615c6c2e595d4716337af383ee38d9f6407", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "1d8aae92-29ca-42af-8e7a-1ab06c752f9b": {"doc_hash": "336c5725b8fe28c2d6dd266e4afff5b0df0841565c3f43915dd4ceda3f9e73f2", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "3e76f5c0-c47e-4ad1-914b-4670cfde61e2": {"doc_hash": "f2b160870e39624f0c58ea1a56bc43008896e2856afd691be9421b28e63f75fd", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "cca75ae7-7613-42b6-b84a-a5d5b566b5ce": {"doc_hash": "b1f8ce72a556088a0cf637e42f21fc3e5e627eddd340d771aa296042fc19d16b", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "90b16756-7400-4b4d-abe7-d60722c5271a": {"doc_hash": "c09c443590635e17e12d2afcafcc705eb261b71894d478d45192d7438f3fe73d", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "d9c1107a-e48f-4129-a9d9-65520668d625": {"doc_hash": "98035ab6d48f5e408e7a19dc9e1ee545238bf7c981e40881d0482089d62fc8bd", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "64913e24-6bfc-4647-9f0a-acc9b700b9de": {"doc_hash": "8a1ade960808c627548efa2e358e8ec2889247430371aed4967bd8d11d81ac7a", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "3c71c78f-aba0-44e8-9208-b95b9b02f196": {"doc_hash": "a2f3bccd992937d16ea9c807ec6861b7a91d6e895d3a709461d1d56a73d74b4f", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "7c81d35a-e279-4af8-9cd4-6ae6944fabb1": {"doc_hash": "645f7a431594b6d1bb4407ed01bcbda8cf62f1c98a5fb184df3900ad94b92b2d", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "a2ac5d99-2e9a-4a16-abee-45e787ebbb54": {"doc_hash": "f8b7315b576dc74529b5a488720e9333b9595991df696e8856c9692f07f9b84d", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "ac6112e0-42ff-4955-8c0a-f3d0603bd502": {"doc_hash": "2b0c1a452541d8edbb905503e4cf02d276917d4ffe5a1c1a65bbdf3a85394dae", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "a732961e-41bd-40e4-8399-3551b76c28ee": {"doc_hash": "8413460e72b45d57aa10b7d6d31fb2c92218228e8c148849a69904263ed55074", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "1caa5c8e-91b0-49ea-8c48-820bd326332d": {"doc_hash": "fb4fdc9d67ebf0639c5242cd9692053b35aece26b79aaf54b2393e82aaec1b70", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "4528246c-dd70-45b0-b109-585b8140c97e": {"doc_hash": "225181fa762a94f216f8884b7d71fb7d467830b534ebca150a993d2804d81de3", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "143c878a-56de-4fde-818c-fdd44c7f34c7": {"doc_hash": "8fcb0b1de94114b1479c0a8f51659d5aba7fa3228aab035391c5db6ec5335424", "ref_doc_id": "e33350b6-8aa3-448f-955e-6a6438e22a26"}, "cb836f82-73c7-4286-8e97-3ce580ce8525": {"doc_hash": "ee6fae5d6cf4027e6261de927e8f13fb47834a6d482524d77de1593af544b1a0", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "29381fd4-fa02-462e-93bd-9137060829cb": {"doc_hash": "3d0997d2c3653e407701b0598dd6b716c407b7aa2db34193f5483aedf92cd46f", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "f25d762c-e5f5-4cb1-b2eb-af85fcfde042": {"doc_hash": "82051d381dc846b24202fe6ad8a4e654f0b9d49b72bf179e03460f47a99af313", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "25c85344-453c-44ff-b8f5-7ce54e870b98": {"doc_hash": "e15ef4893118dd157773c66870b9ed01731543024ae4c50d949f9c9b9686689e", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "75021f30-6f2f-48da-a59d-c3e239e6d358": {"doc_hash": "f72bb072fbf146435291f5510615d1ae8c35fc477618ce7d5b00a78bc184740f", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "e17446ba-e4aa-4471-9e9d-d3608b1b4d26": {"doc_hash": "2791d77c5c5c5f5f4f5a4bcc4cb27ef7a092db0362e6622cbec53b3b637bce06", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "dad71223-f4b5-463b-a376-77578cd379ab": {"doc_hash": "51ee915e48789929e2e5153814234845a26e17110bf9622d482811314bc0d427", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "fb75b24f-2ff6-40ee-820f-05d075823b09": {"doc_hash": "52e72856cb795d8ab7cd9badef19c835eb61bf49bdc0f026d0eca37b581753e4", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "63916d07-4f71-4c21-af2b-611aef96bb74": {"doc_hash": "f30ac6496083e34ceb34ae5641e9834733e799fd1b05cf92ba802f1eb0f1c086", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "cb073199-b3e0-4c0b-942e-dd3a6523f76e": {"doc_hash": "bd78bfaa1e1c358feca52c6ea6402d3895c6ec45de2ffa8fe34601c5bf6bcaae", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "4c75773c-0504-47d2-b3f9-08b9b95eae83": {"doc_hash": "44c64cd16f735c8aba90cd64428f6d1045d7dc12bdb7feef2f4ce5e62ade9ea5", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "4d9c87b5-c40a-4078-b10d-9b93a5a63d8b": {"doc_hash": "82be0784ca097d58290f4a0c64c142321978f6d5651127478bbb935cb8e4ab16", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "0f876901-8e79-4eab-b86e-f3abc3084841": {"doc_hash": "fd3fbac48efc6c4916ba22d5539f951a71b827fb0e7f9b057499d61787211edc", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "35181e82-92f8-453a-b6e1-93e271e7a272": {"doc_hash": "65c37bf13aaea8d242ef9c8db582cea685d3b4bc71bac6f133a1823c9225be2a", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "bb038b25-429f-493f-8cb9-bbebbf5a7400": {"doc_hash": "ec32056c8c198f07df6ec2467a3cd48bc83da437e8243642a786e86c5b97f606", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "788c3ec8-ead7-4979-86d0-d34c4d020514": {"doc_hash": "82a0ef3beba38979fa8cbfafb5c607850d9c53d0a24078d06029a5899563e908", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "5c75d95b-50f3-498d-a31a-518b212e29d5": {"doc_hash": "3ee4330c0df34fdcabef1128d9142c4190cbd80f1b0f59f41a62c33c7efce897", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "2087861a-3354-48f6-9fa1-e387d417880f": {"doc_hash": "66f98b447de48f10085f9e1e18c7ce6624d273f8165e5fc104795e692ae0a980", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "70f3b0b0-3789-4054-b702-9ac7e6e3698c": {"doc_hash": "f5c5801440be9096534653ee3074a2dfabb81b94fe940eedfd42a3932bc472a6", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "66a87917-5548-406d-bd90-701c7b01cecf": {"doc_hash": "c23524b3be3e4bf7c63765b123c0550640eac924cabd58ece4b73c89316cc62a", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "770b16e3-0c20-4901-84b2-6f81594c54aa": {"doc_hash": "754befae91ed01d65cca05933494a3add0e69fa23324ed917717020f9fb9dce9", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "ee7db4a2-d7d0-42f2-bc69-4197b1dc42f1": {"doc_hash": "fd0e610f03bcff025f7292631b3d88f9fdab37dfcdff6c26115cdf0a92e1567f", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "8bb6c6e0-5622-4f39-ab27-4437d1b1c73d": {"doc_hash": "a0a117394b4dabcc0f4a322c7256cd0729724eed7f214160b152504f87ac29ec", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "29f50929-33cd-474f-b86f-04106c7d9474": {"doc_hash": "097c461a898e6e67919471f1ee5291d94e2bb8e1266773cc172995adf0354183", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "c37d9601-c818-4b7b-b600-2033ec09c8e1": {"doc_hash": "6700d6c3e3096388999c739fa4ba021f9b05c6a0cd1df4775aa58d1a2b2bd757", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "91b27834-1006-4c92-a4c0-01005ce4ece9": {"doc_hash": "3db1dceea7e9a8a5dded247b0cdeb93ab635039eb9985b4221417fed63dc52a7", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "0c96feea-06e9-426f-a279-b4446eef1838": {"doc_hash": "66e53acda0b49073afdf1ba55a5b175cc006989ddfa65b49e287b10e7e4a4e97", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "0ae41ae8-9cae-4eaf-acd6-b4a1badb2314": {"doc_hash": "3084dc67d8913bec75e08abafae701d70fae04af265b67ba2d966ba955cca17a", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "81fe9f6d-d2f5-47e9-a2bb-edb03385e2fe": {"doc_hash": "6b8f63f0d4627838d74368c8586f06b5550dc0e8e8153e33de40f0ea1abaf1e0", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "c3520cc9-17c7-4567-b2c1-90b3ea667e8e": {"doc_hash": "98e1e8517fccc32e830dfd317de4c6fcb17edb53158198abe27e5dc84d313e4a", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "031c19dc-af7d-4226-a0df-154c420e82d1": {"doc_hash": "6fe0e522e75d93d53a76ad9ebd5adaf75126e92c025e082aeffb42e54b8d8a39", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "cbe85cc5-2630-42b9-b264-bed37920317f": {"doc_hash": "b2a096d2aa50358035375aa7cfc22a44417d0479d600b1f249d617c997303022", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "c54d3117-4d14-4e1f-9277-f41ec67eb09c": {"doc_hash": "ead0181ae4a046e06efd446b4f533fba5961088f3f150f80b897a09e7cd06137", "ref_doc_id": "01583edb-346a-409d-a686-087dac013a41"}, "95725823-483d-4bdb-8ce9-b135facb2c44": {"doc_hash": "39a4286105e2d164a50cc3b45dd3c979b31e5374f73d3f98ffb4ccea59b8fcdc", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "ab4f640d-2960-4275-8170-148700dcb587": {"doc_hash": "20cb025c751b4355283ae0fc08d5f9d2acd521f527583c30dd69fb9234fa38c9", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "0cfc0f7f-7f4f-4816-b60b-a8afd3c02237": {"doc_hash": "b7ee6e3ed0d15f4ab88d3e8e326dc793c46ea13818f3c9d90a5d06f8bbd2bb66", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "29c89711-2bdd-45a7-8cc6-99371d256f5d": {"doc_hash": "5d48141dbbc7f6b75309c8d3fdfe928169834dba080ee8c48fc10ea9fe79cd96", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "d90aa712-614a-42f7-b68e-fdc44ebb3cda": {"doc_hash": "4addfa067e9932d68ff63e721703cd2dea5f4da87378414dbc574b6d05a1ffef", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "5a32abfc-d5dc-4d35-a269-434ec3052075": {"doc_hash": "e1f3b1da96276bf17f365b53fffea02f9592db425518a32bbafdb6013ed5b08c", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "d31b2b25-c58e-4026-b4b5-83834a74734c": {"doc_hash": "15161c81d981bb10338d55305a8c103908294dfbf15b51b1ac122af079b9c911", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "1d51b350-a222-4d5b-ba6c-efd0b1d357df": {"doc_hash": "98628b3f17a56b7447f627d60a6df56655fa348c02e555338328ac57594cfeb3", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "92eb9d0c-1318-4bfd-97a5-a17bfa6825ee": {"doc_hash": "897f148a1c781daff1b447cdaf59a77a816eb23a89f9b776eefeb9f315aae2a6", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "f624bdeb-13a9-4183-9f0d-d95f045621f1": {"doc_hash": "1c3d5bf04cbeb896154e75f82a9613530aae4a3de5da8127f053532d506f2638", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "92de5baa-297c-4f1e-ba84-26a199c37ab9": {"doc_hash": "97e739c40a06f69b949fa1bdf868721961e9d011de28ee1f75d7d3f3e47bc73e", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "d57673fc-cd17-472f-964a-3731f201b098": {"doc_hash": "4970b95c0c5588bb890c20e7aa0461f78f813fab92aa88b65fa08c00c441154f", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "e7383b0c-bded-4a4b-8844-76f07015d858": {"doc_hash": "82df26061bba6aa16c8a373b02b5daa53c484e50f4bcad72db5a136d9b42a35a", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "2a360186-4bfd-4445-8e1b-7cfeeab56a36": {"doc_hash": "23e770229e6e265816c30601774d0ac2f90e8cfe90b8934539810d9eb541ec3c", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "836d243b-23c5-4ee1-a013-f492a06dc7e1": {"doc_hash": "a42fd83fd9618e80144592b8945d60d37d50f14013c5f53e46ed4cfab34f3eeb", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "99f46372-fcfa-4d83-981f-5e2a12144460": {"doc_hash": "38e306f663b7a84b87067aa57d003d7f925592d94f3bb415295057b6bf6d36a9", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "560c9c98-2967-47ea-8d2f-3f9c98a1f2e4": {"doc_hash": "66f803470e78efe859d04e636e7d484907655b9e9adb76b074294bbff9d79563", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "f615bc8f-e36a-4b1b-9cb3-9aaf48b229d3": {"doc_hash": "d3528425b6dc0aa6fffc79e8b11514c3731662aa8f07d7af910352ec1bbbda49", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "eb96e5e5-0f20-4481-bfea-0d78021d3bb7": {"doc_hash": "ab2a4f13b91de0d8a51501d3da7bedec1d3a8349491584d980c7456050f46b8e", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "f8d496c9-512d-4c86-917e-b1cefe8fcd17": {"doc_hash": "287af90826085592d371aa4b0d783f5bd1949eb83f9b04de64041c2fd8642584", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "8edd8373-aff7-4f35-abae-2fb2c0ca526b": {"doc_hash": "a482d3b2709a4e8e57169f62d0429e0eb51b0281bad9b4d7c3c2362caec32a38", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "5bf40960-8a68-4120-ba36-082610aff97e": {"doc_hash": "2fdac918d8d8746577c63d3ffbaacc5ad0cdda5d1289166ddc64c60b326de56d", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "d504e6fc-afec-4b95-a389-2607c5a637b7": {"doc_hash": "e422e7b049aeb8db899422ccd9055315b4e4edd42e222db5f18f5e8e5b7f7523", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "5bb7aea5-73f2-4671-a153-f286b604f717": {"doc_hash": "69a22d1d75e02b21991caee27c67616f094729421a7f5456ee9213062e3a83c8", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "41c204bf-351a-4738-88b9-3f6d5316245a": {"doc_hash": "852e462a4d5d3c991c1f3f9fb386af2bbe63709fde2fc3aad5e59098d525ff67", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "35a0dd58-3d03-4af0-9b8d-6de23dbd7221": {"doc_hash": "834648cb435b063af219bfc8cfec875e158e54151e8c67888967cf2aec01c878", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "79326658-365b-4fa6-aa77-c7eaba75b05f": {"doc_hash": "ecdb065eeb0fba9732237ee9bce1683c8985bd48ed210da1ff7d4aa4a8dc4175", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "fc26469e-f2dc-4fe5-af0a-09d4ed8134fc": {"doc_hash": "49265152da3295767354930d5d21cef5ccbd131931815f0f2c20251c78b3b5bd", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "1920b398-a5fc-4af5-9dcb-afdc838d51c6": {"doc_hash": "397b5fcbc2a8dc10cf3d2e75aa9473148f5b59c153351f0d5ea548660d0a8537", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "c4ae37a3-774f-4d5f-8b10-33988e478514": {"doc_hash": "576186d8835d2cd5a75a99dbdf7671db5b6fbeb05d587eb4ba1bb1f7461520cb", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "b1923768-9a59-457c-9603-ed6ff58f70ab": {"doc_hash": "fb477a74a3f07b92900c90102aa6d15ae98736e6a5599b0aaac8bbf57b9c5e89", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "4877284b-e3f8-46fc-bdf3-fc36ea888e20": {"doc_hash": "c29e3628a9a98e86ab5ad2d3e7ef31c0e2343c2cbae488a24182ed07a923b538", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "cdcecb0e-7f8d-4c1c-8d09-4f41dd4c51e8": {"doc_hash": "fffef5e27c3647529298bc71245e5e458d28c41b1aab00be23cfa183db66fbf3", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "c224a566-a66e-4796-ba55-4119114dfc7f": {"doc_hash": "da50c87d743ff0d1ae20541775c6806038402450e625764eeca7263db593d7c8", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "38fc554d-c3ab-4bcb-9aef-07fe134c8090": {"doc_hash": "4091e17fe48064e575a582781cbc18e0beac891afd2aab9897858daca4daaa7e", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "7d23fe7e-f5f1-4b7e-b08e-ae1a7b905468": {"doc_hash": "98b427d1c1f532643939bc700f2024d714a0ee5061dfd2e6555f7b855b0ad258", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "9d9f3de0-45fc-4963-a04a-ba7103dab56f": {"doc_hash": "004e1e01e4244ef384eb936bbd33d9db668612bfb7b81dfedb80d349deae1cb4", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "a67a2851-2e10-498f-ae37-c27d453328cb": {"doc_hash": "0ccacfdf3eb933ea08db15406519c9b14b1daebfd0f0db763d5b60ed7167ad6a", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "218bd519-7b29-4b99-9e97-32054231024a": {"doc_hash": "0ba6692da297c3ccf1e4cba0a5efccf5838bdcd38a6bc582ee4b417538c815dc", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "04fdfc4e-1e99-4fb0-929d-00aa359fefff": {"doc_hash": "e8a2277e46760ef4523b3de0d4ecc6340a5606c39fa437f7a43833edd7847ab3", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "1f519fa9-130d-4cbf-80bc-6b6a086e8cca": {"doc_hash": "52450f4bd9a657fe4e468cd0cf043d88b5c3ed17c78e2be251eb036d2e96196b", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "f7cd5573-c078-4d18-be27-45c557cdc035": {"doc_hash": "fd36187697ba85a5d8992558053ba7b93c007325fbbd9150e626f3d15eb34ed5", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "e32f9cf4-7188-4a9f-83a7-f7f7e7cae33d": {"doc_hash": "0ee7ff5b4991713b67fc7c2ebb8c483232e94fbfcdc75f9636c5a66233ffcc73", "ref_doc_id": "e6fc492b-f2a4-4441-ba20-b3ba39d8155a"}, "13bbffca-f782-4613-b272-15f165a262c2": {"doc_hash": "f19fb6344c39c124493587713d71b1d1656817b487479116534bdec1adf0b91a", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "2d0cbfbd-8086-4b6c-8735-81e3533563bf": {"doc_hash": "ddf2742fb921602535a7a52b3324edfdf5cbfd42ff0c2b65a07d94f6309b3c95", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "e8660d11-1316-46b5-b063-92bc449ec6de": {"doc_hash": "bdf6cb348642f1aeadd6926b89489cea89c4fdcf7375cf25a32b739f51993333", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "573bf3e0-dde3-4ea2-84ec-229d12f45cb8": {"doc_hash": "21ce0f2a7430e33c89dc5c4ebfdfd6618d9348097fb0d41b73c36c4d057615e2", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "626be553-4f98-4868-bf70-0d4de2b2d9b4": {"doc_hash": "ed37ce9b4a1fc0f29b5c05ed10a5b2f9304969875e715da9293d757df5665a25", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "52ac8821-89e8-480e-b012-ba2d29e61cd0": {"doc_hash": "84ee075606ea79889e66b9122b3a929a8fcddc700464d12f3b6c99c2b00e20af", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "5cf607b0-5afc-4c12-8b5c-e030d8b3650e": {"doc_hash": "6ebf3defaeb41602b5176ffda255eb8d42bc248e36936009632954ed01d92767", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "4acdf9ef-beaf-4933-95f0-6a9479fb91eb": {"doc_hash": "0155d9b5f8de170cf74385376aa1ab56401317d25ce2b01021cb273692b3a79e", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "42428262-0b13-4887-acfb-f81e4afa83a0": {"doc_hash": "19d3ecf75fe409f82c17bcfa200cb8b25ed9dd961045e3dd63f242ccaef09995", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "8e3b1cbb-bdcf-4c09-953e-0952ed966cbb": {"doc_hash": "8c8d2c9975a6168598e642267b9d2117c49ef7e316ba75137e67da63ea27142f", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "bc2ec5e2-ffca-415c-b952-7fddeee1978e": {"doc_hash": "de23a21b6901f87f43ab0ddd5f5ebbfd3174db32cfcd5324bc9f56bb28edf5e2", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "89e2e0a1-eefa-4595-aa7e-12967894231d": {"doc_hash": "c0513c6de138c0bf2064160b6568a952489d4bc7d22a6cd1204d4fbca8dcb8b3", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "d864c245-3523-4a9b-a0c4-928b75ed6df0": {"doc_hash": "e8825e4b79fb56925fe1e47f9641316590d7e422bac8c2463aa63ae1bf27c78c", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "2ea0f370-dbfd-4a88-959a-aac5692e17ab": {"doc_hash": "70c5ec95a78a1f8d40062c123903a2d54d70af384f311f378825cde4f3af5108", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "bce920e7-5091-4850-acc4-bb80ac85bd49": {"doc_hash": "8a3ba0568595ae36bc9ebdd9b85dc8004cb1e7d00fcdcd5a20aefb4ad0d05ab2", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "e5f8f4ad-1bbc-4357-b9ce-5bd98a789c38": {"doc_hash": "782cea00c0e736445f900ffb908245e036f27412d0c202177820f1579252b300", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "e28686ac-90e7-4092-a296-6f1d63e2c8b0": {"doc_hash": "ae87225e7997ec96b54c4677735c3393e7e759266852f3d15075c8105d859251", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "697b2d87-1d8c-43be-905d-469d3e14ed0e": {"doc_hash": "a44e0e981772e06733093f861a3f80c5396dda654415e58defb24e6c4b22d1d0", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "4cd24739-0d00-47dc-96d3-ffb77d8fb0d7": {"doc_hash": "926cc064e4eefe485edf885d00718f34b93fdd47901a3a5a01f9b233c7b60243", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "1f5dd86f-09a7-4b8c-ab94-757d73214e36": {"doc_hash": "e9939e716baf1df663ec2f2933c5aef4c07059b436e4c7c17176499ef3642dba", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "109494d9-df05-432f-a6b4-80c60a5dc6c7": {"doc_hash": "ced328c6211f3672a439e9f664d35ed48f56f5f1da95d63b3443fa3d8a3abc3e", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "92508790-8fd2-42da-a6f2-9461774cc0c9": {"doc_hash": "9bc2d0adbc59fa27257b503f0ccf3201621dac879a761454bb2c37f209ae6cf6", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "fc802df5-cd78-498a-918d-3b3c66a672eb": {"doc_hash": "2446d010d55689f1b84f77e05199f238c64e6636d8bba7c2ad2c1997c1b821ce", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "683bf2e4-6d1c-458a-a160-8625a85e9c97": {"doc_hash": "54893ef8952bccfbfac5434665ca4b4fcf8fd7136eb8218f7b05e36a593600c2", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "39b79ea0-8599-45a2-a4bd-e62f73b1085e": {"doc_hash": "276fb29e77ed71b1fe991e59b61e12d2495ff2ad72018bf152b4f5c650d3baef", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "27e8d5f7-68d7-4e8e-b24a-2fc2a19781bb": {"doc_hash": "87b9a8c55810115c72824421d2870d0eca438c216f056e16367b2cf543e549b7", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "d0875887-4216-4d1b-be22-81a0a682fbba": {"doc_hash": "26c7113e3f8ff3d7a2939ff2640fd538bf296f48b5658d21615a6391fbe8970b", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "6a197c5e-0527-44a2-a5e4-2a89aaa8a77e": {"doc_hash": "43544d3b8c1692ee5aa982611fcfb5fc18cab04f56a190178e6733b321526499", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "5bef89e9-c379-440d-b1a6-901a1d4d5b7a": {"doc_hash": "11ece3788a93b29931fbbe5057377b66cdb85216938cb4bdbb8c0663e5b9635f", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "91a92ae1-c263-4000-a764-0926371d3acf": {"doc_hash": "e306e6a23b9f60f70d25d8123c41d3751fa5700f54c4733fd45bb09a22f14d39", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "464e7a1f-f878-47cd-b687-b00e389df704": {"doc_hash": "6d83e1147b3d1b6fb082423ca1968b684977f194c6f5d3560bdbe4340b38cb0f", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "9bbb1591-33e3-4174-af32-c6b95ed94060": {"doc_hash": "9ac218222348da4b3708ac8152e123422567f895f2b63011594e5d4e8a814c7b", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "d28b38e7-634d-41b0-a7e1-fb02f042cc86": {"doc_hash": "747899151714f71ea6abd6fc38d0bacaa9a93f6dad77f21c992f8ebd18da6e26", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "866bc74b-9ea1-4b9a-879f-dae7a09e3a7d": {"doc_hash": "28215d6abef02dd1c477adcfb16e5c38f0f291ce14b1a5bba9c224aac80566d9", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "ed998c70-c941-42fe-9a4c-315b40566bab": {"doc_hash": "57bf3b36adadc99cdd6e6e0bfd9020c861e8290b608e3fd34a87d81e3098c629", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "893cdb52-1c1e-4d71-a7aa-2a5351b19d8b": {"doc_hash": "6e41b23645d0637c69e487c891397214b412a85f4151e84a2f0039bdcb128424", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "a0eebf09-e039-4573-8f02-7dba1cfd2506": {"doc_hash": "4332ce2716384d863ac5e61c87c285c8e25d8d5b0440d06c9b96ffb49e275df7", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "420f1933-30ae-4fda-a9c3-b07269df076d": {"doc_hash": "d24e8c0a4e1770eab98675e3786ed1b0c5c37d12211f5ed9f93e96e134892bbc", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "fe6b9d4c-42c5-4b3d-b78b-56e45d006721": {"doc_hash": "22027d9c3897e7c30dadfdec61221303bd3ac3f3bf03514b34b591787d1611e0", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "42a29fa6-8494-4b25-bbac-142e536340d0": {"doc_hash": "2321f8f7bcef1da362235e28b6fd851aa22a8afaaaa97959619292cbb632b378", "ref_doc_id": "02eef37d-46f9-4e4a-9e63-5e153c088023"}, "1ef75655-e58f-46c2-a921-1d4c7e7d62fc": {"doc_hash": "b191fb72fe34db273cf55e2b9fbc5adee5297f13fdcf6f5b08da78c6e35d4063", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "a4912abf-43d2-4468-bf8f-7528a9fb73aa": {"doc_hash": "76b9e5f0fb0973e194457fccb9bd1855a5538ac895a52fc70e26fd0616d4bb8c", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "adaa0c8d-059a-4172-9b84-4e42f2bd9213": {"doc_hash": "ed4445db737825702256396768656cc348d8f7847a0df211988ed3e7e47c882a", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "ab5e5078-d6cc-4700-85b0-af13c0ee4099": {"doc_hash": "bc1dcd64f3f96c4e2911c25f81cff6b4063a346e75f05d358c9bd65e9d17361e", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "819a55da-168f-48cb-a532-6385a394e584": {"doc_hash": "4f746175f7214081197dad8bd7d611fab611106969924669f54f88f8fb139b20", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "121bb126-471a-4977-a468-d092b684921a": {"doc_hash": "d3c0f89614b2110b94220284bcff361a1825688a702f795a2f28d24d82fd58bc", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "8eb2342a-b24e-4fee-b975-ae8f88edac23": {"doc_hash": "ff32972f90914e2cd307b9464e970feae07ccd75b69fbef33cdab6a0c56c9096", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "26e1da9f-8530-46e1-a452-501b338827dc": {"doc_hash": "b5ea011c5a01a346b22dd2eb47dbd15e2e56185dc2cae8b255bf34a06d2efe57", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "6102cce4-fbc5-493c-b817-d6fe372caf79": {"doc_hash": "b6f66883fb68fdbc0a0dbfb12473ecf7fa6e1cf1d6fb8cb429d4526525d73114", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "bd0a8936-dd8e-4002-80a0-8ac12ed192b2": {"doc_hash": "56472f51fe426d96c36975124e566fcdb22590e5d996cca5c3ef93652c14f168", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "ca9b8e99-c2bc-4d8b-a220-47454303a5a5": {"doc_hash": "ec620949d25620956c21fc1828d598e1ef065e40b95da4ee2f6d99835681fe51", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "228820e3-504e-4309-adab-5b65b4daeda1": {"doc_hash": "e1c34cd0781ee9da5839da12a0d1f77499487f81b9b56fdc27af8f0a0c8888c0", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "4dfe9482-6bdf-4a75-b741-07b44eb3a273": {"doc_hash": "4596933e674dd51f7a0ebc32a07536090daa20f7cfadd755d23b66cfa87163d8", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "9a4d36a5-5942-4813-a025-0bb1a1c0e1c3": {"doc_hash": "50bb9c4c842b18149c4f09b45cbd03380ed6827193cf9f4d8bff61978ca760c7", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "b850561e-f5c1-4344-999f-c58069f298c8": {"doc_hash": "91f3dbea40b355a99c20e91c74851708e8648b3dadba199f35446cdedc3f4c6f", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "72384c7b-b67f-41f8-baab-c645dc1f6fe1": {"doc_hash": "c65ce777ac102852364c9bddd288f6212ca010720122cbab85ccb918c51a8a73", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "87a8bd40-8b8d-42cb-b394-1626ac5719db": {"doc_hash": "c0584ddcc7440a82feddba75107c68476143126336c836b057218c6d2af474fa", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "91e11346-4844-46c1-bcd1-5e2d53fa4342": {"doc_hash": "6e694416f157b0ae9f15decf0195a4ed203679828b8c4ab321a0c63ab47bf66c", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "1f704365-2a0e-42ab-864c-70536fb2b441": {"doc_hash": "2ae3c6e28611e1e87d95c80bd79bd4ab15357682fc9940cbb37224b253850b4b", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "facfe395-f03e-4962-be64-f578fe99cea9": {"doc_hash": "a25b11c796efbf5c145dcb1293bc929d59d3a8a95b8c73cd8940c79badcb339c", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "0e20c546-9fb6-4b86-979c-7bc0e3ff6ef6": {"doc_hash": "4bca67dae598de1fedcfb4aac25b264b0b0586bef29ba51d30b9bede54475565", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "ead3158e-9623-4000-9ac4-2b38e4395485": {"doc_hash": "c5796366b697969ed878f0537c080704c45046b0953deffb09651425f17f73aa", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "38d82277-144e-4aeb-8eaa-4d76f64fa31f": {"doc_hash": "e947ad3a29fdf90f0b128503739fa67364b244bafdff3efea8e4c7b0897595d3", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "4964759b-47d6-4d85-8f15-58a420b40b85": {"doc_hash": "488a2bd4ac260086bd2cc92edd822ac8c2147713109e9dc06cbb41e13013aa5e", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "6937cd3f-9e96-455c-b274-880c6ddddb76": {"doc_hash": "79ee3adbc4ac75acfc7880787b5a0d41aa63922d511695641ed0c731b155dc48", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "55b01a16-3fde-44d6-ad4f-caf51ecf526b": {"doc_hash": "fe38a787a328ffff3292285402b6cfbbbdd59e31211f2019077589ced5c3fac6", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "78725f1f-cfc8-41e1-b1dc-0177979f3a8c": {"doc_hash": "51f2025d8c9f25151ebc342c4208e7a08019414a30e44a3a0c37ab811fbe8d88", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "05af221e-ba6a-42eb-8600-339275a7de8e": {"doc_hash": "8a63fd894b2774f1154bcc18771aafbd0954c5a369372eb311a27182f74407f5", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "140b202e-c88d-4424-9ef3-d75c03a024f6": {"doc_hash": "72ab30ddc9d7c805cce63bd77171017ebbd5d8128c48bd538e465f13a1f383cb", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "292b6a48-a2a9-4296-a3a1-4a34aa7bf7ce": {"doc_hash": "45f71dcc8d01eaa6f1d4dbd2aa782a6b3d111203b2a156f1db89c480b4fca2a7", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "b9df4904-afbd-4a73-bdc9-6e57eb30e4ca": {"doc_hash": "cbc61ff6415795953c91fa32ccb4e35feaa860cec341628c920df5a553c915bc", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "68ae2dc9-ec5e-4407-9134-32fe44367431": {"doc_hash": "6ced9e3ad2870b7e87f728a5f184f267f5a4dc388589d5fe794eb127895d1e17", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "0927c8bf-8690-4ec5-ac6a-9f7c82885496": {"doc_hash": "7e39bf26316e28ca65c067061476b30a067098ec8b27023335f2ad8c2ef1e109", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "659da11a-ed42-4dd6-a6b6-27de2f325073": {"doc_hash": "6e5ed0eab205a410f205cfdf2b8401af41ad525f0e0b02a4edba0cb535bcc485", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "9cab3a7a-f3cf-4826-922c-72d5aad7c399": {"doc_hash": "9404fda62362d33e0853ff122e96f5132ab2764eccc60ea346a1401bd122b56e", "ref_doc_id": "66bd28c2-de8d-4ecb-9440-8f4568c07071"}, "80fd47aa-7ac8-4012-86a9-e68a9f063625": {"doc_hash": "63c88d1bcc82dfca32ac435b0949239d3d6f1286d86eea59df2776364df1d18e", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "2e2b3339-2ef8-4ada-80b7-8420ade71761": {"doc_hash": "b70fd6727701607b4f4c0255db617e478d6967da2054d89204ea1d95d3276b61", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "84394342-156c-4fa4-a783-d6ef5ee2c918": {"doc_hash": "ba992da4d4c39ee2db96941391958add50d57fedb914d6ae543a66917f4f0a91", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "ae7e472c-f622-4e54-af91-aa72328563d8": {"doc_hash": "376629a670c31b5e6cf57d3d0565caadc5c92fc69eb1ac10a571638da3f89661", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "51cb00ee-8d5d-4061-a395-4d84a9354f9b": {"doc_hash": "0d68870ce7d3c6d15d96147b6c723feac42e4a11a2e0ddac5c1c5da28030bee3", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "5c29f224-fb22-45f5-9e2a-595b356c6805": {"doc_hash": "19f399c250b92b5eea6f3c2ce29208cbbf6a5695ad88cb0444ffbc55533d50bb", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "0a17b9e4-c6c1-4b83-a025-8c1f5dd8d1ee": {"doc_hash": "d940d3ab5329edd47b6368fc5fc053aa4451f8b184007214f5f44c48321b8f51", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "86a85b95-9236-49bb-8cec-f9266b3be8d3": {"doc_hash": "1d7b9a2ebad85bf7888bf442a364eb1b60d5c2ec1c4e16b1e1db63a03086fe15", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "ad78af9c-3a1c-4068-ad65-f3ee294fb85a": {"doc_hash": "0f979e9c6f025d6831c1531e7cb40d27a5d68a7d37d7de333afc1086f305d636", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "22591419-6fcd-47b5-8378-983ceb0d11d0": {"doc_hash": "515604d1b2535851b62b25ebe758b89d3d03a58a57ddfecc2b49ad817886aaec", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "d175cae6-5708-4572-9cab-830de5a97824": {"doc_hash": "04cf8636e58a36d8f00021120962c677f4ad66e9ae9b40e8e4a37b6a8b0d5e7c", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "2c4d869e-3f29-48b0-9c09-682c27a8376f": {"doc_hash": "feb881d6debb359bb9c9221324de75aa9268d919f731b33ba2503d72c823a22a", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "fedbec4b-8b92-4cc5-8ac7-c9d518e1eaf8": {"doc_hash": "f537d417bab754e2d786ffa8b9bfb3d8e496cebba60d0fcb5bd82756f465ab9d", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "05e08d03-8634-4e61-ba2f-e3e4f98e034b": {"doc_hash": "56d74d19aded23c83af30b1bf831172e29d75764b79a67c117c2aefeb9ed8a53", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "463ffaee-6f01-4568-a447-208f58e1550b": {"doc_hash": "57b04a2939606bea91790fbb4853faa4487c7aa4ef58b43f565318b7cccaf942", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "65f66956-df5f-423c-9d53-6870108f9209": {"doc_hash": "a05d4b48cc5b839d10b4793c94881cbdc65a673ee0cabb3a020f9ca9aa02ed34", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "f9a105fc-d385-4975-9b4f-8307f0b038a3": {"doc_hash": "28b4a6a4494cb3c4e141fffa8b301cc8018d211ff1039415f24977fccd707dde", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "95800ef0-d8b7-46d1-963f-306c4bd1ecae": {"doc_hash": "2500214e35c1a68a1a37556d12cd89521b8bb9616a73946ec6eee43614e1d239", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "aef20ec3-824c-4afe-8712-c08b1dc8e00b": {"doc_hash": "ebe97744773541bfea43d57c80cae42035be9e8d3f0cd45394ca91ef9892a9cf", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "009b2f3f-3f85-4221-9491-9cc80abfd0e1": {"doc_hash": "f87675da28034aa02d47101e93ce4a9d83e0e9721dbeca769467aae18267f0e2", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "0c30cbd3-ae2f-496a-9810-bfe161534b21": {"doc_hash": "0111ada341a15f439c8bda15cf542339aed308ac91d2cdf8ae636de5893b5ab6", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "ecb3850a-9bb0-4f97-97bf-b404317a52cd": {"doc_hash": "826a5257906cc5417fd8ce4f0a97630b9fe6082cbba38149bbe54a578786f1e1", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "3c1e38b6-2901-4102-812d-fb513e8c774e": {"doc_hash": "0b563804be2d72a98d65bd9f4bc676a5c723f72b3ae268b7cfe6e8c765036717", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "6fd0fd0a-680f-4561-a75c-94fd97387600": {"doc_hash": "42e805f8289192e010308a537a7177ae18aed9060fb7397110a5ee86a4ce9c40", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "78df9892-ccd5-4f40-a6d8-33962ae73480": {"doc_hash": "0579819ada257e23513c062b858533665c0342c17e245e97e46c51a6cf0fa689", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "dd3eda59-451f-431d-bdc3-2dc65997ae7d": {"doc_hash": "9e87af89b4d60a91eea1ae0e7acc29eea1187409d6a370653fb9f4f2931add4c", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "8eec68a8-3307-4aa2-b2a8-57ecdcdcb1da": {"doc_hash": "47818cc7e527b60f4ea601980806234e5279333df55543ab726bfe890404b2c5", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "25af6b8d-fc86-4b87-9e46-66d0959789b2": {"doc_hash": "0a04baeeda5f843976fc31e183ef14d99c87b183155f282f507b38376153c3a2", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "32569c4f-69cd-45ad-93c3-5a0080b42beb": {"doc_hash": "ec45e1f4e73067c91b24817f86a8a9144cc7d8555e6213ed99815b4328c5787f", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "5ab1abf1-8bc3-46d0-beb5-acebd66abf4e": {"doc_hash": "521326731e5b385a259b71d6367fdde25c5713fd7f1d1f2f1eeb0cb6a3c1149c", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "c827dc0d-d5a8-40f1-974e-b8058f909484": {"doc_hash": "f9caaa5f7f49de0715b236e84a03b0d433efc13baa57b316570f4a238ea3192e", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "f3576421-06df-4c4c-9901-5b818daf5865": {"doc_hash": "48dcfcfb2a0acfa9ab41318166c5979373323f91a30c86eb71fa3a05e54d7770", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "79da06eb-0237-48c2-a6d4-bf9462347d9e": {"doc_hash": "999ee495aa03ee91e7a377938d39b2f6a06b78da215f4df6fb35aa23417c4721", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "1019c2f8-3773-45d9-b0c7-f955ad5b9bc6": {"doc_hash": "c19853507fc117eaf240c19f06931c6a83da5d70b7caf1a5a2bbad625151856d", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "0840af70-2ad2-4f1a-b6b5-d9b66db64db8": {"doc_hash": "726ca330682f5cdf42b2b325d946be25a919060ccbda5b0297499fd4b468fee0", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "a4640552-d221-4850-8931-1407a4e734a2": {"doc_hash": "5165763664f1daedf8d82ccccc58aac8fcff4c754db9d5c34afe8812675b3fdd", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "7af0c3ce-69d3-4b4d-a6d4-962c9d678a31": {"doc_hash": "1b07600a8254092fd459bfe9d7f0ca7fec6f90e7455c0432e57766c93d6615b1", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "c0d0aafe-bcc4-4ea5-9a35-adf1c8989cb4": {"doc_hash": "defd593891c8095f3891ecec38df7bf4cfbc92e925293f443ccab352ee2b3550", "ref_doc_id": "ddadd0bd-5725-4eff-8441-b8f759e041ef"}, "cb82ab4f-66ae-4aa4-a4a0-6a8b70414548": {"doc_hash": "da7d421dfec08c2cf4777f9f4fd12864053707babaa806bf718bc77f66652c1d", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "da63a681-5ddb-4ba5-a939-9c6cbc8fe525": {"doc_hash": "fe70d3473808d6ee1fdc267b5c5f9400ae79c1dceb0823ec22d2c436a10ffa53", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "46e9ed08-7e5e-4c15-a69d-ccf2a230f797": {"doc_hash": "b0a66e2356ee57378bd23970e374e59f1e850fc243c6439ceab27a206efe7814", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "c5c80509-7867-4050-82b8-5c967abcccee": {"doc_hash": "181519614970af4de1c26f71e0985189a97f012c8dcab404a95ce47b80583ee1", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "8dd82191-3ae3-432a-9c7e-024732462dd3": {"doc_hash": "cab773a201de4b09641a4c825640df0f7833b9ab286f3d8316cc4f99acbfaa93", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "9d9ea95f-42f7-4865-9044-d6c01832c784": {"doc_hash": "166c2f6d4f59bb3b2898e9152ba25da79420640adb11db2e270fb476898ab086", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "6653b48d-f91d-46ad-864f-5279420f254f": {"doc_hash": "f08edc9e701faf3141cb72f1a7e7d8dd2d8771d554cf5a7462daed52be626c79", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "f42b91a8-b516-494e-b0c1-e9bd5fe7c25e": {"doc_hash": "b9c3b8e524e84473aa57cc974860274eb2456e5ed13d909e496bd2a9c6baab5f", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "3c4d19cc-3ef1-4bf7-abf2-b0742a1ef602": {"doc_hash": "a49ef9805a9d20d7b3789347cd5822fed99310c521d3b80c935d6b3045a4741a", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "4a268fd0-15da-4614-b7b6-9c155f74505a": {"doc_hash": "c2a274185969fc691aa9ff686f399926e7d004a72797f25c3dd11f6942d14467", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "ca6b4f04-f05c-4c9f-8c58-cd54604841ee": {"doc_hash": "b5b169421306ef41336e2b9d73a59d2afd93c5de478c4de6981aaebcee0a41f6", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "8ca6837a-182f-43d8-8d32-5d66a681c38b": {"doc_hash": "c8f51dc96f35dbb556a1af4d072ddfce3fce9e3f24850b9ad39995fb06ea3278", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "4fe542aa-e8a2-49da-a858-3440c44267e1": {"doc_hash": "7b2a69134ea13d348e03e6bd9eef3a0e91e0f60bd5b58c887d19c34553ea9e42", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "67e9e836-3445-484a-bd93-b64b438e5e1b": {"doc_hash": "5cc1b0fa23673284abffa0e2597bf955059ed63350f08f9fb7894cd2c628c5f4", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "5c1067b5-2d6b-4c6e-b398-417689b34527": {"doc_hash": "a10985ff26040a93b065c783ae75bb03f0cf5e98e183a2f521df9aafa8e171ba", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "298c6922-84f1-4dd8-916e-fec2e28430c7": {"doc_hash": "dca57fd78b1cb12ebd2377f3ffc191ddc6e8390d33207133f2ab5735b93399e9", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "92c2b25e-5512-427c-b30f-fad229bf0cf6": {"doc_hash": "e4afb24aec31836d1e9ad87f159d1b5d484cef1b3c3b34eb7a820afdd20280d2", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "e000f196-d8a2-41da-8e99-7c4beac70a25": {"doc_hash": "9d684d1e5f0ff8ed7faf2b526af17641c13e2c5846c37fdd5fa9cb6952db7897", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "62dd9cfa-ae96-427c-8743-3c28102d6445": {"doc_hash": "4f14caff813dd371f9ad55917dc92158f281785a2ff383e531ae9b37567b67b0", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "faf7ede7-200d-4b82-9664-24e146991c85": {"doc_hash": "c25dc1d88083cdf918f4468cc48167d5325def7a135b615b180900230e8063bb", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "2683d71d-1cab-44ce-8046-e7e7365c4271": {"doc_hash": "28956cf6d82b4a6adf94516ebcb1e1aebdd441323065005555e5917592aa1a6b", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "2c00344f-a5cb-4620-988d-003dfd4180ae": {"doc_hash": "157f29e57a956577d5938966fdca76f50379e6f13a75db3acdc3b40b606e7085", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "5f43722c-0304-496d-9e8c-2993331f874e": {"doc_hash": "0abfab9b188396e786b0ef1765695521dedf880124f9c10f23020ca8a7341455", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "0f819c91-bef9-4c6a-9873-1bc9cb389338": {"doc_hash": "a79776569b9cd57df2cf843c254c4274abbfdd9540b9a66da47b9e924aa62cf0", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "050005c2-5808-48bf-a47e-b4f16a39a596": {"doc_hash": "7d445be4cf40e96c60372f05e66c7057986098d32555f72d5044a8058eaa071d", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "b414b7d2-2dfc-4cea-9118-2c47199d8628": {"doc_hash": "afcce987acb0fb59573091b781edfebd127e51d7282f6285f14c362131e083bf", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "02c35308-de08-4474-803e-771591258712": {"doc_hash": "528abc978b1c4e977ddfb71a3631374168ec750e67f0d7c287b7812459fddd9f", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "ed77e1ea-3e24-4b8c-bd34-b7f9604dcff9": {"doc_hash": "f84f8971d2cbec2851d413fc3759c80c68f2c3bd8eda1ac52158497d00989162", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "1cca25c6-d309-4a3d-9537-fd7cd61f3d6f": {"doc_hash": "4461630bea8de2eaf86fbddf391014dd9491fe695de6493c1c240727924bb1f6", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "628eab36-d8cf-478e-8b99-b0a97e397570": {"doc_hash": "8f97ff000573dd1d3d1a647cc25c1a208a1272a80d5725a7cbe7f4579b0387a5", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "b0264ab3-1299-4a85-86f1-87525434884e": {"doc_hash": "020cf7c096d50942cb2a7c9bc8fe9c1efcac9a4dba785b471604ffb329c0261e", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "20f07b18-586c-4e35-928a-fec4301bd764": {"doc_hash": "69c97f89b979d38bc517b02b7904b8241e68581fb1bd5f3d51167b641d19d17b", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "d97f0a38-5983-469c-842f-1560042752f2": {"doc_hash": "28cdaea82ce84ba02e5d8fa9e6478521848aba8e078e21a406ab6458475f552d", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "16a3706e-79c2-4069-8127-78fb2189f173": {"doc_hash": "f9cff515eb44679ea17870bad291672aee90e1fb9d2a045097f07d518b5e2bb1", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "5f7068b6-7680-40ca-bdf0-795ec8f4557c": {"doc_hash": "7b463c3d78ccdc54ad69334fb08a2ae25123c957002bf63ff6cba55be2824db1", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "9d2178d8-25ec-4154-b314-ca4fdb9560df": {"doc_hash": "4c8570eb0493363e5d63b7135059acbc41d8e8035fbfe88bd4f8a4a9ee34cac2", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "cb5b7019-eaf8-42f5-adcf-a6d8e6981008": {"doc_hash": "3502e465379d9e89f274bc6248b1efb68bbb40fa3c2539e5f1341bd996418dac", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "90b404be-313e-4ca1-bfba-fc2e29706a27": {"doc_hash": "0350bd201483d75804adfeba65f8592ee539a4765f7e5262919865bb4b97fff4", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "aac21ced-1868-4afa-a88d-0a97d0e970a3": {"doc_hash": "6acf9047b104a5c4618dd23e718336b182a407dd49ddc4d29b14d23409380a93", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "33d860dc-7623-45e9-b21f-2327dcdd1233": {"doc_hash": "3697812266ed9ad3e1b67ed0c6c59341074bca26331ef3f556fcae0e979ffff5", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "06c6bc58-9cb0-47a4-bfec-3cdb2308cb24": {"doc_hash": "5f1523455e1c6ddb30f645dd43e963026e093c8d5ee02bc8f724a9e822b2958f", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "a1a76ac6-a6cc-4504-8e19-e05956b82bab": {"doc_hash": "f55a595eafcb184f79b15a566b55117c054244590a878c5675984fed03d2fc41", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "dd681407-dc7c-46e3-b250-b86d5a411a6f": {"doc_hash": "3ded19559126b0d3b08cd46c8595bbfd4500218f384309bed280051ec5152950", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "2ac06e49-7d13-4ecc-9a6d-ef078d0ddd25": {"doc_hash": "aad976996ca61fc0a873475ab11dc9db54d7929e974a9baf3c5e2e692ad3afbd", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "f980e829-b382-4f51-a631-c52447bfcc9c": {"doc_hash": "0a7b372b041708a519e2b39fd9c4e8bfa49c2eada3c3f3712f783107dc887f39", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "068e0f18-40b7-49e6-b1d2-0b2e9308cd30": {"doc_hash": "9cebb8c51932a5b144630105bfc97c810b31f865ae18c19bdd9da355a7827e13", "ref_doc_id": "7c613460-ae63-4a91-877b-8f0ca3b304e9"}, "f6f248d4-343a-474c-ac22-70243d973a4b": {"doc_hash": "4fd44e2217ca384e84a9d01c1a125b30166832d154b05446e2a9fc753d98b0a6", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "a96aa96e-7f47-4dd8-a8a0-a030602c6ecd": {"doc_hash": "2ff62a42a9d9e12292443a8066659175df2cd73211699d38c4795b5d9b764969", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "4d35d07a-a221-4a14-81e0-21bbe20d0a2a": {"doc_hash": "04479310f46540bdc13f7c1e41ca65c53582855fa8ac15a0059a16560f40e437", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "61cde1c0-0e8a-47e6-808e-52b4c17dea1a": {"doc_hash": "400a6532ce73824228b0893366e3f51c8117ac92d4a98eb940c00c641c170f09", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "8f9451a6-1c88-403c-8e6f-b6fd98eda1cd": {"doc_hash": "810dcbcc170cc21b5c353ba404f91ab770be06e12edbc9c4d9fcd504c572c1a9", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "adcc74ff-8d5f-4a65-aaaf-df89f8e63982": {"doc_hash": "405cde526e6b2f7a84ab4b7397e12df30d7ed02f4d45b4653946a04fd3afdf49", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "230df1f9-7a8e-4f23-97ad-0bc810d2f92a": {"doc_hash": "e0b9cbf9266cba1d0687e61f42411e3c2ccaedf23f724cd5709edd8dccc0a5a7", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "15b5dd4f-f3e5-4596-8642-0cd1f52ce719": {"doc_hash": "c84b0ef372c1f164f921fb7731debee2a7e232462fbf31a6d8f86f017dc25238", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "0013317f-86c5-4e0a-9e97-78f66c81a3b2": {"doc_hash": "ff93ab2fc79a0cecdbd9cf012d5dbe64c0bd1c481309022739ef323b4c879cdb", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "9abec3fa-15d8-4df8-afff-8e864b607319": {"doc_hash": "5874835fe12a8f9a2b134533b16ff6de815e21af5c6dc91005e0db1b7e689b50", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "dcfc5fee-2733-467d-8e68-235f4ecda9e1": {"doc_hash": "880775c226fae2f0a212f13f05fef457f0eecf714c577b8fd0999987694c0efc", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "eef9a186-c76b-467f-8a3f-6542307b1761": {"doc_hash": "7a55b9e36994c0330d839baa762a52ee414b694bdced7ece02fb858c86215ef0", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "2c19e929-e0af-49e1-8634-1449e4e389b5": {"doc_hash": "dab3d62ecb425668f0f152c286317a51ff981e85ea9ca38cf073f4be5d292f3a", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "fd305e06-8588-42df-8718-1b98cea78b4d": {"doc_hash": "5cdf7dcc6ce6d88335e6dc855c910c04d0ae5b46198bba6437531526c0ddefd7", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "b69933b9-0f26-4f20-bdbe-dc8e7be5b9ab": {"doc_hash": "6d748fdc1c39f4c7dd39363ddd3db5c6f2049946ed850f48a6bf885d9d0d5ac2", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "c13a7b86-d4e5-4d81-aaa8-2bd5ea326016": {"doc_hash": "30c70b2c23633127ff54519f423b71d876822e09a694314afde424a6231b1b6b", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "00418c9d-8af5-4055-9591-871776718eac": {"doc_hash": "e66d4ed17bdbe5b3a5a20f73a1b89a825833a15763eaae0bfaef084dd59619b5", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "be042906-1f2b-4ba3-ba33-13576880b6b5": {"doc_hash": "c1b7bda8e3aff6a0cc607169ab71217219cca33a23927bdc7eb5bc56bd45aa96", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "cf9b488e-e8ed-4f91-9dbc-dc3c6f03d99b": {"doc_hash": "a1f1d40342b824d84bdc98adda4b1e2b5a446fff8b058751b6a8819e5cd73532", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "7b6dbb72-934a-4365-8b4b-c673fa080465": {"doc_hash": "a27cdec55ddf800745810bb5410007397468f516d7b22616bdfeec3062c75bc6", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "a8c770d3-ad53-4ecc-abd4-0f8cd2afca88": {"doc_hash": "02793830b495d5a42ec99a780263a8d74515ea16b16176fd3f38611bba583ff7", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "a1af883f-0a4c-4eeb-a107-a19a557a0b0d": {"doc_hash": "4f449daa508f4867d7cf4dcfe74bca13ef17394ece85219079ae0edb31fe4061", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "8a8bc288-e565-4298-aa12-c3f0612d754b": {"doc_hash": "a77d439b9131130f50b981887f7e33c0d3b40fbb9256bbd7ebc60469f92460f1", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "9b16bc99-83f5-4c98-8de2-21a1af68307c": {"doc_hash": "b9624297351c765e312094ea822571ead682a6342cd4e3089805eeaa7f3bbda5", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "4286c17d-a4ae-4a56-8ca1-8ae2aa6e043c": {"doc_hash": "243d29ea8b57d3462a76bc8b8dbdbf27ae8d3270132d9ebaa6d56df5b6668eaa", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "d8dddb62-5f33-47be-a3f4-6bd2a2809b18": {"doc_hash": "43cc7ba768a02d3f81d02f20e09b7aee0f755f72feb97ac1b1d669ad85aeccfd", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "6dda059d-5027-4379-8710-c921750f266c": {"doc_hash": "7b27881bd3fd9bf562b8e1dabaf38f46c30b05f4f3f3d106bd8659bbaa87bf53", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}, "7511bb0b-889a-4e74-bba1-7f6cee4bff76": {"doc_hash": "2dd9bb669822a046a516e34238fbb9d96cf0948da03ce39bccaaa691d6754393", "ref_doc_id": "6371d7f6-efc1-468a-a298-e99cc42a8479"}}, "docstore/ref_doc_info": {"71d91a0a-9d0a-4377-bf98-9c409b54712d": {"node_ids": ["81caa7d6-c7c1-437c-a367-26b8c6136804", "71e330b8-83f5-4e1b-960d-540255721639", "252f0102-48ec-4c5d-8245-3f1bd3afe6e0", "f9b8ed38-af9d-4702-adf3-79c6f6b3022c", "af350fed-2b12-4681-b7d2-57f9760fbf12", "e5037caa-feb0-42ac-acee-20ce03cc98f3", "d9486922-4824-4ad1-b0a0-4f1a1a6a40df", "5b54c581-872d-44fc-aa97-e7ca6176dcda", "9ab69b48-1611-49a9-ae86-ff2ab4ddca30", "f2d08e0e-f486-4771-8bc3-613c82eff296", "87b771c0-83b0-4543-a830-f03088d2f648", "3317a8e1-aff5-47e7-9258-c8e2acb37712", "ed105fb3-1646-4d3d-9c6e-4fc581ea5afa", "a15969ff-44e4-4927-bee6-95dd55bb5a9f", "e8d88eb1-cf78-44cd-8309-a7da8c7c42c4", "d91b5b31-bf19-4516-9bc0-99a6bca5a8a7", "a442c11a-48b6-4869-b4bf-a43d0df1eaff", "67dd57e5-bf30-422c-9010-8863eec1c543", "c820fbec-7290-4955-ba9b-d2ba1e062f6c", "80cbc1df-e4e5-4391-b351-b7bf0bd24789", "1006e2dd-a7c8-49d5-99de-91be004cc0c7", "565b7e1f-b23d-41bf-b3c5-a77dc663dd54", "0f9a4765-fc0a-4dcb-af9a-0b51035f9e60", "f3467e56-299f-4dbc-bece-d96704e87b5d", "b07dfe64-a28a-4d87-b64c-671a7441cb7b"], "metadata": {"window": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 4 , 2022,  8:30AM Eastern  \n \nOperator :   Good day and welcome to first quarter Fiscal Year 2023 Cardinal Health Earnings \nConference Call.   Today's call is being recorded.   I will now hand  the call over to Kevin Moran, Vice \nPresident of Investor Relations.  ", "original_text": " \nPage 1 of 14 \n \nQ1 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0798e667-a5de-4f9c-a0f7-c7240bbb205f": {"node_ids": ["a9d77d99-a2cc-48e0-bc9c-b1fd7770a10d", "bbfb7216-2c91-42c5-9288-2166ac194744", "59e1f5ea-2b8d-4bf6-a853-dfbdb0e929f5", "6e3c5f1c-5113-4ac7-a994-787f3a57a663", "865cf553-177d-4208-b028-4c103c9e121d", "9113967a-48d1-4cc7-a88d-80d7d7f22264", "41883b94-c385-45c2-be31-b2fe3b29863f", "248023f3-f413-45fc-8412-5fe45e76ed99", "ff9fba3a-84bc-41e1-bb0e-0c13a7336ab6", "5b6234ec-4dcd-4b6b-bcab-7b97a4aca040", "11d13401-65af-4c8e-b61b-4b3fd36d6bd3", "2b7c13b5-1129-4aff-9e76-423f7c1c95b2", "ec65bd90-2c17-46dc-b59e-4ad1b7af22a4", "b7cead67-ba2c-40b8-82eb-5a75fb6a8683", "245d7555-986c-4313-a0dc-2ef24eaa1cb5", "99fc5be9-15ef-4c30-9e5d-6a3fd0588523", "3bc58ef3-9ffa-4676-9e40-c8134913385c", "1a151dbb-8668-4d97-b66d-6eee6f3ad314", "64b5de7b-e8e4-46e7-b4d6-9efbeb9bf64b", "ce98f3f6-51cf-4719-8d53-13cfbcda6326"], "metadata": {"window": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds.  We are encouraged by the ongoing stability in pr escription \nvolumes and strong performance of our generics program.  \n \n In Medical, the quarter\u2019s results were also a little better than expectations we announced in \nSeptember .  While I am pleased with our team\u2019s efforts in the quarter to achieve these results,  there is \nmore work to be done to drive better, more predictable financial performance in -line with the \nunderlying potential of this business. ", "original_text": " \nPage 2 of 14 \n \nIn Pharma , we tracked slightly ahead of our expectations, as we delivered growth while managing \nindustry -wide inflationary headwinds. ", "page_label": "2", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bdae2dd7-6e15-4eb8-b8ab-a79d9f86f486": {"node_ids": ["5e34732c-9d26-4c3a-b18d-01c8178fb417", "2d1f62a9-e475-4b36-8ee6-9d16da5f6776", "72418f0c-5b24-4f8a-9911-4820ec7069df", "f5d8a459-c908-405c-87c4-d879593dec84", "88935146-bf2a-403b-8247-c57cef81a366", "f0335b08-bc3d-4e90-a758-d7e0ae2c474c", "db6646ed-4060-4da9-a8ec-0c08e9bdf0a0", "bbbb8af2-fafb-4d84-823f-e9074b4b4952", "bd6c6f48-cbfb-4a58-a498-538911bcc4bb", "50c131ef-9df4-4415-a92b-dd2c95944ebf", "4addedea-9696-4e3b-9be1-81c0d522c757", "ec5fc4c0-9d2c-4133-8004-79f280fc02e5", "85e9c5c1-e98f-4e7e-9263-18aee2fae710", "d134be35-91be-4e4b-ae30-008878b38daf", "ad4897bd-5436-4339-be53-d32f20ea03fe", "f4a4b64d-fe1a-4c07-b00c-cb743a287e74"], "metadata": {"window": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n Now, turning to the balance shee t. \n \nWe generated first quarter operating cash flow of approximately $25 million  dollars.  This includes total \nlitigation payments of approximately $390 million  dollar s, primarily consisting of the second payment \nunder the national opioid settlement.  Adjusted free cash flow  in our first quarter was $342 million  \ndollars.   \n \n", "original_text": " \nPage 3 of 14 \n \nThe net result for the quarter was Earnings Per Share of $1.20 .  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8ceddf62-6ed4-4cd5-90f8-0782ac6370e6": {"node_ids": ["247e6f15-86da-4256-b87f-07e5293fee77", "65d0ea34-5eba-4059-abf5-2949c2015f85", "9dd48c65-b2da-41c7-b83a-71df96e4ea47", "2a293b13-ee8a-4372-beeb-c936fc86ba60", "98c347cf-e956-4ae5-a538-45c93ffa0c8f", "d1b0ca97-5776-4b7c-8106-e27e01d972ba", "19b4a2fa-7f21-47e0-b962-d16e2eb849bb", "a5dd7c53-b8bf-479f-abcb-92df7e0fd629", "c53cdb8b-3497-463f-bb6f-0df913379631", "7b2d5aba-588b-4430-9a58-e6ee13f18d97", "d541af51-676c-48bb-8cc3-2abc7b9c547f", "5a332841-fdc3-4495-868b-c6cc5df1fcd5", "cb952270-1aff-42ab-875d-dcbc8b882736", "a97e93d3-027e-4ba2-acce-be2a79657014", "c6fa57f3-69c1-442e-b636-36ccf1a08904", "c7528849-0e07-4ba9-afd1-d2525d3fbae0", "088258af-f9c5-4c7c-97dd-242a7c60af78", "9030a6dd-34fe-455a-a4cb-5bff2554e42b", "f459b2b6-c821-4c58-b0ea-d7012235d780", "b92fb9e7-16ac-4215-a400-6990be756464", "c61e903c-4521-4c84-9bb6-b8f448e39486"], "metadata": {"window": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears.  These actions, despite the one -time costs, are an example of our ongoing commitment to \nstrengthening the Medical Products and Distribution business through simplification.  \n \n During the quarter, the gross impact from incremental infl ation in our Products and Distribution \nbusiness was in line with our expectations, of approximately $150 million  dollars,  and we successfully \nachieved our inflation mitigation target of 25 %.  Our mitigation efforts have continued to accelerate, \nmost notably with th e implementation of the second wave of product pricing actions in July. ", "original_text": " \nPage 4 of 14 \n \nAs a reminder, this non -core product line has been a source of volatility and distr action in recent \nyears. ", "page_label": "4", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "00b77079-8f9c-4cfd-aff9-bf1e6907a273": {"node_ids": ["5d5b0871-1381-42d9-bb3b-3798bc120c9f", "5ef26e2c-dfa8-446e-8a63-7ce97f736875", "19039780-9c53-4969-be1f-2beaef7f63c7", "aaf89700-0758-4d8f-b4ef-7efc7c86ebfe", "098edc09-2a8e-4319-9b3f-5c0982accedf", "af03e13e-0ede-46ec-8fff-115ad15f7ab4", "8c8c826d-0f4c-4f52-80ab-63b1dc76b872", "6bd52e18-a932-4fb1-8680-ab20ae00d598", "a8c76627-6aa7-4662-b700-9a035ce97629", "e882f0e4-298f-4598-b4c9-e19391b47e7c", "2036cfaa-6705-42fa-a3d1-3a9f00358e13", "0f1fc6e4-eb30-4bdf-af9e-45f97f6e14ff", "48814efd-6010-4515-aab6-d81642da92af", "c4d7685d-2188-462b-aa6a-94e417648253", "9130aa79-47ee-4f84-a7eb-d30296815f69", "143bbc86-2e8f-4f42-9af3-b1001ac395b1", "81d11cb7-2b78-491c-91ba-b61451f40a77", "4f117879-6895-4f16-8878-b8b698754877", "a9b2f28b-abf8-4fac-a679-0288295b588a", "15ef6ca7-914a-43a0-9c3a-9b2b0efb93a0"], "metadata": {"window": " \nPage 5 of 14 \n \nsignificantly elevated.  As a reminder,  these product costs are capitalized into inventory, and in the \ncurrent environment of elongated supply chains, reflected in our P&L results on an approximate two -\nquarter delay.  While we now expect gross inflation in the second quarter to be similar to wha t was \nseen in Q1, we are implementing additional actions and working proactively to mitigate these \npressures.  It\u2019s important to note that we continue to expect that as we exit the year, the run rate of our \nmitigation actions will offset at least 50 % of the  gross impact from inflation.  \n \n", "original_text": " \nPage 5 of 14 \n \nsignificantly elevated. ", "page_label": "5", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "953a8b99-2e10-49a2-a5a2-e16e44e9d92c": {"node_ids": ["805fd641-3afb-40a3-9a4e-99f8a09a7120", "03854e7f-446b-4071-a003-76c1ec07b820", "6740b4cc-e709-4858-baf5-196da7742213", "48871490-f1ac-419f-9677-ea1d14e328cb", "ed650193-7112-4e11-83dd-9ca4b5cba20f", "9bc7cca7-dd98-4d3b-8d8e-70f7b58e98bb", "8dfb2a3b-6c2d-4fe4-ae13-22aacc571005", "fd1f58b2-fc73-45d5-89a2-4cc4650092a8", "968253e0-c3d4-465a-bc07-5995df65972d", "dc766f33-10b3-4466-b0fb-2c6db9d8b6cd", "398cae81-4b01-46d7-ad0e-07661f85b7d9", "b30a55b9-b546-4f31-989e-52f9030b8b72", "af4ec454-722e-4a6b-8629-c2a2008a2e10", "65425950-8017-4de1-a501-5d1ab460c38d", "27efda1e-ec97-4c86-b5f2-65504ddcee4e", "7ec56a46-2688-4b2b-a684-b531b59f034c", "c155191b-e34e-463b-9711-221e077f6136", "5ee7bbad-6d5e-4177-893b-be18e7df3db4", "1ec9d3e0-63ad-497a-bcfe-cbcc780cb46a", "fa45efb6-e593-4b7b-ba1e-41729bd2f3c2"], "metadata": {"window": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n Similarly, continuing on talent and leadership,  we are excited by the appointment of Debbie Weitzman \nto CEO of the Pharma  segment.  Debbie has a deep understanding of our industry landscape, \nlongstanding and strong relationships with our customers, and a proven track record as a commercial \nand operation s leader across her 17 years at Cardinal Health .  \n \n Debbie\u2019s appointment was part of a recently announced segment restructuring designed to reduce \ncomplexity, drive productivity and efficiency gains, and simplify how our customers and our \nmanufacturing par tners do business with us. ", "original_text": " \nPage 6 of 14 \n \nMoving to item number two:  For the Pharma  business, continuing to build upon the growth and the \nresiliency that we\u2019ve seen by executing in the core and accelerating our growth areas, primarily \nSpecialty.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e33350b6-8aa3-448f-955e-6a6438e22a26": {"node_ids": ["b916a725-8134-40e6-91c2-33cc06c068bd", "a7bd5305-bc0d-4097-8a3f-ff1c357b3b2c", "6f2bba4a-84a1-49a9-aef5-f6d95afc4a82", "946eab80-65af-43e9-bfb5-a318cb5704f9", "1902d9df-3330-46e8-8916-6326d824e0d5", "f7e106e6-a6ca-4d77-ada1-b4f3d0b47574", "c529f367-41e3-4c6e-9d64-b2fac6db2b41", "bbb52249-0be1-4d80-9d10-617d1fec82ba", "02f3551a-5139-44e3-8f90-d6d46febaeee", "8e72e1f4-ce98-47cb-ae70-7e986423e13c", "0c1808e2-7339-434a-8c29-30fd2316ae68", "7dea01cf-2a43-441c-bcdc-5c806cf1406e", "b5670436-b17b-4ba7-b7ec-58a2ec12ab04", "3034a288-b5bb-4f23-9bdf-31912a744aa5", "1d8aae92-29ca-42af-8e7a-1ab06c752f9b", "3e76f5c0-c47e-4ad1-914b-4670cfde61e2", "cca75ae7-7613-42b6-b84a-a5d5b566b5ce", "90b16756-7400-4b4d-abe7-d60722c5271a", "d9c1107a-e48f-4129-a9d9-65520668d625", "64913e24-6bfc-4647-9f0a-acc9b700b9de", "3c71c78f-aba0-44e8-9208-b95b9b02f196", "7c81d35a-e279-4af8-9cd4-6ae6944fabb1", "a2ac5d99-2e9a-4a16-abee-45e787ebbb54", "ac6112e0-42ff-4955-8c0a-f3d0603bd502", "a732961e-41bd-40e4-8399-3551b76c28ee", "1caa5c8e-91b0-49ea-8c48-820bd326332d", "4528246c-dd70-45b0-b109-585b8140c97e", "143c878a-56de-4fde-818c-fdd44c7f34c7"], "metadata": {"window": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n Beyond these actions, we also announced enhancements to our governance structure, including four \nnew independent Board members, and a new Business Review Committee tasked with supporting a \ncomp rehensive review of our company\u2019s strategy, portfolio, capital allocation framework, and \noperations.  Our Business Review Committee, which I chair, has already held multiple meetings and is \nworking through the detailed review covering every business.  We exp ect to share conclusions \npublicly at an Investor Day in the first half of calendar 2023.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the first quarter and continue to expect $1.5 to $2 billion  in total share repurchases in fiscal \u201823, in \naddition to our ongoing dividend of over $500 million annually.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "01583edb-346a-409d-a686-087dac013a41": {"node_ids": ["cb836f82-73c7-4286-8e97-3ce580ce8525", "29381fd4-fa02-462e-93bd-9137060829cb", "f25d762c-e5f5-4cb1-b2eb-af85fcfde042", "25c85344-453c-44ff-b8f5-7ce54e870b98", "75021f30-6f2f-48da-a59d-c3e239e6d358", "e17446ba-e4aa-4471-9e9d-d3608b1b4d26", "dad71223-f4b5-463b-a376-77578cd379ab", "fb75b24f-2ff6-40ee-820f-05d075823b09", "63916d07-4f71-4c21-af2b-611aef96bb74", "cb073199-b3e0-4c0b-942e-dd3a6523f76e", "4c75773c-0504-47d2-b3f9-08b9b95eae83", "4d9c87b5-c40a-4078-b10d-9b93a5a63d8b", "0f876901-8e79-4eab-b86e-f3abc3084841", "35181e82-92f8-453a-b6e1-93e271e7a272", "bb038b25-429f-493f-8cb9-bbebbf5a7400", "788c3ec8-ead7-4979-86d0-d34c4d020514", "5c75d95b-50f3-498d-a31a-518b212e29d5", "2087861a-3354-48f6-9fa1-e387d417880f", "70f3b0b0-3789-4054-b702-9ac7e6e3698c", "66a87917-5548-406d-bd90-701c7b01cecf", "770b16e3-0c20-4901-84b2-6f81594c54aa", "ee7db4a2-d7d0-42f2-bc69-4197b1dc42f1", "8bb6c6e0-5622-4f39-ab27-4437d1b1c73d", "29f50929-33cd-474f-b86f-04106c7d9474", "c37d9601-c818-4b7b-b600-2033ec09c8e1", "91b27834-1006-4c92-a4c0-01005ce4ece9", "0c96feea-06e9-426f-a279-b4446eef1838", "0ae41ae8-9cae-4eaf-acd6-b4a1badb2314", "81fe9f6d-d2f5-47e9-a2bb-edb03385e2fe", "c3520cc9-17c7-4567-b2c1-90b3ea667e8e", "031c19dc-af7d-4226-a0df-154c420e82d1", "cbe85cc5-2630-42b9-b264-bed37920317f", "c54d3117-4d14-4e1f-9277-f41ec67eb09c"], "metadata": {"window": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated .  And so we would \nanticipate it's going to take, again, at least a couple of quarters before lower costs actually come \nthrough the P&L.   But as we indicated in our comments, t he international freight is really the only area \nof any significance that we're seeing cost reductions at this point .  We do see some of the other \ncommodities coming down, but not to the same extent.  \n \n", "original_text": " \nPage 8 of 14 \n \nAs Trish highlighted in her comments, the supply chain remains very elongated . ", "page_label": "8", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e6fc492b-f2a4-4441-ba20-b3ba39d8155a": {"node_ids": ["95725823-483d-4bdb-8ce9-b135facb2c44", "ab4f640d-2960-4275-8170-148700dcb587", "0cfc0f7f-7f4f-4816-b60b-a8afd3c02237", "29c89711-2bdd-45a7-8cc6-99371d256f5d", "d90aa712-614a-42f7-b68e-fdc44ebb3cda", "5a32abfc-d5dc-4d35-a269-434ec3052075", "d31b2b25-c58e-4026-b4b5-83834a74734c", "1d51b350-a222-4d5b-ba6c-efd0b1d357df", "92eb9d0c-1318-4bfd-97a5-a17bfa6825ee", "f624bdeb-13a9-4183-9f0d-d95f045621f1", "92de5baa-297c-4f1e-ba84-26a199c37ab9", "d57673fc-cd17-472f-964a-3731f201b098", "e7383b0c-bded-4a4b-8844-76f07015d858", "2a360186-4bfd-4445-8e1b-7cfeeab56a36", "836d243b-23c5-4ee1-a013-f492a06dc7e1", "99f46372-fcfa-4d83-981f-5e2a12144460", "560c9c98-2967-47ea-8d2f-3f9c98a1f2e4", "f615bc8f-e36a-4b1b-9cb3-9aaf48b229d3", "eb96e5e5-0f20-4481-bfea-0d78021d3bb7", "f8d496c9-512d-4c86-917e-b1cefe8fcd17", "8edd8373-aff7-4f35-abae-2fb2c0ca526b", "5bf40960-8a68-4120-ba36-082610aff97e", "d504e6fc-afec-4b95-a389-2607c5a637b7", "5bb7aea5-73f2-4671-a153-f286b604f717", "41c204bf-351a-4738-88b9-3f6d5316245a", "35a0dd58-3d03-4af0-9b8d-6de23dbd7221", "79326658-365b-4fa6-aa77-c7eaba75b05f", "fc26469e-f2dc-4fe5-af0a-09d4ed8134fc", "1920b398-a5fc-4af5-9dcb-afdc838d51c6", "c4ae37a3-774f-4d5f-8b10-33988e478514", "b1923768-9a59-457c-9603-ed6ff58f70ab", "4877284b-e3f8-46fc-bdf3-fc36ea888e20", "cdcecb0e-7f8d-4c1c-8d09-4f41dd4c51e8", "c224a566-a66e-4796-ba55-4119114dfc7f", "38fc554d-c3ab-4bcb-9aef-07fe134c8090", "7d23fe7e-f5f1-4b7e-b08e-ae1a7b905468", "9d9f3de0-45fc-4963-a04a-ba7103dab56f", "a67a2851-2e10-498f-ae37-c27d453328cb", "218bd519-7b29-4b99-9e97-32054231024a", "04fdfc4e-1e99-4fb0-929d-00aa359fefff", "1f519fa9-130d-4cbf-80bc-6b6a086e8cca", "f7cd5573-c078-4d18-be27-45c557cdc035", "e32f9cf4-7188-4a9f-83a7-f7f7e7cae33d"], "metadata": {"window": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry .  The first question on generic .  Yeah .  So it continues to be a \nvery consistent dynamics in the marketplace . ", "original_text": " \nPage 9 of 14 \n \nAnd so your first question - oh, I'm sorry . ", "page_label": "9", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "02eef37d-46f9-4e4a-9e63-5e153c088023": {"node_ids": ["13bbffca-f782-4613-b272-15f165a262c2", "2d0cbfbd-8086-4b6c-8735-81e3533563bf", "e8660d11-1316-46b5-b063-92bc449ec6de", "573bf3e0-dde3-4ea2-84ec-229d12f45cb8", "626be553-4f98-4868-bf70-0d4de2b2d9b4", "52ac8821-89e8-480e-b012-ba2d29e61cd0", "5cf607b0-5afc-4c12-8b5c-e030d8b3650e", "4acdf9ef-beaf-4933-95f0-6a9479fb91eb", "42428262-0b13-4887-acfb-f81e4afa83a0", "8e3b1cbb-bdcf-4c09-953e-0952ed966cbb", "bc2ec5e2-ffca-415c-b952-7fddeee1978e", "89e2e0a1-eefa-4595-aa7e-12967894231d", "d864c245-3523-4a9b-a0c4-928b75ed6df0", "2ea0f370-dbfd-4a88-959a-aac5692e17ab", "bce920e7-5091-4850-acc4-bb80ac85bd49", "e5f8f4ad-1bbc-4357-b9ce-5bd98a789c38", "e28686ac-90e7-4092-a296-6f1d63e2c8b0", "697b2d87-1d8c-43be-905d-469d3e14ed0e", "4cd24739-0d00-47dc-96d3-ffb77d8fb0d7", "1f5dd86f-09a7-4b8c-ab94-757d73214e36", "109494d9-df05-432f-a6b4-80c60a5dc6c7", "92508790-8fd2-42da-a6f2-9461774cc0c9", "fc802df5-cd78-498a-918d-3b3c66a672eb", "683bf2e4-6d1c-458a-a160-8625a85e9c97", "39b79ea0-8599-45a2-a4bd-e62f73b1085e", "27e8d5f7-68d7-4e8e-b24a-2fc2a19781bb", "d0875887-4216-4d1b-be22-81a0a682fbba", "6a197c5e-0527-44a2-a5e4-2a89aaa8a77e", "5bef89e9-c379-440d-b1a6-901a1d4d5b7a", "91a92ae1-c263-4000-a764-0926371d3acf", "464e7a1f-f878-47cd-b687-b00e389df704", "9bbb1591-33e3-4174-af32-c6b95ed94060", "d28b38e7-634d-41b0-a7e1-fb02f042cc86", "866bc74b-9ea1-4b9a-879f-dae7a09e3a7d", "ed998c70-c941-42fe-9a4c-315b40566bab", "893cdb52-1c1e-4d71-a7aa-2a5351b19d8b", "a0eebf09-e039-4573-8f02-7dba1cfd2506", "420f1933-30ae-4fda-a9c3-b07269df076d", "fe6b9d4c-42c5-4b3d-b78b-56e45d006721", "42a29fa6-8494-4b25-bbac-142e536340d0"], "metadata": {"window": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.   We are still funding this \ngap, and that's why we have this urgency on this issue and why it's our highest priority as a business.  \n \n As it relates to the real estate transaction, we've  had some small transactions.  There's nothing \nmaterial at all to call out.  ", "original_text": " \nPage 10 of 14 \n \nstatements to understand that we're not making anything in addition on this.  ", "page_label": "10", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "66bd28c2-de8d-4ecb-9440-8f4568c07071": {"node_ids": ["1ef75655-e58f-46c2-a921-1d4c7e7d62fc", "a4912abf-43d2-4468-bf8f-7528a9fb73aa", "adaa0c8d-059a-4172-9b84-4e42f2bd9213", "ab5e5078-d6cc-4700-85b0-af13c0ee4099", "819a55da-168f-48cb-a532-6385a394e584", "121bb126-471a-4977-a468-d092b684921a", "8eb2342a-b24e-4fee-b975-ae8f88edac23", "26e1da9f-8530-46e1-a452-501b338827dc", "6102cce4-fbc5-493c-b817-d6fe372caf79", "bd0a8936-dd8e-4002-80a0-8ac12ed192b2", "ca9b8e99-c2bc-4d8b-a220-47454303a5a5", "228820e3-504e-4309-adab-5b65b4daeda1", "4dfe9482-6bdf-4a75-b741-07b44eb3a273", "9a4d36a5-5942-4813-a025-0bb1a1c0e1c3", "b850561e-f5c1-4344-999f-c58069f298c8", "72384c7b-b67f-41f8-baab-c645dc1f6fe1", "87a8bd40-8b8d-42cb-b394-1626ac5719db", "91e11346-4844-46c1-bcd1-5e2d53fa4342", "1f704365-2a0e-42ab-864c-70536fb2b441", "facfe395-f03e-4962-be64-f578fe99cea9", "0e20c546-9fb6-4b86-979c-7bc0e3ff6ef6", "ead3158e-9623-4000-9ac4-2b38e4395485", "38d82277-144e-4aeb-8eaa-4d76f64fa31f", "4964759b-47d6-4d85-8f15-58a420b40b85", "6937cd3f-9e96-455c-b274-880c6ddddb76", "55b01a16-3fde-44d6-ad4f-caf51ecf526b", "78725f1f-cfc8-41e1-b1dc-0177979f3a8c", "05af221e-ba6a-42eb-8600-339275a7de8e", "140b202e-c88d-4424-9ef3-d75c03a024f6", "292b6a48-a2a9-4296-a3a1-4a34aa7bf7ce", "b9df4904-afbd-4a73-bdc9-6e57eb30e4ca", "68ae2dc9-ec5e-4407-9134-32fe44367431", "0927c8bf-8690-4ec5-ac6a-9f7c82885496", "659da11a-ed42-4dd6-a6b6-27de2f325073", "9cab3a7a-f3cf-4826-922c-72d5aad7c399"], "metadata": {"window": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish?  And then \non the guidance, and I hear you on especially the trajectory of Medical per Elizabeth's question \nearlier, but if you think about the moving pieces and what you updated today, it seems like there's \nmore tailwinds when it comes to tax  interest expense and share count than there are headwinds on \nthe Medical guide down .  Any thought about why reiterating the guide versus not maybe bringing up \nthe low end at a minimum?  \n \n Jason Hollar :   Sure.  ", "original_text": " \nPage 11 of 14 \n \nquantify how much of the ASR you completed in 1Q relative to the timing of t he 2Q finish? ", "page_label": "11", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ddadd0bd-5725-4eff-8441-b8f759e041ef": {"node_ids": ["80fd47aa-7ac8-4012-86a9-e68a9f063625", "2e2b3339-2ef8-4ada-80b7-8420ade71761", "84394342-156c-4fa4-a783-d6ef5ee2c918", "ae7e472c-f622-4e54-af91-aa72328563d8", "51cb00ee-8d5d-4061-a395-4d84a9354f9b", "5c29f224-fb22-45f5-9e2a-595b356c6805", "0a17b9e4-c6c1-4b83-a025-8c1f5dd8d1ee", "86a85b95-9236-49bb-8cec-f9266b3be8d3", "ad78af9c-3a1c-4068-ad65-f3ee294fb85a", "22591419-6fcd-47b5-8378-983ceb0d11d0", "d175cae6-5708-4572-9cab-830de5a97824", "2c4d869e-3f29-48b0-9c09-682c27a8376f", "fedbec4b-8b92-4cc5-8ac7-c9d518e1eaf8", "05e08d03-8634-4e61-ba2f-e3e4f98e034b", "463ffaee-6f01-4568-a447-208f58e1550b", "65f66956-df5f-423c-9d53-6870108f9209", "f9a105fc-d385-4975-9b4f-8307f0b038a3", "95800ef0-d8b7-46d1-963f-306c4bd1ecae", "aef20ec3-824c-4afe-8712-c08b1dc8e00b", "009b2f3f-3f85-4221-9491-9cc80abfd0e1", "0c30cbd3-ae2f-496a-9810-bfe161534b21", "ecb3850a-9bb0-4f97-97bf-b404317a52cd", "3c1e38b6-2901-4102-812d-fb513e8c774e", "6fd0fd0a-680f-4561-a75c-94fd97387600", "78df9892-ccd5-4f40-a6d8-33962ae73480", "dd3eda59-451f-431d-bdc3-2dc65997ae7d", "8eec68a8-3307-4aa2-b2a8-57ecdcdcb1da", "25af6b8d-fc86-4b87-9e46-66d0959789b2", "32569c4f-69cd-45ad-93c3-5a0080b42beb", "5ab1abf1-8bc3-46d0-beb5-acebd66abf4e", "c827dc0d-d5a8-40f1-974e-b8058f909484", "f3576421-06df-4c4c-9901-5b818daf5865", "79da06eb-0237-48c2-a6d4-bf9462347d9e", "1019c2f8-3773-45d9-b0c7-f955ad5b9bc6", "0840af70-2ad2-4f1a-b6b5-d9b66db64db8", "a4640552-d221-4850-8931-1407a4e734a2", "7af0c3ce-69d3-4b4d-a6d4-962c9d678a31", "c0d0aafe-bcc4-4ea5-9a35-adf1c8989cb4"], "metadata": {"window": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece.  That's the one area that we \nhave some confidence is going to come down.  And so I know your question is specifically on the \nmitigation items, but the gross will come down, is expected to come down right now specifically \nbecause o f the international freight.   The other components to inflation and other commodities, \nespecially, we are seeing them come down a little bit in some areas, but not very significantly and \ncertainly , at a pace less than what we had thought.  ", "original_text": " \nPage 12 of 14 \n \nexpect in Q 2, and especially into Q4 with the int ernational freight piece. ", "page_label": "12", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7c613460-ae63-4a91-877b-8f0ca3b304e9": {"node_ids": ["cb82ab4f-66ae-4aa4-a4a0-6a8b70414548", "da63a681-5ddb-4ba5-a939-9c6cbc8fe525", "46e9ed08-7e5e-4c15-a69d-ccf2a230f797", "c5c80509-7867-4050-82b8-5c967abcccee", "8dd82191-3ae3-432a-9c7e-024732462dd3", "9d9ea95f-42f7-4865-9044-d6c01832c784", "6653b48d-f91d-46ad-864f-5279420f254f", "f42b91a8-b516-494e-b0c1-e9bd5fe7c25e", "3c4d19cc-3ef1-4bf7-abf2-b0742a1ef602", "4a268fd0-15da-4614-b7b6-9c155f74505a", "ca6b4f04-f05c-4c9f-8c58-cd54604841ee", "8ca6837a-182f-43d8-8d32-5d66a681c38b", "4fe542aa-e8a2-49da-a858-3440c44267e1", "67e9e836-3445-484a-bd93-b64b438e5e1b", "5c1067b5-2d6b-4c6e-b398-417689b34527", "298c6922-84f1-4dd8-916e-fec2e28430c7", "92c2b25e-5512-427c-b30f-fad229bf0cf6", "e000f196-d8a2-41da-8e99-7c4beac70a25", "62dd9cfa-ae96-427c-8743-3c28102d6445", "faf7ede7-200d-4b82-9664-24e146991c85", "2683d71d-1cab-44ce-8046-e7e7365c4271", "2c00344f-a5cb-4620-988d-003dfd4180ae", "5f43722c-0304-496d-9e8c-2993331f874e", "0f819c91-bef9-4c6a-9873-1bc9cb389338", "050005c2-5808-48bf-a47e-b4f16a39a596", "b414b7d2-2dfc-4cea-9118-2c47199d8628", "02c35308-de08-4474-803e-771591258712", "ed77e1ea-3e24-4b8c-bd34-b7f9604dcff9", "1cca25c6-d309-4a3d-9537-fd7cd61f3d6f", "628eab36-d8cf-478e-8b99-b0a97e397570", "b0264ab3-1299-4a85-86f1-87525434884e", "20f07b18-586c-4e35-928a-fec4301bd764", "d97f0a38-5983-469c-842f-1560042752f2", "16a3706e-79c2-4069-8127-78fb2189f173", "5f7068b6-7680-40ca-bdf0-795ec8f4557c", "9d2178d8-25ec-4154-b314-ca4fdb9560df", "cb5b7019-eaf8-42f5-adcf-a6d8e6981008", "90b404be-313e-4ca1-bfba-fc2e29706a27", "aac21ced-1868-4afa-a88d-0a97d0e970a3", "33d860dc-7623-45e9-b21f-2327dcdd1233", "06c6bc58-9cb0-47a4-bfec-3cdb2308cb24", "a1a76ac6-a6cc-4504-8e19-e05956b82bab", "dd681407-dc7c-46e3-b250-b86d5a411a6f", "2ac06e49-7d13-4ecc-9a6d-ef078d0ddd25", "f980e829-b382-4f51-a631-c52447bfcc9c", "068e0f18-40b7-49e6-b1d2-0b2e9308cd30"], "metadata": {"window": " \nPage 13 of 14 \n \nJason Hollar :   Sure.  So, yeah, there's a charter for the Busi ness Review committee.  It's very \nconsistent to what I provided my comments.  Of course, there's a portfolio element, there's a strategy \nand operations element.  ", "original_text": " \nPage 13 of 14 \n \nJason Hollar :   Sure. ", "page_label": "13", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6371d7f6-efc1-468a-a298-e99cc42a8479": {"node_ids": ["f6f248d4-343a-474c-ac22-70243d973a4b", "a96aa96e-7f47-4dd8-a8a0-a030602c6ecd", "4d35d07a-a221-4a14-81e0-21bbe20d0a2a", "61cde1c0-0e8a-47e6-808e-52b4c17dea1a", "8f9451a6-1c88-403c-8e6f-b6fd98eda1cd", "adcc74ff-8d5f-4a65-aaaf-df89f8e63982", "230df1f9-7a8e-4f23-97ad-0bc810d2f92a", "15b5dd4f-f3e5-4596-8642-0cd1f52ce719", "0013317f-86c5-4e0a-9e97-78f66c81a3b2", "9abec3fa-15d8-4df8-afff-8e864b607319", "dcfc5fee-2733-467d-8e68-235f4ecda9e1", "eef9a186-c76b-467f-8a3f-6542307b1761", "2c19e929-e0af-49e1-8634-1449e4e389b5", "fd305e06-8588-42df-8718-1b98cea78b4d", "b69933b9-0f26-4f20-bdbe-dc8e7be5b9ab", "c13a7b86-d4e5-4d81-aaa8-2bd5ea326016", "00418c9d-8af5-4055-9591-871776718eac", "be042906-1f2b-4ba3-ba33-13576880b6b5", "cf9b488e-e8ed-4f91-9dbc-dc3c6f03d99b", "7b6dbb72-934a-4365-8b4b-c673fa080465", "a8c770d3-ad53-4ecc-abd4-0f8cd2afca88", "a1af883f-0a4c-4eeb-a107-a19a557a0b0d", "8a8bc288-e565-4298-aa12-c3f0612d754b", "9b16bc99-83f5-4c98-8de2-21a1af68307c", "4286c17d-a4ae-4a56-8ca1-8ae2aa6e043c", "d8dddb62-5f33-47be-a3f4-6bd2a2809b18", "6dda059d-5027-4379-8710-c921750f266c", "7511bb0b-889a-4e74-bba1-7f6cee4bff76"], "metadata": {"window": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics .  It's - the Red Oak \nsourcing is a huge driver for not just cost control , but for delivery .  And certainly there's been some \nstrong demand for some of those products like amoxicillin that you just referenc ed for respiratory \nchallenges that we're seeing some drive for in the marketplace .  But again, it's something that we don't \nthink will be either lasting or any type of impact for us . ", "original_text": " \nPage 14 of 14 \n \nsourcing in general is an inc redibly important function specifically to generics . ", "page_label": "14", "file_name": "CAH-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 187872, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}